effici
detoxif
ammonia
liver
critic
avoid
ammonia
accumul
blood
prevent
hepat
encephalopathi
process
ureagenesi
involv
consumpt
atp
extens
exchang
molecul
cytosol
mitochondria
order
meet
high
energi
demand
ureagenesi
liver
mitochondria
increas
consumpt
make
atp
oxid
phosphoryl
oxygen
consumpt
rate
ocr
cultur
rat
hepatocyt
measur
seahors
bioscienc
extracellular
flux
analyz
panel
protein
kinas
phosphatas
inhibitor
screen
determin
effect
ureagenesisinduc
mitochondri
respir
isol
rat
hepatocyt
cultur
collagenco
seahors
micropl
use
within
h
respir
measur
ph
krebsringerhep
krh
buffer
supplement
mm
inhibitor
ureagen
substrat
mm
mm
ornithin
mm
nalact
rotenon
inject
sequenti
measur
ocr
ureagen
substrat
caus
increas
ocr
rotenon
sensit
basal
respir
screen
identifi
drug
effect
categor
three
main
group
chang
basal
respir
chang
ureagen
respir
chang
basal
respir
chang
ureagen
respir
chang
basal
respir
chang
ureagen
respir
two
group
inhibitor
categori
includ
affect
epiderm
growth
factor
receptor
egfr
protein
kinas
c
pkc
depend
pathway
egfr
inhibitor
includ
tyrosin
kinas
inhibitor
erbstatin
gefitinib
enhanc
wherea
pkc
inhibitor
includ
bisindolylmaleimid
chelerythrin
chlorid
suppress
ureagen
respir
without
affect
basal
respir
although
egf
activ
pkc
downstream
egfr
result
suggest
altern
pathway
aris
egfr
elucid
may
yield
new
inform
natur
regul
ureagenesi
mitochondri
respir
also
found
hydrochlorid
insulinlik
growth
receptor
inhibitor
block
autophosphoryl
enhanc
ureagen
respir
sinc
insulin
inhibit
ureagenesi
result
valid
assay
conclus
activ
egfr
inhibit
ureagen
respir
wherea
pkc
activ
increas
ureagen
respir
niddk
niaaa
follow
peopl
noth
disclos
gut
microbiota
play
crucial
role
regul
physiolog
host
specif
immun
system
recent
evid
suggest
gut
microbiota
involv
liver
diseas
nonalcohol
fatti
liver
diseas
alcohol
viral
hepat
howev
remain
unclear
whether
immunolog
respons
modul
gut
microbiota
directli
indirectli
metabolit
short
chain
fatti
acid
scfa
secondari
bile
salt
import
signal
molecul
gut
liver
far
littl
known
influenc
gut
microbiota
immunemedi
liver
injuri
concanavalin
cona
model
wellestablish
mous
model
cell
mediat
autoimmun
hepatit
therefor
investig
role
gut
microbiota
conainduc
liver
injuri
method
germ
free
broadspectrum
antibiot
treat
firxtig
mice
challeng
cona
multipl
paramet
analyz
initi
peak
recoveri
phase
conamedi
liver
injuri
immunophenotyp
perform
via
flow
cytometri
microbi
composit
fece
analyz
rrna
sequenc
scfa
level
estim
hepat
express
level
receptor
e
g
hepat
express
well
sever
regul
bile
acid
metabol
investig
rtpcr
influenc
scfa
immun
cell
composit
analyz
via
fac
analysi
vitro
cocultur
experi
wo
liver
sinusoid
endotheli
cell
lsec
result
germ
free
well
antibiot
treat
mice
protect
conainduc
liver
injuri
antibiot
treatment
reduc
frequenc
cell
regulatori
cell
treg
follow
conatreat
hepat
express
upregul
respons
antibiot
treatment
downregul
conachalleng
effect
seen
cholesterol
catalyz
convers
cholesterol
primari
bile
acid
opposit
effect
could
determin
case
bile
acid
membran
receptor
vitro
experi
indic
butyr
reduc
product
cell
cocultur
lsec
conclus
clearli
verifi
link
gut
microbiota
conainduc
liver
damag
reduct
via
antibiot
absenc
germ
free
mice
gut
microbiota
led
amelior
conadamag
line
decreas
treg
liver
explain
less
sever
liver
damag
result
indic
analysi
scfa
bile
salt
metabol
need
determin
specif
function
pathogenesi
liver
diseas
background
liver
immun
organ
interpos
portal
peripher
venou
circul
immun
aberr
includ
alter
adapt
immun
respons
occur
chronic
liver
diseas
chang
mainli
explor
cell
isol
liver
peripher
venou
blood
associ
liver
diseas
sever
unclear
chang
cell
subset
subset
distribut
portal
vs
peripher
venou
blood
patient
chronic
hepat
c
chcv
relat
diseas
sever
method
prospect
studi
cohort
compens
chcv
patient
subject
underw
percutan
liver
biopsi
direct
portal
vein
cannul
direct
pressur
dpp
measur
portal
peripher
blood
sampl
obtain
cell
measur
multicolor
flow
cytometri
categor
central
memori
effector
memori
effector
cell
ishak
fibrosi
score
dpp
use
marker
liver
diseas
sever
spearman
rho
r
use
correl
diseas
sever
indic
subset
absolut
count
result
patient
enrol
complet
studi
mean
age
found
patient
respect
dpp
rang
mmhg
portal
blood
central
memori
subset
none
subset
correl
peripher
blood
neither
subset
correl
increas
dpp
portal
blood
deriv
central
memori
subset
trend
toward
signific
wherea
none
subset
show
signific
chang
interestingli
peripher
blood
subset
correl
dpp
effector
memori
subset
show
neg
correl
r
conclus
subset
show
dynam
chang
across
liver
diseas
sever
diseas
sever
associ
quantit
chang
subset
subset
distinct
portal
peripher
venou
system
subset
chang
appear
confin
peripher
circul
suggest
adapt
immun
cell
aberr
chcv
evolv
liver
diseas
progress
diseas
liver
contribut
chang
affect
cell
transit
portal
system
venou
circul
disclosur
follow
peopl
noth
disclos
ohad
etzion
rabab
ali
christoph
koh
elliot
levi
david
e
kleiner
shakuntala
rampertaap
sergio
rosenzweig
varun
k
takyar
ai
thanda
han
shilpa
lingala
nanci
fryzek
vanessa
hayneswilliam
theo
heller
background
aim
hepatocellular
carcinoma
hcc
often
base
chronic
inflamm
malign
transform
hepatocyt
result
liver
fibrogenesi
process
subset
helper
th
cell
involv
mediat
proinflammatori
antiinflammatori
regul
treg
effect
tcell
specif
overexpress
cyclic
adenosin
monophosphaterespons
element
modul
alpha
previous
describ
dispos
tlymphocyt
toward
phenotyp
model
system
lupu
erythematosu
lung
inflamm
addit
increas
respons
associ
poor
prognosi
patient
chronic
liver
diseas
cld
therefor
investig
relev
cell
cld
implic
hepatocellular
carcinoma
hcc
method
transgen
mice
overexpress
crema
cross
hepatocytespecif
nemo
knockout
mice
nemo
gener
nemo
crema
tg
mice
impact
crema
tg
tcell
nemo
mediat
cld
progress
examin
proof
impact
crema
tg
cell
adopt
transfer
bone
marrow
deriv
cell
bmdc
tcell
perform
comprehens
analysi
tcell
phenotyp
nanostr
technolog
tm
fac
analysi
includ
result
overexpress
tcell
nemo
mice
diminish
serum
transaminas
level
associ
reduc
number
infiltr
dendrit
cell
tcell
consequ
fibrosi
hcc
develop
significantli
reduc
simultan
adopt
transfer
bmdc
tcell
tg
nemo
mice
clearli
identifi
tg
tcell
essenti
improv
cours
cld
surprisingli
scenario
tg
tcell
nt
show
phenotyp
product
express
linag
marker
contrast
hepat
tcell
characteris
express
tregrel
marker
like
vitro
tg
tcell
stimul
retino
acid
ra
contain
supernat
activ
hsc
polaris
toward
antiinflammatori
treg
phenotyp
mechanist
administr
specif
retino
acid
receptor
rar
inhibitor
reduc
treg
polaris
find
reveal
tg
tcell
prerequisit
induc
treg
conclus
result
demonstr
overexpress
tcell
chang
inflammatori
milieu
attenu
initi
progress
cld
unexpect
studi
demonstr
transgen
tcell
induc
hsc
shift
chronic
inflamm
nemo
liver
toward
protect
treg
respons
background
secret
cell
implic
autoimmun
inflammatori
diseas
provid
link
innat
adapt
immun
respons
cell
present
around
bile
duct
function
role
mechan
local
poorli
understood
method
primari
human
cholangiocyt
assess
chemokin
cytokin
secret
respons
bacteri
product
proinflammatori
cytokin
includ
effect
cholangiocyt
cell
differenti
stabil
assess
use
cholangiocytecondit
media
stimul
without
result
e
coli
lp
treatment
cholangiocyt
stimul
secret
abl
attract
cell
invitro
migrat
assay
cholangiocyt
secret
polar
cytokin
includ
treat
cell
show
evid
polaris
cell
cocultur
day
stimul
stimul
cholangiocyt
supernat
treatment
induc
depend
prolifer
cholangiocyt
increas
express
treatment
also
induc
cholangiocyt
secret
could
respons
recruit
neutrophil
macrophag
around
bile
duct
conclus
cholangiocyt
respond
prolifer
secret
polar
cytokin
favour
mainten
lineag
infiltr
cell
secret
polaris
cytokin
cholangiocyt
respons
lp
e
coli
suggest
presenc
bacteria
product
inflam
portal
tract
may
contribut
mainten
polaris
microenviron
backgroundaim
clinic
evid
patient
chronic
liver
diseas
increas
immunoglobulin
compar
healthi
subject
regardless
condit
patient
liver
cirrhosi
immunecompromis
whose
risk
sever
bacteri
infect
increas
accord
progress
childpugh
statu
previous
report
peripher
memori
bcell
frequenc
function
significantli
decreas
cirrhot
patient
hepatolog
hypothes
dysregul
b
cell
differenti
viabil
function
involv
excess
product
futil
immunoglobulin
thu
aim
clarifi
b
cell
function
patient
wide
rang
liver
diseas
analyz
profil
serum
immunoglobulin
subtyp
b
cell
gene
signatur
method
retrospect
analyz
igg
iga
igm
level
patient
liver
diseas
medic
record
classifi
depend
etiolog
childpugh
score
five
etiolog
group
hcv
hbv
alcohol
nafld
other
patient
autoimmun
hepat
diseas
aih
pbc
exclud
use
cryopreserv
serum
also
perform
immunoglobulin
isotyp
bioplex
system
measur
mrna
level
activ
marker
realtim
pcr
isol
memori
bcell
recov
cirrhot
patient
healthi
subject
addit
examin
express
activationinduc
cytidin
deaminas
aid
crucial
classswitch
recombin
somat
hypermut
plasma
cell
differenti
result
cirrhot
patient
elev
serum
igg
iga
regardless
underli
etiolog
chang
also
igg
iga
level
increas
progress
childpugh
stage
patient
advanc
cirrhosi
childpugh
b
c
tend
increas
frequenc
rel
decreas
compar
healthi
donor
hd
express
activ
marker
memori
bcell
cirrhosi
group
compar
hd
howev
aid
level
memori
bcell
increas
cirrhot
patient
compar
hd
conclus
cirrhot
patient
wide
rang
etiolog
show
increas
immunoglobulin
statu
enhanc
express
aid
memori
b
cell
disproport
immunoglobulin
profil
may
account
futil
immunoglobulin
statu
advanc
cirrhosi
interplay
macrophag
cell
shape
inflammatori
respons
appropri
balanc
cell
essenti
resolut
fibrosi
shown
model
organ
reject
transplant
tcell
polaris
result
antigen
present
profession
antigenpres
cell
helper
lymphocyt
induc
chronic
liver
fibrosi
carbon
tetrachlorid
inject
mice
defect
last
step
phagocytosi
wildtyp
counterpart
hypothesi
phagocytosi
instrument
antigen
present
setup
correct
cytokin
environ
correct
cell
polaris
occur
increas
damag
observ
mice
lack
phagocyt
cargo
digest
altogeth
imbal
macrophag
polaris
tip
proinflammatori
phenotyp
find
prompt
us
investig
tcell
respons
order
investig
liver
harvest
distinct
time
background
secret
cell
implic
autoimmun
inflammatori
diseas
provid
link
innat
adapt
immun
respons
cell
present
around
bile
duct
function
role
mechan
local
poorli
understood
method
primari
human
cholangiocyt
assess
chemokin
cytokin
secret
respons
bacteri
product
proinflammatori
cytokin
includ
effect
cholangiocyt
cell
differenti
stabil
assess
use
cholangiocytecondit
media
stimul
without
result
e
coli
lp
treatment
cholangiocyt
stimul
secret
abl
attract
cell
invitro
migrat
assay
cholangiocyt
secret
polar
cytokin
includ
treat
cell
show
evid
polaris
cell
cocultur
day
stimul
stimul
cholangiocyt
supernat
treatment
induc
depend
prolifer
cholangiocyt
increas
express
treatment
also
induc
cholangiocyt
secret
could
respons
recruit
neutrophil
macrophag
around
bile
duct
conclus
cholangiocyt
respond
prolifer
secret
polar
cytokin
favour
mainten
lineag
infiltr
cell
secret
polaris
cytokin
cholangiocyt
respons
lp
e
coli
suggest
presenc
bacteria
product
inflam
portal
tract
may
contribut
mainten
polaris
microenviron
backgroundaim
clinic
evid
patient
chronic
liver
diseas
increas
immunoglobulin
compar
healthi
subject
regardless
condit
patient
liver
cirrhosi
immunecompromis
whose
risk
sever
bacteri
infect
increas
accord
progress
childpugh
statu
previous
report
peripher
memori
bcell
frequenc
function
significantli
decreas
cirrhot
patient
hepatolog
hypothes
dysregul
b
cell
differenti
viabil
function
involv
excess
product
futil
immunoglobulin
thu
aim
clarifi
b
cell
function
patient
wide
rang
liver
diseas
analyz
profil
serum
immunoglobulin
subtyp
b
cell
gene
signatur
method
retrospect
analyz
igg
iga
igm
level
patient
liver
diseas
medic
record
classifi
depend
etiolog
childpugh
score
five
etiolog
group
hcv
hbv
alcohol
nafld
other
patient
autoimmun
hepat
diseas
aih
pbc
exclud
use
cryopreserv
serum
also
perform
immunoglobulin
isotyp
bioplex
system
measur
mrna
level
activ
marker
realtim
pcr
isol
memori
bcell
recov
cirrhot
patient
healthi
subject
addit
examin
express
activationinduc
cytidin
deaminas
aid
crucial
classswitch
recombin
somat
hypermut
plasma
cell
differenti
result
cirrhot
patient
elev
serum
igg
iga
regardless
underli
etiolog
chang
also
igg
iga
level
increas
progress
childpugh
stage
patient
advanc
cirrhosi
childpugh
b
c
tend
increas
frequenc
rel
decreas
compar
healthi
donor
hd
express
activ
marker
memori
bcell
cirrhosi
group
compar
hd
howev
aid
level
memori
bcell
increas
cirrhot
patient
compar
hd
conclus
cirrhot
patient
wide
rang
etiolog
show
increas
immunoglobulin
statu
enhanc
express
aid
memori
b
cell
disproport
immunoglobulin
profil
may
account
futil
immunoglobulin
statu
advanc
cirrhosi
point
suspens
analysi
carri
use
qpcr
immunohistochemistri
total
liver
extract
liver
section
respect
studi
show
absenc
correct
phagocyt
cargo
digest
impair
respons
result
defect
product
cytokin
observ
homeostat
condit
also
mrna
express
untreat
mice
lack
phagocyt
cargo
process
vs
wild
type
mice
fold
possibl
point
gener
defect
polaris
mrna
express
untreat
mice
lack
phagocyt
cargo
process
vs
wild
type
mice
fold
also
prolifer
nonparenchym
compart
observ
mice
lack
last
step
phagocytosi
recoveri
immunohistochemistri
vs
cellsfield
view
magnif
micegroup
investig
requir
determin
mechan
phagocytosi
act
respons
whether
defect
phagocytosi
correl
uncontrol
expans
specif
tcell
subtyp
regener
liver
understand
dynam
control
relationship
may
great
impact
elucid
novel
potenti
therapeut
target
scar
process
disclosur
follow
peopl
noth
disclos
lara
campana
sarah
e
mok
antonella
pellicoro
stuart
j
forb
john
p
iredal
role
hepat
inflamm
chronic
liver
diseas
hcc
daniel
patten
jame
c
wadkin
sivesh
k
kathir
kamarajah
chri
j
weston
shishir
shetti
centr
liver
research
univers
birmingham
birmingham
unit
kingdom
introduct
unregul
inflamm
liver
drive
onset
progress
rang
aetiolog
divers
chronic
liver
diseas
ultim
promot
format
neoplast
tumour
hepatocellular
carcinoma
hcc
key
step
hepat
inflamm
recruit
leukocyt
via
hepat
sinusoid
endotheli
cell
hsec
member
tetraspanin
famili
previous
shown
play
role
leukocyt
recruit
vascular
endothelia
howev
presenc
previous
explor
hepat
sinusoid
endothelium
consequ
understand
express
function
liver
could
identifi
new
therapeut
target
limit
hepat
inflamm
method
use
immunohistochemistri
dual
colour
immunofluoresc
colocalis
studi
qrtpcr
western
blot
determin
cellspecif
express
normal
liver
chronic
liver
diseas
hcc
qrtpcr
cellbas
elisa
studi
use
determin
regul
express
hsec
growth
factor
proinflammatori
cytokin
hepatoma
cell
line
supernat
flowbas
adhes
assay
use
studi
function
role
adhes
jurkat
cell
human
cell
line
hsec
monolay
result
increas
protein
express
associ
area
fibrosi
neovascularis
particularli
parenchym
liver
diseas
alcohol
liver
diseas
ald
nonalcohol
steatohepat
nash
well
hcc
shown
highli
express
hsec
vivo
express
maintain
cultur
hsec
vitro
express
hsec
upregul
stimul
supernat
tumourigen
growth
factor
hepatocyt
growth
factor
hgf
vascular
endotheli
growth
factor
vegf
also
found
molecul
cluster
around
adher
cell
follow
captur
physiolog
flow
hsec
monolay
furthermor
functionblock
antibodi
significantli
reduc
adher
cell
flow
condit
conclus
demonstr
first
time
express
human
sinusoid
endotheli
cell
neovessel
rang
chronic
liver
diseas
hcc
also
demonstr
hsec
maintain
vitro
upregul
protumourigen
factor
play
import
function
role
cell
adhes
hsec
taken
togeth
find
understand
hepat
inflamm
lymphocyt
recruit
liver
chronic
diseas
carcinogenesi
could
form
basi
potenti
therapeut
target
disclosur
follow
peopl
noth
disclos
daniel
patten
jame
c
wadkin
sivesh
k
kathir
kamarajah
chri
j
weston
shishir
shetti
health
gain
cost
hcv
treatment
cost
effect
analysi
two
differ
health
polici
scenario
simul
piter
piattaforma
italiana
per
lo
studio
della
terapia
dell
epat
virali
real
life
cohort
background
cur
hcv
treatment
ifnbas
regimen
associ
reduct
rate
hcvassoci
liver
cancer
whether
achiev
sustain
virolog
respons
follow
treatment
ifnfre
directact
antivir
daa
base
regimen
yield
similar
benefit
unknown
object
studi
examin
associ
treatment
complet
daa
sofosbuvir
sof
risk
incid
liver
cancer
realworld
data
method
us
administr
claim
data
januari
march
identifi
adult
hcv
patient
dispens
least
week
sofcontain
therapi
evid
subsequ
hcv
treatment
comparison
identifi
adult
patient
diagnos
hcv
without
evid
hcv
treatment
activ
followup
time
sof
approv
includ
patient
minimum
month
enrol
evid
prior
liver
cancer
baselin
hazard
ratio
hr
estim
risk
incid
liver
cancer
associ
complet
sofcontain
therapi
calcul
adjust
baselin
confound
use
cox
proport
hazard
method
result
patient
complet
sofcontain
treatment
like
year
male
cirrhosi
baselin
vs
untreat
hcv
patient
median
followup
shorter
sofcomplet
vs
untreat
patient
day
respect
stratifi
baselin
cirrhosi
statu
absolut
cumul
incid
rate
confid
interv
ci
differ
sofcomplet
untreat
patient
per
personyear
py
respect
among
noncirrhot
per
py
respect
among
cirrhot
signific
interact
observ
treatment
effect
baselin
cirrhosi
adjust
age
gender
cirrhosi
baselin
condit
signific
p
associ
observ
sof
complet
liver
cancer
ci
absenc
associ
observ
ifnfre
ifncontain
sof
treatment
regimen
ci
ci
respect
conclus
realworld
cohort
studi
complet
sofcontain
treatment
independ
associ
background
aim
hcv
recombin
strain
st
petersburg
variant
report
sever
countri
preval
may
underestim
vast
major
standard
genotyp
assay
base
core
sequenc
far
data
recombin
viru
israel
clinic
import
hcv
recombin
genotyp
lie
upon
mistakenli
identifi
treat
genotyp
treatment
insuffici
genotyp
studi
report
first
case
recombin
strain
israel
addit
aim
assess
abil
abbott
realtim
hcv
genotyp
ii
ruo
gtii
assay
detect
recombin
strain
comparison
sequencebas
analys
method
store
sera
sampl
chronic
hcv
patient
viral
load
unitml
test
central
laboratori
haifa
western
galile
clalit
health
servic
hcv
genotyp
perform
sampl
use
abbott
gtii
commerci
kit
accord
manufactur
instruct
abbott
gtii
assay
amplifi
detect
portion
core
region
sampl
recombin
strain
detect
analyz
sequencebas
analys
result
genotyp
distribut
addit
sampl
sera
diagnos
recombin
strain
nine
patient
immigr
born
former
ussr
mean
age
year
old
sequencebas
analys
perform
sampl
show
sampl
inde
recombin
genotyp
chimera
break
point
meanwhil
follow
patient
reveal
two
patient
relaps
week
pegifn
therapi
two
patient
show
respons
svr
obtain
one
patient
week
daclatasvir
sofosbuvir
therapi
patient
ongo
treat
daa
conclus
found
rate
recombin
hcv
hcv
genotyp
genotyp
test
studi
awar
rais
possibl
patient
identifi
hcv
patient
recommend
use
genotyp
assay
amplifi
core
region
hcv
genom
presenc
recombin
viru
may
affect
outcom
antivir
treatment
maladi
de
lappareil
digestif
huriez
lill
franc
cochin
pari
franc
purpan
toulous
franc
depart
de
biostatistiqu
lill
franc
agenc
de
la
biomedecin
pari
franc
necker
pari
franc
huriez
lill
franc
kidney
transplant
use
antivir
therapi
hbv
hcv
recipi
lower
patient
graft
surviv
noninfect
recipi
last
two
decad
nucleo
id
analogu
wide
use
hbv
patient
wherea
ifnbas
therapi
use
smaller
proport
hcv
patient
aim
updat
impact
hbv
hcv
patient
graft
surviv
assess
prognost
impact
viral
control
hbv
hcv
method
first
patient
graft
surviv
prospect
record
french
nationwid
databas
kidney
recipi
accord
serolog
statu
second
calcul
base
type
error
power
random
sampl
least
hbv
hcv
patient
record
investig
evalu
influenc
viral
control
viral
control
defin
low
dna
level
upon
antivir
therapi
inact
carrier
hbv
patient
svr
spontan
viral
erad
hcv
recipi
result
recipi
median
age
year
analyz
posit
hcv
antibodi
posit
hbsag
non
infect
patient
hcv
kidney
recipi
significantli
lower
patient
surviv
hbv
p
noninfect
recipi
p
without
signific
differ
hbv
noninfect
recipi
also
significantli
lower
graft
surviv
hbv
noninfect
p
adjust
age
recipi
age
donor
time
cold
ischemia
extent
hlab
dr
match
hcv
antibodi
remain
independ
prognost
factor
mortal
hr
ci
p
b
patient
record
investig
viral
control
obtain
almost
hbv
recipi
case
hcv
patient
viral
control
observ
case
among
antivir
therapi
hcv
patient
patient
viral
control
higher
patient
vs
graft
vs
without
multivari
analysi
hcv
infect
remain
independ
associ
mortal
case
viral
replic
wherea
hcv
recipi
neg
pcr
similar
patient
graft
surviv
noninfect
patient
conclus
control
viral
replic
allow
obtain
similar
patient
graft
surviv
hbv
hcv
recipi
comparison
noninfect
recipi
convers
uncontrol
hcv
infect
still
associ
decreas
patient
graft
surviv
disclosur
background
rel
small
proport
hcv
infect
person
develop
hepat
decompens
hepatocellular
carcinoma
even
sever
year
infect
predict
develop
complic
help
priorit
treatment
decis
method
erchiv
calcul
three
commonli
use
clinic
score
liver
diseas
sever
determin
risk
overal
mortal
hepat
decompens
hd
hepatocellular
carcinoma
hcc
year
diagnosi
hcv
exclud
hd
hcc
baselin
hiv
hbsag
receiv
hcv
treatment
day
result
among
hcv
infect
person
identifi
lowest
cp
meld
score
develop
hd
hcc
die
within
year
hcv
diagnosi
howev
proport
increas
fold
next
stratum
score
year
one
fold
year
stratum
mortal
hd
hcc
highest
higher
strata
year
diagnosi
tabl
conclus
mortal
complic
infrequ
first
year
hcv
diagnosi
person
low
liver
diseas
sever
score
exponenti
increas
increas
time
increas
sever
score
data
may
help
determin
optim
time
initi
treatment
minim
mortal
liver
diseas
complic
disclosur
adeel
butt
grantresearch
support
gilead
abbvi
follow
peopl
noth
disclos
yanji
ren
elev
hcv
reinfect
incid
success
treatment
among
hivinfect
men
sex
men
san
diego
background
high
rate
hepat
c
hcv
reinfect
follow
success
treatment
among
hivinfect
men
sex
men
msm
report
europ
data
avail
us
assess
incid
primari
hcv
infect
reinfect
follow
success
treatment
among
hiv
posit
msm
san
diego
method
perform
retrospect
cohort
analysi
hcv
primari
incid
reinfect
incid
success
treatment
among
hivinfect
msm
largest
hiv
clinic
san
diego
ucsd
owen
clinic
incid
hcv
infect
assess
among
hivinfect
msm
neg
antihcv
test
defin
posit
antihcv
hcvrna
test
start
followup
reinfect
defin
posit
hcv
rna
pcr
test
date
sustain
viral
respons
svr
among
hivhcvcoinfect
msm
treat
hcv
reinfect
analysi
patient
censor
reinfect
last
neg
test
april
incid
calcul
use
surviv
time
method
result
among
baselin
neg
patient
seroconvers
occur
personyear
risk
lead
overal
primari
hcv
incid
per
personyear
ci
time
period
among
hivinfect
msm
achiev
svr
follow
hcv
treatment
becam
reinfect
median
time
year
date
svr
personyear
followup
estim
reinfect
rate
py
ci
two
individu
reinfect
occur
inject
drug
use
report
share
syring
drugprepar
equip
sinc
svr
third
individu
histori
drug
use
three
hcv
reinfect
patient
well
control
hiv
infect
conclus
hcv
reinfect
incid
among
hivinfect
msm
san
diego
fold
higher
primari
hcv
incid
increas
effort
prevent
reinfect
posttreat
among
hivinfect
msm
requir
found
major
rass
preval
also
show
highest
preval
rass
respect
major
rass
detect
common
major
ra
major
sofosbuvir
ra
never
found
put
rass
exclus
detect
often
associ
p
covari
analysi
notabl
preval
higher
interferonribavirinexperienc
respect
pt
respect
among
pt
resist
test
gene
show
multipl
rass
preval
associ
rass
mainli
pt
show
rass
drugtarget
lastli
pt
treat
studi
evalu
potenti
role
natur
among
noncirrhot
pt
none
major
rass
baselin
minor
rass
reach
sustain
viral
respons
among
cirrhot
pt
show
major
rass
foldchang
two
treat
notrecommend
regimen
without
ribavirin
experienc
virolog
failur
contrari
receiv
recommendedregimen
ribavirin
reach
svr
conclus
natur
rass
common
across
hcvgt
pt
show
multipleclass
resist
though
socal
major
mutat
seem
clinic
relev
thu
qualit
identif
major
natur
rass
rather
requir
properli
guid
daabas
therapi
introduct
aberr
express
biliari
marker
cytokeratin
epitheli
cell
adhes
molecul
epcam
thought
reflect
abnorm
regener
recruit
hepat
progenitor
cell
aim
describ
express
biliari
marker
hepatocyt
patient
compens
hcvrelat
cirrhosi
investig
potenti
influenc
decompens
event
hepatocellular
carcinoma
occurr
patient
method
among
patient
childpugh
hcvrelat
cirrhosi
enrol
french
prospect
anr
cirvir
cohort
select
patient
avail
liver
biopsi
perform
within
year
inclus
liver
biopsi
reassess
activ
grade
potenti
steatohepat
epcam
immunostain
assess
independ
pathologist
biopsi
consid
posit
least
foci
hepatocyt
observ
categor
extens
one
sever
cirrhot
nodul
show
posit
stain
hepatocyt
epcam
consid
posit
least
one
foci
hepatocyt
stain
patient
prospect
follow
influenc
biliari
marker
decompens
event
ascit
hepat
encephalopathi
gastrointestin
bleed
hepatocellular
carcinoma
occurr
studi
use
univari
analys
cox
multivari
analysi
result
among
patient
elig
studi
men
mean
age
biopsi
show
hepatocyt
patient
among
stain
extens
biopsi
posit
epcam
patient
express
marker
associ
lower
platelet
count
higher
afp
level
histolog
steatohepat
patient
experienc
least
one
decompens
event
hcc
diagnos
patient
extens
stain
independantli
associ
occurr
decompens
event
hr
along
low
albumin
level
absenc
sustain
virolog
respons
epcam
express
independantli
associ
hcc
occurr
hr
along
older
age
low
prothombin
time
steatohepat
observ
biopsi
associ
subsequ
decompens
hcc
occurhepat
c
viru
hcv
screen
taken
new
import
result
updat
guidelin
new
cur
therapi
rew
studi
assess
hcv
homeless
popul
includ
women
shadow
cohort
san
francisco
recruit
studi
homeless
unstabl
hous
women
sampl
systemat
conduct
free
meal
program
homeless
shelter
lowcost
singl
room
occup
hotel
hivinfect
women
oversampl
studi
inclus
criteria
includ
femal
sex
age
year
lifetim
histori
hous
instabl
slept
public
place
shelter
stay
seri
peopl
place
sleep
paper
estim
preval
correl
hcv
exposur
proport
unawar
statu
assess
correl
outcom
among
women
antihcv
posit
hiv
coinfect
consist
recruit
strategi
half
sampl
hivinfect
major
women
babyboom
cohort
born
report
recent
past
inject
drug
use
idu
factor
independ
associ
antihcv
posit
born
earlier
adjust
odd
ratio
aor
ci
histori
idu
aor
ci
number
psychiatr
diagnos
aor
ci
women
symptom
current
depress
lower
adjust
odd
hcv
seroposit
aor
ci
overal
report
never
hcv
test
among
antihcv
posit
unawar
statu
factor
independ
associ
women
know
hcv
statu
control
birth
cohort
statu
idu
includ
lower
incom
per
increas
aor
ci
fewer
psychiatr
diagnosi
per
diagnosi
aor
ci
recent
cocain
use
ye
vs
aor
ci
result
fill
import
gap
inform
regard
hcv
among
homeless
women
confirm
need
enhanc
screen
popul
high
proport
babyboom
histori
drug
use
psychiatr
problem
due
age
risk
profil
high
probabl
women
studi
infect
decad
thu
signific
liver
diseas
associ
mental
ill
hcv
suggest
addit
increas
screen
augment
mental
health
care
support
may
need
enhanc
treatment
success
introduct
hepascor
serum
test
provid
clinic
use
data
regard
stage
liver
fibrosi
subsequ
clinic
outcom
chronic
liver
diseas
aim
studi
determin
chang
hepascor
result
time
delta
hepascor
could
accur
predict
chang
risk
liver
relat
death
lrd
hepatocellular
carcinoma
hcc
liver
decompens
ld
composit
endpoint
lrd
hcc
ld
hcv
infect
method
chronic
hepat
c
patient
attend
depart
hepatolog
sir
charl
gairdner
hospit
western
australia
two
hepascor
test
perform
studi
abil
baselin
delta
hepascor
test
predict
liver
relat
outcom
assess
use
univari
multivari
cox
regress
auroc
kaplanmei
analysi
result
patient
year
follow
develop
hepatocellular
carcinoma
liver
decompens
andor
liver
relat
death
baselin
hepascor
p
delta
hepascor
independ
associ
composit
endpoint
baselin
hepascor
associ
signific
increas
lrd
ld
hcc
patient
baselin
hepascor
subsequ
improv
delta
hepascor
significantli
decreas
risk
lrd
ld
composit
endpoint
compar
baselin
hepascor
stabl
hepascor
valu
delta
deterior
hepascor
valu
delta
optimum
time
interv
hepascor
test
determin
compar
improv
delta
hepascor
stabl
wors
delta
hepascor
combin
baselin
hepascor
delta
hepascor
significantli
predict
improv
liver
relat
outcom
time
test
year
conclus
studi
show
improv
hepascor
valu
significantli
associ
reduc
rate
liverrel
mortal
morbid
find
implic
patient
manag
follow
hcv
erad
may
determin
time
reduc
need
varic
hcc
screen
background
wisteria
floribunda
agglutininposit
bind
protein
report
noninvas
marker
liver
fibrosi
predictor
hepatocellular
carcinoma
hcc
chronic
hepat
c
chc
patient
studi
aim
assess
timedepend
associ
hcc
develop
chc
patient
use
sampl
collect
longterm
followup
method
particip
studi
r
e
v
e
l
hcv
cohort
serum
level
evalu
total
sampl
consist
hcc
case
control
case
control
serial
sampl
collect
variou
time
throughout
followup
associ
hcc
analyz
use
multivari
logist
regress
model
stratifi
accord
time
sampl
collect
hcc
diagnosi
area
receiv
oper
characterist
auroc
curv
use
evalu
predict
accuraci
model
integr
risk
factor
predict
hcc
risk
result
level
sampl
closer
hcc
diagnosi
higher
collect
farther
hcc
diagnosi
howev
level
consist
low
time
control
sampl
analysi
use
sampl
collect
variou
occas
show
level
associ
hcc
risk
dosedepend
manner
adjust
gender
age
serum
alt
ast
afp
hcv
rna
level
hcv
genotyp
adjust
odd
ratio
ci
respect
coi
compar
coi
refer
stratifi
time
sampl
collect
hcc
diagnosi
associ
level
hcc
strongest
shortterm
period
decreas
longer
time
compar
level
coi
adjust
odd
ratio
ci
level
coi
respect
predict
hcc
within
year
year
year
year
auroc
incorpor
level
predictor
respect
predict
hcc
within
period
conclus
level
significantli
predict
hcc
develop
patient
chronic
hepat
c
associ
predict
accuraci
stronger
sampl
collect
closer
hcc
diagnosi
collect
farther
hcc
diagnosi
liver
elastographi
wide
use
assess
liver
fibrosi
patient
chronic
hepat
c
also
recommend
monitor
regress
liver
fibrosi
success
antivir
therapi
studi
earli
chang
liver
stiff
initi
antivir
treatment
studi
popul
compris
patient
chronic
hepat
c
mean
age
sd
year
metavir
fibrosi
stage
n
n
genotyp
gt
n
n
n
mean
bmi
sd
patient
treat
interferonfre
oral
regimen
prior
therapi
week
initi
antivir
treatment
fibrosi
stage
assess
transient
elastographi
use
touch
devic
mprobe
echosen
pari
franc
classifi
accord
metavir
score
system
cutoff
valu
liver
stiff
defin
kpa
f
kpa
f
kpa
f
mean
liver
stiff
baselin
kpa
decreas
kpa
followup
perform
week
week
cutoff
valu
appli
baselin
appli
initi
antivir
therapi
follow
result
obtain
within
week
initi
treatment
fibrosi
stage
improv
least
one
stage
patient
remain
stabl
worsen
patient
classifi
baselin
classifi
week
patient
classifi
baselin
classifi
week
patient
baselin
classifi
week
decreas
liver
stiff
correl
baselin
ast
alt
level
studi
mark
decreas
liver
stiff
observ
within
two
week
initi
antivir
therapi
pathophysiolog
point
view
clinic
signific
decreas
liver
fibrosi
within
short
period
time
seem
imposs
therefor
assum
decreas
caus
resolut
inflammatori
activ
within
liver
current
cutoff
valu
assess
fibrosi
stage
patient
chronic
hepat
c
transient
elastographi
obtain
patient
fibrosi
activ
inflamm
therefor
data
clearli
indic
lower
cutoff
valu
liver
stiff
appropri
monitor
liver
fibrosi
initi
antivir
therapi
background
aim
analysi
volatil
organ
compound
voc
exhal
breath
identifi
marker
alcohol
nonalcohol
fatti
liver
diseas
aim
pilot
studi
investig
util
breath
test
diagnosi
advanc
fibrosi
patient
chronic
hepat
c
viru
hcv
infect
method
patient
undergo
liver
biopsi
recruit
fibrosi
determin
experienc
pathologist
stage
accord
metavir
score
advanc
fibrosi
defin
exhal
breath
plasma
sampl
collect
within
week
biopsi
infrar
isotop
analyz
iri
use
analyz
breath
sampl
aminopyrin
result
patient
includ
mean
age
year
male
advanc
fibrosi
iri
analysi
exhal
breath
reveal
patient
advanc
fibrosi
significantli
lower
valu
compar
without
advanc
fibrosi
min
min
respect
min
min
patient
patient
level
respect
sensit
specif
posit
predict
valu
neg
predict
valu
breath
test
min
min
use
new
cutoff
valu
compar
standard
valu
shown
tabl
auroc
use
diagnosi
advanc
fibrosi
breath
test
min
min
ci
respect
conclus
aminopyrin
breath
test
potenti
biomark
advanc
fibrosi
warrant
valid
breath
test
good
neg
test
detect
nonsever
fibrosi
new
cutoff
min
min
background
despit
advanc
therapi
chronic
hepat
c
chc
remain
import
worldwid
public
health
problem
aim
studi
extern
valid
longitudin
predict
model
konerman
hepatolog
risk
advers
clinic
outcom
deriv
cohort
advanc
chc
among
patient
pt
earli
advanc
stage
chc
method
adult
chc
seen
hepatolog
clinic
retrospect
analyz
pt
hepat
decompens
hepatocellular
carcinoma
hcc
liver
transplant
lt
hepat
b
hiv
coinfect
present
exclud
pt
followup
also
exclud
outcom
includ
hepat
decompens
hcc
lt
free
surviv
machin
learn
method
use
predict
outcom
year
result
cohort
pt
mean
age
male
white
genotyp
present
treatment
cirrhosi
pt
develop
outcom
median
follow
year
interquartil
rang
area
receiv
oper
characterist
curv
auroc
year
risk
predict
composit
clinic
outcom
decompens
hcc
lt
liverrel
death
ci
ci
model
perform
retain
account
achiev
sustain
virolog
respons
baselin
cirrhosi
model
accur
assess
transplant
free
surviv
hcc
figur
mean
aspart
aminotransferas
platelet
ratio
index
mean
maximum
baselin
platelet
count
mean
albumin
contribut
significantli
risk
predict
conclus
accur
assess
risk
clinic
outcom
among
pt
chc
obtain
use
routin
collect
longitudin
data
model
retain
accuraci
across
pt
minim
fibrosi
baselin
differ
treatment
exposur
vari
genotyp
given
worldwid
burden
chc
model
convey
use
prognost
inform
mitochondria
provid
energi
eukaryot
cell
via
oxid
phosphoryl
regul
cellular
surviv
via
control
apoptosi
mutat
mitochondri
dna
mtdna
relat
mani
human
diseas
mtdna
mutat
acquir
throughout
human
histori
natur
select
allow
subdivid
human
popul
number
discret
mitochondri
clade
haplogroup
defin
basi
specif
mtdna
polymorph
european
mtdna
haplogroup
found
influenc
liver
fibrosi
progress
hivhcvcoinfect
patient
aid
aim
studi
assess
relationship
mtdna
haplogroup
liverrel
event
lre
hivhcvcoinfect
patient
method
studi
clinic
characterist
outcom
hivhcvcoinfect
patient
baselin
liver
biopsi
simultan
blood
serum
sampl
follow
median
month
year
primari
endpoint
occurr
lre
defin
decompens
hepatocellular
carcinoma
whichev
occur
first
mtdna
genotyp
perform
sequenom
massarray
platform
univari
multivari
fine
gray
proport
hazard
regress
take
account
death
compet
risk
use
test
associ
mtdna
haplogroup
lre
variabl
adjust
alcohol
intak
score
sustain
viral
respons
svr
result
followup
patient
treat
interferon
ribavirin
achiev
svr
total
patient
lre
patient
die
patient
patient
mtdna
haplogroup
h
lre
wherea
patient
haplogroup
lre
haplogroup
h
associ
lower
hazard
lre
univari
analysi
subhazard
ratio
shr
multivari
analysi
adjust
shr
ashr
wherea
haplogroup
associ
signific
higher
hazard
lre
univari
analysi
multivari
analysi
conclus
mtdna
haplogroup
associ
increas
hazard
lre
wherea
haplogroup
h
associ
reduc
hazard
lre
result
suggest
mtdna
haplogroup
background
individu
infect
hepat
c
viru
hcv
spontan
clear
infect
risk
reinfect
data
spontan
clearanc
hcv
reinfect
reclear
particularli
reinfect
heterolog
genotyp
human
limit
examin
hcv
reclear
larg
populationbas
cohort
british
columbia
canada
method
analysi
use
data
bc
hepat
tester
cohort
includ
individu
test
hcv
link
data
medic
visit
hospit
prescript
drug
identifi
peopl
hcv
reinfect
underw
follow
hcvrna
test
clear
first
infect
spontan
achiev
sustain
virolog
respons
svr
treatment
examin
hcv
reclear
multivari
cox
proport
hazard
model
use
identifi
potenti
predictor
reclear
result
half
particip
spontan
clear
reinfect
incid
rate
confid
interv
ci
per
personyear
py
proport
incid
rate
reclear
per
py
spontan
clear
first
infect
proport
rate
twice
achiev
svr
treatment
proport
rate
adjust
analysi
likelihood
hcv
reclear
higher
among
spontan
clear
first
infect
compar
achiev
svr
adjust
hazard
ratio
ahr
ci
lower
reinfect
heterolog
hcv
genotyp
ahr
ci
conclus
abil
spontan
clear
first
infect
markedli
increas
likelihood
clear
subsequ
infect
confer
protect
heterolog
viru
mel
krajden
grantresearch
support
roch
merck
siemen
boerhing
ingelheim
holog
follow
peopl
noth
disclos
nazrul
islam
jeanni
shovel
paul
gustafson
mark
gilbert
jason
wong
mark
tyndal
nave
z
janjua
costeffect
screen
strategi
hepat
c
franc
time
chang
recommend
sylvi
deufficburban
alexandr
huneau
adelin
verleen
brouard
josian
pillonel
yann
le
strat
sabrina
cossai
valeri
canvadelcambr
philipp
mathurin
daniel
dhumeaux
yazdan
yazdanpanah
inserm
iam
univ
pari
diderot
sorbonn
pari
pari
franc
univ
lill
inserm
chu
lill
lill
franc
de
maladi
infectieus
publiqu
franc
saint
mauric
franc
servic
publiqu
henri
mondor
franc
servic
de
maladi
de
lappareil
digestif
et
de
la
nutrit
huriez
chru
lill
lill
franc
inserm
franc
servic
de
maladi
infectieus
et
tropical
bichat
claud
bernard
pari
franc
franc
recommend
hepat
c
viru
hcv
screen
still
target
peopl
high
risk
infect
infectedperson
remain
unawar
statu
context
highli
effect
toler
therapi
recommend
patient
near
futur
reassess
hcv
screen
strategi
need
costeffect
studi
conduct
french
gener
popul
age
year
undiagnos
chronic
hepat
c
chc
markov
model
simul
life
expect
discount
qualiti
adjust
life
year
qali
direct
lifetim
discount
cost
increment
costeffect
ratio
icer
differ
strategi
death
strategi
target
risk
popul
studi
popul
effect
screen
risk
popul
risk
men
year
peopl
year
peopl
year
peopl
year
assum
reach
target
agecohort
popul
chc
diagnos
treatment
initi
regardless
fibrosi
either
least
expens
treatment
combin
reli
publish
literatur
nation
preval
survey
characterist
undiagnos
person
term
fibrosi
accord
gender
age
alcohol
consumpt
time
screen
obtain
previous
publish
mathemat
model
whatev
treatment
combin
tabl
consid
treatment
compar
current
screen
strategi
ad
men
age
year
associ
lowest
icer
target
peopl
age
effect
target
men
age
year
remain
costeffect
univers
screen
even
effect
target
peopl
remain
costeffect
franc
although
univers
screen
associ
highest
cost
effect
strategi
costeffect
treatment
initi
regardless
fibrosi
background
risk
hepatocellular
carcinoma
hcc
peopl
spontan
clear
hcv
infect
sc
achiev
treatmentbas
svr
rxsvr
fail
treatment
rxfail
untreat
chronic
hcv
norx
well
establish
evalu
hcc
risk
patient
group
use
bc
hepat
tester
cohort
bchtc
method
bchtc
includ
million
individu
test
hcv
hiv
report
case
hbv
hcv
hiv
activ
tb
link
medic
visit
hospit
cancer
prescript
drug
mortal
cumul
incid
function
multivari
cox
proport
hazard
model
use
examin
hcc
risk
four
hcv
group
sc
rxsvr
rxfail
norx
result
elig
individu
sc
treat
rxsvr
rxfail
chronic
hcv
norx
four
group
follow
median
iqr
year
sc
rxsvr
rxfail
norx
rxfail
group
higher
level
cirrhosi
vs
diabet
vs
group
annual
hcc
incid
rate
per
personyr
py
sc
rxsvr
rxfail
norx
hcc
incid
rate
higher
among
cirrhosi
group
multivari
model
compar
norx
sc
hazard
ratio
hr
rxsvr
associ
reduc
hcc
risk
rxfail
higher
hcc
risk
expect
cirrhosi
older
age
yr
yr
compar
yr
male
sex
ci
genotyp
vs
infect
ci
problemat
alcohol
use
ci
increas
adjust
hcc
risk
conclus
expect
hcc
risk
sc
low
rxfail
group
highest
hcc
risk
like
reflect
poorer
prognost
profil
treatment
initi
highlight
limit
hcc
prevent
benefit
treat
later
stage
diseas
older
interferonbas
regimen
even
svr
achiev
higher
hcc
risk
rxsvr
compar
sc
suggest
earlier
hcv
treatment
requir
achiev
risk
reduct
observ
sc
background
hepat
c
viru
hcv
infect
system
diseas
associ
hepat
extrahepat
manifest
ehm
diseas
burden
associ
hepat
manifest
hcv
well
document
howev
econom
impact
ehm
hcv
outsid
unit
state
remain
unknown
object
estim
annual
direct
medic
cost
associ
ehm
hcv
franc
method
previous
valid
econom
model
use
estim
annual
direct
medic
cost
associ
ehm
hcv
preval
nine
ehm
mix
type
cryoglobulinemia
vascul
chronic
kidney
diseas
type
diabet
mellitu
dm
lymphoma
lichen
planu
sjogren
syndrom
porphyria
cutanea
tarda
rheumatoidlik
arthriti
depress
obtain
recent
systemat
review
metaanalysi
younossi
et
al
perpatientperyear
pppi
inpati
outpati
medic
cost
treat
ehm
franc
obtain
literatur
french
medicoadministr
databas
pmsi
expert
opinion
unavail
otherwis
prescript
drug
cost
taken
vidal
websit
cost
adjust
euro
overal
nation
direct
medic
cost
associ
ehm
hcv
calcul
multipli
total
pppi
cost
ehm
respect
preval
rate
size
hcvinfect
popul
franc
inse
corinn
pioch
sensit
analysi
perform
consid
confid
interv
report
younossi
et
al
result
individu
estim
infect
hcv
franc
mean
averag
pppi
cost
ehm
total
annual
direct
medic
cost
associ
care
patient
ehm
hcv
purpos
examin
outcom
along
hcv
care
cascad
among
popul
babi
boomer
screen
hcv
infect
academ
primari
care
set
target
underserv
individu
method
tiltc
program
fund
cdc
implement
babi
boomer
screen
linkag
care
gradi
memori
hospit
primari
care
center
atlanta
ga
usa
twenti
month
complet
screen
program
evalu
record
patient
screen
posit
hcv
antibodi
outcom
report
subset
chronic
hcv
infect
includ
type
initi
linkag
care
number
followup
visit
number
refer
antivir
treatment
reason
nontreat
number
achiev
rapid
virolog
respons
rvr
end
treatment
respons
etr
sustain
virolog
respons
week
complet
therapi
result
birth
cohort
popul
african
american
uninsur
patient
screen
hcv
antibodi
hcv
rna
test
complet
antibodyposit
patient
virem
virem
patient
initi
linkag
care
visit
onsit
primari
carebas
hcv
clinic
infecti
diseas
clinic
primari
care
clinic
subsequ
patient
attend
second
specialti
visit
third
visit
fourth
fifth
eightytwo
patient
refer
direct
act
antivir
daa
treatment
reason
nontreat
includ
lack
advanc
fibrosi
lost
followup
await
newer
medic
substanc
abus
among
patient
result
avail
initi
daa
therapi
achiev
rvr
achiev
etr
achiev
conclus
result
show
follow
highli
success
hcv
screen
linkag
care
program
remain
signific
drop
along
later
stage
hcv
care
cascad
result
suboptim
number
patient
initi
daa
therapi
despit
fact
excel
outcom
achiev
patient
initi
therapi
find
lost
follow
signific
contributor
nontreat
suggest
intervent
focus
maintain
patient
care
patient
navig
case
manag
could
improv
treatment
uptak
underserv
popul
high
hcv
preval
disclosur
background
aim
new
treatment
allow
increas
number
patient
cure
chronic
hepat
c
viru
hcv
infect
anecdot
mani
patient
complain
sustain
virolog
respons
svr
accompani
weight
gain
aim
studi
analyz
weight
chang
factor
associ
weight
chang
patient
cure
hcv
treatment
sofosbuvir
sof
ledipasvir
ldv
method
data
collect
patient
treat
sofldv
achiev
svr
bodi
weight
measur
record
baselin
within
eight
week
start
treatment
within
four
week
svr
patient
without
document
weight
diuret
furosemid
spironolacton
signific
ascit
andor
comorbid
like
caus
weight
chang
e
g
malign
exclud
cirrhosi
determin
diagnost
code
diabet
defin
hemoglobin
obes
bodi
mass
index
bmi
weight
chang
analyz
pair
ttest
two
interv
baselin
svr
baselin
end
follow
day
baselin
result
patient
patient
male
mean
age
yr
mean
weight
chang
baselin
svr
pound
lb
p
baselin
svr
patient
gain
weight
lost
weight
remain
within
lb
baselin
mean
gain
lb
mean
loss
lb
sixti
patient
gain
lb
gain
lb
lost
lb
diabet
patient
n
gain
significantli
weight
lb
nondiabet
n
lb
p
statist
signific
differ
weight
chang
male
femal
p
patient
without
cirrhosi
p
patient
without
obes
p
patient
treatment
less
week
p
pretreat
albumin
total
cholesterol
ldl
hdl
triglycerid
differ
significantli
patient
gain
weight
lost
weight
among
patient
second
postsvr
weight
measur
mean
chang
lb
p
conclus
patient
achiev
svr
sof
ldv
treatment
gain
weight
gain
entir
group
modest
lb
greater
diabet
lb
weight
increas
continu
follow
prevent
excess
weight
gain
patient
receiv
hcv
treatment
especi
diabet
may
benefit
advic
diet
exercis
da
dk
background
aim
interferon
ifn
free
direct
antivir
agent
daa
effect
erad
hepat
c
virus
hcv
rapidli
improv
liver
residu
function
howev
whether
ifnfre
daa
prevent
hcc
primarili
secondarili
still
unknown
chronic
hepat
c
chc
caus
dysregul
iron
metabol
lead
moder
iron
overload
featur
hyperferritinemia
iron
overload
also
suspect
one
factor
favor
hcvrelat
hepatocellular
carcinoma
hcc
howev
whether
ifnfre
daa
normal
hcvrelat
hyperferritinemia
may
ferritin
possibl
predict
factor
hcc
undergo
daa
yet
elucid
method
commit
institut
review
board
prior
inform
consent
genotyp
chc
patient
undergo
ifnfre
daa
daclatasvir
asunaprevir
sofosbuvir
ledipasvir
recruit
laboratori
data
day
pre
end
treatment
eot
analyz
patient
activ
bleed
iron
supplement
endstag
renal
diseas
women
menopaus
exclud
analysi
hcc
surveil
patient
follow
accord
guidelin
aasldidsa
hcc
identifi
eot
within
month
defin
earli
emerg
result
eight
case
earli
posttreat
hcc
emerg
notic
eot
serum
ferritin
decreas
significantli
iul
vs
iul
p
signific
decreas
also
notic
adjust
gender
age
chang
rate
serum
ferritin
compar
pretreat
valu
correl
significantli
chang
rate
alt
p
type
collagen
p
ldl
p
albumin
p
p
tend
correl
chang
rate
alphafetoprotein
afp
p
case
earli
posttreat
emerg
hcc
significantli
lower
vs
p
multivari
analysi
along
hcc
past
histori
p
auc
cutoff
valu
reduct
signific
predict
factor
earli
postdaa
emerg
hcc
conclus
hyperferritinemia
normal
rapidli
ifnfre
daa
accord
hcv
erad
improv
clinic
marker
hepat
injuri
hepat
stellat
cell
activ
lipid
protein
metabol
one
independ
signific
predict
factor
earli
hcc
emerg
ifnfre
daa
sinc
obes
excess
alcohol
intak
may
also
caus
hyperferritinemia
serum
ferritin
might
use
collect
predict
marker
hcc
patient
achiev
svr
ifnfre
daa
disclosur
follow
peopl
noth
disclos
posung
chu
nobuhiro
nakamoto
aya
ugamura
hirotoshi
ebinuma
hidetsugu
saito
takanori
kanai
serum
metabolom
analysi
hcvinfect
patient
success
treat
ifnfre
daa
regimen
hcv
infect
million
subject
worldwid
viru
high
propens
persist
host
lead
cirrhosi
liver
cancer
metabolom
studi
metabol
chang
biolog
system
may
identifi
specif
profil
associ
subtl
alter
induc
diseas
studi
avail
metabolit
chang
liver
injuri
sinc
none
focus
hcvinfect
patient
reach
svr
follow
treatment
direct
act
antivir
daa
aim
studi
perform
serum
metabolom
analysi
set
sera
collect
hcv
patient
men
mean
age
success
undergo
differ
ifnfre
daa
regimen
therapi
baselin
posttreat
week
hcv
genotyp
metavir
score
indic
score
patient
remain
also
analyz
small
group
sera
healthi
subject
order
local
pl
plot
respect
baselin
preliminari
neg
control
group
sampl
analyz
use
proton
nuclear
magnet
reson
spectroscopi
hnmr
partial
least
squar
pl
canon
analysi
ca
appli
demonstr
signific
pairwis
discrimin
accuraci
two
timepoint
patient
highlight
metabol
shift
sever
metabolit
unequivoc
assign
e
amino
acid
organ
acid
creatin
creatinin
lactat
cholin
differ
compar
baselin
baselin
featur
higher
level
format
acet
p
methionin
higher
p
preliminari
analysi
reveal
also
progress
near
healthi
fingerprint
serum
metabolom
analysi
preand
posttreat
sampl
show
remark
profil
chang
baselin
found
variat
opposit
direct
format
produc
adult
hepatocyt
methionin
metabolit
take
part
biochem
way
e
glucos
metabol
also
involv
acet
amino
acid
go
synthesi
folat
alter
could
impli
metabol
impair
previous
observ
chronic
infect
hcvpatient
also
sinc
methionin
major
sourc
methyl
group
understand
variat
could
reveal
import
dysfunct
liver
essenti
pathway
requir
methyl
e
epigenet
regul
dna
hcvrelat
chronic
infect
follow
peopl
noth
disclos
giorgia
ceccotti
gaia
meoni
leonardo
tenori
laura
gragnani
elisa
fognani
elena
gianni
claudio
luchinat
anna
linda
zignego
background
aim
amino
acid
mutat
posit
hcv
core
protein
associ
increas
risk
hepatocellular
carcinoma
hcc
asian
patient
infect
hcv
first
time
studi
evalu
prognost
signific
mutat
unit
state
popul
method
hcv
quasispeci
baselin
serum
sampl
patient
chronic
hcv
infect
enrol
haltc
trial
investig
use
miseq
deep
sequenc
relationship
percentag
quasispeci
mutat
posit
incid
hcc
evalu
receiv
oper
characterist
roc
kaplanmei
multivari
cox
regress
analys
result
roc
analysi
quasispeci
percentag
cutpoint
nonarginin
posit
nonr
nonleucin
posit
nonl
optim
sensit
discern
higher
lower
hcc
risk
baselin
quasispeci
patient
later
develop
hcc
median
followup
year
rang
nonr
wherea
match
control
remain
hccfree
median
followup
year
rang
nonr
fisher
exact
probabl
test
baselin
quasispeci
patient
develop
hcc
nonl
wherea
match
control
nonl
kaplanmei
analysi
hcc
incid
higher
among
patient
baselin
nonr
differ
signific
significantli
lower
among
patient
baselin
nonl
addit
cox
regress
model
increas
hcc
risk
associ
presenc
nonr
quasispeci
baselin
hazzard
ratio
hr
confid
interv
ci
higher
astalt
ratio
higher
alkalin
phosphatas
p
greater
number
white
blood
cell
associ
reduc
hcc
risk
ci
conclus
pilot
studi
unit
state
patient
add
previou
evid
hcv
core
protein
mutat
associ
hcc
risk
indic
potenti
util
hcv
quasispeci
analysi
noninvas
biomark
hcc
risk
detect
linkag
care
howev
awar
hcv
screen
guidelin
may
lack
especi
among
urban
safetynet
popul
high
preval
socioeconom
disadvantag
nonenglish
speak
minor
aim
evalu
rate
hcv
screen
hcv
awar
among
patient
high
risk
chronic
hcv
divers
safetynet
hospit
method
prospect
cohort
studi
consecut
adult
undergo
outpati
endoscopi
juli
evalu
hcv
screen
rate
among
high
risk
patient
base
u
prevent
servic
task
forc
guidelin
focu
birth
cohort
riskbas
histori
drug
use
incarcer
blood
transfus
prior
factor
awar
prior
hcv
result
rate
accept
hcv
test
evalu
chisquar
test
multivari
logist
regress
result
among
patient
high
risk
chronic
hcv
male
birth
cohort
histori
drug
use
histori
incarcer
blood
transfus
hiv
among
cohort
receiv
prior
hcv
test
among
awar
test
result
hcv
posit
patient
like
hcv
neg
patient
awar
result
vs
p
among
high
risk
patient
offer
hcv
test
accept
compar
nonhispan
white
black
asian
hispan
like
accept
test
p
nonenglish
speak
patient
like
accept
test
vs
p
patient
born
patient
born
less
like
accept
test
vs
multivari
regress
black
asian
hispan
significantli
like
accept
hcv
test
compar
nonhispan
white
tabl
conclus
among
adult
present
outpati
endoscopi
urban
safetynet
hospit
high
risk
hcv
receiv
prior
test
receiv
prior
test
awar
result
lower
rate
test
accept
among
birth
cohort
concern
given
higher
risk
among
group
disclosur
robert
j
wong
advisori
committe
review
panel
gilead
grant
research
support
gilead
follow
peopl
noth
disclos
brendan
campbel
yael
bogler
rachel
baden
taft
bhuket
benni
liu
assess
risk
acut
kidney
injuri
associ
exposur
sofosbuvircontain
hcv
treatment
regimen
hcv
infect
laura
telep
andrea
brown
diana
brainard
anand
p
chokkalingam
epidemiolog
gilead
scienc
inc
foster
citi
ca
background
relationship
chronic
kidney
diseas
hepat
c
viru
hcv
infect
well
describ
less
known
acut
kidney
injuri
aki
hcvinfect
popul
addit
directact
antivir
sofosbuvir
sof
wide
use
treatment
hcv
object
cohort
studi
character
rate
aki
hcvinfect
patient
versu
patient
without
hcv
examin
rate
exposur
sofcontain
nonsof
contain
treatment
regimen
method
adult
patient
evid
hcv
infect
identifi
larg
us
administr
medic
claim
databas
claim
incur
januari
march
data
patient
compar
random
sampl
adult
patient
without
evid
hcv
infect
databas
valid
administr
claim
code
use
determin
first
diagnosi
aki
includ
patient
least
month
continu
enrol
medic
plan
prior
cohort
entri
prior
akirel
claim
absolut
rate
correspond
exact
poisson
confid
interv
ci
determin
group
adjust
incid
rate
ratio
irr
determin
use
poisson
regress
result
among
identifi
hcv
patient
absolut
aki
rate
per
personyear
py
ci
versu
per
py
ci
nonhcv
popul
aki
rate
higher
among
patient
concomit
cirrhosi
concomit
endstag
liver
diseas
liver
transplant
per
py
respect
adjust
age
sex
baselin
covari
includ
renal
insuffici
cirrhosi
hcv
infect
found
associ
approxim
increas
risk
aki
ci
p
among
hcvinfect
patient
receiv
treatment
absolut
aki
rate
exposur
sofcontain
regimen
per
py
ci
rate
exposur
altern
treatment
per
py
ci
adjust
age
sex
baselin
covari
includ
renal
insuffici
cirrhosi
exposur
sofcontain
regimen
associ
nonsignific
reduc
risk
treatmentemerg
aki
event
ci
conclus
result
realworld
observ
studi
indic
hcv
infect
independ
associ
increas
risk
aki
independ
associ
exposur
sof
risk
treatmentemerg
aki
result
confirm
futur
investig
chronolog
chang
hepatocellular
carcinoma
develop
patient
chronic
hepat
c
success
viru
erad
takuya
genda
ayato
murata
nozomi
amano
sho
sato
hironori
tsuzura
shunsuk
sato
yutaka
narita
yoshio
kanemitsu
yuji
shimada
katsuyori
iijima
akihito
nagahara
sumio
watanab
gastroenterolog
hepatolog
juntendo
univers
shizuoka
hospit
izunokuni
japan
background
aim
histolog
hepat
fibrosi
import
predict
factor
hepatocellular
carcinoma
hcc
develop
patient
chronic
hepat
c
chc
howev
owe
invas
natur
liver
biopsi
sever
altern
fibrosi
marker
propos
index
combin
standard
biochem
valu
age
recogn
simpl
reliabl
altern
liver
biopsi
assess
hepat
fibrosi
also
use
predict
marker
hcc
develop
recent
advanc
antivir
treatment
improv
rate
sustain
virolog
respons
svr
patient
chc
howev
risk
hcc
develop
persist
even
patient
achiev
svr
achiev
svr
result
alter
standard
biochem
valu
patient
chang
associ
hcc
develop
svr
fulli
clarifi
method
studi
includ
chc
patient
receiv
interferonbas
antivir
therapi
achiev
svr
estim
immedi
treatment
week
end
treatment
last
laboratori
examin
followup
last
visit
multivari
cox
proport
hazard
analysi
use
estim
hazard
ratio
hr
variabl
hcc
develop
cumul
incid
hcc
develop
evalu
use
kaplanmei
plot
analysi
logrank
test
result
median
followup
time
year
rang
year
patient
develop
hcc
median
valu
pretreat
last
visit
respect
valu
time
point
significantli
differ
one
anoth
p
time
point
patient
develop
hcc
significantli
higher
develop
hcc
area
receiv
oper
characterist
curv
indic
pretreat
predict
hcc
develop
high
diagnost
accuraci
superior
predict
valu
last
visit
multivari
cox
proport
hazard
analysi
demonstr
pretreat
significantli
associ
hcc
develop
hr
p
cutoff
valu
pretreat
identifi
cumul
incid
hcc
develop
respect
p
conclus
although
decreas
time
patient
high
pretreat
remain
high
risk
hcc
develop
achiev
svr
disclosur
follow
peopl
noth
disclos
takuya
genda
ayato
murata
nozomi
amano
sho
sato
hironori
tsuzura
shunsuk
sato
yutaka
narita
yoshio
kanemitsu
yuji
shimada
katsuyori
iijima
akihito
nagahara
sumio
watanab
increas
incid
hepat
c
viru
among
hivinfect
men
sex
men
san
diego
retrospect
cohort
analysi
antoin
chaillon
thoma
c
martin
background
intern
report
hepat
c
viru
hcv
epidem
among
hivposit
men
sex
men
hiv
msm
associ
recreat
drug
use
sex
caus
concern
howev
littl
known
hcv
epidem
among
msm
san
diego
assess
incid
hcv
among
hiv
msm
san
diego
method
perform
retrospect
cohort
analysi
hcv
incid
among
hiv
msm
attend
largest
hiv
clinic
san
diego
ucsd
owen
clinic
incid
hcv
infect
assess
among
hiv
msm
baselin
neg
antihcv
test
incid
infect
defin
new
posit
antihcv
hcvrna
test
start
followup
incid
calcul
use
surviv
time
method
result
among
baselin
neg
patient
hcv
seroconvers
occur
personyear
risk
incid
rate
personyear
ci
hcv
incid
increas
time
figur
trend
test
individu
test
median
time
interquartil
rang
iqr
median
test
interv
incid
case
averag
year
age
year
hiv
diagnosi
hcv
diagnosi
year
first
hcv
neg
test
hcv
diagnosi
msm
report
ever
inject
drug
use
hcv
incid
significantli
higher
p
among
msm
report
idu
ci
compar
report
idu
ci
signific
differ
test
rate
conclus
hcv
incid
among
hivposit
msm
san
diego
increas
rate
similar
london
major
european
citi
doubl
observ
us
multicent
aid
cohort
studi
studi
also
document
hcv
infect
among
hiv
msm
inject
drug
work
determin
epidem
trajectori
prevent
requir
control
epidem
need
adher
hcv
birth
cohort
screen
guidelin
primari
care
subspecialti
physician
integr
healthcar
system
amoah
yeboahkorang
mohammad
beig
jay
l
goldstein
amnon
sonnenberg
clau
fimmel
gastroenterolog
chicago
il
oregon
health
scienc
univers
portland
purpos
despit
cdc
uspstf
recommend
patient
born
receiv
onetim
hcv
antibodi
test
major
us
babi
boomer
screen
date
indic
gap
implement
guidelin
primari
aim
studi
compar
hcv
screen
rate
primari
care
subspecialti
clinic
patient
integr
healthcar
system
compris
babi
boomer
method
identifi
babi
boomer
present
least
one
outpati
visit
intern
famili
medicin
gynecolog
subspecialti
clinic
northshor
univers
healthsystem
juli
patient
electron
medic
record
emr
search
hcv
antibodi
test
result
date
back
frequenc
hcv
antibodi
test
stratifi
age
gender
prior
histori
hcv
infect
provid
specialti
influenc
patient
physician
characterist
frequenc
test
analyz
use
multivari
logist
regress
result
patient
met
hcv
screen
criteria
onemonth
sampl
period
undergon
hcv
antibodi
test
nineti
screen
patient
hcv
antibodyposit
patient
underw
follow
hcv
rna
test
hcvrna
detect
antibodyposit
patient
hcv
test
slightli
less
common
men
women
significantli
common
patient
younger
vs
older
age
vs
respect
highest
hcv
screen
rate
observ
gynecolog
clinic
patient
follow
intern
medicin
famili
medicin
subspecialti
includ
gastroenterolog
multivari
analysi
characterist
except
gender
exert
independ
statist
signific
influenc
hcv
antibodi
test
among
patient
posit
hcv
antibodi
test
result
rate
hcv
rna
test
affect
physician
specialti
patient
characterist
conclus
overal
observ
low
adher
hcv
birth
cohort
screen
guidelin
among
differ
outpati
set
integr
healthcar
system
emrdocu
hcv
antibodi
test
result
found
elig
patient
patient
younger
age
like
test
older
patient
signific
variabl
differ
specialti
clinic
screen
rate
vari
studi
identifi
opportun
increas
hcv
antibodi
screen
effort
could
incorpor
ageand
clinicspecif
practic
pattern
hcv
independ
predictor
hospit
readmiss
inmat
background
understand
burden
hcvrelat
hospit
inmat
import
make
ration
polici
hcv
treatment
prison
compar
hospit
length
stay
readmiss
hcv
infect
statu
among
inmat
method
lemuel
shattuck
hospit
lsh
provid
inpati
medic
servic
inmat
use
bill
record
develop
databas
inmat
discharg
lsh
data
collect
includ
age
race
gender
date
admiss
discharg
length
stay
lo
report
code
disposit
hospit
die
back
prison
anoth
hospit
identifi
hcvinfect
individu
use
hcvassoci
code
compar
hcvinfect
uninfect
individu
primari
outcom
lo
odd
readmiss
lsh
logist
regress
adjust
confound
age
sex
race
lo
first
admiss
comorbid
elixhaus
index
result
inmat
contribut
total
discharg
inmat
male
white
median
age
first
hospit
yr
iqr
hcv
code
associ
hospit
median
lo
day
iqr
inmat
hcv
older
vs
p
longer
mean
lo
day
vs
day
p
multivari
model
hcv
remain
associ
increas
odd
readmiss
conclus
hcvinfect
associ
inmat
admiss
increas
lo
increas
odd
readmiss
hospit
treatment
may
avert
observ
increas
hospit
hcv
associ
mani
admiss
modest
reduct
hospit
util
svr
could
help
offset
treatment
cost
factor
associ
readmiss
inmat
n
elixhaus
index
variabl
use
multivari
model
hiv
liver
diseas
remov
index
follow
peopl
noth
disclos
alyss
g
wurcel
introduct
although
highest
european
screen
rate
franc
patient
nt
take
care
hepat
c
diagnos
drug
inject
main
contamin
rout
hepat
c
viru
hcv
franc
western
europ
sinc
french
guidelin
treat
inmat
drug
user
even
fibrosi
level
access
hcv
screen
care
treatment
drug
user
prison
homeless
low
franc
less
consid
difficult
treat
popul
patient
need
support
especi
psychoeduc
intervent
hepat
mobil
team
hmt
creat
juli
increas
screen
care
treatment
hepat
b
c
patient
propos
servic
screen
dri
blood
spot
db
hiv
hbv
hcv
mobil
fibroscan
differ
site
social
screen
diagnosi
epic
score
outreach
center
specif
health
care
worker
free
blood
test
primari
care
social
insur
advanc
onsit
specialist
consult
access
obligatori
pretreat
commiss
individu
psychoeduc
session
collect
educ
workshop
staff
train
drug
user
prevent
peer
peer
program
low
cost
specif
patient
mobil
phone
specif
one
day
hospit
antivir
treatment
green
thread
outsid
db
fibroscan
specif
convert
truck
object
increas
screen
care
treatment
access
cure
target
popul
patient
method
target
popul
drug
user
prison
homeless
precari
peopl
migrant
psychiatr
patient
propos
part
servic
medic
social
partner
choos
servic
need
result
juli
decemb
db
peopl
hcv
db
hcv
activ
file
patient
includ
new
patient
screen
db
realiz
blood
test
fibroscan
need
treatment
accord
french
recommend
start
treatment
cure
qualiti
program
patient
free
access
close
outsid
hospit
speed
result
avail
nurs
social
worker
conclus
specif
screen
follow
support
difficult
treat
popul
essenti
increas
medic
manag
cure
hcv
patient
hmt
offer
complement
servic
substitut
exist
servic
new
use
tool
screen
diagnosi
treat
patient
outsid
pathway
care
predict
hepatocellular
carcinoma
develop
overal
surviv
chronic
hepat
c
use
liver
stiff
measur
longterm
outcom
studi
ryo
nakagomi
ryosuk
tateishi
ryota
masuzaki
taijiro
wake
mizuki
nishibatak
naoto
fujiwara
masaya
sato
tatsuya
minami
kenichiro
enooku
hayato
nakagawa
yoshinari
asaoka
yuji
kondo
kazuhiko
koik
depart
gastroenterolog
graduat
school
medicin
univers
tokyo
tokyo
japan
background
aim
evalu
util
liver
stiff
measur
predict
hepatocellular
carcinoma
hcc
develop
surviv
chronic
hepat
c
patient
method
enrol
patient
liver
stiff
measur
use
author
hospit
decemb
decemb
exclud
patient
alreadi
achiev
sustain
virolog
respons
svr
initi
liver
stiff
measur
assess
hcc
develop
overal
surviv
base
liver
stiff
use
kaplanmei
method
result
patient
consist
male
femal
median
age
liver
stiff
enrol
kpa
kpa
kpa
respect
mean
followup
period
year
hcc
develop
patient
cumul
incid
rate
hcc
year
respect
cumul
hcc
incid
rate
year
kpa
kpa
respect
p
studi
period
patient
die
caus
death
liver
cancer
liver
failur
gastrointestin
bleed
other
overal
surviv
rate
year
respect
tenyear
surviv
rate
kpa
kpa
respect
p
conclus
liver
stiff
predict
longterm
outcom
year
chronic
hepat
c
patient
ryosuk
tateishi
grantresearch
support
kyowa
hakko
kirin
co
ltd
speak
teach
taisho
pharmaceut
co
ltd
bayer
yakuhi
ltd
otsuka
pharmaceut
co
ltd
astrazeneca
k
k
eisai
co
ltd
gilead
scienc
co
ltd
msd
k
k
sumitomo
dinippon
pharma
co
ltd
covidien
japan
inc
purpos
georgia
first
countri
world
adopt
nation
hcv
elimin
goal
set
abstract
present
result
georgia
first
nation
repres
hepat
c
viru
hcv
seropreval
survey
use
monitor
progress
toward
hcv
elimin
method
crosssect
nation
repres
seropreval
survey
individu
age
year
conduct
georgia
mayaugust
use
stratifi
multistag
cluster
design
give
inform
consent
particip
provid
epidemiolog
data
includ
demograph
medic
histori
knowledg
hcv
transmiss
prevent
method
hcvrelat
risk
factor
blood
specimen
collect
particip
test
antibodi
hcv
hcv
rna
data
weight
base
probabl
select
calibr
use
censu
data
sex
age
geographi
descript
statist
comput
result
nation
hcv
seropreval
ci
preval
chronic
hcv
infect
ci
seropreval
ci
capit
citi
tbilisi
ci
urban
area
overal
ci
rural
area
seropreval
highest
among
person
age
year
male
ci
person
report
histori
inject
drug
use
idu
ci
incarcer
ci
blood
transfus
georgia
began
test
donor
blood
hcv
ci
respect
major
respond
demonstr
knowledg
hcv
transmit
infect
blood
ci
share
needl
syring
ci
hcv
prevent
avoid
needl
share
ci
avoid
unsterileus
medic
devic
ci
less
half
seroposit
respond
awar
infect
report
initi
treatment
prior
avail
allor
introduct
increas
number
licens
directact
antivir
daa
treatment
chronic
hcv
infect
choos
right
treatment
regimen
right
patient
becom
paramount
believ
baselin
sequenc
presenc
resistanceassoci
substitut
ra
import
contributor
decisionmak
process
present
studi
irish
cohort
perform
retrospect
analysi
hcv
sampl
receiv
drug
resist
test
irish
nation
viru
refer
laboratori
septemb
may
particular
attent
paid
patient
experienc
virolog
failur
attempt
identifi
predictor
failur
method
sanger
sequenc
data
cover
hcv
proteas
code
region
obtain
sampl
receiv
studi
period
sequenc
data
region
sampl
also
obtain
singl
nucleotid
polymorph
site
examin
allel
discrimin
realtim
pcr
result
analysi
viral
sequenc
demonstr
hcv
subtyp
subtyp
subtyp
infect
ra
proven
reduc
suscept
inhibitor
treatment
detect
case
although
vast
major
ra
detect
found
subtyp
virus
subtyp
sampl
also
contain
one
ra
polymorph
found
hcv
subtyp
almost
exclus
clade
versu
clade
virus
among
cohort
patient
experienc
virolog
failur
whilst
treatment
ra
could
detect
patient
sequenc
could
gener
includ
major
patient
found
possess
deleteri
singl
nucleotid
polymorph
snp
site
within
gene
locu
nine
eleven
patient
detect
ra
found
also
either
ct
tt
one
patient
cc
snp
preliminari
data
patient
experienc
treatment
failur
inhibitor
also
indic
presenc
ra
individu
discuss
high
incid
ra
within
hcv
proteas
sequenc
detect
ra
sequenc
appar
risk
treatment
failur
albeit
small
number
patient
ra
present
highlight
import
sequenc
virus
prior
commenc
treatment
proteas
inhibitor
need
identifi
addit
predictor
failur
peter
va
medic
center
bronx
ny
dept
medicin
icahn
school
medicin
mount
sinai
new
york
ny
research
program
jame
j
peter
va
medic
center
bronx
ny
background
acut
hepat
c
viru
hcv
infect
patient
clear
infect
spontan
immunolog
mechan
spontan
clearanc
chronic
hcv
infect
without
antivir
therapi
describ
rare
case
report
frequenc
clearanc
unknown
influenc
hiv
coinfect
method
hcv
clinic
case
registri
singl
tertiari
care
facil
review
quantit
plasma
hcv
rna
level
measur
year
patient
least
one
hcv
rna
iuml
evid
acut
infect
includ
chronic
infect
case
spontan
clearanc
defin
least
one
hcv
rna
iuml
undetect
preced
least
one
hcv
rna
iuml
antivir
therapi
time
interv
measur
result
among
chronic
hcvinfect
patient
confid
interv
experienc
spontan
clearanc
five
patient
hivhcvcoinfect
suppress
hiv
rna
copiesml
antiretrovir
therapi
median
cell
count
rang
patient
hepat
b
viru
hcvcoinfect
hbsag
three
compens
cirrhosi
one
prior
liver
transplant
hcv
recurr
among
hivhcvcoinfect
patient
frequenc
spontan
clearanc
c
hcvmonoinfect
patient
rate
c
risk
ratio
spontan
hcv
clearanc
hivhcv
coinfect
hcv
monoinfect
c
rate
spontan
clearanc
chronic
hcv
genotyp
infect
c
c
c
risk
ratio
c
c
conclus
spontan
clearanc
chronic
hcv
infect
without
antivir
therapi
rare
occur
patient
clearanc
significantli
common
hivhcvcoinfect
hcvmonoinfect
patient
patient
compar
objectiveaim
major
hcv
posit
individu
england
peopl
inject
drug
pwid
poor
engag
health
servic
go
studi
assess
feasibl
noninvas
detect
stage
treatment
hcv
relat
chronic
liver
diseas
commun
method
fouryear
prospect
studi
dec
nov
conduct
larg
substanc
misus
servic
se
england
individu
offer
dri
blood
spot
test
dbst
mobil
transient
elastographi
te
hcv
treatment
includ
daa
qualit
interview
recent
addit
patient
report
outcom
sfldqol
health
econom
preval
posit
serolog
markerspcr
hbcab
hcv
antibodi
hcv
pcr
genotyp
logist
regress
independ
predictor
posit
hcv
serolog
ever
inject
posit
hbcab
ci
psychiatr
diagnosi
ci
posit
hcv
pcr
underw
te
mean
lsm
kpa
sd
lsm
kpa
cirrhosi
lsm
kpa
signific
associ
posit
hcv
serolog
lsm
kpa
lsm
posit
compar
lsm
p
none
prior
hcv
treatment
fortyeight
treatment
candid
chaotic
lifestyl
remain
commenc
treatment
characterist
treat
cohort
age
yr
sd
male
substancealcohol
use
undergo
te
genotyp
treatment
receiv
inf
rbv
daa
treatment
outcom
svreotr
nine
ongo
treatment
six
nr
includ
four
rr
twentytwo
pretreat
questionnair
done
conclus
preval
posit
hcv
serolog
marker
remain
high
pwid
might
explain
almost
preval
signific
hepat
fibrosi
complianc
difficult
engag
cohort
hcv
treatment
outcom
compar
secondari
care
go
prospect
studi
endors
success
novel
easi
replic
onestop
commun
base
hcv
treatment
model
onsit
mobil
te
role
primari
cell
immunodefici
hepat
b
spontan
clearanc
hepat
c
nazrul
islam
mel
krajden
mark
gilbert
paul
gustafson
mark
tyndal
nave
z
janjua
school
popul
public
health
univers
british
columbia
vancouv
bc
canada
british
columbia
centr
diseas
control
vancouv
bc
canada
depart
patholog
laboratori
medicin
univers
british
columbia
vancouv
bc
canada
ontario
hiv
treatment
network
toronto
canada
depart
statist
univers
british
columbia
vancouv
bc
canada
background
tcell
host
immun
respons
hepat
c
viru
hcv
suggest
play
import
role
determin
hcv
outcom
examin
populationbas
cohort
studi
concurr
hepat
b
hbv
infect
found
signific
predictor
spontan
clearanc
hcv
highrisk
popul
studi
examin
effect
two
along
factor
spontan
clearanc
hcv
populationbas
cohort
british
columbia
canada
method
bc
hepat
tester
cohort
bchtc
includ
individu
test
hcv
link
data
medic
visit
hospit
prescript
drug
hcv
posit
individu
least
one
valid
hcv
pcr
test
hcv
diagnosi
includ
studi
examin
factor
associ
spontan
clearanc
hcv
fit
multivari
logist
regress
full
sampl
cox
proport
hazard
model
seroconvert
e
hcv
neg
individu
subsequ
becam
hcv
posit
result
spontan
clearanc
observ
test
hcv
adjust
potenti
confound
odd
spontan
clearanc
hcv
lower
peopl
preexist
primari
tcell
immunodefici
adjust
odd
ratio
aor
ci
higher
femal
aor
ci
preexist
hbv
aor
ci
hcv
infect
aor
ci
compar
conclus
spontan
clearanc
lower
peopl
primari
tcell
immunodefici
higher
among
femal
preexist
hbv
hcv
infect
mel
krajden
grantresearch
support
roch
merck
siemen
boerhing
ingelheim
holog
follow
peopl
noth
disclos
nazrul
islam
mark
gilbert
paul
gustafson
mark
tyndal
nave
z
janjua
hepat
c
viru
exposur
infect
associ
risk
behaviour
two
maximumsecur
prison
new
south
wale
australia
scaleup
interferonfre
hcv
therapi
hcv
transmiss
prison
new
south
wale
australia
analysi
characteris
hcv
epidemiolog
risk
behaviour
among
prison
two
maximumsecur
prison
stopc
studi
method
data
analysi
includ
prison
enrol
two
maximumsecur
prison
octob
march
prison
age
elig
particip
enrol
particip
receiv
test
hcv
antibodiesrna
complet
detail
survey
includ
inject
behaviour
inject
behaviour
hcv
infect
exposur
statu
evalu
result
march
prison
enrol
prison
prison
b
median
age
year
median
durat
stay
current
prison
time
enrol
year
overal
hcv
antibodi
neg
ab
hcv
antibodi
positivehcv
rna
neg
abrna
includ
selfreport
previou
hcv
treatment
hcv
rna
posit
rna
inject
illicit
drug
current
imprison
report
rna
abrna
compar
ab
p
inject
previou
month
report
rna
abrna
compar
ab
p
among
inject
previou
month
report
share
inject
equip
conclus
high
proport
prison
hcv
infect
maximumsecur
prison
report
inject
risk
behaviour
among
prison
risk
hcv
previou
hcv
exposur
clearanc
like
report
high
risk
inject
previou
exposur
suggest
risk
reinfect
need
increas
prevent
activ
surveil
hcv
incid
focu
detect
hcv
reinfect
primari
infect
frankfurt
germani
background
regress
cirrhosi
portal
hypertens
pt
major
goal
treatment
patient
hepat
c
viru
hcv
associ
cirrhosi
improv
childpughturcott
cpt
model
end
stage
liver
diseas
meld
score
consist
observ
current
trial
investig
direct
antivir
agent
daa
base
treatment
hcv
associ
cirrhosi
howev
persist
pt
report
despit
sustain
virolog
respons
svr
improv
ctpmeldscor
current
studi
prospect
evalu
dynam
liver
spleen
stiff
patient
hcv
associ
cirrhosi
svr
daabas
antivir
treatment
method
total
patient
male
hcv
associ
cirrhosi
svr
daabas
antivir
treatment
includ
liver
spleen
stiff
assess
baselin
bl
end
treatment
eot
week
eot
transient
elastographi
liver
lte
well
acoust
radiat
forc
impuls
arfi
liver
larfi
spleen
sarfi
biochem
virolog
clinic
data
obtain
parallel
result
signific
reduct
liver
stiff
bl
median
rang
kpa
eot
median
rang
kpa
p
well
bl
median
rang
ms
spleen
stiff
assess
sarfi
decreas
significantli
b
eot
improv
liver
stiff
pronounc
bl
eot
eot
addit
signific
improv
meldscor
bl
median
rang
median
rang
observ
conclus
liver
spleen
elastographi
improv
significantli
patient
hcv
associ
cirrhosi
svr
daabas
antivir
therapi
effect
mainli
associ
first
week
treatment
must
discuss
amount
improv
liver
stiff
associ
decreas
hepat
necroinflamm
regress
fibrosi
portal
hypertens
studi
investig
dynam
ctpand
meldscor
liver
stiff
may
overestim
degre
put
regress
cirrhosi
background
hepat
c
viru
hcv
infect
major
caus
chronic
liver
diseas
associ
sever
extrahepat
manifest
sever
studi
demonstr
signific
associ
among
hcv
infect
insulin
resist
chronic
kidney
diseas
ckd
cardiovascular
diseas
cvd
conduct
taiwan
unclear
whether
result
studi
appli
us
popul
given
differ
prevail
genotyp
level
comorbid
observ
differ
natur
histori
hcv
object
assess
risk
ckd
cvd
associ
chronic
hcv
infect
u
method
retrospect
cohort
analysi
truven
health
marketscan
databas
conduct
patient
age
year
newli
diagnos
hcv
infect
identifi
hcv
cohort
outcom
includ
incid
ckd
cvd
coronari
heart
diseas
cerebrovascular
diseas
peripher
arteri
diseas
congest
heart
failur
patient
exclud
experienc
outcom
year
prior
first
diagnosi
hcv
match
hcv
cohort
patient
without
hcv
infect
nonhcv
cohort
use
propens
score
match
followup
continu
studi
outcom
end
enrol
decemb
whichev
come
first
use
cox
proport
hazard
model
compar
risk
develop
ckd
cvd
hcv
nonhcv
cohort
addit
covari
adjust
model
includ
alcoholdrug
abus
disord
hivaid
diseasemodifi
medic
hepat
b
viru
cirrhosi
result
mean
followup
time
year
overal
incid
rate
ckd
per
personyear
hcv
patient
nonhcv
cohort
patient
respect
overal
incid
rate
cvd
per
personyear
hcv
patient
nonhcv
cohort
patient
respect
multivari
adjust
model
hcv
infect
associ
fold
higher
incid
ckd
hazard
ratio
hr
confid
interv
ci
almost
two
fold
higher
incid
cvd
hr
ci
background
hepat
c
b
viru
infect
highli
preval
worldwid
main
caus
liver
diseas
children
adult
vertic
transmiss
hcv
major
rout
hcv
infect
children
spain
mark
increas
immigr
popul
recent
year
may
chang
preval
hcv
hbv
pregnanc
object
determin
preval
epidemiolog
hcv
hbv
pregnant
women
spain
method
prospect
cohort
studi
conduct
nation
spanish
hospit
women
year
old
follow
center
januari
till
octob
enrol
preval
hcv
antihcv
hbv
hbsag
determin
cohort
subgroup
pregnant
mother
moreov
studi
epidemiolog
hbvhcv
infect
among
pregnant
mother
result
overal
hbv
preval
women
hcv
women
preval
viral
hepat
higher
among
women
year
age
howev
preval
hbv
hcv
differ
significantli
group
hbv
hcv
preval
pregnant
women
respect
vs
preval
viral
hepat
among
women
fertil
age
respect
p
coinfect
data
hbvhcv
hbv
hiv
hcvhiv
caucasian
chines
popul
predomin
hbv
preval
wherea
caucasian
latin
gypsi
popul
hcv
relat
countri
origin
vhb
infect
women
spain
eastern
europ
hcv
women
form
spain
asia
mainli
china
eastern
europ
africa
south
america
main
risk
factor
hbv
infect
vertic
transmiss
presenc
tattoo
person
anteced
surgeri
howev
hcv
infect
use
parenter
drug
surgeri
tattoo
person
anteced
transfus
conclus
import
percentag
women
infect
virus
immigr
popul
differ
hbvhcv
preval
pregnant
fertil
age
women
may
due
fertil
age
group
high
number
women
high
risk
infect
relat
hcv
preval
hcv
screen
spain
univers
gestat
therefor
perform
mainli
highrisk
women
women
year
age
increas
risk
viral
hepat
infect
due
lack
prophylact
care
hbv
lack
hcv
blood
screen
follow
peopl
noth
disclos
jose
antonio
munozgamez
javier
salmeron
angel
ruizextremera
hepat
c
svr
affect
metabol
syndrom
diabet
patient
treat
singl
va
hospit
clinic
background
hepat
c
viru
hcv
infect
one
main
caus
chronic
liver
diseas
worldwid
metabol
syndrom
ms
highli
preval
within
va
patient
popul
repres
heterogen
group
patient
potenti
genet
basi
especi
certain
ethnic
patient
popul
increas
preval
disord
increas
likelihood
progress
fibrosi
cirrhosi
hepatocellular
carcinoma
risk
progress
chronic
hcv
infect
cirrhosi
highli
variabl
mani
factor
compon
ms
believ
acceler
diseas
progress
impact
likelihood
sustain
virolog
respons
svr
ms
thought
decreas
efficaci
antivir
therapi
chronic
hepat
c
newer
hepat
c
treatment
regimen
use
within
va
healthcar
system
could
affect
hcv
outcom
patient
ms
aim
evalu
presenc
metabackground
hepat
e
viru
hev
endem
primarili
zoonot
infect
u
western
europ
recent
data
nhane
suggest
approxim
popul
expos
evidenc
serolog
test
seri
describ
higher
rate
infect
hcv
andor
hiv
sought
evalu
crosssect
preval
hev
larg
cohort
hcv
hcvhiv
coinfect
patient
method
serum
sampl
obtain
hcvre
heppro
cohort
longitudin
cohort
develop
hcv
monoinfect
hcv
hiv
coinfect
person
seek
care
clinic
facil
district
columbia
surround
environ
sampl
collect
near
baselin
enrol
period
evalu
hev
igg
evalu
use
sensit
elisa
assay
wantai
beij
china
test
perform
accord
manufactur
instruct
posit
confirm
repeat
duplic
test
recommend
manufactur
parametr
nonparametr
test
perform
use
statistix
result
individu
includ
hcv
monoinfect
hcvhiv
coinfect
test
antihev
igg
mean
age
year
rang
year
male
black
median
cellsmm
rang
cellmm
lower
hiv
mean
vs
hivenrolle
overal
antihev
igg
detect
confirm
proport
confirm
case
statist
similar
regardless
hiv
statu
hcv
vs
hcvhiv
p
n
antihev
preval
affect
sex
race
ethnic
univari
analysi
hev
igg
significantli
common
older
vs
younger
particip
p
modest
invers
correl
count
hev
igg
odcutoff
ratio
r
subject
aid
definit
hev
igg
od
cutoff
ratio
significantli
lower
mean
higher
count
among
antihev
igg
posit
person
p
conclus
hev
exposur
higher
hcv
andor
hiv
report
gener
popul
survey
older
hcv
monoinfect
hcvhiv
coinfect
person
like
expos
howev
hcvhiv
coinfect
patient
low
less
robust
immun
respons
evidenc
lower
antibodi
titer
specul
may
lead
increas
proport
fals
neg
result
subgroup
evalu
qualit
profil
antibodi
hev
includ
determin
bind
avid
indic
outbreak
acut
hepat
c
ahc
transmit
iv
inject
computer
tomographi
ct
background
incid
acut
hepat
c
ahc
declin
worldwid
howev
almost
year
identif
hepat
c
viru
hcv
new
case
still
occur
sinc
acut
hcv
infect
gener
asymptomat
seldom
diagnos
thu
specif
mode
transmiss
number
patient
expos
sourc
infect
well
clinic
laboratori
cours
given
case
rare
ascertain
real
time
describ
outbreak
ahc
wherein
paramet
known
case
report
three
patient
present
medic
center
new
onset
jaundic
april
may
tabl
ahc
diagnos
review
patient
histori
identifi
common
potenti
sourc
exposur
ct
scan
iv
contrast
one
commun
imag
center
march
last
patient
undergo
ct
center
march
known
chronic
hepat
c
patient
health
author
notifi
patient
summon
test
ct
contrast
day
found
posit
hcv
rna
seven
treat
medic
center
describ
tabl
patient
followedup
close
viral
load
declin
significantli
without
antivir
treatment
patient
number
undergo
workup
lung
mass
defer
treatment
patient
treat
daa
patient
prefer
non
declin
viral
load
respect
conclus
iatrogen
acut
hepat
c
still
occur
due
combin
technic
eg
multidos
vial
human
factor
given
ahc
rare
lead
fulmin
hepat
failur
know
exact
date
infect
close
monitor
viral
load
present
uniqu
opportun
follow
patient
viral
load
close
anticip
spontan
viral
clearanc
treatment
offer
viral
load
declin
thu
everi
effort
made
ascertain
date
infect
contact
patient
potenti
expos
aim
quantit
clinic
observ
sever
ahc
lead
greater
chanc
spontan
recoveri
backgroundobject
hepat
c
viru
hcv
infect
major
caus
cirrhosi
worldwid
sever
studi
link
hcv
infect
higher
risk
develop
intrahepat
cholestasi
pregnanc
icp
result
inconsist
metaanalysi
conduct
aim
assess
associ
icp
hcv
infect
diagnosi
icp
method
studi
consist
two
metaanalys
literatur
search
perform
use
medlin
embas
incept
januari
first
studi
includ
observ
studi
report
rel
risk
odd
ratio
hazard
ratio
associ
hcv
infect
risk
icp
second
analysi
includ
studi
compar
risk
later
hcv
infect
icp
patient
without
icp
pool
risk
ratio
rr
confid
interv
ci
calcul
use
randomeffect
gener
invers
varianc
method
result
three
studi
includ
first
analysi
pool
rr
icp
hcvinfect
pregnant
women
compar
nonhcv
pregnant
women
ci
two
studi
includ
second
analysi
pool
rr
later
hcv
infect
among
icp
patient
compar
nonicp
patient
ci
conclus
studi
demonstr
increas
risk
icp
among
hcvinfect
pregnant
women
also
increas
risk
later
hcv
infect
among
icp
patient
physician
awar
associ
strongli
suggest
test
hepat
c
women
sign
icp
forest
plot
includ
studi
associ
hepat
c
infect
risk
intrahepat
cholestasi
pregnanc
top
forest
plot
includ
studi
associ
intrahepat
cholestasi
pregnanc
risk
later
hepat
c
infect
follow
peopl
noth
disclos
karn
wijarnpreecha
charat
thongprayoon
sikarin
upala
anawin
sanguankeo
patompong
ungprasert
wisit
cheungpasitporn
estim
liver
fibrosi
use
noncommerci
serum
score
comparison
transient
elastographi
hcv
patient
receiv
direct
act
antivir
treatment
introduct
treatment
decis
make
direct
act
antivir
daa
patient
chronic
hepat
c
chc
mainli
base
baselin
hcv
rna
concentr
hcv
genotyp
presenc
absenc
liver
cirrhosi
sinc
estim
liver
fibrosi
histolog
result
low
accept
transient
elastographi
te
serum
score
often
use
addit
clinic
find
assess
diagnost
accuraci
panel
noncommerci
serum
score
comparison
te
method
dhcr
deutsch
hepat
cregist
german
hepat
cregistri
nation
multicent
realworld
cohort
includ
approx
patient
patient
treat
discret
physician
data
collect
webbas
system
data
qualiti
analyz
plausibl
check
site
monitor
data
analysi
base
patient
observ
least
week
initi
antivir
treatment
valid
data
te
avail
patient
patient
examin
coevolut
hiv
hcv
infect
mental
ill
substanc
use
dispar
time
bc
use
bc
hepat
tester
cohort
bchtc
bchtc
includ
million
individu
test
hcv
hiv
report
case
hcv
hiv
hbv
tuberculosi
link
administr
healthcar
databas
classifi
individu
hivhcv
hivhcv
hivhcv
seroconvert
hivhcv
preval
hivhcv
million
elig
individu
preval
hcv
infect
hivmonoinfect
hivhcv
coinfect
hcv
seroconvert
overal
hiv
monoinfect
individu
live
urban
area
low
inject
drug
use
idu
problem
alcohol
use
materi
privileg
group
hivhcv
coinfect
hcv
seroconvert
materi
depriv
higher
idu
problem
alcohol
use
major
mental
ill
hiv
hcv
hivhcv
coinfect
began
increas
rural
area
materi
depriv
idu
opioid
substitut
therapi
increas
overtim
among
seroconvert
multivari
multinomi
regress
model
mirror
descript
trend
overtim
odd
idu
declin
among
hcv
preval
hiv
monoinfect
individu
seroconvert
declin
odd
problem
alcohol
use
observ
seroconvert
coinfect
individu
overtim
figur
result
could
inform
optim
align
prevent
care
support
servic
hiv
hcv
infect
popul
within
context
chang
epidemiolog
dispar
risk
profil
group
chronic
liver
diseas
cirrhosi
th
lead
caus
death
u
viral
hepat
lead
signific
morbid
mortal
use
nation
databas
updat
estim
viral
hepat
burden
u
method
nation
ambulatori
hospit
ambulatori
medic
care
survey
nationwid
inpati
sampl
vital
statist
u
databas
use
estim
medic
care
mortal
primari
diagnosi
viral
hepat
b
c
rate
ageadjust
shown
per
popul
recent
year
avail
result
hepat
c
contribut
million
ambulatori
visit
hospit
discharg
death
ambulatori
visit
hospit
discharg
rate
higher
middl
compar
older
age
among
men
african
american
compar
women
white
respect
rate
increas
significantli
howev
greater
avail
treatment
option
might
contribut
rise
mortal
rate
higher
middl
compar
older
age
among
men
compar
women
vs
african
american
compar
white
vs
mortal
rate
increas
overal
popul
demograph
subgroup
figur
hepat
b
contribut
ambulatori
visit
hospit
discharg
death
ambulatori
visit
hospit
discharg
rate
higher
middl
compar
older
age
along
mortal
rate
higher
among
men
african
american
nonhispan
compar
women
white
hispan
respect
medic
care
rate
doubl
contrast
mortal
rate
declin
one
third
conclus
viral
hepat
burden
u
today
primarili
reflect
hepat
c
greater
among
men
african
american
knust
kumasi
ghana
purpos
populationbas
studi
sought
determin
ageand
regionspecif
hepat
c
viru
hcv
estim
ghana
lack
avail
data
assess
led
uncertainti
regard
burden
diseas
method
studi
sampl
consist
individu
current
locat
ashanti
region
ghana
studi
particip
complet
survey
oraquick
rapid
screen
assay
hcv
statu
posit
screen
test
underw
confirmatori
test
cia
hcv
antibodi
assay
confirm
seroposit
age
gender
region
origin
identifi
particip
bayesian
logist
regress
use
obtain
odd
ratio
assess
risk
hcv
ageand
regionspecif
preval
estim
median
posterior
estim
report
highest
posterior
densiti
hpd
credibl
interv
result
averag
age
particip
rang
year
subject
women
children
age
compris
sampl
individu
origin
ashanti
region
northern
region
region
ghana
compar
ashantiborn
subject
ageadjust
odd
hcv
infect
hpd
higher
origin
northern
upper
west
upper
east
region
respect
odd
correspond
hcv
preval
estim
hpd
hpd
hpd
northern
upper
west
upper
east
region
compar
ashanti
adjust
region
origin
lowest
preval
hpd
hpd
age
group
respect
begin
age
regionadjust
preval
increas
hpd
peak
hpd
among
year
old
declin
individu
older
subanalysi
involv
subject
origin
northern
region
northern
upper
west
upper
east
suggest
agespecif
preval
may
even
higher
north
preval
estim
hpd
among
year
old
increas
hpd
among
individu
year
old
conclus
signific
age
region
differ
hcv
preval
exist
ghana
higher
preval
among
individu
origin
northern
region
among
individu
age
case
observ
among
particip
less
year
age
find
suggest
either
age
cohort
effect
transmiss
exposur
low
childhood
increas
age
disclosur
follow
peopl
noth
disclos
stephani
klietherm
jason
gantenberg
nall
mora
richard
phillip
ohen
oparesem
dorca
owusu
jennif
e
layden
associ
liver
stiff
measur
serum
wisteria
floribunda
agglutininposit
bind
protein
among
japanes
patient
hepat
b
c
nafldnash
shinjiro
uchida
kazumi
yamasaki
kohei
hayashi
yuki
kugiyama
shigemun
bekki
satoru
hashimoto
akira
saeki
shinya
nagaoka
seigo
abiru
atsumasa
komori
hiroshi
yatsuhashi
nation
hospit
organ
nagasaki
medic
center
omura
japan
background
optim
manag
chronic
liver
diseas
depend
degre
liver
fibrosi
accur
noninvas
evalu
liver
fibrosi
import
though
liver
stiff
measur
lsm
use
fibroscan
serum
wisteria
floribunda
agglutininposit
bind
protein
novel
noninvas
reliabl
techniqu
assess
degre
liver
fibrosi
transetiolog
comparison
two
paramet
yet
avail
literatur
aim
studi
assess
correl
lsm
serum
level
among
japanes
patient
hepat
b
c
nafld
method
total
patient
underw
lsm
hospit
review
patient
whose
lsm
valu
invalid
failur
exclud
among
remain
patient
patient
patient
infect
hbv
patient
infect
hcv
patient
nafld
enrol
studi
serum
wfa
aspart
transaminas
platelet
ratio
index
apri
fibrosi
index
platelet
ratio
index
simultan
measur
calcul
occas
lcm
result
baselin
characterist
elig
patient
male
median
age
year
median
valu
lsm
apri
kpa
coi
respect
posit
correl
lsm
level
p
apri
p
p
observ
multipl
linear
regress
analysi
reveal
level
significantli
associ
factor
effect
p
correl
coeffici
lsm
fibrosi
marker
follow
ascend
order
hbv
p
nafld
p
hcv
p
diagnost
perform
apri
evalu
use
receiv
oper
characterist
curv
analysi
auc
apri
lsm
level
lsm
level
lsm
level
respect
optim
cutoff
valu
best
predict
lsm
level
respect
optim
cutoff
valu
best
predict
lsm
level
distinct
etiolog
hbv
nafld
hcv
respect
conclus
lsm
valu
measur
fibroscan
close
correl
serum
level
compar
either
apri
especi
hepat
c
patient
consider
etiolog
liver
diseas
requir
regard
predict
lsm
cutoff
valu
host
viral
environment
interact
play
major
role
clinic
outcom
hcv
infect
spontan
clearanc
sc
may
associ
immunolog
mechan
well
genet
metabol
factor
relat
serum
lipid
therefor
apolipoprotein
e
apo
isoform
interact
lowdens
lipoprotein
cholesterol
ldlc
could
alter
cours
diseas
aim
analyz
anthropometr
metabol
lipid
alter
sc
patient
associ
apo
allel
ldlc
sc
method
total
antihcv
posit
patient
includ
patient
classifi
chronic
hepat
ch
least
two
detect
viral
load
vl
sc
two
undetect
vl
last
month
clinic
record
elabor
particip
bodi
mass
index
bmi
evalu
electr
bioimped
inbodi
biochem
test
access
dri
chemistri
assay
vl
determin
coba
taqman
hcv
test
liver
damag
evalu
transit
elastographi
apo
genotyp
identifi
taqman
realtim
pcr
result
statist
differ
detect
age
gender
risk
factor
hcv
infect
group
howev
bmi
higher
sc
ch
predomin
ch
patient
normal
weight
sc
vs
total
cholesterol
chol
hypercholesterolemia
mgdl
higher
sc
ch
patient
mgdl
vs
mgdl
p
vs
p
respect
signific
differ
detect
insulin
resist
type
diabet
sc
ch
group
vs
vs
respect
liver
damag
detect
sc
patient
despit
low
level
alt
ast
iuml
apo
allel
frequenc
significantli
higher
sc
patient
compar
ch
group
also
allel
subgroup
total
chol
ldlc
valu
higher
patient
sc
compar
ch
patient
mgdl
mgdl
vs
mgdl
mgdl
respect
ldlc
allel
bmi
associ
sc
p
ci
wherea
alt
associ
risk
background
new
treatment
hcv
allow
major
patient
achiev
sustain
virolog
respons
svr
howev
mani
patient
advanc
liver
diseas
continu
impair
liver
function
noninvas
test
need
predict
clinic
cours
mani
center
routin
perform
ctmri
imag
patient
advanc
liver
diseas
provid
data
use
calcul
liver
spleen
volum
aim
assess
pretreat
liver
volum
predictor
postsvr
liver
function
method
studi
group
compris
cirrhot
patient
achiev
svr
impair
liver
function
defin
serum
albumin
gdl
prior
start
treatment
pretreat
liver
spleen
volum
calcul
ctmri
imag
obtain
within
one
year
start
hcv
treatment
adjust
ideal
bodi
weight
use
vitrea
softwar
demograph
anthropometr
medic
record
data
collect
preand
postsvr
logist
regress
use
identifi
factor
associ
recoveri
liver
function
defin
postsvr
albumin
level
gdl
result
median
pretreat
age
patient
year
iqr
albumin
gdl
meld
score
iqr
liver
volum
ml
spleen
volum
ml
liver
function
return
normal
patient
recoveri
albumin
normal
significantli
relat
higher
liver
volum
pretreat
odd
ratio
per
mlkg
lower
spleen
volum
everi
mlkg
lower
meld
score
everi
increas
meld
score
subgroupanalysi
patient
pretreat
albumin
gdl
liver
function
return
normal
strong
trend
toward
associ
recoveri
higher
liver
volum
per
mlkg
lower
spleen
volum
per
mlkg
recoveri
significantli
relat
lower
meld
score
everi
increas
meld
score
qualiti
control
test
perform
liver
explant
spleen
explant
known
volum
reveal
liver
spleen
volum
comput
ctmri
accur
estim
liver
weight
median
error
iqr
spleen
weight
median
error
iqr
valid
approach
conclus
liver
spleen
volum
may
sensit
noninvas
prognost
indic
liver
function
statu
grow
number
patient
advanc
liver
diseas
achiev
svr
background
patient
chronic
hcv
infect
increas
risk
chronic
kidney
diseas
ckd
kidney
failur
hepat
c
viru
hcv
also
common
ckd
patient
gener
popul
purpos
studi
estim
preval
ckd
stage
hcv
infect
patient
look
correl
liver
diseas
sever
patient
method
analyz
estim
glomerular
filtrat
rate
egfr
use
ckdepi
formula
patient
posit
viru
c
serolog
multicent
observ
prospect
nation
cohort
hepath
n
exclus
criteria
kidney
transplant
recipi
result
analysi
includ
patient
pt
hcv
pt
characterist
men
year
hypertens
hcv
sinc
year
detect
hcv
rna
genotyp
respect
cirrhot
patient
child
meld
averag
previous
treat
antivir
combin
c
includ
associ
interferon
ribavirin
preval
mlmin
inclus
univari
analysi
risk
factor
sex
age
bmi
durat
infect
hcv
treatment
diabet
hypertens
high
cholesterol
level
educ
histori
heart
diseas
liver
transplant
genotyp
without
influenc
stage
fibrosi
cirrhosi
child
score
multivari
analysi
predictor
irc
tabl
conclus
anr
hepath
cohort
ckd
preval
associ
age
hypertens
diabet
hypercholesterolemia
histori
cardiac
diseas
sever
liver
diseas
cirrhosi
child
meld
score
longitudin
analysi
analyz
effect
antivir
combin
longterm
renal
function
base
usual
nephropathi
risk
factor
background
sinc
develop
direct
act
antivir
daa
sustain
virolog
respons
svr
rate
chronic
hepat
c
patient
increas
dramat
daa
combin
therapi
howev
presenc
resistanceassoci
substitut
ra
decreas
suscept
daa
within
viral
quasispeci
prior
therapi
consid
main
respons
treatment
failur
viral
relaps
current
test
ra
prior
firstlin
daa
therapi
recommend
clinic
guidelin
gt
patient
simeprevir
base
regimen
elbasvirbas
treatment
present
work
analyz
baselin
preval
ra
among
treatment
patient
geograph
area
massiv
parallel
sequenc
use
platform
method
total
sampl
treatment
chronic
hcv
patient
select
fragment
region
amplifi
sequenc
use
gsjunior
sequenc
platform
compar
consensu
sequenc
provid
lo
alamo
sequenc
databas
cutoff
detect
follow
ra
mutat
consid
present
studi
result
overal
ra
region
detect
patient
patient
present
ra
frequenc
preval
ra
follow
subtyp
preval
substitut
follow
frequenc
ra
rang
patient
interestingli
patient
substitut
baselin
associ
reduc
suscept
daclatasvir
ledipasvir
ombitasvir
sampl
observ
minor
mutant
carrier
show
mutat
sequenc
conclus
highresolut
hcvsequenc
technolog
good
tool
studi
ra
methodolog
reveal
high
preval
ra
region
spain
howev
clinic
signific
variant
depend
frequenc
type
ra
sens
shown
higher
level
daa
resist
substitut
besid
show
preval
ra
subtypedepend
instanc
preval
subtyp
compar
still
unknown
minim
frequenc
minor
ra
clinic
relev
introduct
hepat
c
viru
hcv
infect
common
chronic
blood
born
infect
unit
state
account
signific
morbid
mortal
increas
effort
perform
birth
cohort
screen
get
high
risk
group
diagnos
treat
hcv
usual
report
peopl
expos
hcv
develop
chronic
infect
group
conduct
studi
determin
tradit
report
rate
develop
chronic
hcv
consist
rate
chronic
hcv
see
era
birth
cohort
screen
method
health
system
consist
hospit
health
center
electron
medic
record
epic
integr
entir
health
system
januari
therefor
januari
abl
collect
data
patient
within
health
system
born
screen
hcv
hcv
antibodi
ab
test
identifi
test
hcv
rna
calcul
percentag
patient
hcv
ab
calcul
percentag
patient
hcv
rna
result
patient
screen
hcv
test
posit
patient
hcv
rna
test
test
posit
chronic
infect
patient
screen
hcv
test
posit
patient
hcv
rna
test
test
posit
first
month
patient
screen
hcv
test
posit
patient
hcv
rna
test
test
posit
conclus
base
larg
health
system
patient
born
develop
chronic
hcv
infect
expos
hcv
therefor
patient
expos
hcv
clear
viru
without
treatment
percentag
clearanc
higher
typic
report
patient
clear
hcv
without
treatment
like
spontan
clearanc
hcv
common
previous
expect
backgroundaim
advent
highli
effect
antivir
therapi
hepat
c
viru
hcv
infect
patient
decompens
cirrhosi
abl
achiev
sustain
virolog
respons
svr
widespread
optim
erad
hcv
would
lead
revers
cirrhosi
thu
obviat
need
liver
transplant
ltx
explant
ltx
recipi
present
opportun
accur
assess
histolog
chang
liver
svr
patient
alreadi
advanc
liver
diseas
method
institut
databas
medic
record
review
identifi
adult
liver
transplant
recipi
hcv
patient
divid
svr
versu
nonsvr
group
latter
defin
viremia
time
ltx
patient
stratifi
presenc
hcc
explant
liver
specimen
retriev
review
singl
pathologist
fibrosi
stage
grade
inflamm
nodul
size
overal
histolog
descript
compar
two
group
result
adult
patient
underw
ltx
primari
diagnosi
hcv
patient
achiev
svr
prior
ltx
remain
patient
nonsvr
select
match
age
meld
categori
year
transplant
date
five
svr
explant
review
character
complet
tabl
patient
exhibit
advanc
stage
fibrosi
vari
degre
inflamm
grade
nodul
size
regardless
recent
achiev
svr
studi
ongo
complet
data
svr
nonsvr
patient
avail
time
present
conclus
although
sampl
size
date
small
mark
regress
cirrhosi
observ
hcv
patient
decompens
liver
diseas
may
cirrhosi
far
advanc
regress
complet
analysi
studi
sampl
may
suggest
hcv
therapi
ltx
candid
individu
patient
postpon
antivir
therapi
postltx
may
advantag
particularli
region
high
median
meld
score
shebl
cde
yale
school
public
health
new
ct
background
approxim
million
american
live
hepat
c
viru
hcv
infect
sinc
incid
acut
hcv
infect
rise
therefor
expect
observ
increas
hcvrelat
morbid
mortal
includ
cancer
excess
risk
liver
cancer
among
hcvinfect
well
document
howev
excess
risk
extrahepat
cancer
less
document
extrahepat
cancer
nonhodgkin
lymphoma
thyroid
pancreat
multipl
myeloma
observ
therefor
examin
risk
extrahepat
cancer
well
possibl
mediat
mechan
among
hcvinfect
subject
compar
nonhcvinfect
method
surveil
epidemiolog
end
result
seer
medicarelink
seermedicar
databas
use
assess
cancer
risk
among
year
older
unit
state
use
hcv
code
classifi
subject
hcv
posit
claim
includ
follow
studi
includ
cancer
case
well
frequenc
match
control
use
uncondit
logist
regress
calcul
adjust
odd
ratio
or
confid
interv
ci
adjust
match
variabl
includ
age
sex
calendar
year
cancer
examin
cancerspecif
mediat
mechan
use
structur
equat
model
sem
result
multivari
model
individu
hcv
infect
higher
likelihood
overal
cancer
ci
lip
cancer
stomach
anorect
intrahepat
cancer
nhl
acut
myeloid
leukemia
nonepitheli
skin
cancer
pancreat
cancer
diabet
main
mediat
hcv
infect
might
oper
mediat
includ
pancreat
pancreat
cancer
peptic
ulcer
stomach
cancer
conclus
hcv
potenti
risk
factor
sever
inflammationrel
immunerel
type
cancer
associ
hcv
infect
cancer
partial
mediat
diabet
cancerspecif
factor
pancreat
peptic
ulcer
studi
need
identifi
mechan
hcv
infect
may
induc
extrahepat
cancer
follow
peopl
noth
disclos
fatma
shebl
direct
act
antivir
daa
therapi
chronic
hepat
c
viru
hcv
infect
associ
regress
liver
fibrosi
assess
serial
transient
elastographi
fibroscan
regress
fibrosi
time
studi
aim
assess
effect
hcv
daa
therapi
chang
liver
fibrosi
use
transient
elastographi
fibroscan
method
patient
treat
daa
therapi
chronic
hcv
enrol
prospect
cohort
studi
perform
pretreat
baselin
fibroscan
repeat
scan
end
treatment
eot
month
posttreat
primari
outcom
signific
improv
liver
fibrosi
decreas
fibroscan
score
month
treatment
rel
baselin
multivari
logist
regress
analysi
use
control
confound
sign
rank
test
use
assess
chang
liver
stiff
measur
lsm
time
point
result
patient
complet
protocol
signific
baselin
liver
fibrosi
lsm
kpa
treatmentexperienc
svr
rate
primari
outcom
improv
lsm
met
patient
relaps
reach
outcom
baselin
metavir
stage
lsm
kpa
improv
lsm
kpa
cutoff
refer
baselin
lsm
kpa
associ
reach
primari
outcom
remain
signific
control
bmi
elev
alt
ci
subgroup
baselin
lsm
kpa
median
intrapati
chang
lsm
pretreat
month
posttreat
kpa
iqr
p
conclus
treatment
chronic
hcv
daa
lead
clinic
relev
reduct
liver
fibrosi
first
year
posttreat
measur
fibroscan
even
control
bmi
elev
alt
outcom
like
baselin
signific
liver
fibrosi
experienc
improv
metavir
fibrosi
stage
refer
tapper
directact
antivir
treatment
pattern
among
hepat
c
patient
advanc
chronic
kidney
diseas
retrospect
cohort
studi
amanda
w
singer
brian
l
mcnabb
anu
osinusi
diana
brainard
marcu
littman
anneruth
van
troostenburg
de
bruyn
anand
p
chokkalingam
gilead
scienc
foster
citi
ca
background
patient
chronic
hepat
c
viru
hcv
infect
advanc
chronic
kidney
diseas
ckd
face
substanti
barrier
treatment
limit
data
current
hcv
treatment
pattern
directact
antivir
daa
therapi
patient
hcv
advanc
ckd
examin
us
administr
claim
data
character
treatment
uptak
among
patient
hcv
advanc
ckd
daa
era
method
patient
chronic
hcv
claim
advanc
ckd
stage
iv
v
end
stage
renal
diseas
enrol
januari
march
includ
differ
treat
untreat
advanc
ckd
popul
baselin
e
prior
one
year
follow
first
hcv
claim
analyz
chisquar
test
proport
advanc
ckd
patient
initi
treatment
distribut
treatment
regimen
examin
per
calendar
year
result
adult
patient
chronic
hcv
identifi
receiv
antihcv
treatment
observ
period
total
hcv
patient
diagnosi
advanc
ckd
age
year
male
claim
dialysi
baselin
advanc
ckd
patient
ever
receiv
antihcv
treatment
advanc
ckd
claim
prior
treatment
start
compar
untreat
advanc
ckd
patient
advanc
ckd
patient
treat
hcv
like
year
age
male
diagnosi
cirrhosi
less
like
diagnos
anemia
type
diabet
receiv
dialysi
baselin
treatment
uptak
median
durat
year
shown
common
regimen
among
treat
advanc
ckd
patient
ribavirin
rbv
interferon
ifn
telaprevir
rbv
ifn
specif
marker
predict
develop
complic
patient
childpugh
post
hepat
c
cirrhosi
sustain
virolog
respons
except
aim
studi
analyz
place
surrog
marker
fibrosi
french
nation
multicent
prospect
cohort
hcvinfect
patient
biopsyproven
cirrhosi
anr
cirvir
includ
center
order
predict
develop
complic
especi
hcc
studi
case
control
studi
ratio
main
event
collect
month
period
hcc
ascit
digest
hemorrag
actitestfibrotest
fibromet
perform
independ
one
lab
fibroscan
analys
everi
month
month
multivari
analysi
took
account
confound
factor
match
chang
marker
time
condit
logist
regress
mixedeffect
model
includ
case
hcc
control
cirrhot
patient
without
liver
relat
event
group
mean
age
year
male
group
compar
comorbid
diabet
kidney
failur
ha
dyslipidemia
viral
factor
except
svr
vs
p
lab
data
bilirubin
gammagt
platelet
tp
result
systemat
adjust
svr
onward
signific
differ
case
control
systemat
found
mean
marker
score
persist
fibrotest
vs
fibromet
fibrosi
vs
vs
fibroscan
vs
p
signific
differ
found
svr
patient
except
fibroscan
kinet
show
clinic
relev
chang
thu
multivari
explor
predict
valu
test
carri
adjust
svr
marker
remain
associ
occurr
complic
conclud
surrog
marker
fibrosi
abl
earli
predict
occurr
complic
especi
hcc
patient
post
hepat
c
cirrhosi
marker
kinet
give
addit
inform
herebi
propos
monitor
accur
patient
high
initi
valu
threshold
remain
determin
introduct
brachial
flow
mediat
dilat
fmd
wellknown
noninvas
method
assess
endotheli
function
chronic
liver
diseas
endotheli
function
shown
impair
suggest
signific
correl
among
liver
damag
sinusoid
endotheli
function
liver
stiff
aim
method
investig
relationship
endotheli
function
liver
stiff
perform
crosssect
studi
includ
consecut
hcv
genotyp
patient
underw
complet
clinic
laboratori
screen
hcv
infect
liver
stiff
assess
transientelastographi
te
fmd
carotid
intimamedia
thick
cimt
evalu
ultrasound
mean
age
year
woman
base
te
score
accord
liver
fibrosi
metavir
score
patient
group
follow
result
show
signific
invers
linear
correl
fmd
te
valu
stiff
p
te
higher
correl
shown
signific
although
tendenc
fmd
enhanc
note
whole
popul
spearman
test
fmd
invers
correl
te
p
age
male
sex
ggt
low
plt
apri
p
cimt
directli
unconjug
bilirubin
multivari
regress
analysi
te
p
cimt
invers
unconjug
bilirubin
directli
associ
fmd
sub
analysi
conduct
patient
te
patient
te
kpa
multivari
analysi
unconjug
bilirubin
low
albumin
directli
correl
fmd
group
te
kpa
independ
factor
invers
associ
fmd
te
cimt
conclus
impair
fmd
significantli
associ
worst
te
chronic
hcv
relat
hepat
patient
sickest
diseas
liver
failur
surprisingli
seem
associ
reconstitut
endotheli
function
share
needl
ancillari
inject
drug
equip
place
peopl
inject
drug
pwid
risk
hepat
c
viru
hcv
highli
infecti
bloodborn
infect
avail
data
hcv
infect
context
inject
anoth
person
previous
use
needl
limit
goal
estim
percontact
probabl
hcv
infect
reinfect
accompani
inject
previous
use
needl
classifi
recept
needl
share
rn
probabilist
exposur
model
link
observ
hcv
infect
outcom
selfreport
rn
exposur
appli
data
ufo
studi
prospect
observ
cohort
studi
activ
pwid
age
survey
test
quarterli
hcv
particip
first
survey
hcvneg
statu
first
survey
hcvposit
statu
select
return
particip
analysi
maximum
likelihood
estim
consid
rn
yield
percontact
hcv
infect
rang
among
hcv
suscept
group
tabl
show
percontact
probabl
hcv
bootstrap
confid
interv
among
differ
suscept
group
becam
infect
reinfect
least
strength
studi
includ
abil
assess
infect
specif
data
recept
needl
share
contact
vs
share
needl
well
short
recal
hcv
test
period
ascertain
exposur
outcom
event
factor
like
account
higher
infect
estim
found
other
ci
boelen
et
al
analysi
fill
import
gap
inform
due
focu
percontact
probabl
hcv
associ
rn
primari
rout
hcv
transmiss
among
pwid
result
inform
model
research
impact
prevent
scale
popul
level
impact
reduc
rn
frequenc
rn
contribut
reduc
spread
hcv
found
younger
popul
greater
probabl
fluctuat
apri
score
progress
advanc
liver
diseas
use
measur
predict
futur
outcom
conclus
apri
score
power
diagnost
tool
measur
progress
advanc
liver
diseas
pattern
emerg
fluctuat
score
easili
view
tree
ring
diagram
model
progress
markov
process
provid
uniqu
novel
way
predict
futur
liver
diseas
outcom
hcv
patient
accur
predict
outcom
specif
patient
group
ultim
improv
hcv
patient
care
reduc
cost
associ
unnecessari
treatment
consid
threedigit
zip
code
area
cluster
identifi
high
risk
cirrhosi
hot
spot
use
two
geospati
metric
e
lisa
gi
eb
rate
threezip
code
area
classifi
nonclust
result
preval
hcvrelat
cirrhosi
total
hcvrelat
cirrhosi
case
within
cluster
area
case
within
nonclust
area
cirrhosi
cluster
region
higher
cirrhosi
event
rate
per
person
ci
compar
nonclust
per
person
ci
background
fibrosi
assess
prior
hepat
c
hcv
treatment
recommend
howev
access
elastographi
limit
resourc
mani
set
even
highincom
countri
studi
aim
assess
whether
routin
blood
test
use
triag
need
noninvas
fibrosi
assess
communitybas
cohort
peopl
inject
drug
pwid
backgroundaim
distribut
hepat
c
viru
hcv
genotyp
vari
accord
ethnic
geograph
differ
world
hcv
genotyp
prevail
type
japan
preval
hcv
rare
mainland
japan
contrast
okinawa
island
locat
south
japan
histori
us
militari
occup
world
war
ii
preval
okinawa
report
higher
mainland
reason
may
influenc
geograph
histor
social
background
aim
elucid
rout
timescal
transmiss
hcv
clarifi
genet
featur
hcv
okinawa
island
use
whole
genom
sequenc
hcv
subsequ
phylogenet
analysi
patientsmethod
studi
patient
hcv
infect
determin
serolog
test
enrol
born
bred
okinawa
island
mean
age
year
male
femal
perform
whole
hcv
genom
sequenc
cover
region
core
use
sever
pair
primer
phylogenet
analys
obtain
sequenc
align
use
mafft
set
global
refer
retriev
hcv
databas
phylogenet
tree
construct
method
bootstrap
time
confirm
reliabl
phylogenet
tree
neighborjoin
method
use
mega
result
success
obtain
full
genom
sequenc
hcv
sampl
phylogenet
analys
sequenc
cluster
hcv
group
consist
us
strain
asian
cluster
suggest
possibl
rout
transmiss
us
estim
epidem
period
hcv
okinawa
perform
phylodynam
analysi
use
sampl
time
spread
hcv
estim
around
viet
nam
war
sever
rout
hcv
infect
observ
specif
cluster
consist
okinawa
sampl
observ
phylogenet
tree
conclus
okinawa
hcv
estim
introduc
us
spread
acceler
increas
intraven
drug
user
ivdu
viet
nam
war
present
hcv
infect
risk
via
medic
activ
exceedingli
zero
japan
educ
activ
take
screen
test
hcv
infect
patient
also
need
reduc
chronic
hepat
c
patient
background
account
econom
burden
extrahepat
manifest
essenti
accur
correct
quantif
benefit
treatment
hcv
hcv
infect
main
caus
cryoglobulinemia
vascul
cryova
evolut
hcv
treatment
allow
chang
manag
cryova
object
estim
effect
cost
hcvcryova
treatment
direct
act
antivir
daa
era
compar
predaa
era
tertiari
nation
refer
french
center
method
chart
review
hcvcryova
patient
treat
perform
patient
divid
two
group
accord
first
hcv
treatment
group
interferon
ifn
ribavirin
rbv
pegifnrbv
group
hcv
treatment
daa
main
clinicbiolog
characterist
assess
diagnosi
follow
first
antivir
session
effect
evalu
three
dimens
clinic
respons
cr
improv
organ
affect
cryova
baselin
absenc
clinic
relaps
immunolog
respons
ir
decreas
absenc
cryoglobulinemia
treatment
sustain
virolog
respons
svr
neg
viremia
posttreat
cost
analys
resourc
use
patient
collect
includ
hcv
treatment
nonvir
drug
dialysi
durat
hospit
rehabilit
care
cryova
result
patient
cryova
treat
center
sinc
women
mean
age
cryova
diagnosi
year
metavir
score
main
genotyp
main
cryova
symptom
neuropathi
purpura
arthralgia
glomerulonephr
sicca
syndrom
mean
extrahepat
cryova
manifest
per
patient
cryoglobulinemia
posit
type
ig
mk
mean
level
gl
statist
signific
differ
baselin
characterist
group
cr
improv
ir
svr
hcv
drug
cost
increas
mean
total
cost
increas
less
due
decreas
hospit
cost
nonantivir
treatment
conclus
larg
cohort
hcvcryova
patient
improv
antivir
effect
safeti
hcv
drug
daa
era
result
higher
rate
clinic
immunolog
respons
cryova
signific
reduct
hospit
nonantivir
treatment
cost
patient
requir
baselin
continu
insur
prior
first
hcv
diagnosi
patient
preval
hcv
cancer
diagnos
period
exclud
patient
healthcar
util
baselin
reduc
detect
bia
identifi
cancer
outcom
interest
valid
algorithm
diagnos
within
month
incid
rate
hcv
cohort
estim
standard
age
sex
u
censu
popul
compar
rate
nonhcv
cohort
seer
area
also
standard
popul
nonhcv
cohort
includ
patient
hcv
diagnos
start
follow
one
healthcar
util
date
result
hcv
patient
younger
mean
age
compar
nonhcv
patient
mean
age
crude
incid
rate
mostli
similar
nonhcv
rate
standard
age
sex
incid
rate
increas
substanti
standard
rate
significantli
higher
hcv
vs
nonhcv
rate
ratio
rr
confid
interv
lung
liver
background
cirrhosi
due
hcv
infect
associ
increas
risk
hepatocellular
carcinoma
aim
studi
assess
chang
liver
transient
elastographi
te
score
patient
chronic
hepat
c
chc
achiev
sustain
viral
respons
svr
method
retrospect
prospect
studi
includ
patient
chc
baselin
liver
biopsi
achiev
svr
treatment
daa
regimen
pretreat
te
studi
least
one
follow
te
measur
week
later
post
end
treatment
respons
eotr
similar
cdc
bc
estim
perhap
due
low
protocol
adher
test
possibl
lower
infect
risk
region
test
differ
urban
nonurban
site
interestingli
though
overal
posit
previous
report
medstar
washington
hospit
center
current
rate
alon
remain
high
work
underway
increas
test
educ
implement
geocod
analysi
understand
variabl
test
posit
rate
protocol
potenti
provid
essenti
intellig
magnitud
distribut
hcv
within
differ
region
washington
dc
maryland
significantli
impact
push
elimin
hcv
background
interferoninduc
svr
patient
hcv
associ
reduc
rate
liverrel
morbid
mortal
noninvas
method
assess
liver
fibrosi
stage
frequent
use
propos
cure
hcv
follow
daa
therapi
defin
svr
least
week
lead
regress
liver
fibrosi
use
noninvas
measur
prospect
assess
develop
cirrhosi
relat
complic
baselin
predictor
liver
fibrosi
regress
determin
method
conduct
retrospectiveprospect
studi
hcv
patient
achiev
svr
daa
treatment
abbvi
regimen
baselin
liver
fibrosi
stage
fibrosi
stage
determin
use
elastographi
shear
wave
aixplor
superson
imagin
franc
biopredict
franc
well
apri
score
baselin
month
year
month
end
treatment
demograph
clinic
socioeconom
data
insur
proxim
resid
clinic
drug
alcohol
use
histori
incarcer
collect
compar
patient
treat
versu
treat
delay
treatment
e
treat
start
beyond
initi
visit
multivari
logist
regress
done
evalu
factor
predict
treatment
delay
noniniti
result
mean
interv
initi
consult
treatment
start
day
month
among
treat
directact
antivir
daa
within
month
delay
mean
month
initi
treatment
receiv
treatment
mean
age
seventi
five
percent
male
estim
live
within
mile
clinic
histori
incarcer
remot
histori
illicit
drug
use
remot
histori
alcohol
abus
treat
delayednottr
group
signific
differ
factor
two
group
howev
differ
insur
type
treat
group
like
nonmedicaid
insur
delayednottr
group
vs
p
patient
delay
treatment
higher
rate
recent
histori
illicit
drug
use
vs
p
posit
urin
drug
screen
evalu
vs
p
multivari
analysi
insur
type
signific
predictor
treatment
initi
patient
nonmedicaid
insur
higher
likelihood
start
treatment
within
month
vs
medicaid
ci
p
background
aim
last
two
year
european
medicin
agenc
approv
highli
effect
direct
act
antivir
daa
regimen
treatment
hepat
c
access
revolutionari
daa
sofosbuvir
andor
ledipasvir
daclatasvir
ombitasvirparitaprevir
ritonavir
without
dasabuvir
pervas
remain
countri
level
differ
due
part
variat
nation
level
insur
countrymanufactur
deal
apart
variabl
patient
level
factor
also
influenc
access
aim
studi
analyz
order
influenc
resid
demograph
clinic
condit
access
daa
use
recent
patient
chart
audit
data
chisquar
automat
interact
detect
chaid
method
ipso
hcv
therapi
monitor
run
sinc
eu
report
physician
per
quarter
across
itali
spain
franc
unit
kingdom
germani
physician
provid
patient
demograph
diseas
treatment
data
hcv
patient
seen
within
period
eu
therapi
monitor
data
chaid
analysi
use
creat
decis
tree
tree
determin
hierarchi
influenc
viral
load
comorbid
countri
substanc
abus
fibrosi
score
patient
access
daa
result
chaid
analysi
split
data
fibrosi
level
reveal
fibrosi
strongest
impact
daa
access
countri
substanc
abus
statu
case
next
influenti
variabl
treatment
access
focus
patient
germani
spain
abus
substanc
chanc
daa
access
whilst
abus
germani
spain
lower
chanc
respect
similar
trend
persist
throughout
individu
fibrosi
level
cohort
apart
cirrhot
patient
clinic
characterist
greater
influenc
resid
conclus
decis
tree
reveal
treatment
access
significantli
depend
fibrosi
countri
substanc
abus
viral
load
comorbid
play
lesser
role
countri
similar
fibrosi
level
adjud
experi
minor
diverg
substanc
abus
statu
integr
access
decis
differ
treatment
rate
abus
nonabus
diminish
abus
commonli
deni
noncompli
risk
yet
deni
access
leav
potenti
futur
strain
payer
system
background
sensit
accur
hepat
c
viru
hcv
rna
detect
quantif
essenti
manag
chronic
hepat
c
therapi
current
avail
platform
assay
usual
batch
requir
least
one
full
day
work
complet
analys
object
aim
studi
evalu
abil
newli
develop
aptima
hcv
quant
dx
assay
holog
inc
san
diego
ca
transcriptionmedi
amplif
tma
base
assay
make
use
fulli
autom
panther
system
elimin
need
batch
process
autom
aspect
nucleic
acid
test
singl
step
accur
detect
quantifi
hcv
rna
larg
seri
patient
infect
differ
hcv
genotyp
result
limit
detect
estim
iuml
specif
assay
confid
interv
intraassay
interassay
coeffici
variat
rang
respect
background
littl
known
risk
hepat
b
viru
hbv
reactiv
hepat
c
viru
hcv
infect
patient
receiv
interferon
ifn
free
direct
act
antivir
agent
daa
method
hcvinfect
patient
receiv
week
ifnfre
daa
therapi
consecut
enrol
baselin
ontreat
offtherapi
hbv
dna
hbv
surfac
antigen
hbsag
hbv
surfac
antibodi
antihb
alanin
aminotransferas
alt
serial
examin
hbv
reactiv
defin
detect
serum
hbv
dna
follow
baselin
undetect
hbv
dna
increas
log
iuml
hbv
dna
compar
baselin
detect
hbv
dna
signific
hbvrelat
alt
flare
defin
alt
time
upper
limit
normal
uln
alt
time
baselin
level
concomit
hbv
dna
iuml
hbvrelat
hepat
decompens
defin
signific
hbvrelat
alt
flare
combin
jaundic
coagulopathi
hepat
encephalopathi
ascit
result
patient
enrol
hbv
reactiv
none
signific
hbvrelat
alt
flare
hepat
decompens
hbsagposit
patient
hbv
reactiv
remain
hbsagneg
patient
none
hbv
reactiv
daa
therapi
patient
baselin
hbsag
neg
withwithout
antihb
posit
chang
hbv
serolog
marker
conclus
risk
hbv
reactiv
low
hcvinfect
patient
receiv
ifnfre
daa
treatment
hbv
reactiv
limit
hbvhcvcoinfect
patient
furthermor
risk
hbvrelat
alt
flare
hepat
decompens
also
minim
hbv
reactiv
introduct
inform
epidemiolog
impact
hcv
genotyp
hcvhiv
patient
spain
scarc
data
avail
number
spread
hcv
lineag
design
set
order
determin
preval
distribut
pattern
hcv
hcvhiv
coinfect
individu
multicent
retrospect
observ
cohort
studi
conduct
spanish
hospit
descript
epidemiolog
analysi
random
sampl
case
perform
portion
hcv
region
nucleotid
amplifi
sequenc
associ
plasma
sampl
hcv
subtyp
perform
use
comet
hcv
onlin
tool
compar
subtyp
system
base
phylogenet
reconstruct
maximumlikelihood
phylogenet
tree
bootstrap
support
branch
built
raxml
use
detect
cluster
sequenc
result
within
initi
cohort
hivinfect
patient
individu
hiv
hcv
coinfect
present
vhc
characterist
averag
age
male
inject
drug
user
year
estim
time
infect
stage
hepat
fibrosi
greater
equal
region
preval
hcv
exceed
within
hcv
averag
preval
subtyp
respect
southnorth
distribut
pattern
hcv
subtyp
detect
proport
patient
hcv
mainli
present
north
spain
subtyp
tend
increas
north
south
presenc
greater
equal
southern
spain
addit
detect
signific
cluster
subtyp
form
sequenc
madrid
one
canari
island
share
recent
common
ancestor
moreov
genet
close
sequenc
along
sequenc
belong
dutch
hcvhiv
coinfect
individu
studi
publish
also
form
signific
cluster
cluster
suggest
transnat
transmiss
network
hcv
associ
risk
factor
detect
use
methodolog
contrast
signific
cluster
found
among
subtyp
sequenc
inner
citi
preval
rate
hcv
thought
high
diagnosi
linkag
care
suboptim
cdc
estim
babi
boomer
born
account
percent
american
hepat
c
howev
screen
popul
dismal
despit
recommend
cdc
uspstf
cm
institut
provid
primari
healthcar
babi
boomer
via
primari
care
physician
less
popul
risk
screen
prior
intervent
year
cdc
publish
recommend
object
object
studi
improv
hcv
screen
babi
boom
gener
method
use
prong
approach
creat
popup
emr
prompt
primari
care
physician
order
screen
test
patient
visit
also
sent
letter
patient
explain
rational
screen
along
order
form
blood
test
letter
sent
approv
primari
care
physician
address
patient
sign
primari
care
physician
patient
found
posit
hcv
educ
link
care
dedic
coordin
collect
number
complet
order
popup
prompt
letter
use
emr
improv
diseas
awar
also
conduct
cme
event
primari
care
physician
addit
coordin
met
offic
staff
provid
educ
materi
result
ongo
studi
mail
letter
patient
primari
care
physician
first
month
period
screen
rate
increas
compar
previou
month
patient
screen
mail
order
patient
found
hcv
antibodi
patient
test
hcv
rna
posit
hcv
rna
total
screen
addit
patient
screen
emr
popup
identifi
anoth
hcv
antibodi
posit
patient
test
hcv
rna
posit
hcv
rna
total
screen
screen
popup
also
receiv
letter
conclus
use
autom
process
incorpor
electron
medic
record
system
effect
way
increas
screen
rate
viral
infect
combin
target
mail
campaign
expand
abil
primari
care
physician
test
patient
identifi
infect
individu
preval
rate
hcv
babi
boom
gener
institut
appear
lower
previous
report
inc
architect
hcv
ag
abbott
japan
total
frozen
sera
posit
neg
lp
ortho
hcv
ag
hospit
total
fresh
sera
neg
lportho
hcv
ag
obtain
day
examin
perform
use
studi
basic
examin
reproduc
stabil
quantit
limit
examin
correl
concord
rate
lppresto
hcv
ag
convent
assay
perform
specif
test
lppresto
hcv
ag
examin
total
frozen
sera
hypergammaglobulinemia
neg
lportho
hcv
ag
measur
lppresto
hcv
ag
result
reproduc
stabil
quantit
limit
lppresto
hcv
ag
support
result
efficaci
case
posit
lportho
hcv
ag
correl
found
lportho
hcv
ag
introduct
hepat
c
viral
infect
hcv
becom
curabl
diseas
due
develop
direct
act
antivir
daa
therefor
world
health
organ
set
target
elimin
hcv
largest
group
risk
hcv
present
peopl
inject
drug
pwid
especi
western
world
due
variou
barrier
risk
group
still
underserv
hcv
goal
studi
case
manag
polici
could
improv
uptak
screen
treatment
hcv
pwid
method
perform
prospect
intervent
cohort
studi
evalu
effect
case
manag
screen
treatment
hcv
pwid
opiat
substitut
treatment
ost
set
limburg
belgium
goal
address
pwid
set
provid
step
continuum
care
propos
meyer
jp
et
al
int
j
drug
polici
cohort
exist
four
group
pwid
firstli
larg
group
receiv
methadon
local
pharmaci
second
larg
group
receiv
methadon
ost
set
thirdli
smaller
group
activ
user
needl
exchang
program
final
small
group
recruit
referr
hospit
former
pwid
result
result
present
figur
group
case
screen
except
pharmaci
group
present
time
year
ost
set
could
explain
lower
screen
rate
howev
address
pwid
pharmaci
group
test
pwid
cohort
approxim
hcv
rna
posit
chronic
infect
pwid
assess
treatment
elig
antivir
treatment
howev
treatment
could
start
within
belgian
reimburs
criteria
requir
metavir
fibrosi
score
rule
therapi
present
treatment
start
conclus
case
manag
effect
way
screen
welldefin
cohort
highrisk
individu
hcv
also
improv
treatment
uptak
purpos
introduct
oral
directact
antivir
daa
dramat
chang
landscap
hcv
treatment
mani
patient
elig
therapi
due
absenc
interferon
ribavirin
realworld
effect
mirror
result
phase
clinic
trial
object
quantifi
number
hcv
gt
patient
popul
fail
current
approv
oral
daa
includ
vs
failur
time
u
method
use
hepat
c
diseas
burden
simul
model
hepsim
previous
valid
nhane
cdc
studi
use
project
chang
hcv
preval
u
simul
current
clinic
manag
hcv
includ
birthcohort
riskbas
screen
use
market
research
data
im
ipso
model
daa
treatment
differ
wave
start
launch
st
gener
daa
follow
nd
gener
daa
includ
sofosbuvir
simeprevir
ledipasvir
multipl
contain
daa
svr
rate
obtain
realworld
trio
target
dataset
within
model
patient
fail
elig
retreat
unless
cirrhot
project
number
patient
undergo
treatment
number
patient
fail
daa
result
estim
million
patient
would
receiv
treatment
nd
gener
daa
would
fail
achiev
svr
daa
inhibitor
failur
figur
characterist
patient
fail
daa
cirrhosi
conclus
even
era
highli
efficaci
daa
signific
number
patient
fail
achiev
svr
limit
retreat
option
popul
repres
group
signific
unmet
medic
need
safe
effect
therapi
need
popul
prevent
longterm
sequela
hcv
simeprevir
major
infect
genotyp
cirrhot
none
diagnosi
autoimmun
diseas
subject
cryoglobulinsrel
kidney
damag
trend
neutrophil
increas
chang
observ
leukocyt
ratio
ferritin
cryoglobulin
posit
decreas
significantli
antithyroglobulin
canca
panca
decreas
significantli
ana
posit
remain
stabl
fluoresc
chang
trend
anti
ring
rod
antirr
antibodi
increas
conclus
analysi
show
achiev
svr
partial
improv
immunolog
paramet
within
short
follow
immunolog
respons
term
cryoglobulin
clearanc
signific
ana
show
chang
fluoresc
regist
antirr
antibodi
consid
interferoninduc
coinfect
subject
alreadi
present
baselin
increas
virolog
clearanc
even
without
interferon
thu
suggest
virolog
clearancemedi
instead
druginduc
effect
disclosur
follow
peopl
noth
disclos
roberto
rossotti
background
aim
quantif
hcv
rna
antivir
therapi
essenti
guidanc
treatment
durat
decid
futil
determin
sustain
respons
aim
studi
evalu
perform
recent
fdaapprov
realtim
pcr
hcv
rna
assay
coba
hcv
use
coba
system
coba
hcv
roch
diagnost
method
analyt
sensit
linear
lower
concentr
iuml
assess
coba
hcv
use
standard
traceabl
panel
repres
hcv
genotyp
gt
compar
two
establish
hcv
rna
assay
coba
ampliprepcoba
taqman
hcv
test
capctm
coba
taqman
hcv
test
use
high
pure
system
hpsctm
addit
pairwis
assay
comparison
perform
use
clinic
serum
sampl
repres
hcv
concord
baselin
sampl
assess
use
million
iuml
cutoff
use
tailor
treatment
durat
noncirrhot
patient
receiv
ledipasvirsofosbuvir
result
analyt
sensit
coba
hcv
iu
ml
ci
sampl
repres
gt
background
earli
treatment
acut
hepat
c
viru
hcv
infect
interferon
alfa
monotherapi
highli
effect
associ
frequent
unfavor
side
effect
fulli
publish
studi
yet
explor
safeti
efficaci
requir
treatment
durat
interferon
free
treatment
acut
hepat
c
viru
monoinfect
preliminari
report
suggest
ledipasvirsofosbuvir
therapi
effect
acut
hepat
c
relaps
report
hivcoinfect
patient
week
treatment
method
german
hepnet
acut
hcv
iv
studi
design
singl
arm
prospect
multicent
pilot
studi
evalu
efficaci
safeti
treatment
sofosbuvir
plu
ledipasvir
sofldv
week
without
ribavirin
patient
acut
genotyp
hcv
monoinfect
report
final
week
post
treatment
result
result
twenti
patient
includ
center
male
mean
age
year
patient
hcv
genotyp
patient
genotyp
main
risk
factor
hcv
infect
sexual
transmiss
medic
proceduresneedl
stick
injuri
median
alanin
aminotransferas
alt
median
bilirubin
level
start
antivir
treatment
ul
rang
rang
respect
alt
level
rapidli
declin
therapi
valu
normal
alreadi
treatment
week
patient
week
patient
hcv
rna
undetect
roch
hcv
test
week
patient
respect
patient
alreadi
complet
fuweek
remain
hcvrna
neg
conclus
treatment
week
ldvsof
well
toler
highli
effect
hcv
genotyp
monoinfect
patient
acut
hepat
c
virolog
respons
durabl
therapi
least
week
rapid
improv
biochem
diseas
activ
observ
therapi
shortdur
treatment
acut
hepat
c
could
prevent
spread
hcv
high
risk
popul
may
costsav
compar
treatment
chronic
hepat
c
coadministr
achiev
high
sustain
virolog
respons
rate
patient
hcv
genotyp
gt
infect
well
patient
previous
fail
daacontain
regimen
report
present
character
variant
detect
sampl
subject
enrol
part
studi
treatment
rbv
week
noncirrhot
patient
previous
fail
regimen
contain
pi
andor
inhibitor
polymeras
inhibitor
method
next
gener
sequenc
ng
perform
hcv
gene
baselin
sampl
first
avail
sampl
virolog
failur
hcv
rna
iu
ml
sequenc
result
detect
cutoff
examin
presenc
resistanceassoci
variant
rav
gene
result
ng
cutoff
baselin
sampl
patient
identifi
rav
patient
target
sampl
rav
also
present
use
ng
detect
cutoff
daaexperienc
patient
cohort
broad
represent
baselin
variant
key
resistanceassoci
posit
includ
well
patient
baselin
variant
posit
confer
high
level
resist
current
approv
inhibitor
achiev
patient
experienc
virolog
failur
patient
baselin
rav
patient
baselin
rav
conclus
combin
demonstr
potent
antivir
activ
high
barrier
resist
noncirrhot
hcv
patient
previous
fail
daacontain
regimen
regardless
divers
profil
high
preval
baselin
andor
rav
among
patient
promis
result
support
studi
combin
regimen
larger
cohort
daaexperienc
patient
initi
treatment
period
least
one
ae
occur
patient
ebrgzr
noncirrhot
placebo
arm
respect
cirrhot
seriou
ae
occur
ebrgzr
noncirrhot
placebo
patient
respect
cirrhot
patient
grade
grade
alt
elev
observ
ebrgzr
arm
placebo
arm
grade
alt
elev
observ
cirrhot
arm
patient
grade
alt
elev
common
ae
nasopharyng
alt
increas
ebrgzr
arm
nasopharyng
alt
ast
increas
cirrhot
arm
data
defer
treatment
data
also
present
meet
conclus
oncedaili
ebrgzr
week
highli
effect
gener
well
toler
noncirrhot
compens
cirrhot
japanes
patient
hcv
background
administr
pangenotyp
fixeddos
combin
sofosbuvir
sof
velpatasvir
vel
mg
oncedaili
week
result
overal
rate
hcvhiv
coinfect
subject
includ
subject
boost
cobicist
ritonavircontain
unboost
antiretrovir
arv
regimen
pharmacokinet
pk
data
collect
evalu
relationship
exposur
extrinsicintrins
variabl
treatment
outcom
compar
pk
coinfect
hcv
monoinfect
subject
method
studi
popul
includ
hcv
hiv
coinfect
subject
receiv
sofvel
mg
week
stabl
arv
regimen
includ
variou
combin
abacavir
atazanavir
cobicistat
darunavir
elvitegravir
emtricitabin
lamivudin
lopinavir
raltegravir
rilpivirin
ritonavir
tenofovir
disoproxil
fumar
tdf
pk
sof
vel
tenofovir
tfv
evalu
subject
measur
plasma
concentr
use
previous
establish
popul
pk
model
pk
sof
vel
hcvhiv
coinfect
subject
compar
across
arv
regimen
treatment
outcom
subject
hcv
monoinfect
pk
tfv
compar
across
arv
regimen
boost
vs
unboost
result
exposur
sof
vel
similar
across
arv
regimen
similar
exposur
observ
hcv
monoinfect
popul
ci
rang
introduct
phase
clinic
studi
conduct
evalu
efficaci
safeti
elbasvir
ebr
hcv
inhibitor
grazoprevir
gzr
hcv
proteas
inhibitor
pi
ifn
experienc
japanes
patient
without
compens
cirrhosi
hcv
genotyp
infect
studi
result
show
daili
coadministr
ebrgzr
week
highli
effect
well
toler
hcv
japanes
patient
preval
hcv
resistanceassoci
variant
rav
baselin
bl
impact
svr
also
assess
studi
method
popul
sequenc
perform
bl
sampl
patient
sampl
viral
load
log
iuml
patient
met
criteria
virolog
failur
vf
rav
interest
confer
resist
proteas
inhibitor
class
includ
posit
rav
interest
confer
resist
inhibitor
class
includ
posit
addit
select
sampl
analyz
clonal
sequenc
clone
baselin
sampl
patient
sampl
vf
patient
phase
program
analyz
next
gener
sequenc
ng
resist
analysi
popul
rap
exclud
nonvf
earli
discontinu
ed
lost
followup
ltfu
well
patient
placebo
arm
background
aim
sofosbuvir
velpatasvir
sof
vel
oral
singl
tablet
regimen
shown
clinic
trial
set
excel
efficaci
toler
tn
treatmentexperienc
te
patient
chronic
hepat
c
viru
hcv
genotyp
decisionanalyt
markov
model
evalu
health
outcom
sofvel
compar
current
treatment
option
method
analysi
model
two
cohort
chronic
hcv
patient
noncirrhot
nc
cirrhot
cc
averag
age
us
thirdparti
payer
perspect
lifetim
horizon
cohort
tn
sofvel
compar
ldvsof
ribavirin
rbv
elbasvirgrazoprevir
ebrgrz
rbv
treatment
nt
sustain
virolog
respons
svr
rate
extrapol
phase
iii
clinic
trial
stratifi
baselin
resist
associ
variant
ebrgrz
transit
probabl
util
base
literatur
review
consensu
panel
hepatologist
result
initi
sofvel
patient
result
best
health
outcom
term
lowest
number
patient
liverrel
complic
compar
ebrgrz
ldvsof
nt
tabl
result
consist
across
patient
subpopul
includ
tn
pegintereronribavirin
pr
te
prproteas
inhibitort
nc
cc
conclus
compar
ebrgrz
ldv
sof
sofvel
demonstr
better
overal
health
outcom
reduct
case
decompens
cirrhosi
dcc
hepatocellular
carcinoma
hcc
liver
transplant
lt
respect
result
highlight
longerterm
benefit
treat
chronic
hcv
sofvel
versu
current
avail
option
background
gender
differ
safeti
efficaci
report
interferonbas
hcv
treatment
data
larg
cohort
women
hcv
treat
direct
act
antivir
lack
aim
analysi
evalu
influenc
gender
efficaci
safeti
rbvfree
regimen
sofvel
mg
patient
hcv
genotyp
gt
method
secondari
analysi
includ
patient
enrol
astral
receiv
sofvel
mg
daili
week
patient
decompens
liver
diseas
astral
exclud
analysi
astral
hivhcv
coinfect
studi
patient
enrol
women
men
demograph
sustain
virolog
respons
week
advers
event
ae
assess
gender
use
fisher
exact
chisquar
test
result
overal
patient
treat
sofvel
phase
iii
astral
trial
overal
women
relaps
rate
men
overal
relaps
rate
demograph
ae
gender
describ
tabl
women
report
higher
rate
nausea
headach
nasopharyng
men
analysi
ae
women
done
howev
treatment
gener
well
toler
women
men
discontinu
rate
low
conclus
pool
analysi
daili
singl
tablet
regimen
sofvel
mg
week
highli
efficaci
regardless
gt
gender
safe
rbvfree
option
women
age
hcv
background
aim
new
oral
singl
tablet
regimen
sofosbuvir
velpatasvir
sofvel
shown
excel
efficaci
safeti
patient
hepat
c
viru
hcv
genotyp
gt
particular
patient
consid
difficulttotreat
popul
limit
treatment
option
decisionanalyt
markov
model
evalu
health
outcom
sofvel
compar
current
recommend
altern
high
realworld
util
method
analysi
model
cohort
chronic
hcv
patient
mean
age
year
us
thirdparti
payer
perspect
lifetim
horizon
cirrhot
cc
treatmentexperienc
te
respect
sofvel
compar
sofribavirin
r
treatment
nt
sofvel
compar
sofdaclatasvir
dcv
r
nt
sustain
virolog
respons
svr
rate
base
phase
iii
clinic
trial
transit
probabl
util
base
literatur
review
consensu
panel
hepatologist
result
sofvel
regimen
result
best
health
outcom
term
lowest
number
decompens
cirrhosi
dcc
hepatocellular
carcinoma
hcc
liver
transplant
lt
compar
compar
tabl
result
consist
across
patient
subpopul
includ
treatment
pegintereronribavirint
sofrt
noncirrhot
cirrhot
conclus
result
demonstr
sofvel
highli
effect
hcv
patient
lead
fewest
case
liverrel
complic
vs
sofr
sofdcv
furthermor
sofvel
provid
rbvfree
option
avail
pangenotyp
allor
oncedaili
singl
tablet
regimen
chronic
hcv
simplifi
treatment
across
gt
although
studi
report
efficaci
adher
rate
allor
singl
tablet
regimen
similar
realworld
clinic
trial
set
addit
analys
necessari
determin
impact
realworld
util
background
era
directact
antivir
therapi
daa
chronic
hepat
c
hcv
decis
treat
hcv
liver
transplant
lt
waitlist
candid
controversi
thought
treat
candid
prior
lt
model
endstag
diseas
meld
score
may
improv
therebi
place
purgatori
meld
would
reduc
likelihood
receiv
lt
data
report
determin
purgatori
meld
inde
exist
method
use
unit
network
organ
share
uno
databas
compar
hcv
lt
waitlist
candid
month
predaa
may
octob
postdaa
januari
june
fda
approv
daa
agent
novemb
decemb
determin
rate
transplant
death
use
remov
code
deceas
donor
transplant
death
sick
transplant
statist
analys
perform
use
sa
result
overal
total
hcv
waitlist
lt
candid
candid
predaa
period
candid
postdaa
period
compar
predaa
period
hcv
waitlist
lt
candid
postdaa
significantli
lower
rate
remov
due
death
p
sick
transplant
p
tabl
postdaa
hcv
waitlist
lt
candid
howev
significantli
lower
rate
liver
transplant
p
discuss
although
postdaa
hcv
lt
waitlist
candid
lower
likelihood
receiv
transplant
likelihood
die
waitlist
significantli
lower
data
need
evalu
determin
role
purgatori
meld
within
popul
serum
afp
level
measur
treatment
year
antivir
treatment
exclud
analysi
patient
develop
hcc
followup
baselin
afp
level
ngml
daa
group
higher
pegifnrbv
group
ngml
afp
level
gradual
decreas
group
antivir
therapi
similar
year
start
antivir
therapi
p
valu
signific
conclus
demonstr
present
studi
rate
hcc
develop
reduc
patient
infect
hcv
genotyp
achiev
svr
daabas
regimen
impact
daabas
treatment
similar
ifnbas
treatment
regard
hcc
risk
reduct
patient
achiev
svr
background
although
current
direct
act
antivir
daa
taken
big
step
forward
hcv
therapi
experi
patient
hcvcryoglobulinem
vascul
cv
limit
aim
evalu
clinic
immunolog
outcom
hcvcv
subject
treat
oral
daa
week
end
therapi
method
prospect
observ
studi
hcvpatient
circul
cryoglobulin
receiv
daa
therapi
patient
group
two
cohort
asymptomat
cryoglobulin
acc
patient
cv
hcvcv
complet
immunolog
respons
cir
defin
complement
normal
cryoglobulin
negativ
week
therapi
among
hcvvc
clinic
remiss
consid
complet
bva
affect
organ
improv
partial
bva
entri
score
result
caucasian
patient
includ
acc
signific
differ
observ
group
regard
age
median
year
viralgenotyp
nullrespond
antivir
therapi
ldvsof
femal
gender
common
hcvcv
group
vs
cirrhosi
acc
group
vs
hcvcv
patient
show
significantli
elev
rheumatoid
factor
rf
vs
iuml
lower
complement
fraction
vs
gl
slightli
higher
cryoglobulin
among
hcvcv
common
manifest
asthenia
purpura
polyneuropathi
arthralgia
renal
involv
twelv
patient
receiv
glucocorticoid
rituximab
rate
cryoglobulin
improv
equal
group
rf
decreas
greater
hcvcv
vs
iu
cir
achiev
without
signific
differ
group
cryocrit
median
baselin
associ
noncir
despit
persist
cryoglobulin
abnorm
hcvcv
patient
patient
achiev
clinic
remiss
complet
partial
median
bva
score
decreas
p
resolut
purpura
arthralgia
plu
improv
renal
neurolog
symptom
respect
glucocorticoid
dosag
could
reduc
patient
conclus
despit
short
followup
patient
hcv
circul
cryoglobulin
achiev
cir
svr
baselin
cryocrit
independ
factor
relat
nonimmunolog
respons
howev
associ
clinic
improv
signific
proport
hcvcv
patient
consult
janssen
gilead
bm
speak
teach
msd
abbvi
xavier
forn
consult
jansen
abbvi
grantresearch
support
jansen
abbvi
introduct
studi
hcv
infect
patient
childpugh
b
cirrhosi
achiev
week
sofosbuvirvelpatasvir
sofvel
ribavirin
rbv
contrast
regimen
evalu
patient
decompens
cirrhosi
rbv
dose
mgday
weight
base
rbv
dose
mgday
use
studi
analysi
compar
safeti
toler
sofvel
weight
base
ribavirin
dose
safeti
toler
ledipasvirsofosbuvir
ldvsof
rbv
mg
report
studi
method
treatmentemerg
advers
event
laboratori
abnorm
compar
patient
cptb
cirrhosi
pretranspl
treat
sofvel
weightbas
rbv
week
studi
patient
treat
ldvsof
mg
rbv
week
studi
toler
rbv
assess
review
rbv
dose
modif
dose
reduct
discontinu
result
patient
treat
sofvel
weightbas
rbv
lower
incid
advers
event
compar
patient
treat
ldvsof
mg
rbv
howev
regimen
advers
event
mild
moder
sever
one
patient
treat
sofvel
weightbas
rbv
one
patient
treat
ldvsof
rbv
treatment
relat
seriou
advers
event
three
patient
receiv
sofvel
weightbas
rbv
die
one
patient
receiv
ldvsof
rbv
die
death
assess
treatment
relat
tabl
present
summari
postbaselin
hemoglobin
rbv
dose
modif
higher
incid
rbv
dose
reduct
interrupt
modif
among
patient
treat
sofvel
weight
base
rbv
compar
patient
treat
ldvsof
rbv
conclus
higher
incid
hemoglobin
reduct
hcv
infect
patient
cptb
cirrhosi
treat
sofvel
weight
base
rbv
compar
patient
treat
ldvsof
mg
rbv
manag
frequent
dose
modif
rbv
without
discontinu
treatment
group
patient
treat
provid
experienc
care
patient
advanc
liver
diseas
manag
rbv
associ
toxic
introduct
phase
trial
directact
antivir
regimen
ombitasvirparitaprevirritonavir
paritaprevir
identifi
abbvi
enanta
dasabuvir
ribavirin
rbv
achiev
high
sustain
virolog
svr
rate
favor
safeti
profil
hcv
patient
includ
compens
cirrhosi
topazi
evalu
impact
longterm
progress
liver
diseas
year
posttreat
pt
followup
patient
chronic
hcv
infect
receiv
rbv
method
topazi
ongo
phase
intern
multicent
open
label
studi
enrol
hcv
treatmentna
interferonexperienc
patient
without
cirrhosi
compens
cirrhosi
across
center
countri
patient
receiv
rbv
week
base
subtyp
cirrhosi
statu
consist
approv
local
label
first
interim
result
includ
hcv
rna
lloq
week
pt
safeti
clinic
outcom
chang
liver
fibrosi
baselin
evalu
fibroscan
result
patient
receiv
studi
drug
male
white
compens
cirrhosi
patient
reach
time
point
itt
achiev
patient
reach
patient
without
cirrhosi
respect
patient
achiev
mean
fibroscan
score
improv
time
greatest
improv
seen
patient
cirrhosi
mean
kpa
chang
baselin
total
patient
experienc
ae
fatigu
headach
nausea
pruritu
insomnia
occur
patient
major
ae
mildmoder
sever
patient
experienc
seriou
ae
patient
discontinu
studi
drug
due
ae
grade
laboratori
abnorm
rare
clinic
outcom
report
tabl
conclus
data
larg
studi
confirm
efficaci
safeti
result
observ
registr
trial
rbv
hcv
patient
preliminari
data
show
benefici
impact
liver
fibrosi
clinic
outcom
infrequ
updat
safeti
efficaci
clinic
outcom
present
follow
peopl
noth
disclos
adrian
streinucercel
raul
j
andrad
igor
g
bakulin
resat
ozara
li
liu
melanni
co
combin
resist
demograph
phylogenet
analys
hcv
genotyp
patient
treat
ombitasvirparitaprevirr
ribavirin
pearli
studi
background
hcv
regimen
contain
ombitasvir
inhibitor
paritaprevir
proteas
inhibitor
identifi
abbvi
enanta
ritonavir
obvptvr
plu
ribavirin
rbv
highli
efficaci
treatment
hcv
genotyp
gt
infect
util
larg
dataset
sequenc
contain
divers
hcv
subtyp
isol
patient
treat
obvptvr
rbv
assess
genet
divers
geograph
region
analyz
patient
demograph
baselin
sequenc
variabl
across
subtyp
report
develop
viral
resist
virolog
failur
vf
patient
method
fulllength
gene
sequenc
popul
nextgener
sequenc
ng
baselin
sampl
noncirrhot
pearli
cirrhot
patient
sequenc
includ
phylogenet
analysi
assess
genet
relationship
among
within
subtyp
countri
preval
baselin
polymorph
treatmentemerg
resistanceassoci
variant
rav
analyz
result
sixteen
subtyp
identifi
combin
dataset
subtyp
preval
vari
countri
enrol
studi
subtyp
preval
countri
origin
close
associ
report
distribut
subtyp
africa
europ
north
america
phylogenet
analysi
sequenc
reveal
two
sequenc
cluster
within
subtyp
correl
countri
origin
sampl
one
cluster
contain
sequenc
egypt
middl
east
second
cluster
contain
sequenc
origin
europ
baselin
demograph
analys
also
reveal
distribut
patient
race
significantli
differ
across
subtyp
baselin
amino
acid
variabl
frequent
detect
across
subtyp
impact
treatment
outcom
overal
patient
experienc
vf
infect
infect
predomin
rav
time
failur
conclus
overal
high
respons
rate
observ
among
patient
infect
hcv
subtyp
impact
baselin
polymorph
treatment
outcom
subtyp
distribut
differ
base
patient
demograph
geographi
two
phylogenet
cluster
within
subtyp
found
segreg
countri
origin
suggest
genet
distinct
strain
circul
egypt
versu
europ
background
major
metabolit
sofosbuvir
sof
clear
renal
accumul
sever
renal
impair
end
stage
renal
diseas
although
popul
exclud
phase
clinic
trial
patient
mild
moder
renal
impair
enrol
retrospect
analysi
present
safeti
profil
sofbas
therapi
group
method
safeti
data
patient
without
compens
cirrhosi
enrol
phase
studi
sofrbv
assess
accord
rbv
degre
renal
impair
normal
renal
function
estim
glomerular
filtrat
rate
egfr
use
cockcroftgault
equat
mlmin
mild
renal
impair
egfr
mlmin
moder
renal
impair
egfr
mlmin
result
patient
includ
analysi
mild
moder
renal
impair
baselin
mean
egfr
mlmin
patient
normal
renal
function
mild
moder
renal
impair
respect
baselin
characterist
gener
similar
across
group
except
patient
impair
renal
function
older
tabl
provid
summari
advers
event
ae
patient
receiv
rbv
higher
rate
grade
ae
sae
discontinu
compar
patient
receiv
rbv
differ
pronounc
among
renal
impair
among
patient
receiv
rbv
similar
rate
grade
ae
discontinu
due
ae
across
group
patient
moder
renal
impair
higher
rate
sae
treatmentrel
conclus
treatment
sofbas
regimen
welltoler
patient
mild
moder
renal
impair
differ
seen
rbv
toler
patient
moder
renal
impair
compar
mild
renal
impair
overal
summari
safeti
patient
treat
sofcontain
regimen
accord
renal
function
presenc
rbv
daa
outstand
safeti
profil
phase
iii
trial
postmarket
surveil
gener
addit
safeti
warn
drug
interact
restrict
use
decompens
cirrhosi
aim
evalu
detail
safeti
data
across
broad
spectrum
patient
treat
daa
usual
clinic
practic
method
patient
enrol
hcvtarget
treat
accord
region
standard
care
academ
commun
medic
center
north
america
europ
detail
inform
demograph
clinic
cours
advers
event
ae
abstract
medic
record
central
data
core
data
monitor
systemat
review
data
accuraci
result
jan
may
patient
pt
treat
oral
daa
includ
pt
cirrhosi
evid
prior
hepat
decompens
regimen
includ
sofrbv
sofsmvrbv
ldvsofrbv
prodrbv
prorbv
sofdcvrbv
therapi
complet
earli
discontinu
due
ae
occur
higher
among
rbvcontain
vs
rbvfree
regimen
vs
death
report
pt
varieti
caus
increas
bilirubin
baselin
bilirubin
occur
pt
evalu
data
prematur
discontinu
treatment
sever
bilirubin
baselin
occur
pt
concomit
alt
elev
die
pt
bilirubin
associ
biliari
tract
diseas
sepsi
transplant
multivari
logist
analys
exclud
patient
cirrhosi
prior
hepat
decompens
low
albumin
higher
baselin
bilirubin
associ
bilirubin
treatment
de
novo
hepat
decompens
occur
previous
compens
cirrhot
pt
wherea
secondari
decompens
event
among
prior
histori
decompens
higher
ribavirin
use
associ
secondari
hepat
decompens
latter
group
ci
p
conclus
event
rate
hyperbilirubinemia
decompens
low
even
among
patient
advanc
cirrhosi
infrequ
led
prematur
discontinu
therapi
featur
advanc
cirrhosi
associ
increas
risk
ae
note
ribavirin
independ
increas
risk
hepat
decompens
sever
hyperbilirubinemia
clinic
sequela
usual
occur
absenc
alt
elev
deserv
scrutini
co
inc
kenilworth
nj
background
estim
onethird
hepatitisc
viru
hcv
infect
patient
use
proton
pump
inhibitor
ppi
acid
reduc
agent
concomit
ppi
use
inhibitor
impact
pharmacokinet
pk
directact
antivir
agent
daa
potenti
reduc
efficaci
phase
studi
result
demonstr
effect
ppi
use
pk
fixeddos
combin
elbasvirgrazoprevir
ebrgzr
healthi
volunt
post
hoc
analysi
studi
phase
clinic
program
ebrgzr
assess
sustain
viral
respons
subject
selfreport
ppi
use
pk
ebrgzr
patient
method
data
deriv
six
phase
ebrgzr
trial
treatment
experienc
subject
without
cirrhosi
analys
done
modifi
full
analysi
set
popul
exclud
administr
discontinu
selfreport
baselin
ppi
use
defin
consecut
day
use
day
day
bivari
analys
assess
ppi
use
factor
associ
svr
gender
age
continu
dichotom
cirrhosi
statu
prior
treatment
statu
baselin
hcv
rna
continu
dichotom
hcv
genotyp
baselin
resist
associ
variant
variabl
model
result
overal
ebrgzrtreat
subject
report
baselin
use
ppi
achiev
patient
without
ppi
use
achiev
ppi
use
predict
factor
achiev
base
univari
analysi
p
bivari
model
none
interact
term
statist
signific
indic
potenti
effect
ppi
consist
across
factor
consid
addit
ppi
usag
statist
signific
effect
regardless
adjust
factor
consid
studi
popul
pk
data
avail
estim
auc
cmax
valu
ebr
compar
among
patient
without
report
ppi
use
tabl
conclus
result
demonstr
ppi
use
ebrgzr
clinic
signific
effect
rate
patient
without
cirrhosi
aucarea
background
although
treatmentemerg
proteas
inhibitor
pi
resist
variant
typic
decreas
frequenc
cessat
pi
therapi
chronic
hepat
c
patient
suscept
pi
patient
previous
fail
respond
pi
therapi
address
method
total
genotyp
chronic
hepat
c
patient
detect
drug
resistantassoci
variant
rav
neither
hcv
prior
treatment
determin
invad
assay
treat
daclatasvir
plu
asunaprevir
human
hepatocyt
chimer
mice
inject
serum
sampl
obtain
either
patient
daclatasvir
plu
asunaprevir
nonrespond
treat
simeprevir
sofosbuvir
telaprevir
nucleotid
amino
acid
sequenc
resistanceassoci
region
determin
deep
sequenc
result
sustain
virolog
respons
svr
achiev
daa
patient
wherea
patient
experienc
simeprevir
plu
pegifnrbv
treatment
failur
p
multivari
logist
regress
analysi
identifi
histori
simeprevir
treatment
odd
ratio
absenc
p
independ
predictor
svr
viral
breakthrough
daclatasvir
asunaprevir
treatment
rav
persist
high
frequenc
contrast
deep
sequenc
analysi
show
frequenc
rav
gradual
decreas
complet
replac
wildtyp
cessat
therapi
mice
inject
serum
patient
daclatasvir
plu
asunaprevir
nonrespond
treat
simeprevir
alon
sofosbuvir
combin
either
simeprevir
telaprevir
simperevir
alon
simperevir
plu
sofosbuvir
treatment
result
rapid
emerg
mutat
significantli
higher
frequenc
mice
inject
serum
daclatasvir
asunaprevir
nonrespond
compar
mice
inject
serum
daa
patient
contrast
sofosbuvir
plu
simeprevir
treatment
sofosbuvir
plu
telaprevir
treatment
reduc
serum
hcv
rna
level
sustain
emerg
rav
suppress
mice
inject
serum
daclatasvir
asunaprevir
nonrespond
conclus
virolog
respons
daclatasvir
plu
asunaprevir
treatment
low
patient
simeprevir
plu
pegifnrbv
treatment
failur
pi
resist
remain
even
disappear
mutant
strain
ultradeep
sequenc
daa
combin
therapi
without
pi
recommend
patient
fail
pi
treatment
st
vincent
hospit
melborn
vic
australia
merck
co
inc
kenilworth
nj
backgroundpurpos
high
rate
efficaci
observ
costar
phase
trial
week
elbasvirgrazoprevir
ebr
hcv
inhibitor
gzr
hcv
proteas
inhibitor
patient
opioid
agonist
therapi
oat
hcv
reinfect
observ
patient
end
treatment
eot
followup
week
aim
costar
three
year
followup
studi
evalu
hcv
reinfect
inject
risk
behavior
patient
treat
ebrgzr
method
year
observ
cohort
studi
enrol
patient
receiv
least
one
dose
ebr
gzr
phase
trial
everi
month
patient
test
hcv
rna
detect
viral
genotyp
sequenc
perform
patient
complet
questionnair
assess
drug
use
result
patient
treat
costar
patient
enrol
patient
enrol
gener
repres
parent
trial
averag
age
year
male
white
race
sixti
percent
patient
studi
phase
trial
posit
urin
drug
screen
ud
result
enrol
respect
median
time
eot
first
visit
day
rang
addit
reinfect
observ
eot
followup
week
two
viral
recurr
identifi
first
visit
one
patient
baselin
patient
report
noninject
drug
use
intranas
cocain
inhal
amphetamin
inhal
cannabinoid
followup
identifi
opiat
cannabinoid
detect
ud
one
patient
baselin
hcv
rna
iuml
detect
first
visit
howev
genotyp
unabl
determin
due
low
viral
load
drug
use
report
patient
previou
month
drug
besid
oat
detect
ud
patient
consid
reinfect
addit
followup
pend
patient
report
drug
use
noninject
inject
past
month
inject
drug
use
past
month
report
patient
among
report
inject
drug
use
past
month
patient
inject
drug
includ
heroin
amphetamin
cocain
opioid
conclus
hcv
reinfect
among
patient
opioid
agonist
therapi
follow
elbasvirgrazoprevir
treatment
uncommon
despit
ongo
drug
use
addit
followup
ongo
background
ribavirin
rbv
compon
guidelinesrecommend
treatment
regimen
certain
patient
popul
hepat
c
viru
hcv
infect
known
caus
decreas
hemoglobin
andor
elev
indirect
bilirubin
rbv
typic
administ
weightbas
daili
dosag
mg
studi
investig
safeti
efficaci
directact
antivir
agent
daa
ombitasvirparitaprevir
identifi
abbvi
enanta
ritonavir
obvptvr
plu
dasabuvir
dsv
fix
low
dose
rbv
patient
genotyp
chronic
hcv
infect
without
cirrhosi
method
geodeii
phase
openlabel
multicent
studi
design
evalu
safeti
efficaci
obvptvrdsv
coadminist
lowdos
rbv
mg
qd
week
hcvinfect
patient
without
cirrhosi
either
hcv
tn
treatmentexperienc
te
previou
interferon
ifn
pegyl
ifn
rbv
therapi
efficaci
assess
sustain
virolog
respons
posttreat
week
compar
histor
rate
regimen
coadminist
weight
base
rbv
safeti
assess
patient
receiv
least
dose
studi
drug
result
present
intenttotreat
itt
modifi
itt
exclud
discontinu
due
nonvir
failur
nondrug
relat
ae
popul
result
total
patient
femal
white
enrol
studi
tn
data
cutoff
date
may
patient
reach
end
treatment
rate
itt
patient
reach
posttreat
week
ae
mostli
mild
moder
sever
fatigu
headach
insomnia
frequent
report
one
patient
breakthrough
patient
relaps
patient
discontinu
studi
drug
nonvir
failur
patient
discontinu
due
drug
relat
ae
subject
requir
rbv
dose
reduct
per
protocol
grade
hemoglobinlevel
abnorm
report
patient
treatment
period
grade
grade
elev
total
bilirubin
level
report
full
safeti
data
rate
avail
meet
conclus
preliminari
data
ongo
studi
demonstr
rate
itt
popul
regimen
well
toler
hemoglobin
bilirubin
abnorm
observ
infrequ
preliminari
result
suggest
use
lowdos
rbv
regimen
may
suffici
patient
achiev
svr
reduc
rbvrelat
ae
background
previou
multin
phase
studi
demonstr
treatment
directact
antivir
agent
daa
ombitasvirparitaprevir
identifi
abbvi
enanta
ritonavir
obvptvr
dasabuvir
dsv
well
toler
achiev
sustain
virolog
respons
posttreat
week
patient
infect
genotyp
hepat
c
viru
hcv
without
cirrhosi
despit
find
interferon
ifn
peglat
ifn
pegifn
ribavirin
rbv
still
current
standard
care
asian
countri
hcv
infect
high
preval
present
studi
evalu
safeti
efficaci
obvptvr
plu
dsv
adult
chronic
hcv
infect
mainland
china
taiwan
south
korea
method
phase
random
doubleblind
placebocontrol
studi
safeti
efficaci
obvptvr
dsv
administ
week
evalu
treatmentexperienc
ifnpegifn
rbv
noncirrhot
adult
chronic
hcv
infect
patient
arm
receiv
activ
drug
week
doubleblind
period
patient
arm
b
receiv
placebo
period
follow
activ
drug
treatment
week
openlabel
period
efficaci
assess
compar
arm
rate
histor
svr
rate
telaprevir
plu
pegifn
rbv
safeti
assess
patient
receiv
least
dose
studi
drug
result
total
patient
mainland
china
south
korea
taiwan
random
arm
b
patient
asian
femal
treatment
experienc
data
cutoff
date
may
south
korean
taiwanes
arm
patient
reach
posttreat
week
achiev
rate
chines
patient
yet
reach
posttreat
week
treatment
emerg
advers
event
ae
patient
receiv
activ
drug
mild
sever
common
ae
arm
b
upper
respiratori
tract
infect
headach
dizzi
nine
patient
seriou
ae
doubleblind
treatment
arm
arm
b
one
case
arm
drug
relat
result
alanin
aminotransferas
elev
two
patient
arm
b
discontinu
treatment
conclus
preliminari
data
ongo
studi
demonstr
rate
hcv
korean
taiwanes
patient
treat
obvptvr
dsv
week
regimen
well
toler
mostli
mild
ae
report
rate
entir
studi
report
confer
denot
aasld
presidenti
poster
distinct
co
inc
kenilworth
nj
common
hcv
genotyp
global
account
largest
proport
infect
europ
latin
america
russia
turkey
east
asia
report
efficaci
week
oncedaili
elbasvirgrazoprevir
mg
proteas
inhibitor
hcv
patient
enrol
clinic
develop
program
analysi
treatmentexperienc
patient
use
data
pool
trial
involv
countri
includ
patient
withwithout
cirrhosi
chronic
kidney
diseas
ckd
hiv
coinfect
cirrhosi
compens
confirm
either
liver
biopsi
noninvas
test
patient
stage
stage
ckd
hemodialysi
includ
hivhcv
coinfect
patient
requir
stabl
antiretrovir
regimen
arv
tenofovir
abacavir
emtricitabin
lamivudin
either
raltegrevir
dolutegravir
rilpivirin
hiv
viral
load
undetect
arv
viral
load
iuml
primari
endpoint
proport
patient
hcv
rna
lower
limit
quantit
week
treatment
efficaci
data
present
full
analysi
set
fa
includ
patient
receiv
least
one
dose
studi
medic
perprotocol
pp
popul
exclud
nonvirolog
failur
total
patient
includ
analysi
mean
patient
age
year
rang
male
white
asian
black
african
american
treatmentexperienc
baselin
viral
load
iuml
evid
cirrhosi
fa
patient
categor
virolog
failur
categor
nonvirolog
failur
losttofollowup
withdraw
exclud
nonvirolog
failur
pp
analysi
notabl
differ
subgroup
analys
treatmentexperienc
patient
cirrhot
noncirrhot
patient
baselin
viral
load
iuml
patient
baselin
viral
iuml
hivhcv
coinfect
patient
patient
stage
ckd
respect
high
efficaci
achiev
popul
treat
elbasvirgrazoprevir
week
compar
efficaci
across
subgroup
includ
cirrhosi
high
baselin
viral
load
prior
treatment
failur
background
previou
multin
phase
studi
demonstr
treatment
directact
antivir
agent
daa
ombitasvirparitaprevir
identifi
abbvi
enanta
ritonavir
obvptvr
dasabuvir
dsv
ribavirin
rbv
well
toler
achiev
sustain
virolog
respons
posttreat
week
patient
infect
genotyp
hepat
c
viru
hcv
compens
cirrhosi
despit
find
interferon
ifn
peglat
ifn
pegifn
ribavirin
rbv
still
current
standard
care
asian
countri
hcv
infect
high
preval
present
studi
evalu
safeti
efficaci
obvptvr
plu
dsv
coadminist
rbv
adult
chronic
hcv
infect
compens
cirrhosi
mainland
china
south
korea
taiwan
method
phase
openlabel
multicent
studi
safeti
efficaci
obvptvr
plu
dsv
rbv
administ
week
evalu
treatment
experienc
ifnpegifn
rbv
adult
hcv
infect
compens
cirrhosi
fibrosi
stage
efficaci
assess
sustain
virolog
respons
post
treatment
week
compar
histor
svr
rate
telaprevir
plu
pegifn
rbv
safeti
efficaci
assess
patient
receiv
least
dose
studi
drug
result
total
patient
femal
asian
treatmentexperienc
enrol
mainland
china
south
korea
taiwan
patient
chronic
hcv
infect
compens
cirrhosi
data
cutoff
date
may
posttreat
week
data
avail
patient
achiev
rate
treatment
emerg
advers
event
teae
mild
sever
common
teae
increas
blood
bilirubin
level
pruritu
anemia
asthenia
dizzi
four
patient
seriou
teae
assess
relat
daa
regimen
one
assess
possibl
relat
rbv
one
patient
achiev
discontinu
treatment
due
drugrel
teae
day
dose
due
elev
alanin
aminotransferas
aspart
aminotransferas
blood
bilirubin
conclus
high
rate
achiev
hcv
asian
patient
compens
cirrhosi
treat
obvptvr
plu
dsv
rbv
week
regimen
well
toler
mostli
mild
teae
report
rate
entir
studi
report
confer
purpos
aim
studi
assess
costeffect
treat
chronic
hepat
c
hcv
infect
patient
noncirrhot
stage
compar
treat
patient
develop
cirrhosi
method
markov
model
develop
follow
cohort
patient
lifetim
year
age
two
strategi
compar
treat
patient
independ
fibrosi
stage
versu
treat
cirrhot
patient
analysi
perform
gener
patient
popul
age
distribut
patient
differ
fibrosi
stage
cost
reflect
uk
set
patient
treat
ledipasvirsofosbuvir
ldvsof
week
noncirrhot
stage
ldvsof
week
cirrhot
stage
model
structur
base
model
submit
nation
institut
health
care
excel
nice
hcv
previou
health
technolog
apprais
sustain
virolog
respons
rate
transit
probabl
cost
util
obtain
literatur
clinic
trial
ldvsof
cost
outcom
discount
recommend
nice
reinfect
includ
sensit
analysi
well
proport
patient
retreat
reinfect
determinist
probabilist
sensit
analys
conduct
investig
differ
rang
paramet
altern
valu
collect
literatur
onward
transmiss
consid
analysi
result
longterm
cost
lower
qualityadjust
life
year
qali
gain
higher
treatment
start
earlier
stage
diseas
result
analysi
therefor
show
treat
fibrosi
stage
costsav
cost
per
cure
treat
patient
versu
furthermor
treat
patient
earlier
gener
fewer
case
decompens
cirrhosi
hepatocellular
carcinoma
liver
transplant
save
live
result
robust
sensit
analysi
conclus
analysi
demonstr
treat
hcv
earli
fibrosi
stage
includ
costsav
uk
therefor
treat
patient
soon
diagnos
hcv
gener
save
also
reduc
burden
hcv
intens
pk
assess
done
day
respect
pk
leadin
addit
patient
cohort
inadvert
receiv
adult
dose
sof
mg
ldv
sof
mg
day
upon
complet
pk
leadin
patient
continu
sofrbv
week
respect
ldvsof
wk
sof
major
circul
metabolit
ldv
pk
paramet
compar
via
anova
exposur
phase
sof
ldvsof
adult
clinic
program
predefin
equival
bound
safeti
assess
throughout
studi
result
patient
complet
pk
assess
screen
median
rang
age
patient
male
femal
sofrbv
weight
kg
median
rang
age
weight
ldvsof
patient
male
femal
respect
studi
treatment
well
toler
sof
ldv
sof
exposur
similar
pediatr
phase
popul
tabl
conclus
studi
treatment
well
toler
sof
mg
rbv
ldvsof
mg
provid
compar
exposur
observ
adult
data
support
ongo
evalu
dose
children
background
aim
signific
advanc
treatment
chronic
hepat
c
made
direct
act
antivir
daa
regimen
sustain
virolog
respons
svr
rate
may
achiev
patient
data
long
term
virolog
clinic
outcom
regimen
need
recent
report
suggest
hcc
incid
may
reduc
success
daa
therapi
object
ongo
registri
studi
evalu
long
term
outcom
patient
cirrhosi
achiev
svr
follow
treatment
sofosbuvir
sof
base
regimen
method
patient
compens
decompens
cirrhosi
achiev
svr
receiv
sofbas
regimen
elig
enrol
patient
may
enrol
within
week
complet
treatment
studi
transfer
anoth
svr
registri
studi
within
year
achiev
svr
follow
treatment
clinic
practic
set
patient
return
visit
everi
week
year
durabl
svr
clinic
outcom
decompens
hcc
transplant
liverrel
death
laboratori
paramet
relat
diseas
progressionregress
follow
patient
result
patient
enrol
may
mean
age
rang
male
mean
rang
meld
score
baselin
cpt
cpt
b
c
cirrhosi
respect
median
rang
time
sinc
end
treatment
clinic
studi
patient
day
baselin
svr
maintain
patient
hcc
tabl
show
chang
pretreat
cpt
class
start
registri
studi
decompens
cirrhosi
pretreat
chang
laboratori
paramet
time
event
clinic
sign
week
registri
studi
present
conclus
baselin
registri
studi
svr
maintain
patient
cirrhosi
posttreat
sofbas
regimen
patient
decompens
cirrhosi
pretreat
cpt
class
improv
entri
registri
studi
cpt
b
cpt
c
b
unchang
ongo
studi
provid
inform
whether
achiev
svr
follow
treatment
hcv
daa
regimen
improv
longer
term
liver
function
reduc
rate
liverrel
complic
includ
hcc
clinic
studi
choic
antivir
therapi
associ
treatment
outcom
addit
higher
age
posit
factor
presenc
cirrhosi
neg
factor
achiev
dropout
rate
low
confirm
good
adher
patient
regimen
chronic
hcv
preval
doc
although
svr
daa
treatment
tx
high
feasibl
svr
patient
pt
doc
unknown
compar
virginia
doc
daa
telemedicin
hcv
pt
privatelyinsur
indig
clinic
treat
ledipasvirsofosbuvir
method
doc
pt
evalu
via
telemedicin
diseas
sever
appropri
tx
follow
aasldidsa
guidelin
decompens
cirrhosi
signific
comorbid
less
month
sentenc
exclud
demograph
baselin
lab
hiv
prior
tx
statu
tn
experienc
te
advanc
fibrosi
af
bridg
fibrosiscirrhosi
durat
tx
use
ribavirin
rbv
primari
outcom
record
compar
doc
pt
control
group
privatelyinsur
indig
tx
clinic
time
period
provid
exclud
nongenotyp
gt
n
treat
daa
introduct
ledipasvirsofosbuvir
ldvsof
week
approv
treatment
chronic
hepat
c
studi
week
ldvsof
noninferior
wk
previous
untreat
patient
without
cirrhosi
although
number
patient
elig
week
accord
summari
product
characterist
smpc
high
larg
proport
patient
still
receiv
longer
treatment
durat
one
reason
might
uncertainti
whether
week
treatment
durat
suffici
harder
cure
popul
hiv
coinfect
patient
patient
opioid
substitut
treatment
ost
older
patient
yr
aim
analysi
evalu
virolog
respons
rate
wk
treatment
real
world
condit
patient
method
german
hepat
c
registri
nation
multicent
cohort
patient
treat
discret
physician
data
collect
webbas
data
system
confirm
plausibl
check
site
monitor
analysi
data
patient
wk
treatment
ldvsof
avail
data
data
cut
includ
baselin
characterist
prior
treatment
histori
safeti
effect
investig
result
femal
pt
treat
week
mean
sd
age
yr
fibrosi
stage
evalu
elastographi
fibroscan
mean
sd
stiff
valu
kpa
background
hepat
c
viru
hcv
genotyp
gt
account
estim
global
hcv
infect
difficult
cure
directact
antivir
daa
therapi
especi
patient
cirrhosi
prior
treatment
failur
previous
present
safeti
efficaci
ombitasvir
inhibitor
coformul
proteas
inhibitor
paritaprevir
identifi
abbvi
enanta
ritonavir
obvptvr
plu
sofosbuvir
sof
ribavirin
rbv
patient
quartziiiii
arm
b
investig
safeti
efficaci
treatment
durat
patient
assess
rbv
addit
patient
includ
cirrhosi
method
quartz
iiiii
openlabel
multicent
studi
patient
receiv
obvptvr
sof
weightbas
rbv
arm
c
arm
week
patient
cirrhosi
arm
e
receiv
week
patient
without
cirrhosi
receiv
arm
b
without
arm
af
rbv
week
primari
efficaci
endpoint
percentag
patient
achiev
result
studi
enrol
patient
tabl
show
select
baselin
demograph
efficaci
safeti
data
patient
posttreat
week
patient
avail
data
hcv
rna
lloq
two
patient
one
arm
c
week
arm
week
experienc
relaps
date
virolog
failur
patient
infect
regardless
cirrhosi
statu
common
ae
fatigu
headach
nausea
diarrhea
seriou
ae
relat
daa
daarel
ae
led
discontinu
studi
drug
conclus
well
toler
patient
infect
patient
achiev
complet
resist
safeti
data
present
result
first
cohort
previous
present
present
safeti
efficaci
data
second
cohort
arm
ce
includ
patient
compens
cirrhosi
method
particip
either
treatment
tn
treatment
experienc
te
ifnpegifn
rbv
patient
hcv
infect
fibrosi
stage
assign
arm
c
receiv
regimen
rbv
mg
qd
week
fibrosi
stage
assign
arm
treat
regimen
week
patient
hcv
infect
fibrosi
stage
assign
arm
e
treat
regimen
without
rbv
week
efficaci
assess
svr
posttreat
week
safeti
assess
patient
receiv
least
dose
studi
drug
result
total
patient
chronic
hcv
infect
without
cirrhosi
sever
renal
impair
end
stage
renal
diseas
enrol
cohort
arm
c
arm
arm
e
among
male
black
patient
either
stage
chronic
kidney
diseas
includ
hemodialysi
data
cutoff
date
may
achiev
patient
arm
c
e
respect
intenttotreat
popul
patient
achiev
prematur
discontinu
treatment
treatment
emerg
advers
event
ae
mild
moder
sever
anemia
decreas
hemoglobin
fatigu
frequent
report
ten
patient
experienc
seriou
ae
one
patient
discontinu
treatment
arm
c
conclus
preliminari
data
ongo
studi
demonstr
rate
ae
mild
moder
sever
result
support
use
regimen
patient
advanc
renal
diseas
treatment
option
limit
octob
fda
releas
warn
use
ritonavirboost
paritaprevir
ombitasvir
dasabuvir
prod
ribavirin
patient
cirrhosi
consequ
prod
contraind
patient
childturcott
pugh
class
bc
hepat
impair
hyperbilirubinemia
elev
alt
concentr
observ
therapi
sever
clinic
signific
abnorm
realworld
set
report
aim
studi
character
bilirubin
alt
chang
observ
prod
therapi
larg
realworld
popul
determin
impact
chang
outcom
earli
discontinu
therapi
method
patient
particip
australian
compassion
access
program
treat
hepat
c
octob
juli
includ
analysi
receiv
least
one
dose
prod
elev
bilirubin
character
accord
common
terminolog
criteria
advers
event
ctcae
result
patient
includ
analysi
major
cirrhosi
cirrhot
patient
complet
respons
data
hyperbilirubinemia
prod
common
elev
valu
occur
subject
tabl
small
proport
patient
mild
elev
prior
comemnc
patient
experienc
elev
bilirubin
mgdl
cirrhot
develop
hyperbilirubinemia
within
first
week
therapi
ceas
therapi
earli
mean
week
instanc
alt
diminish
prod
mean
iul
howev
patient
increas
alt
least
iul
baselin
associ
hyperbilirubinemia
cirrhot
conclus
realworld
studi
hcv
genotyp
patient
mostli
cirrhosi
rate
excel
hyperbilirubinemia
occur
commonli
instanc
abnorm
mildmoder
lead
discontinu
significantli
impact
upon
svr
small
proport
patient
bilirubin
exceed
frequent
result
earli
discontinu
associ
protect
ribavirininduc
hemolyt
anemia
peginterferon
ifn
ribavirinbas
treatment
hepat
c
viru
hcv
studi
patient
treat
ifn
ribavirin
shown
improv
treatment
efficaci
patient
reduc
itpas
activ
ribavirin
import
compon
ifncontain
regimen
current
recommend
combin
sever
ifnfre
regimen
treatment
hcv
infect
present
studi
genet
analys
conduct
interrog
effect
itpa
variant
anemia
platelet
count
virolog
respons
hcv
genotyp
subject
treat
directact
antivir
daa
regimen
ombitasvirparitaprevirritonavir
dasabuvir
without
ribavirin
method
dna
sampl
obtain
appropri
consent
subject
enrol
pearliv
studi
analyz
itpa
variant
use
pyrosequenc
result
reduct
itpas
activ
protect
ribavirininduc
anemia
effect
signific
gender
ad
covari
analys
male
subject
lower
itpas
activ
protect
ribavirininduc
anemia
hb
chang
gdl
low
itpas
vs
gdl
high
itpas
wherea
signific
associ
note
among
femal
subject
gdl
low
itpas
vs
gdl
high
itpas
ns
itpas
activ
signific
impact
platelet
count
overal
howev
femal
subject
lower
itpas
activ
significantli
higher
incid
thrombocytosi
l
low
itpas
vs
l
high
itpas
associ
note
itpas
activ
reduct
hb
level
platelet
count
patient
treat
without
ribavirin
reduct
itpas
activ
impact
virolog
respons
daa
treatment
viral
kinet
baselin
level
conclus
studi
demonstr
genet
variant
itpa
associ
reduc
activ
may
help
predict
anemia
chronic
hepat
c
patient
treat
ifnfre
regimen
contain
ribavirin
may
particularli
help
context
subject
difficult
treat
hcv
infect
patient
cirrhosi
ribavirincontain
regimen
recommend
contrast
studi
analyz
ifncontain
regimen
studi
show
impact
itpas
activ
reduct
treatment
outcom
relaps
rate
daabas
regimen
purpos
among
patient
chronic
hcv
littl
inform
benefit
achiev
svr
term
liver
function
comparison
nonrespond
assess
liver
function
recent
devis
albi
score
method
patient
followedup
median
year
ci
classifi
achiev
svr
relaps
respons
nr
receiv
interferon
base
therapi
result
differ
liver
function
group
evid
end
treatment
improv
fall
rapidli
nr
relaps
cohort
figur
surviv
better
svr
svr
nonsvr
respect
year
p
fibrosi
assess
index
progress
significantli
r
nr
group
hcc
major
caus
death
great
major
occur
among
nonsvr
group
overal
die
overal
record
die
liver
failur
conclus
within
timefram
studi
svr
associ
improv
liver
function
less
progress
fibrosi
improv
surviv
appear
larg
result
reduct
hcc
develop
background
compassionateus
program
directact
antivir
daa
chronic
hepat
c
viru
hcv
infect
provid
access
daa
pend
approv
provid
realworld
data
effect
safeti
regimen
collect
data
compassionateus
nationwid
program
promot
italian
medicin
agenc
provid
access
regimen
ombitasvir
paritaprevir
pharmacokinet
enhanc
ritonavir
dasabuvir
obvptvr
dsv
ribavirin
rbv
infect
regimen
obvptvr
rbv
infect
patient
cirrhosi
high
risk
decompens
method
hcv
patient
cirrhosi
high
risk
decompens
receiv
oncedaili
coformul
obvptvr
mg
twicedaili
dasabuvir
mg
week
patient
receiv
coformul
obvptvr
mg
week
primari
efficaci
endpoint
sustain
virolog
respons
week
posttreat
univari
multivari
logist
regress
use
identifi
baselin
characterist
associ
advers
event
record
throughout
studi
result
overal
rate
among
cirrhot
patient
receiv
obvptvr
dsv
rbv
therapi
week
logist
regress
analys
identifi
bilirubin
mgd
ci
margin
albumin
gdl
ci
associ
respect
advanc
fibrosi
associ
increas
risk
hd
group
death
proport
person
egfr
increas
higher
among
prod
group
presenc
cirrhosi
appear
affect
conclus
overal
incid
hd
person
treat
prod
regimen
treatment
week
complet
treatment
compar
treat
sofldv
regimen
lower
among
treat
sofsim
regimen
risk
predominantli
observ
cirrhosi
baselin
extent
liver
function
improv
cirrhot
patient
receiv
interferonfre
therapi
unknown
method
dhcr
deutsch
hepat
cregist
german
hepat
cregistri
nation
multicent
realworld
cohort
includ
approx
patient
patient
treat
discret
physician
data
collect
webbas
system
data
qualiti
analyz
plausibl
check
site
monitor
data
analysi
base
patient
observ
least
week
initi
antivir
treatment
patient
advanc
liver
cirrhosi
defin
least
one
follow
criteria
fibroscan
thrombocyt
albumin
sign
liver
decompens
analyz
result
patient
advanc
liver
cirrhosi
median
meldscor
rang
patient
fu
week
includ
major
patient
infect
hcvgenotyp
hcvgenotyp
present
patient
respect
introduct
recent
cohort
analys
claim
hiv
coinfect
independ
impair
respons
directact
antivir
daa
base
therapi
chronic
hepat
c
hcv
real
life
cohort
aim
studi
therefor
compar
rate
hivhcv
coinfect
hcv
monoinfect
subject
nation
german
hcv
cohort
method
dhcr
deutsch
hepat
cregist
german
hepat
cregistri
nation
multicent
realworld
cohort
includ
approx
patient
patient
treat
discret
physician
data
collect
webbas
system
data
qualiti
analyz
plausibl
check
site
monitor
data
analysi
base
patient
observ
least
week
initi
antivir
hcv
treatment
result
overal
hivhcv
coinfect
hcv
monoinfect
subject
includ
analysi
baselin
characterist
group
shown
tabl
introduct
hcv
infect
associ
increas
risk
chronic
kidney
diseas
ckd
manag
hcv
patient
advanc
ckd
remain
challeng
previous
report
treatment
hcv
patient
ombitasvir
paritaprevir
identifi
abbvi
enanta
pharmacokinet
enhanc
ritonavir
dasabuvir
obvptvr
dsv
rbv
associ
overal
chang
renal
function
howev
observ
mean
gain
egfr
follow
treatment
patient
baselin
bl
egfr
ml
ml
analysi
investig
bl
patient
characterist
laboratori
predictor
egfr
improv
obvptvr
dsv
rbv
method
renal
function
categor
egfr
use
mdrd
equat
patient
group
accord
bl
egfr
analysi
includ
patient
treat
obvptvr
dsv
rbv
trial
sapphireiii
turquoiseiiiii
topazii
pearliiiii
iv
rubyi
exclud
patient
dialysi
bl
factor
associ
increas
egfr
examin
stepwis
logist
regress
introduct
hepat
c
viral
infect
hcv
remain
one
main
caus
chronic
liver
diseas
worldwid
becom
curabl
diseas
due
develop
direct
act
antivir
daa
therefor
set
target
elimin
hcv
complet
reach
target
peopl
inject
drug
pwid
need
treat
largest
risk
group
hcv
western
world
furthermor
treatment
hcv
pwid
recommend
treatment
guidelin
aim
studi
uptak
outcom
treatment
hcv
pwid
gener
popul
method
perform
belgian
nationwid
retrospect
cohort
studi
hospit
patient
treat
hospit
simeprevirsofosbuvir
daclatasvirsofosbuvir
ombitasvirparitaprevir
ritonavir
dasabuvir
decemb
novemb
includ
regimen
chosen
base
belgian
reimburs
criteria
center
experienc
treat
hcv
infect
pwid
case
antivir
treatment
start
data
collect
central
databas
pwid
subdivid
activ
user
defin
drug
use
therapi
daa
former
pwid
pwid
defin
someon
use
intraven
drug
least
result
studi
popul
consist
patient
pwid
subdivid
activ
user
former
pwid
nonpwid
treat
one
daa
regimen
ribavirin
pwid
activ
former
younger
predominantli
male
lower
bmi
abus
alcohol
use
benzodiazepin
infect
genotyp
activ
pwid
less
treatment
experienc
use
less
comed
differ
fibrosi
score
group
pwid
similar
rate
sideeffect
trend
toward
psycholog
complaint
pwid
similar
rate
treatment
complet
svr
achiev
irrespect
activ
substanc
abus
conclus
although
daa
safe
effect
also
activ
drug
user
pwid
still
highli
underrepres
belgian
treatment
cohort
even
era
new
daa
therapi
riskgroup
heart
hcv
epidem
effort
necessari
reach
group
auditc
questionnair
within
one
year
prior
initi
therapi
compris
final
studi
sampl
daa
includ
sofosbuvir
sof
ledipasvirsofosbuvir
ldvsof
ombitasvirparitaprevirritonavir
dasabuvir
prod
sustain
virolog
respons
svr
defin
viral
load
limit
quantif
perform
week
end
treatment
auditc
score
categor
abstin
lowlevel
drink
unhealthi
drink
men
women
rate
svr
confid
interv
calcul
perform
multipl
logist
regress
model
without
imput
miss
svr
data
respect
absenc
variant
treat
simeprevir
found
significantli
associ
svr
p
among
patient
treat
sofldv
treatment
discontinu
necessari
two
patient
due
esophag
pneumonia
respect
rate
one
patient
cirrhosi
variant
relaps
therapi
among
patient
treat
sofrbv
treatment
discontinu
rate
rate
patient
achiev
svr
complet
treatment
patient
cirrhot
rbv
dose
reduc
patient
cirrhosi
found
significantli
associ
nonsvr
conclus
cohort
includ
substanti
proport
cirrhot
patient
gener
exhibit
high
respons
rate
hcv
variant
associ
nonsvr
among
patient
treat
dcvasv
cirrhosi
associ
reduct
svr
rate
among
patient
treat
sofbas
regimen
disclosur
follow
peopl
noth
disclos
tatsuya
thank
nation
strategi
plan
tackl
hepat
c
spain
around
infect
patient
cure
mainli
gener
popul
howev
plan
also
consid
prioriti
infect
patient
prison
accordingli
plan
project
northern
region
spain
cantabria
inhabit
focus
region
longstay
prison
el
dueso
object
perform
systemat
screen
evalu
infect
relat
bloodborn
virus
evalu
efficaci
safeti
ifnfre
antivir
regimen
includ
impact
rate
reinfect
shortlong
term
method
project
plan
start
follow
consecut
phase
viral
test
character
treatment
hcv
infect
inmat
followup
patient
month
new
entri
prison
test
immedi
treatment
initi
first
week
hcvposit
list
variabl
analyz
includ
demograph
clinic
virolog
variabl
includ
baselin
resist
deep
analysi
nucleotid
sequenc
quasispeci
complex
region
endotheli
dysfunct
neurocognit
function
test
treatment
month
efficaci
safeti
qol
throughout
studi
rate
persist
hcv
infect
reinfect
superinfect
result
inmat
includ
full
test
bloodborn
virus
major
inmat
male
median
age
yr
seventi
patient
antihcv
posit
hcv
rna
posit
hcv
genotyp
background
aim
peopl
inject
drug
pwid
drive
forc
chronic
hepat
c
chc
western
world
treatment
uptak
low
direct
act
antivir
daa
cure
patient
outreach
treatment
program
drug
treatment
center
dtc
feasibl
shorter
treatment
durat
desir
four
week
daa
trial
disappoint
far
hypothesis
maintain
ribavirin
rbv
week
daa
regimen
ad
pegylatedinterferon
alpha
peg
could
give
high
cure
rate
drug
user
method
studi
conduct
one
dtc
thirti
two
patient
random
either
ldvsofrbv
ldvsofrbvpeg
week
rbv
dose
weight
base
peg
ug
weekli
main
inclus
criteria
treatment
patient
chc
genotyp
opium
substitut
therapi
ost
p
age
year
weight
kg
viral
load
iuml
liver
stiff
measur
lsm
kpa
subject
allow
kind
concomit
drug
alcohol
use
compliant
ost
program
primari
endpoint
sustain
virolog
respons
week
end
treatment
svr
intent
treat
itt
popul
result
forti
seven
person
screen
initi
treatment
date
submiss
svr
itt
popul
interferon
arm
interferon
free
arm
one
virolog
relap
detect
remain
three
failur
due
lost
followup
prematur
withdrawel
therapi
pp
far
interferon
arm
interferon
free
arm
full
svr
data
present
meet
conclus
week
sofosbuvir
ledipasvir
ribavirin
without
interferon
highli
effect
cure
chc
hard
reach
easi
treat
popul
noncirrhot
drug
user
ost
one
virolog
relaps
detect
pp
patient
deliv
treatment
dtc
concurr
ost
feasibl
svr
rate
suggest
short
regiment
evalu
larger
trial
background
hcv
affect
approxim
million
person
southeast
asia
one
preval
genotyp
treatment
data
limit
especi
new
direct
act
antivir
daa
agent
ldvsof
fdc
week
shown
effect
multipl
hcv
genotyp
includ
goal
examin
treatment
outcom
divers
popul
method
prospect
enrol
patient
four
medic
center
california
texa
usa
patient
receiv
ldv
mg
singl
tablet
regimen
oral
day
week
cirrhosi
week
cirrhosi
experienc
treatmentexperienc
cirrhosi
noncirrhosi
patient
prior
solid
organ
transplant
exclud
primari
outcom
sustain
virolog
respons
week
therapi
secondari
outcom
advers
event
ae
patient
gave
written
consent
result
overal
mean
age
male
patient
asian
foreignborn
group
includ
patient
includ
patient
statist
signific
differ
baselin
clinic
laboratori
characterist
cirrhosi
statu
prior
treatment
histori
two
group
baselin
hcv
rna
level
receiv
medic
evalu
particip
initi
treatment
receiv
alcohol
counsel
health
promot
treatment
readi
counsel
medic
coordin
twothird
particip
receiv
first
health
promot
session
within
day
enrol
project
implement
two
major
medic
center
start
mani
treatment
expect
vast
major
cure
next
year
plan
dissemin
care
coordin
protocol
health
promot
materi
develop
cost
care
coordin
calcul
integr
payment
model
expect
chang
svr
ldr
compar
wbr
across
easytotreat
noncirrhot
femal
cc
hardtotreat
cirrhot
male
noncc
subpopul
safeti
analys
paritaprevir
rbv
auc
valu
baselin
tbil
associ
tbil
elev
rbv
auc
baselin
hgb
sex
cirrhosi
associ
hgb
reduct
predict
probabl
grade
tbil
elev
grade
hgb
reduct
ldr
significantli
lower
observ
wbr
respect
conclus
exposurerespons
analys
demonstr
lower
rbv
dose
mg
weight
base
dose
regimen
would
improv
toler
minim
effect
svr
chang
hcv
infect
patient
avail
data
posttreat
achiev
patient
patient
achiev
elect
undergo
renal
transplant
withdrew
consent
treatment
week
one
patient
discontinu
studi
drug
achiev
safeti
summar
tabl
rbvfree
directact
antivir
regimen
obvptvr
dsv
week
treatment
patient
sever
endstag
renal
diseas
hcv
infect
appear
safe
effect
patient
esrd
includ
hemodialysi
complet
data
avail
present
backgroundaim
asunaprevir
asv
administr
daclatasvir
dcv
genotyp
hepat
c
patient
japan
alanin
aminotransferas
alt
elev
frequent
advers
event
howev
precis
mechan
elucid
ursodeoxychol
acid
udca
use
hepatoprotect
medicin
case
liver
dysfunct
studi
investig
signific
serum
asv
concentr
relationship
alt
elev
patient
method
patient
genotyp
chronic
hepat
c
treat
asv
twice
dcv
daili
pharmacokinet
pk
asv
investig
case
trough
concentr
asv
casv
trough
week
measur
intens
pk
studi
perform
case
casv
hour
asv
administr
measur
day
casv
trough
week
measur
case
casv
measur
hplc
case
administr
udca
continu
start
combin
therapi
case
improv
alt
iul
maintain
treatment
period
classifi
stabl
rel
group
relaps
rel
group
result
intens
pk
studi
median
c
max
ngml
max
hour
mean
casv
trough
week
wide
distribut
ledipasvirsofosbuvir
respect
hcv
treatment
failur
encount
particip
frequent
liver
id
specialist
vs
p
liver
specialist
treat
hcv
decompens
cirrhosi
id
specialist
vs
p
hcv
recurr
liver
transplant
lt
vs
p
year
experi
treat
hcv
affect
approach
hcv
treatment
failur
hepat
fibrosi
assess
method
hcv
treatment
liver
biopsi
obtain
respond
insur
coverag
major
limit
factor
prevent
initi
daa
practition
discuss
knowledg
largest
survey
pattern
hcv
manag
liver
id
specialist
major
respond
adher
aasldidsa
hcv
treatment
guidelin
liver
specialist
treat
decompens
cirrhot
post
lt
patient
liver
biopsi
larg
replac
noninvas
method
assess
hepat
fibrosi
id
specialist
identifi
group
could
expand
hcv
treatment
workforc
less
idsa
respond
treat
hcv
essenti
identifi
barrier
id
specialist
treat
hcv
augment
hcv
care
capac
survey
rais
import
issu
need
consensu
amongst
insur
program
improv
hcv
treatment
access
global
scale
valu
number
fisher
exact
test
disclosur
follow
peopl
noth
disclos
maen
masadeh
huafeng
shen
yazan
hasan
andrew
johann
antonio
j
sanchez
risk
factor
still
relev
hcv
treatment
directlyact
agent
hcv
hivhcvcoinfect
result
german
hepat
c
cohort
gecco
introduct
directlyact
agent
daa
hcv
improv
treatment
chronic
hepat
c
due
higher
efficaci
better
toler
substanti
reduct
contraind
despit
major
progress
relaps
still
occur
assess
influenc
tradit
risk
factor
treatment
outcom
hivhcvcoinfect
method
gecco
cohort
multicent
cohort
site
germani
patient
start
follow
daa
regimen
includ
analysi
pegyl
interferon
pegifn
ribavirin
rbv
sofosbuvir
sof
sof
rbv
sof
simeprevir
smv
sof
daclatasvir
dcv
rbv
sofledipasvir
ldv
paritaprevirritonavir
prtr
ombitasvir
obv
rbv
dasabuvir
dsv
treatment
outcom
measur
sustain
virolog
respons
week
end
therapi
itt
proport
patient
gecco
also
part
german
hepat
c
registri
result
analysi
base
hivhcvcoinfect
patient
gecco
cohort
risk
factor
associ
lower
rate
presenc
liver
cirrhosi
vs
vs
although
presenc
liver
cirrhosi
strongli
correl
cell
count
p
without
cirrhosi
also
associ
lower
svr
rate
figur
age
sex
hcvrna
mio
iuml
alt
level
cdc
stage
specif
antiretrovir
therapi
hcv
treatment
regimen
associ
statist
lower
svr
rate
conclus
despit
consider
improv
efficaci
treatment
chronic
hepat
c
daa
hivhcvcoinfect
low
cell
liver
cirrhosi
remain
risk
factor
treatment
failur
associ
presenc
liver
cirrhosi
low
cell
count
may
explain
portal
hypertens
splenomegali
consecut
lymphopenia
background
aim
phase
studi
daa
patient
chronic
hepat
c
cirrhosi
includ
patient
year
itali
restrict
prescript
ifnfre
regimen
patient
sever
fibrosi
cirrhosi
skew
usag
daa
toward
advanc
age
fascia
contain
patient
frequent
comorbid
comed
candid
olt
evalu
safeti
efficaci
daa
regimen
use
ongo
dataset
region
databas
resisthcv
includ
hcv
patient
present
treatment
liver
centr
throughout
sicili
order
evalu
appropri
prioriti
conclus
use
ifnfre
daa
regimen
practic
safe
effect
elderli
patient
cirrhosi
sever
fibrosi
due
hcv
younger
popul
lifetim
util
hcv
erad
elder
term
reduct
event
overal
surviv
need
evalu
longterm
observ
cohort
background
directlyact
antivir
safe
effect
advanc
hepat
c
cirrhosi
impact
svr
morbid
mortal
advanc
diseas
unknown
examin
outcom
ukeld
albi
score
hcv
patient
advanc
cirrhosi
treat
uk
hcv
earli
access
program
either
sofosbuvirledipasvir
sofosbuvirdaclatasvir
result
patient
childpugh
score
baselin
averag
followup
time
week
posttreat
svr
achiev
patient
whilst
relaps
svr
predict
death
year
overal
progress
transplant
overal
associ
signific
improv
ukeld
preversu
year
postsvr
albi
score
preversu
year
postsvr
seen
patient
relaps
strikingli
cumul
probabl
hcc
incid
year
posttreat
signifcantli
higher
relaps
group
versu
svr
group
fisher
exact
test
svr
signific
predictor
posttreat
diagnosi
hcc
independ
meld
ukeld
albi
multivari
analysi
conclus
data
suggest
rapid
benefit
daa
treatment
advanc
hcv
cirrhosi
reduct
transplant
rate
may
becom
evid
longer
followup
strongli
predict
fall
ukeld
group
unclear
whether
lower
incid
hcc
svr
group
repres
inhibit
tumour
initi
reduc
growth
radiolog
undetect
lesion
pretreat
either
scenario
improv
liver
function
svr
widen
treatment
option
time
hcc
diagnosi
purpos
direct
act
antivir
therapi
daa
expans
resourcelimit
set
urgenc
valid
best
practic
populationbas
screen
treatment
hepat
c
hcv
deutsch
gesellschaft
international
zusammenarbeit
giz
gmbh
german
develop
cooper
implement
communitybas
screen
treatment
model
monoinfect
hivhcv
coinfect
person
nepal
individu
live
hcv
genotyp
genotyp
kinkel
h
method
pivot
hcv
screen
treatment
within
exist
opioid
substitut
treatment
ost
site
screen
patient
hcv
viral
load
gt
ast
platelet
ratio
index
apri
fibroscan
enrol
hcv
monoinfect
hivhcv
coinfect
individu
treatment
ongo
studi
patient
diseas
optim
predictor
baselin
hcv
viral
load
iu
ml
hivneg
cirrhosi
age
bodi
mass
index
favor
snp
receiv
sofosbuvirpegifnrbv
sir
vs
sdaclatasvir
sd
r
cirrhot
includ
sledipasvir
sl
sd
r
cirrhot
result
demonstr
optim
complet
rapid
virolog
respons
rvr
c
without
signific
toxic
among
first
patient
treat
hiv
tenofovir
disoproxil
fumar
tdf
contain
antiretrovir
regimen
treatment
regimen
sd
sl
r
patient
compens
cirrhosi
sir
apri
cutoff
compar
fibroscan
sensit
specif
neg
predict
valu
advanc
fibrosi
conclus
optim
outcom
drug
toler
demonstr
effect
commun
ostbas
hcv
screen
treatment
resourcelimit
set
simpl
individu
daabas
therapi
excel
earli
outcom
across
gt
reallif
set
encompass
hivinfect
inject
drug
user
support
simpl
hcv
diagnostictreat
model
implement
ost
site
result
valuabl
extend
populationbas
hcv
treatment
resourcelimit
set
background
rate
hepat
c
viru
hcv
posit
higher
patient
hemodialysi
gener
popul
sever
studi
report
hcv
infect
associ
poor
prognosi
hemodialysi
patient
interferonbas
therapi
show
lower
sustain
virolog
respons
rate
svr
hemodialysi
patient
patient
requir
dialysi
combin
oral
administ
daclatasvir
dcv
plu
asunaprevir
asv
effect
patient
infect
hcv
genotyp
expect
safe
chronic
hemodialysi
patient
drug
mainli
metabol
liver
studi
evalu
safeti
efficaci
dcv
plu
asv
combin
therapi
hemodialysi
patient
infect
hcv
method
nineteen
hemodialysi
patient
infect
hcv
genotyp
infect
treat
dcv
plu
asv
combin
therapi
decemb
januari
sixteen
patient
nine
men
seven
women
follow
week
end
treatment
svr
week
discontinu
therapi
dose
reduct
owe
advers
event
evalu
result
patient
three
treat
interferonbas
regimen
median
patient
age
year
rang
year
patient
older
age
year
seven
patient
compens
liver
cirrhosi
despit
two
patient
resistanceassoci
variant
rav
hcv
region
baselin
patient
achiev
one
patient
cirrhosi
discontinu
treatment
week
owe
onset
acut
pneumonia
anoth
patient
requir
asv
dose
reduct
owe
mild
hepat
disord
patient
recov
discontinu
dose
reduct
later
achiev
conclus
dcv
plu
asv
combin
therapi
hemodialysi
patient
infect
hcv
high
antivir
activ
toler
even
older
patient
patient
liver
cirrhosi
rav
aim
hepat
c
viru
hcv
one
import
agent
chronic
hepat
liver
cirrhosi
hepatocellular
carcinoma
far
interferonfre
daa
combin
therapi
one
effect
treatment
chronic
hepat
c
patient
effect
therapi
might
involv
immun
respons
compos
innat
immun
respons
adapt
immun
respons
aim
studi
examin
effect
daa
combin
therapi
innat
immun
respons
nk
cell
activ
frequenc
dim
bright
nk
cell
subset
peripher
blood
chronic
hepat
c
patient
patient
method
twentythre
chronic
hepat
c
patient
hcv
genotyp
combin
therapi
daa
perform
asunaprevir
daclatasvir
fifteen
harvoni
sofosbuvir
ledipasvir
five
viekirax
ombitasvir
paritaprevir
ritonavir
three
ten
patient
male
thirteen
patient
femal
end
therapi
eot
nk
cell
activ
frequenc
dim
nk
cell
bright
nk
cell
peripher
blood
estim
cr
releas
assay
threecolor
flowcytometri
statist
analysi
perform
oneway
anova
studi
approv
ethic
committe
institut
written
inform
consent
obtain
patient
procedur
studi
conduct
accord
declar
helsinki
result
analysi
anova
show
nk
cell
activ
significantli
improv
eot
compar
therapi
p
also
show
frequenc
dim
nk
cell
peripher
blood
significantli
increas
eot
compar
therapi
p
conclus
combin
therapi
daa
chronic
hepat
c
patient
improv
nk
cell
activ
increas
frequenc
dim
nk
cell
peripher
blood
reveal
reduct
hcv
load
chronic
hepat
c
patient
could
restor
nk
cell
activ
reduc
hcv
therefor
result
studi
impli
daa
combin
therapi
might
abl
reduc
risk
hcc
chronic
hepat
c
patient
restor
activ
innat
immun
respons
disclosur
follow
peopl
noth
disclos
ikuo
nakamura
yoshihiro
background
egypt
hcv
infect
account
hcv
infect
agateii
larg
egyptian
phase
trial
enrol
treatmentna
previous
treat
pegifn
rbv
patient
infect
hcv
without
cirrhosi
arm
compens
cirrhosi
arm
bc
patient
receiv
directact
antivir
agent
regimen
ombitasvir
obv
inhibitor
paritaprevir
ptv
proteas
inhibitor
ritonavir
r
pharmacokinet
enhanc
plu
ribavirin
rbv
method
patient
receiv
obvptvr
mg
daili
plu
weightbas
rbv
overal
patient
without
cirrhosi
alloc
treatment
arm
patient
compens
cirrhosi
random
treatment
arm
b
treatment
arm
c
patient
follow
week
posttreat
primari
object
agateii
assess
safeti
sustain
virolog
respons
week
post
treatment
assess
chang
liver
biomark
cirrhot
patient
baselin
bl
posttreat
week
ptw
arm
b
arm
c
result
among
patient
compens
cirrhosi
rate
arm
itt
mitt
popul
exclud
nonvirolog
failur
arm
rate
itt
mitt
popul
respect
advers
event
mainli
mildmoder
sever
patient
discontinu
due
advers
event
liver
biomark
includ
fibrosi
liver
function
show
improv
bl
arm
b
arm
c
tabl
final
data
liver
biomark
chang
present
conclus
hcv
egyptian
patient
compens
cirrhosi
treatment
obvptvr
rbv
week
well
toler
result
high
svr
rate
improv
bl
liver
background
although
novel
directact
antivir
daa
achiev
high
sustain
virolog
respons
svr
rate
chronic
hepat
c
hcv
global
access
daa
limit
due
high
price
reduc
price
offer
voluntari
licens
avail
countri
repres
worldwid
epidem
perkilogram
price
activ
pharmaceut
ingredi
api
steadi
high
demand
volum
key
determin
total
product
cost
medicin
background
phase
iii
registr
trial
ritonavir
boost
paritaprevir
ombitasvir
dasabuvir
prod
ribavirin
safe
well
toler
excel
efficaci
rate
howev
realworld
data
safeti
efficaci
prod
therapi
cirrhot
patient
limit
method
octob
juli
compassion
access
program
support
abbvi
pti
ltd
conduct
australia
across
treatment
center
patient
includ
receiv
least
one
dose
prod
primari
endpoint
hcv
viral
load
lloq
least
week
post
treatment
drug
discontinu
rate
due
advers
event
frequenc
natur
seriou
advers
event
particular
focu
death
hepat
decompens
grade
biochem
abnorm
collect
current
analysi
patient
cirrhosi
cpb
complet
treatment
outcom
data
avail
overal
svr
rate
similar
cirrhot
noncirrhot
patient
respect
patient
infect
genotyp
receiv
ribavirin
baselin
featur
fulli
character
patient
shown
tabl
similar
previou
report
baselin
viral
load
meld
score
liver
stiff
influenc
svr
earli
cessat
therapi
occur
patient
patient
lower
hyperbilirubinaemia
therapi
common
patient
cirrhot
report
overt
fatigu
rate
sofrbv
ldvsof
baselin
score
similar
two
group
howev
soon
treatment
number
hrql
declin
receiv
sofrbv
point
end
treatment
p
contrast
improv
hrql
score
receiv
ldvsof
observ
start
improv
continu
throughout
treatment
end
treatment
p
notabl
hrql
decrement
observ
ldvsof
treatment
cessat
receiv
rbv
decrement
observ
posttreat
hrql
impair
resolv
posttreat
p
contrast
complet
ldv
sof
hrql
improv
posttreat
posttreat
p
multivari
analysi
use
rbv
independ
associ
mild
impair
hrql
beta
rang
introduct
hepat
c
viru
hcv
infect
approxim
time
common
among
us
veteran
receiv
care
veteran
affair
va
medic
center
among
gener
popul
infect
classifi
genotyp
histor
hcv
therapi
less
success
veteran
gener
popul
comorbid
psychiatr
disord
regular
alcoholtobacco
use
may
account
differ
ombitasvir
paritaprevirritonavir
dasabuvir
ribavirin
rbv
approv
us
hcv
adult
without
cirrhosi
studi
prospect
evalu
safeti
efficaci
hcv
us
veteran
includ
patient
ongo
psychiatr
disord
current
past
alcoholtobacco
use
method
topazva
phase
openlabel
trial
conduct
hcv
treatmentna
experienc
us
veteran
without
cirrhosi
us
va
medic
center
particip
receiv
rbv
except
noncirrhot
individu
receiv
treatment
durat
week
except
patient
cirrhosi
week
sustain
virolog
respons
drugassoci
resist
variant
advers
event
ae
assess
result
select
baselin
demograph
present
tabl
current
alcohol
consumpt
tobacco
use
report
baselin
patient
respect
addit
patient
report
ongo
psychiatr
disord
achiev
patient
ongo
psychiatr
disord
intenttotreat
popul
miss
data
imput
failur
total
patient
experienc
ae
commonli
fatigu
headach
nausea
seriou
ae
observ
patient
consid
case
patient
discontinu
treatment
due
ae
conclus
hcv
us
veteran
rbv
associ
high
rate
well
toler
presenc
psychiatr
disord
alcohol
consumpt
appear
impact
avail
safeti
efficaci
resist
result
present
purpos
hepat
c
viru
hcv
caus
inflamm
hepatocyt
time
lead
cirrhosi
addit
effect
liver
caus
extrahepat
complic
insulin
resist
studi
demonstr
associ
hcv
progress
insulin
resist
diabet
well
improv
glycem
control
upon
virolog
respons
howev
clinic
impact
improv
glycem
control
diabet
patient
achiev
sustain
virolog
respons
week
posttreat
svr
unknown
object
primari
object
studi
determin
impact
antihyperglycem
medic
need
patient
achiev
svr
hcv
directact
antivir
daa
secondari
object
determin
impact
antihyperglycem
medic
need
patient
relaps
determin
impact
hemoglobin
patient
achiev
svr
methodolog
patient
diagnosi
diabet
complet
cours
hcv
daa
februari
octob
identifi
use
code
medic
dispens
histori
retrospect
patient
data
collect
electron
medic
record
coprimari
endpoint
chang
antihyperglycem
medic
categor
deescal
chang
escal
baselin
end
hcv
treatment
baselin
month
posttreat
patient
achiev
svr
secondari
endpoint
includ
chang
antihyperglycem
medic
relaps
chang
baselin
month
posttreat
achiev
svr
descript
statist
use
endpoint
pair
ttest
use
data
result
patient
patient
met
inclus
criteria
major
patient
male
mean
age
primarili
black
advanc
fibrot
liver
diseas
present
patient
patient
achiev
svr
deescal
antihyperglycem
baselin
month
posttreat
compar
hcv
daa
relaps
avail
data
patient
achiev
svr
show
statist
signific
decreas
percentag
point
ci
conclus
studi
found
clinic
meaning
deescal
antihyperglycem
well
signific
decreas
diabet
patient
abl
achiev
svr
hcv
daa
demonstr
addit
potenti
benefit
svr
close
diabet
followup
posthcv
treatment
warrant
prospect
larger
studi
need
valid
result
tabl
contraind
potenti
ddi
frequent
present
pt
age
yr
daa
genotyp
g
daa
except
ldvsof
tabl
multivari
analys
presenc
contraindicationspotenti
ddi
agent
independ
associ
fibrosi
conclus
contraindicationspotenti
ddi
current
daa
frequent
present
inh
also
present
inh
sof
probabl
ddi
higher
pt
prioriti
daa
therapi
eg
advanc
liver
diseas
therefor
caution
care
select
appropri
daa
regimen
warrant
clinic
practic
background
aim
improv
cognit
function
liver
transplant
lt
relat
decreas
cerebr
white
matter
lesion
induc
microvascular
lesion
leukoaraiosi
secondari
lowgrad
cerebr
edema
system
inflamm
howev
studi
address
chang
acut
set
immedi
lt
cirrhosi
well
acut
liver
failur
evalu
longterm
chang
cerebr
hemodynam
popul
therefor
aim
investig
longterm
chang
cerebr
hemodynam
cirrhot
patient
lt
tabl
clinic
improv
cognit
observ
patient
overt
lt
conclus
result
show
improv
cerebr
hemodynam
longterm
lt
cirrhosi
indic
less
arteri
cerebr
vasoconstrict
decreas
piri
seem
influenc
system
inflamm
could
explain
improv
cognit
function
lt
tcd
could
consid
use
tool
assess
chang
cerebr
hemodynam
pre
postlt
cirrhosi
background
biomark
profil
diagnost
acut
reject
ar
could
enhanc
diagnosi
manag
liver
transplant
lt
recipi
aim
identifi
diagnost
genom
mrna
signatur
ar
distinct
patient
caus
graft
dysfunct
normal
function
method
lt
recipi
undergo
liver
biopsi
caus
blood
collect
mrna
express
plu
peg
microarray
two
independ
pathologist
hepatologist
confirm
follow
phenotyp
tx
normal
function
ar
hcvr
hepat
c
recurr
mix
arhcvr
blood
analysi
discoveri
train
set
gener
lock
classif
model
phenotyp
test
second
valid
set
use
leaveon
crossvalid
loocv
addit
subset
biopsi
tissu
underw
discoveri
comparison
ar
vs
hcvr
vs
arhcvr
result
lt
recipi
tx
ar
hcvr
arhcvr
age
year
male
mean
year
lt
analyz
predict
accuraci
signatur
differenti
ar
tx
hcvr
arhcvr
well
hcvr
arhcvr
high
vari
base
cv
vs
loocv
model
tabl
biopsi
tissu
mrna
profil
differenti
ar
hcvr
mix
hcvar
accuraci
biolog
function
canon
pathway
map
blood
graft
profil
suggest
sever
immuneinflammatori
gene
differenti
express
recipi
ar
vs
etiolog
conclus
identifi
blood
graft
mrna
signatur
distinguish
ar
major
caus
graft
injuri
lt
recipi
high
accuraci
biomark
may
use
manag
lt
recipi
noninvas
diagnos
ar
immun
monitor
guid
immunosuppress
modif
sampl
recent
complet
prospect
multicent
studi
niaid
use
extern
valid
signatur
test
predict
valu
prior
ar
liver
transplant
lt
effect
therapi
treatment
chronic
liver
diseas
hepat
liver
failur
howev
unbal
organ
avail
increas
number
potenti
candid
undergo
lt
serious
limit
therapeut
approach
fact
prompt
need
expand
inclus
criteria
graft
lt
graft
accept
transplant
present
steatosi
liver
steatosi
consid
primari
factor
graft
failur
lt
mechan
involv
process
fulli
character
although
macrovesicular
steatosi
consid
key
factor
determin
outcom
lt
recent
find
shown
cholesterol
accumul
control
hepat
ischemiareperfus
injuri
sensit
inflammatori
cytokin
oxid
stress
henc
aim
character
level
cholesterol
express
regulatori
enzym
order
optim
select
criteria
liver
graft
predict
outcom
lt
method
graft
biopsi
collect
donor
recipi
liver
transplant
total
donor
biopsi
analyz
chop
pdk
hmgcoa
r
mrna
express
rtpcr
free
cholesterol
analyz
hplc
graft
reject
clinic
outcom
lt
follow
first
year
patient
result
meld
score
recipi
mrna
level
donor
biopsi
correl
month
lt
meld
score
hmgcoa
r
mrna
level
donor
biopsi
correl
month
lt
mrna
level
donor
biopsi
correl
total
cholesterol
triglycerid
level
graft
clinic
data
mrna
profil
statist
relat
patient
surviv
follow
lt
meld
score
significantli
increas
patient
bad
prognosi
exhibit
higher
hmgcoa
r
mrna
level
donor
liver
biopsi
mrna
level
free
cholesterol
content
donor
biopsi
show
trend
increas
patient
die
first
year
lt
moreov
percentag
patient
enhanc
hmgcoa
r
mrna
level
significantli
increas
third
tertil
indic
bad
prognosi
patient
hmgcoa
r
express
beyond
specif
threshold
final
multivari
analysi
confirm
elev
hazard
risk
patient
elev
mrna
level
hmgcoa
r
donor
biopsi
level
chop
less
impact
low
high
meld
group
signific
differ
observ
oper
time
graft
weight
grwr
type
graft
harvest
group
howev
patient
high
meld
score
requir
significantli
transfus
fresh
frozen
plasma
vs
p
background
although
screen
liver
transplant
olt
candid
coronari
arteri
diseas
cad
recommend
lack
data
effect
screen
strategi
centr
adopt
cardiac
risk
assess
protocol
stratifi
patient
risk
group
base
age
cardiac
riskfactor
object
assess
safeti
efficaci
cardiac
risk
stratif
protocol
patient
undergo
olt
assess
method
consecut
patient
year
undergo
olt
assess
period
prospect
includ
patient
stratifi
one
cardiac
risk
group
receiv
standardis
investig
tabl
primari
outcom
perior
postop
cardiac
event
figur
risk
graft
loss
chronic
reject
higher
younger
compar
older
aa
women
hr
ci
p
signific
risk
differ
older
aa
caucasian
women
howev
noncompli
caus
graft
loss
significantli
differ
younger
older
aa
women
younger
aa
younger
caucasian
women
p
valu
conclus
aa
women
especi
age
year
higher
risk
graft
loss
compar
older
aa
women
women
racialethn
group
graft
loss
chronic
reject
frequent
young
aa
women
explain
medic
noncompli
studi
racial
differ
drug
metabol
therefor
need
better
understand
mechan
underli
differenti
rate
reject
graft
loss
year
lt
beyond
year
lt
respect
achiev
svr
variabl
strongli
associ
prevent
declin
egfr
end
follow
hr
p
figur
achiev
svr
prior
lt
led
least
frequenc
declin
egfr
compar
treat
lt
figur
background
although
surgeri
potenti
cur
treatment
intrahepat
cholangiocarcinoma
ihcc
outcom
still
unsatisfactori
aim
establish
preoper
prognost
score
identifi
patient
need
therapeut
option
method
total
patient
collect
prospect
maintain
institut
databas
among
patient
underw
hepatectomi
enrol
preoper
avail
predictor
inflamm
paramet
tumor
marker
evalu
remain
inoper
patient
use
control
perform
surviv
analysi
result
overal
median
surviv
time
mst
surviv
month
multivari
analys
use
preoper
predictor
identifi
nlr
crp
iu
ml
independ
associ
poorer
overal
surviv
given
result
preoper
prognost
score
defin
follow
none
factor
presenc
one
factor
presenc
factor
mst
surviv
score
month
compar
month
score
month
score
p
p
respect
moreov
surviv
patient
score
inoper
control
patient
almost
mst
month
year
surviv
respect
conclus
preoper
prognost
score
icc
simpl
use
identifi
patient
need
therapeut
option
background
liver
transplant
lt
success
treatment
option
endstag
liver
lt
liverrel
infecti
cardiovascular
complic
contribut
reduc
graft
patient
surviv
condit
associ
increas
von
willebrand
factor
antigen
vwfag
previous
also
correl
surviv
cirrhot
patient
evalu
vwfag
predict
marker
lt
method
conduct
prospect
studi
patient
first
lt
treat
univers
hospit
heidelberg
patient
seen
followup
lt
outpati
clinic
depart
novemb
august
screen
includ
patient
least
year
age
time
inclus
patient
first
lt
elig
measur
vwfag
patient
follow
prospect
regard
primari
endpoint
name
retransplantationfre
surviv
summari
six
patient
die
receiv
relt
followup
median
vwfag
patient
significantli
higher
patient
aliv
end
followup
median
roc
analysi
auc
reveal
optim
cutoff
predict
primari
endpoint
sensit
specif
surviv
longer
patient
vwfag
cutoff
compar
higher
vwfag
p
accord
logrank
test
vwfag
associ
retransplantationfre
surviv
multivari
analysi
alkalin
phosphatas
alp
meld
score
donor
age
cold
ischemia
time
score
combin
vwfag
alp
show
impress
capabl
roc
analysi
auc
distinguish
patient
regard
primari
endpoint
conclus
vwfag
noninvas
marker
predict
outcom
patient
lt
diagnost
perform
increas
combin
alp
newli
develop
score
purpos
studi
identifi
clinic
risk
factor
genet
variant
associ
recurr
nonalcohol
fatti
liver
diseas
nafld
postliv
transplant
lt
preval
recurr
nafld
high
liver
transplant
occur
make
import
clinic
issu
cohort
patient
underw
liver
transplant
april
august
methodist
univers
hospit
transplant
institut
middl
age
patient
mean
year
old
mostli
nonhispan
white
among
patient
patient
liver
biopsi
within
year
transplant
histolog
slide
blindli
rescor
patient
recurr
nafld
perform
candid
gene
approach
use
dna
extract
donor
recipi
liver
tissu
fix
formalin
embed
paraffin
use
taqman
snp
genotyp
assay
focus
polymorph
gene
known
associ
prelt
nafld
pathogenesi
combin
public
health
inform
extract
patient
medic
record
investig
associ
nafld
recurr
univari
analysi
found
higher
triglycerid
postlt
lower
creatinin
level
prelt
diabet
develop
postlt
calcineurin
inhibitor
use
postlt
associ
nafld
recurr
multivari
logist
analysi
month
median
credta
excret
compar
cirrhot
control
overal
p
lt
recipi
vs
cirrhot
lt
vs
control
p
figur
ip
increas
time
lt
recipi
median
valu
month
month
month
lt
differ
significantli
associ
laboratori
paramet
immunosuppress
medic
type
level
ip
found
except
etiolog
previou
liver
diseas
higher
ip
case
nonvir
etiolog
median
followup
month
ci
among
lt
recipi
develop
infecti
complic
die
correl
found
ip
valu
p
conclus
lt
recipi
increas
ip
probabl
due
multifactori
chronic
alter
gutliv
axi
studi
need
assess
clinic
impact
increas
ip
patient
conclus
observ
suggest
mri
gadolinium
nonnephrotox
imag
modal
patient
follow
liver
transplant
importantli
renal
safeti
modal
extend
case
baselin
renal
insuffici
defin
cr
mgdl
contrast
enhanc
ct
may
contraind
due
risk
contrast
nephropathi
therefor
gadolinium
enhanc
iv
contrast
imag
provid
invalu
imag
modal
diagnosi
patholog
follow
liver
transplant
especi
set
renal
insuffici
disclosur
follow
peopl
noth
disclos
mari
flynn
mehul
parikh
sebastian
perez
sonali
sakaria
ram
subramanian
nikhilesh
r
mazumd
stuart
russel
aliaksei
pustavoitau
andrew
cameron
benjamin
philosoph
behnam
saberi
ahmet
gurakar
medicin
john
hopkin
hospit
nottingham
md
hyperdynam
cardiovascular
state
often
present
advanc
cirrhosi
thought
revers
liver
transplant
wish
examin
extent
pretranspl
physiolog
influenc
long
term
outcom
patient
undergo
major
oper
retrospect
collect
data
patient
underw
liver
transplant
indic
oper
period
exclud
patient
age
receiv
graft
live
donor
patient
receiv
organ
simultan
patient
previous
undergon
liver
transplant
primari
outcom
time
either
death
retranspl
advanc
univari
model
multivari
model
use
anova
test
compar
cox
proport
hazard
model
stepwis
fashion
surviv
analysi
treat
time
risk
time
date
transplant
date
outcom
censorship
last
known
follow
covari
includ
demograph
data
preoper
echocardiogram
analyz
data
liver
transplant
patient
white
male
averag
age
year
sd
averag
meld
transplant
sd
background
patient
undergo
liver
transplant
olt
coronari
arteri
diseas
cad
associ
high
mortal
risk
rel
contraind
procedur
evalu
cad
commonli
accomplish
dobutamin
stress
echocardiographi
dse
follow
coronari
angiographi
ca
ischemia
detect
cardiac
ct
angiographi
ctca
allow
noninvas
detect
signific
coronari
arteri
stenos
howev
effect
screen
tool
uncertain
transplant
set
aim
assess
feasibl
outcom
ctca
olt
candid
high
risk
cad
method
patient
undergo
olt
assess
consid
highrisk
cad
age
diabet
patient
prospect
includ
period
patient
dse
follow
ctca
patient
receiv
betablock
heart
rate
control
nitroglycerin
per
standard
ctca
protocol
primari
outcom
perior
postop
cardiac
event
result
patient
includ
median
age
year
iqr
male
common
indic
olt
assess
hepatocellular
carcinoma
hepat
c
alcohol
nafld
document
cardiac
risk
factor
includ
diabet
smoke
hypertens
hypercholesterolemia
famili
person
histori
ischaem
heart
diseas
ihd
obes
patient
risk
factor
ctca
complet
patient
abandon
patient
due
tachycardia
normal
show
nonobstruct
stenosi
plaqu
show
least
one
obstruct
lesion
stenosi
patient
abnorm
ctca
result
refer
highrisk
cardiolog
clinic
patient
reject
transplant
due
sever
cad
proceed
ca
patient
nonflow
limit
diseas
list
proceed
pci
list
combin
coronari
arteri
bypass
graft
surgeri
olt
patient
list
without
investig
mean
coronari
arteri
calcium
score
hu
significantli
differ
nafld
nonnafld
patient
patient
underw
olt
cardiac
event
nonfat
cardiac
arrest
reperfus
patient
normal
dse
ctca
conclus
ctca
feasibl
patient
undergo
assess
olt
identifi
cad
signific
proport
high
cardiac
risk
patient
normal
dse
small
number
case
impact
select
transplant
find
suggest
ctca
may
play
use
role
screen
olt
candid
occult
coronari
arteri
diseas
background
preval
obes
us
increas
past
decad
nash
wellrecogn
complic
obes
sinc
number
adult
await
liver
transplant
lt
nash
almost
tripl
criteria
list
obes
patient
lt
variabl
across
lt
center
due
concern
obes
relat
complic
posttranspl
aim
studi
evalu
earli
posttranspl
outcom
obes
patient
undergo
liver
transplant
use
nation
databas
method
retrospect
cohort
studi
use
nation
inpati
sampl
largest
public
avail
inpati
databas
us
patient
princip
procedur
icd
code
lt
includ
exclus
criteria
primari
outcom
inhospit
mortal
secondari
outcom
morbid
measur
intens
care
unit
icu
admiss
shock
multiorgan
failur
resourc
util
measur
length
hospit
stay
lo
total
hospit
charg
patient
classifi
obes
nonobes
use
icd
code
multivari
logist
regress
odd
ratio
mean
adjust
age
sex
race
median
incom
patient
zip
code
charlson
comorbid
index
hospit
region
urban
locat
size
teach
statu
result
total
patient
underw
liver
transplant
studi
time
frame
obes
mean
age
year
femal
overal
inhospit
mortal
obes
vs
nonobes
tabl
show
adjust
odd
ratio
adjust
mean
p
valu
multivari
analysi
inhospit
mortal
obes
nonobes
patient
undergo
liver
transplant
differ
term
morbid
differ
odd
shock
icu
admiss
multiorgan
dysfunct
compar
obes
nonobes
resourc
util
obes
patient
display
total
decreas
lo
total
hospit
charg
compar
nonobes
differ
signific
multivari
analysi
conclus
obes
gener
associ
increas
risk
mortal
icu
admiss
shock
multiorgan
failur
resourc
util
patient
undergo
liver
transplant
background
recent
studi
describ
strong
associ
earli
postlt
outcom
aim
confirm
find
multicent
la
fe
hospit
toronto
gener
hospit
retrospect
cohort
longterm
follow
method
tac
csa
trough
level
obtain
first
postlt
day
collect
high
defin
median
tac
ngml
ngml
ngml
respect
andor
peak
tac
ngml
optim
defin
median
tac
level
ngml
ngml
respect
low
defin
threshold
optim
exclus
criteria
lack
avail
data
determin
earli
switch
agent
introduct
renal
failur
first
year
post
liver
transplant
lt
predict
longterm
kidney
diseas
excess
risk
mortal
nephrotox
effect
administ
calcineurin
inhibitor
major
concern
goal
proof
concept
studi
develop
joint
model
investig
relationship
longitudin
exposur
tacrolimu
risk
renal
failur
first
year
post
lt
occurr
postlt
infect
arf
significantli
common
subject
die
respect
trend
toward
signific
higher
estim
intraop
blood
loss
howev
variabl
readili
identifi
subject
exclud
multivari
model
adjust
postlt
infect
subject
arf
time
like
die
ci
background
perform
earli
post
liver
transplant
lt
meld
even
dynam
chang
time
nmeld
predict
mortal
lt
still
controversi
aim
assess
abil
absolut
nmeld
calcul
day
lt
predict
mortal
method
data
consecut
patient
underw
lt
two
center
review
patient
receiv
lt
hcc
exclud
well
surviv
least
one
month
meld
nmeld
calcul
patient
day
lt
result
one
hundr
fiftysix
patient
includ
mostli
male
mean
age
year
main
indic
transplant
decompens
hcvrelat
liver
cirrhosi
hcvhbv
coinfect
donor
live
deceas
patient
surviv
year
respect
mean
surviv
month
univari
analysi
absolut
nmeld
postop
day
significantli
predict
postlt
mortal
multivari
analysi
meld
postop
day
significantli
associ
ci
p
mortal
ci
p
figur
regraft
free
surviv
figur
background
endogen
peptid
plasma
includ
lowabund
messeng
hormon
cytokin
involv
physiolog
diseas
process
liver
detail
analysi
plasma
peptidom
hold
promis
sourc
biomark
use
diagnosi
stage
diseas
well
monitor
postop
complic
liver
failur
partial
hepatectomi
phx
hypothes
alter
plasma
peptid
profil
may
reflect
liver
regener
follow
phx
method
test
hypothesi
perform
comprehens
plasma
peptidom
analys
partial
hepatectom
microminipig
smallest
pig
world
recent
establish
model
biomed
research
five
microminipig
underw
phx
gener
anesthesia
plasma
sampl
collect
minut
hour
phx
use
magnet
bead
purif
success
massspectrometri
ms
base
analysi
plasma
sampl
well
liquid
chromatographi
follow
tandem
ms
identifi
endogen
circul
peptid
specif
phase
postop
cours
phx
result
identifi
peptid
might
biolog
relev
notabl
peptid
fragment
nucleosom
compon
includ
histon
detect
soon
phx
presenc
fragment
may
trigger
liver
regener
acut
phase
phx
endogen
peptid
deriv
vasodilatorstimul
phosphoprotein
detect
acutephasespecif
peptid
valid
protein
level
plasma
liver
addit
differ
epitop
protein
includ
albumin
hemoglobin
subunit
show
differ
pattern
chang
phx
mani
biomark
discoveri
effort
search
variat
total
abund
particular
protein
howev
consid
data
differ
epitop
protein
could
sensit
biomark
variou
process
healthi
andor
diseas
liver
includ
liver
regener
phx
conclus
endogen
plasma
peptid
clearli
reflect
postop
cours
phx
pig
molecul
could
becom
sensit
biomark
monitor
postop
complic
futur
studi
need
valid
find
clinic
set
background
employ
trajectori
liver
transplant
recipi
return
work
may
influenc
longterm
outcom
especi
patient
experi
job
loss
test
associ
new
unemploy
surviv
method
firsttim
liver
transplant
recipi
age
year
transplant
may
subsequ
return
work
identifi
unit
network
organ
share
registri
surviv
time
work
resumpt
analyz
use
kaplanmei
curv
multivari
cox
proport
hazard
model
unemploy
work
resumpt
classifi
temporari
patient
later
return
work
continu
patient
remain
unemploy
death
censor
result
liver
recipi
identifi
studi
period
return
work
median
day
includ
analysi
employ
trajectori
includ
continu
employ
unemploy
report
return
work
temporari
unemploy
continu
unemploy
kaplanmei
plot
demonstr
wors
surviv
continu
unemploy
group
rel
temporarili
unemploy
continu
employ
patient
p
figur
multivari
analysi
unemploy
timevari
covari
found
becom
unemploy
associ
greater
mortal
hazard
ci
p
adjust
patient
demograph
clinic
characterist
time
transplant
initi
return
work
conclus
although
liver
transplant
recipi
return
work
better
posttranspl
outcom
studi
demonstr
employ
discontinu
pose
risk
longterm
surviv
popul
hepatolog
octob
denot
aasld
presidenti
poster
distinct
background
weight
gain
metabol
syndrom
occur
liver
transplant
lt
though
mechan
poorli
understood
hypothes
may
relat
reduc
metabol
rate
follow
lt
particularli
exercis
purpos
studi
compar
energi
expenditur
rest
exercis
lt
recipi
control
method
fourteen
postlt
subject
nonalcohol
steatohepat
post
thirteen
nonlt
subject
nonalcohol
fatti
liver
diseas
nafld
perform
exercis
test
subject
underw
analysi
bodi
composit
rest
energi
expenditur
ree
exercis
energi
expenditur
vo
max
vo
max
test
conduct
use
rampedbruc
protocol
assess
respiratori
exchang
ratio
peak
heart
rate
subject
stratifi
sex
transplant
statu
match
bmi
age
male
femal
analyz
separ
due
inher
sexrel
differ
metabol
rate
result
baselin
demograph
significantli
differ
group
tabl
postlt
femal
significantli
lower
mean
ree
kcaldaykg
nafld
femal
adjust
total
bodi
mass
vs
lean
bodi
mass
vs
vo
max
ml
kgmin
also
lower
postlt
femal
compar
nafld
femal
vs
p
among
male
mean
ree
lower
postlt
patient
compar
nafld
differ
statist
signific
adjust
either
total
bodi
mass
vs
lean
bodi
mass
vs
vo
max
lower
postlt
male
nafld
male
though
statist
signific
vs
discuss
lt
recipi
particularli
femal
lower
ree
exercis
energi
expenditur
compar
nafld
control
despit
similar
metabol
risk
factor
may
relat
hormon
factor
well
loss
hepat
innerv
follow
lt
individu
aggress
diet
exercis
program
account
lower
calori
expenditur
rest
exercis
institut
postlt
optim
weight
manag
background
stenosi
portal
vein
pv
rare
complic
liver
transplant
lt
pediatr
patient
shown
advers
affect
graft
outcom
increas
lifespan
pediatr
patient
transplant
import
take
proactiv
measur
ensur
longterm
graft
surviv
studi
review
safeti
efficaci
percutan
transhepat
balloon
angioplasti
ptba
treatment
portal
vein
stenosi
pv
post
liver
transplant
method
januari
april
pediatr
patient
receiv
liver
transplant
tertiari
referr
transplant
center
review
record
found
children
evalu
pv
lt
use
percutan
transhepat
portal
venographi
ptpv
result
patient
median
age
year
iqr
diagnos
pv
use
ptpv
treat
ptba
two
patient
exclud
analysi
one
pv
receiv
surgic
shunt
surgeri
instead
ptba
patient
also
underw
intravascular
ultrasonographi
ivu
median
time
lt
ptba
month
iqr
half
patient
transplant
due
biliari
atresia
transhepat
approach
use
patient
mean
preprocedur
pv
pressur
gradient
mm
hg
sd
vein
complet
occlus
mean
postprocedur
pv
pressur
gradient
mm
hg
sd
mean
percentag
improv
pressur
gradient
across
stenot
region
pv
sd
averag
fluoroscopi
time
minut
sd
median
platelet
ast
alt
ggt
level
time
ptba
l
iqr
iqr
iqr
iqr
ptba
time
month
followup
visit
l
iqr
iqr
iqr
iqr
month
ptba
mean
percentag
increas
platelet
level
sd
mean
percentag
decreas
ast
alt
ggt
bilirubin
sd
sd
sd
sd
patient
requir
intervent
stent
portal
venou
patenc
maintain
median
conclus
percutan
transhepat
angioplasti
portal
vein
stenosi
pediatr
liver
transplant
safe
effect
treatment
longterm
patenc
improv
clinic
outcom
lead
increas
longev
graft
improv
qualiti
life
background
postop
care
fragment
defin
readmiss
hospit
hospit
patient
underw
initi
surgic
procedur
sever
surgic
popul
postop
fragment
associ
increas
risk
short
longterm
advers
outcom
object
studi
evalu
whether
care
fragment
associ
reduc
surviv
olt
method
retrospect
cohort
review
perform
use
healthcar
cost
util
project
hcup
state
inpati
databas
florida
california
patient
underw
olt
includ
follow
year
primari
exposur
postop
care
fragment
defin
readmiss
nonindex
hospit
within
day
discharg
patient
transfer
back
index
hospit
within
hour
consid
nonfrag
group
primari
outcom
surviv
gamma
share
frailti
model
use
risk
adjust
adjust
patient
demograph
clinic
transplant
encount
variabl
result
total
patient
receiv
olt
readmit
cohort
fragment
postop
care
mortal
patient
care
fragment
vs
fragment
care
group
women
nonfrag
group
vs
p
differ
charlson
comorbid
index
age
race
etiolog
liver
diseas
group
signific
differ
note
characterist
index
inpati
stay
group
time
liver
transplant
patient
ultim
fragment
care
longer
preoper
length
stay
lo
vs
day
p
longer
postop
lo
vs
day
p
higher
cost
index
hospit
vs
p
adjust
factor
well
age
gender
charlson
comorbid
index
reason
transplant
patient
care
fragment
remain
heighten
risk
mortal
compar
without
fragment
care
hr
c
conclus
postop
care
fragment
follow
olt
associ
significantli
increas
risk
mortal
given
complex
postdischarg
care
patient
popul
effort
made
ensur
inpati
care
first
day
follow
transplant
occur
index
transplant
center
introduct
biliari
strictur
expect
complic
liver
transplant
lt
occur
liver
transplant
recipi
ltr
suspect
abnorm
note
liver
enzym
addit
work
usual
entail
addit
imag
follow
confirmatori
endoscop
retrograd
cholangiopancreatographi
ercp
diagnost
accuraci
liver
enzym
imag
modal
us
mri
detect
biliari
strictur
ltr
unknown
aim
current
studi
evalu
diagnost
accuraci
liver
enzym
imag
modal
predict
posttranspl
biliari
strictur
method
retrospect
studi
evalu
adult
patient
lt
subsequ
ercp
suspect
biliari
strictur
presenc
biliari
strictur
confirm
via
blind
review
three
expert
intervent
endoscopist
unanim
agre
presenc
biliari
strictur
defin
previous
tabibian
et
al
ann
hepatol
optim
cutoff
liver
enzym
predict
biliari
strictur
determin
use
youden
index
final
diagnost
accuraci
us
mri
predict
biliari
strictur
postlt
evalu
result
total
subject
male
age
year
met
inclus
criteria
mean
time
ercp
year
transplant
subject
biliari
strictur
blind
review
warm
ischemia
time
associ
presenc
biliari
strictur
p
invers
relationship
biliari
strictur
durat
lt
ercp
p
relationship
biliari
strictur
type
donat
live
donor
vs
deceas
donor
observ
optim
cutoff
determin
biliari
strictur
rise
liver
enzym
compar
baselin
follow
alkalin
phosphatas
ap
ast
alt
ul
respect
use
cutoff
alt
elev
highli
sensit
neg
predict
valu
limit
specif
contrast
increas
ap
iul
highest
specif
much
lower
sensit
imag
modal
demonstr
even
lower
accuraci
predict
presenc
biliari
strictur
postlt
mri
us
conclus
imag
modal
us
mri
reliabl
predict
presenc
biliari
strictur
ltr
although
imag
modal
rise
liver
enzym
modest
accuraci
predict
biliari
strictur
rise
serum
alt
without
altern
explan
offer
high
neg
predict
valu
follow
peopl
noth
disclos
divyanshoo
r
kohli
ravi
vachhani
doumit
bouhaidar
tilak
shah
andrew
moweri
mohammad
siddiqui
background
sinc
avail
entecavir
tenofovir
number
chronic
hepat
b
viru
hbv
patient
progress
diseas
lead
liver
transplant
lt
plateau
proport
hbvrelat
hepatocellular
carcinoma
hcc
continu
rise
unclear
trend
affect
men
women
raceethn
group
equal
aim
evalu
sexspecif
raceethnicityspecif
trend
hbvrelat
lt
list
waitlist
surviv
probabl
receiv
lt
among
adult
chronic
hbv
u
method
use
unit
network
organ
share
registri
data
retrospect
evalu
u
adult
age
chronic
hbv
without
hcc
list
lt
compar
sexspecif
raceethnicityspecif
trend
lt
list
year
lt
list
stratifi
time
period
era
vs
era
vs
era
overal
waitlist
surviv
odd
receiv
lt
evalu
multivari
logist
regress
model
stratifi
presenc
hcc
adjust
sex
race
ethnic
age
meld
score
bodi
mass
index
uno
region
result
overal
adult
chronic
hbv
list
lt
major
asian
men
recent
era
men
account
asian
account
hbvrelat
lt
waitlist
registr
although
total
number
hbv
patient
list
lt
remain
stabl
proport
hbv
patient
hcc
increas
era
era
compar
era
hbv
patient
era
less
like
die
wait
lt
without
hcc
hcc
asian
hbv
also
lower
odd
waitlist
death
compar
nonhispan
white
without
hcc
p
hcc
p
compar
women
hbv
men
hbv
lower
odd
waitlist
death
seen
nonhcc
cohort
evalu
odd
receiv
lt
hbv
patient
latter
time
period
less
like
receiv
lt
compar
nonhispan
white
hbv
trend
toward
higher
odd
receiv
lt
among
asian
among
nonhcc
cohort
compar
women
hbv
trend
toward
higher
odd
lt
seen
among
men
hcc
cohort
conclus
recent
era
major
hbvrelat
lt
list
attribut
asian
men
account
hbvrelat
lt
list
u
respect
nearli
half
hbv
patient
list
lt
concurr
hcc
malign
liver
transplant
lt
lead
caus
mortal
data
limit
small
sampl
size
predominantli
singlecent
studi
aim
determin
incid
risk
factor
de
novo
malign
lt
larg
multicent
databas
method
scientif
registri
transplant
recipi
srtr
databas
compris
adult
liver
transplant
recipi
across
unit
state
analyz
median
year
followup
result
liver
transplant
recipi
includ
mean
age
year
male
caucasian
mean
bodi
mass
index
bmi
year
cancer
free
surviv
malign
skin
cancer
hematolog
malign
solid
malign
hepatocellular
carcinoma
cholangiocarcinoma
recurr
exclud
analysi
univari
analysi
age
male
gender
previou
malign
multiorgan
transplant
alcohol
liver
diseas
nash
obes
diabet
donor
bmi
donor
age
mtor
exposur
year
associ
increas
risk
howev
multivari
analysi
age
decad
hr
ci
p
male
gender
hr
ci
p
caucasian
race
hr
ci
multiorgan
transplant
hr
ci
previou
malign
hr
ci
p
psc
prelt
hr
ci
independ
predictor
postlt
malign
africanamerican
hr
ci
p
hispan
hr
ci
p
asian
hr
ci
p
race
associ
fewer
malign
compar
caucasian
prelt
bmi
hr
diabet
hr
also
associ
fewer
malign
donor
factor
age
gender
ethnic
bmi
recipi
creatinin
predict
malign
neither
calcineurin
inhibitor
mtor
inhibitor
exposur
within
first
year
post
transplant
associ
malign
transplant
mv
analysi
conclus
liver
transplant
recipi
probabl
de
novo
malign
respect
increas
age
male
gender
caucasian
race
multiorgan
transplant
psc
predict
higher
risk
malign
lt
patient
highrisk
characterist
screen
vigilantli
malign
follow
peopl
noth
disclos
mamatha
bhat
kristin
mara
ross
dierkhis
kymberli
watt
shear
wave
elastographi
use
tool
assess
preoper
liver
function
predictor
postop
hepat
failur
patient
hepatocellular
carcinoma
seikan
hai
etsuro
hatano
tadamichi
hirano
yuichi
kondo
nobuhiro
aizawa
hiroko
iijima
jiro
fujimoto
depart
surgeri
hyogo
colleg
medicin
nishinomiya
japan
purpos
shear
wave
elastographi
vtq
virtual
touch
quantif
novel
noninvas
tool
assess
liver
fibrosi
measur
liver
stiff
vtq
also
possibl
evalu
liver
function
hepatectomi
present
studi
demonstr
associ
shear
wave
veloc
swv
liver
function
test
investig
whether
swv
would
avail
predict
factor
postop
complic
patient
method
clinic
cours
patient
underw
hepatectomi
hepatocellular
carcinoma
depart
januari
march
review
patient
underw
vtq
undergo
hepatectomi
vtq
perform
five
time
differ
area
right
hepat
lobe
mean
swv
calcul
patient
postop
hepat
failur
defin
accord
intern
studi
group
liver
surgeri
result
base
hepat
fibrosi
stage
swv
ms
ms
ms
ms
ms
respect
swv
cirrhosi
significantli
faster
p
swv
show
correl
albumin
p
prothrombin
time
p
astplt
ratio
index
apri
p
indocyanin
green
p
postop
hepat
failur
develop
patient
six
patient
inhospit
death
univari
analysi
swv
alt
platelet
count
apri
oper
time
intraop
blood
loss
shown
significantli
risk
postop
hepat
failur
multivari
analysi
use
logist
regress
model
involv
seven
signific
factor
determin
univari
analysi
confirm
two
signific
independ
variabl
apri
intraop
blood
loss
p
valu
swv
swv
tendenc
risk
postop
hepat
failur
conclus
shear
wave
elastographi
may
use
tool
evalu
liver
function
hepatectomi
predict
possibl
postop
hepat
failur
follow
peopl
noth
disclos
seikan
hai
etsuro
hatano
tada
background
aim
recent
report
singl
inject
stem
cell
deriv
human
exfoli
decidu
teeth
shed
popul
selfrenew
msc
serumfre
condit
medium
shed
shedcm
markedli
improv
condit
injur
liver
rat
model
acut
liver
failur
alf
induc
dgalactosamin
dgal
anoth
studi
identifi
set
macrophag
induc
monocyt
chemoattract
secret
ectodomain
sialic
acidbind
iglik
shedcm
show
promot
function
recoveri
rat
spinal
cord
injuri
studi
investig
role
therapeut
potenti
treat
alf
method
rat
alf
induc
intraperiton
inject
dgal
dgal
inject
mixtur
equival
volum
pb
inject
tail
vein
assess
surviv
rate
serum
transaminas
level
liver
histopatholog
gene
express
real
timepcr
addit
bone
marrow
cell
rat
isol
differenti
bone
marrow
macrophag
macrophag
colonystimul
factor
incub
dmem
dmem
incub
cell
morpholog
mrna
express
pattern
examin
supernat
use
macrophag
cm
subsequ
apoptosi
model
primari
hepatocyt
made
use
dgal
lp
evalu
abil
antiapoptosi
hepatocyt
macrophag
cm
result
found
singl
intraven
inject
separ
inject
administ
h
dgal
inject
markedli
decreas
ast
alt
level
improv
surviv
rate
compar
group
p
rat
also
exhibit
significantli
lower
number
tunel
apoptot
cell
higher
number
albumin
prolifer
hepatocyt
pbstreat
rat
mrna
level
antiinflammatori
marker
significantli
elev
group
compar
control
addit
promot
differenti
bone
marrowderiv
macrophag
vitro
cm
suppress
dgallp
induc
primari
hepatocyt
apoptosi
p
conclus
uniqu
combin
amelior
rat
alf
induct
antiinflammatorytissuerepair
macrophag
hidemi
goto
grantresearch
support
msd
roch
bayer
bristolmy
eisai
ajinomoto
otsuka
astra
tanab
takeda
follow
peopl
noth
disclos
takanori
nodlik
receptor
dsdna
receptor
absent
melanoma
involv
assembl
inflammasom
trigger
activ
product
inflammatori
cytokin
hypothes
inflammasom
activ
chronic
liver
injuri
creat
inflammatori
environ
promot
develop
hepatocellular
carcinoma
hcc
object
investig
function
inflammasom
hcc
initi
promot
mice
explor
inhibit
therapeut
tool
mous
model
hcc
evalu
express
inflammasom
compon
human
hcc
patient
method
evalu
develop
deninduc
hcc
mice
wt
mice
defici
studi
initi
promot
phase
hcc
use
combin
den
carbon
tetrachlorid
administr
inhibit
mice
perform
use
antibodi
last
analyz
pbmc
isol
patient
hcc
patient
advanc
liver
diseas
without
hcc
control
result
month
singl
den
inject
show
strike
reduct
tumor
incid
number
size
compar
wt
mice
liver
injuri
express
inflammatori
mediat
liver
tissu
also
reduc
mice
contrast
tumor
develop
liver
injuri
significantli
differ
wt
control
den
administr
augment
concentr
free
dsdna
serum
wt
hcc
initi
postden
acut
hepatocyt
damag
liver
inflamm
decreas
time
blockad
amelior
hepatocyt
damag
express
inflammatori
prolif
marker
liver
tissu
dentreat
wt
mice
highlight
role
model
also
reduc
hepatocyt
damag
express
inflammatori
prolif
marker
liver
tissu
hcc
promot
addit
treatment
increas
protein
express
inflammasom
compon
liver
wt
mice
last
express
upregul
pbmc
patient
hcc
show
posit
associ
sever
liver
damag
patient
conclus
promot
develop
hcc
mice
increas
injuryinflammationregener
respons
tumor
initi
promot
express
hcc
patient
suggest
inflammasom
may
also
play
import
role
human
hcc
medic
center
telaviv
israel
liver
fibrosi
excess
accumul
extracellular
matrix
ecm
protein
includ
collagen
occur
type
chronic
liver
diseas
enzym
lysyl
oxidas
lox
famili
catalyz
coval
crosslink
collagen
fiber
specif
lysyl
oxidas
observ
regul
ecm
stiff
stabil
sever
liver
diseas
associ
collagen
scar
format
therefor
inhibit
liver
fibrosi
propos
potenti
target
therapeut
intervent
show
mous
model
liver
fibrosi
treatment
novel
antibodi
ab
target
catalyt
site
inhibit
extracellular
activ
significantli
improv
liver
resolut
comparison
mice
treat
isotyp
control
ab
siriu
red
stain
reveal
reduc
collagen
deposit
histopatholog
score
monitor
matrix
proteas
activ
situ
zymographi
uncov
acceler
augment
collagen
degrad
mice
began
alreadi
fibrot
phase
accompani
increas
infiltr
monocytederiv
macrophag
local
specif
area
fibrot
fiber
induc
select
ablat
negat
activ
collagenolyt
activ
observ
treat
mice
furthermor
provid
evid
specif
macrophagederiv
mmp
e
invivo
effici
collagenas
involv
degrad
collagen
follow
treatment
ab
altogeth
result
demonstr
inhibit
ecm
crosslink
reduc
amount
fibrosi
liver
break
ground
arriv
collagenolyt
macrophag
thu
constitut
promis
therapeut
strategi
accumul
evid
suggest
offspr
obes
mother
wors
obes
nonalcohol
fatti
liver
diseas
nafld
mechan
development
program
nafld
appear
involv
innat
immun
system
studi
shown
hedgehog
hh
morphogen
involv
embryogenesi
regul
immun
cell
develop
addit
hh
signal
shown
play
import
role
fat
distribut
obes
nafld
investig
interact
hh
signal
pathway
matern
obes
regul
immun
develop
offspr
program
nafld
method
adult
wildtyp
mice
shown
increas
hh
signal
vivo
subject
either
control
highfathighsugar
diet
week
timem
embryon
day
foetal
liver
analys
result
interestingli
foetal
liver
embryo
obes
mother
obem
consist
upregul
inflammatori
marker
tumour
necrosi
marker
liver
injuri
transform
growth
muscl
actin
asma
collagen
type
flow
cytometri
result
show
increas
percentag
neutrophil
natur
killer
nk
cell
foetal
liver
obem
compar
wildtyp
embryo
lean
mother
conem
also
increas
percentag
neutrophil
nk
cell
compar
wildtyp
conem
howev
show
statist
differ
compar
wildtyp
conem
neutrophil
nk
cell
popul
conclus
matern
obes
increas
liver
inflamm
injuri
accompani
alter
hepat
immun
earli
interuterin
stage
hh
signal
pathway
interact
matern
diet
alter
foetal
liver
develop
cellular
adhes
molecul
carcinoembryon
antigenrel
cell
adhes
molecul
member
immunoglobulin
superfamili
express
epithelia
endothelia
especi
leukocyt
immuneinhibitori
receptor
long
cytoplasm
domain
contain
immun
receptor
tyrosinebas
inhibit
motif
itim
pivot
neg
regul
leukocyt
activ
specif
suppress
activ
nk
cell
cell
myeloid
cell
control
inflamm
role
immunemedi
liver
damag
model
resembl
autoimmun
hepat
unknown
therefor
studi
role
concanavalinmedi
liver
inflamm
method
use
concanavalin
inject
induc
immunemedi
liver
damag
liverresid
immun
cell
popul
character
flow
cytometri
alanin
aminotransferas
activ
alt
measur
coba
analyz
cytokin
level
determin
elisa
flow
cytometri
qrtpcr
result
upon
cona
inject
mice
develop
sever
liver
injuri
increas
plasma
transaminas
activ
compar
wt
anim
effect
cell
intrins
independ
liver
sinc
mice
receiv
cell
mice
sensit
toward
cona
challeng
compar
anim
receiv
wt
cell
furthermor
mice
show
significantli
reduc
plasma
cytokin
level
reduc
secret
cell
nkt
cell
moreov
treg
accumul
blunt
liver
mice
upon
cona
stimul
although
treg
mice
still
suppress
vitro
suppress
assay
howev
treg
fail
prevent
conainduc
liver
injuri
show
reduc
prolifer
upon
adopt
transfer
conclus
result
disclos
previous
undescrib
protect
role
model
liver
injuri
result
reduct
liver
patholog
concanavalin
amedait
hepat
specif
tregmedi
protect
immunemedi
injuri
reli
express
cell
nkt
cell
modul
cytokin
product
aid
treg
prolifer
follow
peopl
noth
disclos
andrea
k
horst
claudia
wegscheid
christoph
schaefer
gisa
tieg
determin
protect
level
igg
antihev
antibodi
hepat
e
viru
reinfect
experiment
infect
rhesu
macaqu
youkyung
choi
xiugen
zhang
coleen
tran
brianna
skinner
center
diseas
control
prevent
atlanta
ga
global
hepat
e
viru
hev
may
caus
mani
million
infect
annual
result
death
mostli
due
fulmin
liver
failur
hev
infect
present
signific
public
health
problem
asia
africa
hev
caus
larg
waterborn
epidem
acut
jaundic
develop
countri
seropreval
antihev
antibodi
highest
clinic
attack
rate
among
young
adult
better
understand
secondari
spread
hev
infect
often
occur
endem
set
develop
countri
rhesu
macaqu
reinocul
homolog
strain
hev
genotyp
assess
host
immun
respons
contribut
protect
subsequ
reinfect
recoveri
initi
hev
infect
rhesu
macaqu
reinocul
homolog
hev
genotyp
follow
day
three
naiv
monkey
use
control
initi
igg
antihev
concentr
previous
infect
monkey
rang
uml
nine
rhesu
macaqu
reinocul
monkey
infecti
dose
mid
anim
mid
hev
evid
viral
replic
assess
detect
hev
rna
stool
serum
realtim
pcr
evid
hepat
measur
serum
alanin
aminotransferas
alt
activ
igg
antihev
antibodi
concentr
igg
antihev
avid
index
analyz
serum
sampl
seven
monkey
igg
antihev
conc
uml
initi
titer
primari
infect
develop
infect
shed
viru
fece
reinocul
five
anim
igg
antihev
conc
uml
reinfect
evidenc
hev
rna
stool
day
postreinocul
five
reinocul
anim
develop
infect
lower
hevigg
avid
index
averag
anim
averag
avid
index
becom
infect
reinocul
none
reinocul
monkey
show
elev
alt
activ
three
control
monkey
primari
infect
significantli
lower
igg
antihev
avid
index
averag
p
conclus
studi
indic
preexist
antibodi
hevigg
avid
index
import
factor
protect
reinfect
experiment
infect
rhesu
macaqu
studi
provid
evid
antihev
antibodydepend
protect
hev
reinfect
background
aim
mice
lack
regulatori
cell
treg
mutat
transcript
factor
display
multisystem
autoimmun
includ
lymphocyt
periport
hepat
infiltr
biochem
hepat
develop
antimitochondri
antibodi
ama
analog
drawn
primari
biliari
cholang
mutat
autoimmun
regul
gene
air
impair
thymic
present
otherwis
tissuerestrict
antigen
develop
cell
associ
hepat
autoimmun
human
mice
method
cell
prepar
thymus
mutant
pup
transfer
cell
defici
host
day
later
host
replet
peripherallyderiv
lymphocyt
provid
treg
mice
air
treg
noth
defici
air
confirm
commerci
pcr
anim
sacrif
onset
system
diseas
assess
technician
blind
treatment
week
sacrific
anim
assess
serum
alanin
aminotransferas
alt
lactat
dehydrogenas
ldh
activ
ama
titr
elisa
spleen
weight
proxi
generalis
autoimmun
leucocyt
content
liver
spleen
flow
cytometri
histolog
immunohistochemistri
result
anim
replet
air
treg
aliv
well
six
week
wherea
anim
receiv
treg
control
demonstr
overt
autoimmun
transfer
either
air
treg
prevent
splenomegali
reduc
serum
alt
reduc
serum
compar
mice
receiv
defici
cell
without
subsequ
treg
replet
assess
flow
cytometri
number
cell
per
gram
liver
spleen
reduc
transfer
either
air
treg
number
b
cell
unchang
nonsignific
trend
reduct
serum
ldh
ama
titr
air
transfer
develop
periport
infiltr
contain
numer
cell
abolish
either
air
treg
signific
differ
air
treg
recipi
group
conclus
result
suggest
treg
air
defici
anim
suffici
control
generalis
hepat
autoimmun
dysfunct
result
contrast
work
describ
revers
hepat
autoimmun
older
air
balbc
anim
adopt
transfer
wildtyp
treg
differ
implic
host
genet
factor
includ
hla
type
environment
influenc
background
aim
mice
lack
regulatori
cell
treg
mutat
transcript
factor
display
multisystem
autoimmun
includ
lymphocyt
periport
hepat
infiltr
biochem
hepat
develop
antimitochondri
antibodi
ama
analog
drawn
human
primari
biliari
cholang
pbc
secondari
costimulatori
receptorligand
pair
implic
perpetu
effector
cell
respons
maintain
cell
memori
investig
whether
antibodi
blockad
would
amelior
liver
diseas
treg
defici
mous
model
also
assess
human
diseas
dysregul
method
cell
prepar
thymus
mutant
pup
transfer
cell
defici
host
day
later
host
commenc
block
antibodi
ip
twice
weekli
control
anim
sacrif
onset
system
diseas
week
assess
serum
alanin
aminotransferas
alt
lactat
dehydrogenas
ldh
ama
titr
lymphocyt
content
liver
flow
cytometri
histolog
liver
section
human
explant
liver
section
stain
serum
measur
pbc
patient
healthi
control
captur
elisa
result
anim
receiv
aliv
well
six
week
wherea
anim
receiv
treg
control
demonstr
overt
autoimmun
cull
end
experi
administr
reduc
spleen
weight
reduc
alt
reduc
ldh
compar
control
assess
flow
cytometri
number
cell
per
gram
liver
spleen
reduc
b
cell
number
alter
develop
periport
infiltr
contain
numer
cell
abolish
blockad
stain
present
within
posit
infiltr
case
human
pbc
autoimmun
hepat
sever
case
nonalcohol
steatohepat
absent
almost
normal
liver
significantli
differ
pbc
patient
control
conclus
data
suggest
blockad
murin
model
treg
defici
effect
reduc
hepat
autoimmun
express
appar
human
autoimmun
liver
diseas
aih
pbc
normal
liver
howev
express
also
seen
nonautoimmun
inflammatori
state
hepat
overexpress
oncogen
transcript
factor
promot
hepatocyt
death
hepat
inflamm
mice
tomohid
kurahashi
yuichi
yoshida
satoshi
ogura
mayumi
egawa
kunimaro
furuta
yoshihiro
kamada
shinichi
kiso
hayato
hikita
tomohid
tatsumi
tetsuo
takehara
depart
gastroenterolog
hepatolog
osaka
univers
graduat
school
medicin
suita
japan
background
aim
forkhead
box
transcript
factor
belong
fox
famili
protein
share
homolog
wing
helix
dna
bind
domain
shown
regul
cell
cycl
progress
liver
regener
play
import
role
develop
hepatocellular
carcinoma
howev
despit
numer
evid
liver
regener
carcinogenesi
role
liver
injuri
develop
chronic
liver
diseas
fulli
understood
studi
elucid
issu
develop
novel
transgen
murin
model
enabl
us
control
hepat
express
method
use
teton
creloxp
system
gener
transgen
tg
mice
condit
express
protein
hepatocyt
cross
mice
mice
albumincr
mice
design
tg
mice
tg
control
mice
design
wt
mice
treat
doxycyclin
time
birth
induc
express
liver
result
first
demonstr
protein
express
induc
liver
mice
fed
high
fat
diet
suggest
possibl
involv
progress
chronic
liver
diseas
next
confirm
overexpress
protein
liver
tg
mice
western
blot
immunohistochem
analysi
week
age
tg
mice
elev
serum
alt
level
compar
wt
mice
ul
tg
vs
ul
wt
p
tg
mice
also
show
fold
increas
number
tunel
posit
hepatocyt
compar
wt
mice
p
enhanc
liver
injuri
tg
mice
associ
increas
gene
express
p
p
p
consist
data
vivo
sirnamedi
knockdown
mous
hepatoma
cell
line
result
signific
reduct
gene
express
suggest
possibl
mechan
regul
express
hepatocyt
conclus
current
studi
demonstr
transgen
express
hepatocyt
caus
hepatocyt
death
mice
data
suggest
may
play
role
pathogenesi
hepat
inflamm
develop
chronic
liver
diseas
cell
liver
damag
kill
macrophag
becom
activ
releas
cytokin
phagocytos
dead
cell
debri
facilit
liver
repair
mechan
liver
injuri
stimul
macrophag
activ
liver
fulli
understood
demonstr
previous
activ
transcript
factor
hypoxiainduc
hepat
stellat
cell
hsc
requir
macrophag
clear
region
necrot
cell
produc
inflammatori
cytokin
liver
injuri
suggest
commun
hsc
macrophag
critic
macrophag
activ
liver
injuri
support
show
necrot
hepatocyt
directli
activ
liver
macrophag
vitro
wherea
treatment
hepat
macrophag
condit
medium
hsc
treat
necrot
hepatocyt
activ
hepat
macrophag
remain
identifi
mediat
releas
hsc
modul
hepat
macrophag
function
current
studi
test
hypothesi
eicosanoid
requir
activ
liver
macrophag
hsc
treat
necrot
hepatocyt
treatment
liver
macrophag
condit
medium
hsc
expos
necrot
hepatocyt
activ
macrophag
measur
increas
inflammatori
cytokin
howev
pretreat
hsc
phospholipas
inhibitor
methyl
arachidonyl
fluorophosphon
prevent
hscmediat
macrophag
activ
treatment
primari
mous
hsc
cell
human
hsc
cell
line
necrot
hepatocyt
increas
prostaglandin
e
synthas
mrna
level
addit
necrot
hepatocyt
stimul
primari
mous
hsc
produc
conclus
studi
expand
upon
previou
vivo
studi
demonstr
necrot
cell
stimul
hsc
produc
arachidon
acid
metabolit
regul
liver
macrophag
activ
character
pathway
could
provid
groundwork
novel
therapi
aim
manipul
macrophag
phenotyp
order
allevi
liver
injuri
facilit
liver
repair
high
mobil
group
releas
damag
associ
molecular
pattern
damp
liver
ischemia
reperfus
ir
exacerb
organ
damag
inflammatori
respons
neutrophil
extracellular
trap
net
recent
found
also
exacerb
steril
inflammatori
injuri
liver
ir
howev
role
intracellular
net
format
understood
sought
determin
role
intracellular
neutrophil
net
format
liver
ir
myloid
cell
specif
knockout
ko
control
mice
subject
nonleth
warm
liver
ir
liver
damag
assess
alt
level
histolog
protein
cytokin
mrna
innat
immun
cell
popul
evalu
ko
mice
significantli
decreas
serum
transaminas
salt
fig
less
necrosi
inflammatori
cytokin
product
compar
control
ir
suggest
less
degre
liver
injuri
myeloid
cell
absent
significantli
less
net
format
identifi
sinusoid
ischem
liver
lobe
ko
mice
compar
flox
control
mice
confoc
immunofluoresc
imag
associ
significantli
less
net
marker
serum
level
myeloperoxidas
mpo
dna
complex
tissu
level
citrullin
histon
ko
mice
compar
flox
control
mice
vitro
net
format
observ
ko
neutrophil
harvest
ko
mice
stimul
pma
posit
control
damp
histon
confirm
confoc
immunofluoresc
imag
addit
gene
delet
neutrophil
complet
block
citrullin
histon
key
step
net
format
compar
control
neutrophil
respons
variou
stimul
fig
b
conclus
studi
demonstr
domin
role
intracellular
net
format
lack
neutrophil
lead
diminish
net
format
protect
liver
organ
damag
cell
death
liver
ir
innat
immun
cell
phenotyp
function
differ
compart
gutliveraxi
chronic
liver
disea
fabian
j
bolt
ashley
okeef
ohad
etzion
rabab
ali
elisavet
serti
jake
liang
theo
heller
barbara
rehermann
liver
diseas
branch
niddk
nation
institut
health
dhh
bethesda
md
liver
equip
uniqu
repertoir
innat
adapt
immun
cell
respond
viral
infect
gutderiv
bacteri
product
rel
contribut
microbi
product
virusinduc
cytokin
innat
immun
cell
activ
inflamm
sever
liver
diseas
current
known
aim
studi
analyz
innat
immun
cell
activ
function
three
compart
gutliv
axi
system
blood
portal
vein
blood
liver
method
isol
lymphocyt
monocyt
liver
portal
vein
system
blood
hepat
c
patient
examin
multicolor
flow
cytometri
addit
plasma
marker
monocytemacrophag
activ
intestin
barrier
integr
ifabp
inflamm
studi
elisa
result
monocyt
natur
killer
nk
cell
mucos
associ
invari
mait
cell
activ
liver
system
portal
vein
blood
indic
increas
hladr
express
nk
mait
cell
display
cytotox
phenotyp
liver
two
compart
shown
ex
vivo
express
degranul
marker
consist
find
innat
immun
cell
activ
liver
level
higher
system
portal
plasma
level
compart
correl
activ
intrahepat
monocyt
addit
observ
higher
level
hcv
infect
patient
compar
healthi
control
level
similar
system
portal
plasma
correl
liver
inflamm
assess
histolog
activ
index
level
ifabp
marker
intestin
barrier
loss
increas
hcvinfect
patient
compar
healthi
control
moreov
higher
portal
system
plasma
howev
innat
immun
cell
activ
degranul
differ
system
portal
vein
blood
likewis
vitro
function
respons
monocyt
lipopolysaccharid
mait
cell
well
riboflavinsynthes
microorgan
differ
system
portal
vein
blood
overal
degre
innat
immun
cell
activ
correl
stage
liver
diseas
assess
direct
portal
vein
pressur
ishak
fibrosi
score
conclus
innat
immun
cell
activ
inflamm
compartment
liver
patient
compens
hcvrelat
liver
diseas
activ
intrahepat
monocyt
shed
result
higher
level
plasma
marker
system
portal
plasma
background
primari
biliari
cholang
pbc
progress
cholestat
liver
diseas
mostli
affect
women
though
autoimmun
postul
pathogenesi
pbc
genderspecif
mechan
underli
develop
pbc
larg
unknown
studi
therefor
investig
gender
differ
murin
cholang
induc
repeat
inject
synthet
doublestrand
rna
resembl
human
pbc
method
male
mice
given
repeat
intraperiton
inject
poli
c
twiceweek
week
liver
histolog
assess
mice
sacrif
follow
singl
inject
poli
c
serum
antimitochondria
antibodi
detect
elisa
hepat
mrna
level
measur
realtim
rtpcr
hepat
protein
level
rigi
measur
western
blot
result
femal
mice
given
repeat
inject
poli
c
week
develop
overt
inflammatori
infiltr
surround
bile
duct
portal
area
wherea
male
mice
show
minim
patholog
chang
serum
level
increas
follow
chronic
poli
c
treatment
femal
male
mice
femal
mice
hepat
mrna
level
swiftli
elev
follow
singl
inject
poli
c
peak
level
hr
reach
nearli
basal
level
respect
contrast
peak
level
mrna
male
mice
reach
femal
peak
respect
hepat
express
level
major
receptor
doublestrand
rna
differ
male
femal
mice
prior
inject
poli
c
turn
hepat
mrna
level
elev
transient
hr
follow
singl
poli
c
inject
valu
femal
reach
almost
fold
higher
male
moreov
hepat
protein
level
rigi
significantli
higher
femal
mice
compar
male
mice
inject
poli
c
conclus
find
clearli
indic
femal
mice
exclus
develop
autoimmun
cholangiopathi
induc
poli
c
acut
reaction
poli
c
liver
appear
potenti
femal
phenomena
like
initi
femalepredomin
express
hepat
rigi
level
follow
synergist
enhanc
therefor
hypothes
gender
differ
innat
immun
respons
doublestrand
rna
play
pivot
role
pathogenesi
autoimmun
cholangiopathi
includ
pbc
follow
peopl
noth
disclos
shunin
someya
kenichi
ikejima
akira
uchiyama
kumiko
arai
kazuyoshi
kon
tomonori
aoyama
shunhei
yamashina
sumio
watanab
signal
regul
liver
inflamm
activ
pathway
mous
druginduc
damageassoci
hepat
background
notch
signal
known
key
regul
cell
prolifer
differenti
apoptosi
immun
cell
function
interact
notch
receptor
ligand
crucial
regul
innat
adapt
immun
liver
inflamm
studi
design
dissect
innat
immun
network
regul
receptor
ligand
acetaminopheninduc
liver
injuri
method
myeloid
specif
knockout
mko
flox
flfl
mice
inject
intraperiton
pb
acetaminophen
ugg
p
experi
flfl
mice
inject
recombin
p
pb
sacrif
indic
time
vitro
studi
bone
marrowderiv
macrophag
bmm
isol
mko
flfl
mice
treat
treat
ugml
pb
incub
lp
ngml
result
flfl
mice
receiv
resist
acetaminopheninduc
liver
injuri
increas
target
gene
express
akt
phosphoryl
significantli
decreas
serum
alt
level
compar
pbstreat
control
disrupt
mko
mice
diminish
phosphoryl
akt
enhanc
proapoptot
activ
significantli
increas
alt
level
liver
damag
acetaminophen
challeng
mice
unlik
treat
mice
mko
significantli
increas
macrophag
neutrophil
accumul
hepatocellular
apoptosi
furthermor
treatment
lpsstimul
bmm
activ
phosphoryl
akt
wherea
knockdown
bmm
result
reduc
phosphoryl
augment
releas
express
well
activ
follow
lp
stimul
conclus
studi
demonstr
signal
regul
innat
immun
respons
acetaminopheninduc
liver
injuri
activ
inhibit
releas
activ
activ
pathway
novel
find
underscor
critic
role
signal
cascad
regul
innat
immun
respons
acetaminopheninduc
liver
injuri
might
impli
novel
therapeut
potenti
druginduc
damageassoci
lethal
hepat
background
primari
biliari
cholang
pbc
progress
autoimmun
cholestat
liver
diseas
consid
cellmedi
immun
reaction
previou
studi
exhibit
major
contribut
cell
cytokin
pathogenesi
pbc
dendrit
cell
dc
profession
antigen
present
cell
compos
distinct
subset
uniqu
function
phenotyp
characterist
play
differ
role
elicit
key
immun
respons
dc
identifi
liver
section
pbc
patient
embed
damag
bile
duct
transcript
factor
necessari
develop
dendrit
cell
previou
studi
suggest
import
role
dc
defens
intracellular
pathogen
via
crosspresent
cell
secret
aim
assess
role
depend
dc
pbc
develop
method
util
induc
murin
model
pbc
immun
mice
xenobiot
acid
conjug
bovin
serum
albumin
bsa
took
advantag
ko
transgen
mice
lack
transcript
factor
result
lack
subset
analysi
includ
histolog
assess
ama
serum
titer
flow
cytometri
immunohistochemistri
immun
cell
liver
well
hepat
cytokin
profil
rtpcr
result
histopatholog
assess
demonstr
periport
infiltr
lymphocyt
mononuclear
cell
wt
mice
wherea
ko
mice
minor
abnorm
observ
histolog
find
associ
increas
level
alkalin
phosphatas
total
bile
acid
serum
wt
mice
compar
ko
mice
flow
cytometri
analysi
reveal
significantli
decreas
ratio
hepat
cell
mice
furthermor
quantit
pcr
studi
reveal
higher
express
level
proinflammatori
cytokin
wt
mice
compar
ko
mice
indic
tissu
inflamm
process
liver
induct
autoimmun
cholang
conclus
result
indic
critic
role
dc
specif
subset
pathogenesi
particularli
break
immun
toler
mechan
pbc
may
pave
road
new
immun
base
cell
specif
target
therapeut
endeavor
follow
peopl
noth
disclos
debbi
reuveni
patrick
leung
oren
shibolet
eric
gershwin
ehud
zigmond
vate
receptor
gamma
ligand
implic
antiinflammatori
compound
found
inhibit
bmm
migrat
inflammatori
cytokin
product
still
unclear
whether
involv
inflamm
regul
bmm
polar
evalu
role
axi
polar
bmm
also
explor
whether
mirna
involv
process
sinc
mirna
report
key
regul
immun
cell
function
mice
lethal
irradi
receiv
bm
transplant
enhanc
green
fluoresc
protein
transgen
mice
follow
four
week
carbon
tetrachlorid
ccl
administr
bm
reconstruct
flowcytometr
analysi
perform
detect
amount
type
bmm
express
marker
mirna
measur
rtqpcr
western
blot
cytometr
bead
array
high
content
analysi
transcript
factor
assay
kit
use
test
activ
vivo
suppress
polar
bmm
reduc
popul
type
bmm
express
injur
liver
vitro
bmm
challeng
upon
lp
polar
phenotyp
inhibit
process
via
sinc
agonist
caus
suppress
polar
bmm
wherea
specif
antagonist
sirna
attenu
induc
downregul
inde
increas
activ
type
bmm
bioinformat
analysi
http
www
targetscan
org
http
www
microrna
org
show
target
respect
use
mimic
inhibitor
three
mirna
confirm
three
mirna
regul
correspond
predict
target
gene
respect
meanwhil
three
mirna
express
decreas
damag
liver
type
bmm
renew
furthermor
result
specif
agonist
antagonist
sirna
indic
induc
upregul
mirna
depend
conclus
data
suggest
axi
inhibit
polar
bmm
toward
phenotyp
mirna
depend
manner
follow
peopl
noth
disclos
weiyang
li
lei
tian
na
chang
jieshi
xie
lin
yang
liy
li
augment
shed
leukocyt
migrat
inhibitor
solubl
combin
increas
plasma
level
human
alcohol
hepat
introduct
aim
human
alcohol
hepat
ah
monocyt
activ
directli
ethanol
indirectli
via
inflammatori
factor
lp
henc
number
liver
increas
monocyt
especi
intermedi
inflammatori
type
express
famili
integrin
activ
form
elicit
bind
monocyt
endotheli
adhes
receptor
bring
extravas
tissu
known
induc
shed
form
recent
discov
solubl
thought
inhibit
extravas
leukocyt
conceal
endotheli
adhes
receptor
known
whether
tissu
inflamm
moder
mechan
intact
mediat
ah
therefor
measur
monocyt
express
activ
inact
plasma
level
monocyt
abil
shed
patient
materi
method
flow
cytometri
detect
surfac
express
activ
inact
monocyt
subset
patient
sever
ah
healthi
control
quantifi
plasma
macrophag
activ
marker
patient
sever
ah
diagnosi
day
day
healthi
control
inhous
immunosorb
assay
likewis
vitro
shed
pbmc
respons
ethanol
lp
measur
result
patient
ah
monocyt
subset
higher
surfac
express
activ
control
p
wherea
differ
express
inact
increas
activ
express
highest
subset
intermedi
inflammatori
monocyt
ah
vs
control
plasma
concentr
increas
patient
compar
control
vs
correl
monocyt
activ
measur
plasma
plasma
chang
followup
period
spontan
product
vitro
elev
two
fold
ah
compar
control
vs
stimul
either
lp
ethanol
increas
shed
patient
ah
control
p
conclus
sever
ah
shed
like
result
monocyt
activ
suggest
antiinflammatori
mechan
oper
within
pictur
florid
hepat
inflamm
follow
peopl
noth
disclos
sidsel
stoey
thoma
sandahl
annelouis
hansen
bent
deleuran
thoma
vorupjensen
hendrik
vilstrup
tue
w
kragstrup
digoxin
protect
steril
inflamm
liver
target
pyruv
kinas
promot
transactiv
background
steril
inflamm
tissu
damag
ubiquit
immun
respons
occur
highest
amplitud
liver
major
clinic
consequ
alcohol
nonalcohol
steatohepat
ash
nash
lack
effect
therapi
key
requir
sustain
steril
inflamm
high
degre
cellular
oxid
stress
activ
pathway
cardiac
glycosid
digoxin
identifi
potent
suppressor
mechan
hepat
protect
well
defin
aim
assess
whether
digoxin
therapeut
effect
nash
ash
mice
investig
molecular
mechan
mous
human
cell
method
male
mice
place
high
fat
diet
hfd
without
digoxin
ip
mg
kg
twice
week
digoxin
ip
daili
mice
result
therapeut
serum
level
achiev
human
ngml
plasma
alt
liver
histolog
leukocyt
profil
mitochondri
ro
gene
transcriptom
microarray
analyz
chronic
plu
bing
model
ash
perform
identif
digoxin
interact
protein
maintain
cellular
redox
homeostasi
suppress
activ
investig
proteom
rtpcr
report
luciferas
chippcr
assay
result
digoxin
dosedepend
reduc
histolog
injuri
neutrophil
infiltr
inflammasom
activ
serum
alt
valu
cotreat
start
digoxin
time
hfd
alt
ul
hfd
vs
ul
hfddig
p
posttreat
start
digoxin
week
hfd
neutrophil
hfd
vs
hfddig
monocyt
hfd
vs
hfddig
alt
ul
hfd
vs
ul
hfddig
p
without
reduct
food
intak
low
dose
digoxin
mgkg
also
show
signific
protect
effect
injuri
oxid
stress
steril
inflamm
nash
ald
model
microarray
transcriptom
analysi
reveal
digoxin
treatment
result
signific
downregul
ro
metabol
antioxid
signal
pathway
gene
express
hfd
liver
tissu
broad
mass
spectrometrybas
proteom
screen
reveal
digoxin
bind
pyruv
kinas
independ
kinas
activ
result
chromatin
remodel
downregul
transactiv
conclus
data
identifi
novel
mediat
therapeut
target
regul
liver
steril
inflamm
demonstr
protect
role
digoxin
ash
nash
follow
peopl
noth
disclos
xinshou
ouyang
shengna
han
georg
lau
dechun
feng
rebecca
cardon
shiy
cai
rafaz
hoqu
yonglin
chen
weihong
yang
irma
garciamartinez
fusheng
wang
bin
gao
natali
j
torok
richard
kibbey
wajahat
z
mehal
glycogen
synthas
sens
metabol
control
inflammasom
activ
liver
injuri
direct
bind
asc
protein
background
metabol
syndrom
result
steril
inflamm
liver
depend
activ
inflammasom
cytosol
protein
complex
compris
protein
adaptor
protein
asc
apoptosisassoci
specklik
protein
activ
inflammatori
glycogen
synthas
import
metabol
regul
compos
two
isoform
aim
identifi
role
isoform
inhibit
inflammasom
activ
metabol
liver
injuri
method
inflammasom
activ
lpsatp
glucos
primari
mous
macrophag
effect
specif
inhibit
isoform
inflammasom
activ
assay
quantifi
supernat
activ
cell
lysat
molecular
mechan
investig
protein
pulldown
assay
confoc
imag
use
forc
gene
express
system
endogen
protein
tag
mous
macrophag
vivo
role
inhibit
metabol
liver
injuri
demonstr
use
high
fat
diet
hfd
induc
nash
diabet
model
apoedefici
mice
result
pharmacolog
inhibit
total
suppress
inflammasom
activ
respons
atp
urat
crystal
microbi
alkaloid
toxin
staurosporin
inhibit
inhibit
inflammasom
activ
respons
doublestrand
dna
affect
noncanon
inflammasom
activ
inhibit
suppress
high
glucos
mediat
inflammasom
activ
inhibit
block
inflammasom
reduc
activ
asc
speck
format
inhibit
block
inflammasom
activ
without
affect
level
reactiv
oxygen
speci
ro
pull
endogen
show
directli
bind
asc
inhibit
reduc
oglcnacyl
asc
protein
oglcnac
transferasedefici
macrophag
also
result
signific
reduct
matur
secret
respons
inflammasom
activ
predict
inhibit
attenu
urat
crystalinduc
periton
suppress
secret
serum
alt
ast
level
hfdnash
hfddiabet
apoedefici
mice
conclus
result
demonstr
critic
role
metabolismsens
mediat
inflammasom
activ
liver
injuri
thu
defin
new
therapeut
target
steril
inflamm
liver
follow
peopl
noth
disclos
shengna
han
ziwen
liang
wajahat
z
mehal
xinshou
ouyang
agata
bartczak
max
xuezhong
yujia
li
kim
tsoi
oyedel
adeyi
ian
mcgilvray
multiorgan
transplant
depart
univers
health
network
toronto
canada
sever
coronaviru
cov
infect
led
global
epidem
respiratori
failur
one
caus
fulmin
liver
failur
case
sever
clinic
ill
caus
strong
host
inflammatori
respons
viru
particularli
true
mous
liver
damag
follow
infect
murin
hepat
viru
strain
previous
shown
macrophag
activ
drive
much
host
inflamm
ubiquitin
specif
peptidas
pathway
link
type
inflammatori
respons
gener
ask
whether
modul
liver
macrophag
kupffer
cell
kc
inflammatori
respons
found
mice
increas
number
kc
kc
regulatori
phenotyp
character
increas
phagocyt
activ
express
antiinflammatori
cytokin
respons
lp
respons
kc
lp
induc
proinflammatori
cytokin
pattern
cytokin
express
replic
vivo
follow
infect
suscept
mice
mice
decreas
level
proinflammatori
cytokin
increas
antiinflammatori
cytokin
express
liver
compar
mice
contrast
mice
kc
proinflammatori
base
criteria
much
express
liver
follow
infect
base
data
hypothes
kc
deleteri
inflammationdriven
pathogenesi
kc
might
protect
elimin
kc
would
benefici
mice
detriment
mice
surprisingli
deplet
kc
clodron
treatment
led
improv
surviv
mice
day
p
expect
kc
deplet
elimin
cytokin
storm
mice
howev
see
evid
increas
inflamm
liver
damag
group
anim
kcdeplet
decreas
earli
viral
replic
liver
log
depend
macrophag
number
sinc
macrophag
constitut
minor
cell
liver
homogen
replic
macrophag
hepatocyt
similar
studi
first
time
illustr
macrophagepermiss
effect
infect
liver
outlin
potenti
new
target
treatment
sever
cov
infect
independ
host
inflammatori
respons
purpos
chronic
alcohol
abus
lead
liver
inflamm
fibrosi
cirrhosi
inflamm
contribut
alcohol
liver
diseas
ald
particularli
alcohol
steatohepat
ash
monocyt
chemoattract
chemokin
cc
motif
ligand
rant
interact
respect
receptor
drive
inflammatori
respons
ash
aim
hypothes
dual
inhibit
cenicriviroc
cvc
attenu
featur
ald
method
use
lieberdecarli
diet
model
chronic
alcohol
feed
vv
alcohol
week
prevent
cohort
cvc
vehicl
solutol
steril
water
inject
c
daili
entir
length
alcohol
feed
week
treatment
cohort
cvc
vehicl
inject
last
week
alcohol
feed
week
liver
injuri
serum
alt
h
e
steatosi
oilredo
stain
triglycerid
assess
cytokin
express
analyz
qpcr
elisa
liver
immun
cell
infiltr
fac
result
mice
receiv
alcoholcvc
prevent
cohort
significantli
lower
serum
alt
level
compar
alcoholvehicl
control
entir
cours
alcohol
feed
sacrific
alcoholcvc
group
significantli
reduc
inflammatori
cytokin
level
steatosi
compar
alcoholvehicl
group
mice
alcohol
diet
show
signific
induct
serum
alt
week
introduct
cvc
treatment
rapidli
normal
alt
level
baselin
liver
inflammatori
cytokin
significantli
reduc
cvc
treatment
compar
alcoholvehicl
mice
mice
cvc
treatment
group
show
lower
liver
triglycerid
lipid
accumul
upon
alcohol
administr
final
cvc
prevent
treatment
cohort
significantli
lower
serum
level
compar
alcoholvehicl
group
cvc
administr
prevent
treatment
cohort
significantli
prevent
macrophag
infiltr
liver
restor
alcoholrel
reduct
hepat
nk
b
cell
count
conclus
block
cvc
attenu
chronic
alcoholinduc
macrophag
infiltr
liver
therebi
lower
inflamm
alcohol
hepat
inhibit
prevent
liver
damag
improv
histolog
attenu
steatosi
serum
mous
model
ald
data
indic
therapeut
potenti
cvc
human
aldash
background
primari
biliari
cholang
pbc
chronic
autoimmun
liver
diseas
character
presenc
antimitochondri
antibodi
ama
hepat
antigen
specif
cell
result
progress
cholestasi
eventu
lead
cirrhosi
monocyt
plastic
cell
massiv
recruit
inflam
tissu
differenti
antigen
present
cell
apc
express
monocyt
crucial
emigr
cell
bone
marrow
circul
monocyt
isol
pbc
patient
found
sensit
tlr
signal
result
secret
proinflammatori
cytokin
interleukin
proinflammatori
cytokin
belong
famili
posit
cell
detect
portal
area
liver
tissu
advanc
stage
pbc
thu
previou
studi
suggest
involv
monocytederiv
cell
pbc
pathogenesi
howev
solid
data
evalu
import
function
invivo
context
still
miss
method
util
induc
murin
model
pbc
immun
mice
xenobiot
acid
conjug
bovin
serum
albumin
bsa
knockout
ko
mice
mice
apc
restrict
defici
cre
flox
compar
wild
type
wt
flox
control
mice
respect
analysi
includ
histolog
assess
ama
serum
titer
flow
cytometri
immunohistochemistri
immun
cell
liver
fibrosi
evalu
hepat
cytokin
profil
rtpcr
result
histopatholog
evalu
reveal
hepat
infiltr
lymphocyt
mononuclear
cell
wt
mice
compar
mice
exhibit
liver
abnorm
immunofluorec
microscopi
flow
cytometri
analys
show
massiv
accumul
monocytederiv
macrophag
around
portal
triad
wt
mice
flow
cytometri
analysi
reveal
significantli
increas
ratio
hepat
cell
wt
mice
hepat
express
level
proinflammatori
cytokin
includ
ama
titer
serum
elev
wt
mice
siriu
red
stain
liver
section
exhibit
periport
collagen
deposit
wt
mice
find
support
profibrot
geneexpress
signatur
liver
cre
flox
mice
exhibit
significantli
milder
diseas
phenotyp
assess
histolog
flow
cytometri
hepat
cytokin
profil
compar
creneg
litterm
conclus
result
indic
major
role
apc
deriv
pathogenesi
progress
pbc
may
pave
road
develop
new
immunebas
therapeut
modal
follow
peopl
noth
disclos
debbi
reuveni
patrick
leung
oren
shibolet
eric
gershwin
ehud
zigmond
high
mobil
group
box
neutrophil
nafld
inhibit
cell
activ
prolifer
background
aim
injur
cell
releas
endogen
molecul
call
alarmin
activ
immun
respons
studi
alarmin
transloc
nucleu
cytoplasm
activ
innat
immun
system
liver
failur
elev
plasma
level
observ
point
sensit
marker
hepatotox
nonalcohol
fatti
liver
diseas
nafld
common
chronic
liver
diseas
goe
steatosi
hepatocellular
carcinoma
earli
phase
nafld
effect
neutrophil
cell
suppress
cellmedi
liver
damag
remain
elus
henc
aim
investig
relationship
involv
method
analyz
serum
level
earli
nafld
patient
healthi
donor
hd
elisa
laboratori
clinic
data
collect
immunohistochemistri
ihc
use
show
local
paraffinembed
liver
biopsi
flow
cytometri
analysi
fac
use
studi
neutrophil
prolifer
cfse
dilut
phenotyp
mitogen
activ
cell
perform
cocultur
neutrophil
pbmc
stain
cfse
activ
platebound
antibodi
hd
patient
result
conclus
interestingli
nafld
patient
level
threefold
higher
hd
addit
serum
concentr
posit
correl
absolut
rel
number
circul
neutrophil
ihc
found
resid
nuclei
healthi
hepatocyt
wherea
cytoplasm
local
steatot
hepatocyt
suggest
forthcom
releas
damag
tissu
demonstr
neutrophil
abl
suppress
prolifer
helper
cytotox
cell
inhibit
express
activ
marker
hd
nafld
patient
moreov
found
hd
nafld
patient
prestimul
neutrophil
enhanc
immunesuppress
particular
result
hd
demonstr
potenti
suppress
activ
neutrophil
cell
mayb
establish
protect
inflammatori
respons
earli
nafld
patient
whose
level
threefold
higher
hd
neutrophil
show
profil
hd
neutrophil
stimul
vitro
instead
neutrophil
nafld
patient
stimul
nt
increas
suppress
activ
cell
allow
progress
liver
diseas
preliminari
data
lead
us
consid
one
main
actor
suppress
cell
prolifer
alreadi
earli
phase
nafld
acetaminophen
apap
induc
liver
injuri
number
one
caus
acut
liver
failur
unit
state
although
great
deal
research
focus
develop
therapi
limit
liver
injuri
apap
overdos
mani
patient
benefit
type
therapi
liver
injuri
often
extens
time
reach
clinic
patient
would
like
benefit
therapi
aim
stimul
liver
repair
mechan
regul
liver
repair
apap
overdos
howev
fulli
understood
particular
mechan
regul
macrophagedepend
clearanc
necrot
cell
liver
known
greater
understand
mechan
could
lead
new
therapi
stimul
liver
repair
patient
suffer
acut
liver
failur
present
studi
test
hypothesi
plasmin
critic
macrophagedepend
clearanc
necrot
cell
liver
test
hypothesi
mice
treat
mgkg
apap
tranexam
acid
inhibit
convers
plasminogen
plasmin
vehicl
steril
salin
tranexam
acid
effect
apapinduc
increas
alt
hour
treatment
similarli
area
necrosi
hour
treatment
differ
tranexam
acidtr
vehicletr
mice
strike
contrast
wherea
necrosi
larg
absent
vehicletr
mice
given
apap
area
necrosi
mice
treat
apap
tranexam
acid
indic
plasmin
inhibit
prevent
macrophagedepend
remov
necrot
cell
liver
apaptr
mice
macrophag
number
differ
two
group
indic
defect
result
improp
recruit
macrophag
similarli
opson
necrot
cell
affect
necrot
cell
similarli
coat
complement
factor
two
group
determin
whether
plasmin
direct
effect
macrophag
function
bone
marrowderiv
macrophag
treat
plasmin
plasmin
increas
phagocytosi
upregul
matrix
metalloproteinas
mrna
collect
studi
demonstr
plasmin
critic
remov
necrot
cell
liver
apap
treatment
plasmin
may
promot
clearanc
necrot
cell
directli
stimul
macrophag
phagocytosi
greater
understand
mechan
plasmin
promot
macrophag
phagocytosi
could
lead
new
treatment
stimul
remov
dead
cell
liver
process
essenti
liver
repair
follow
peopl
noth
disclos
nikita
joshi
ryan
albe
jame
p
luyendyk
bryan
l
coppl
benedetta
piombanti
elisa
vivoli
valentina
l
cacciato
francesco
vizzutti
roberto
g
romanelli
andrea
cappon
giacomo
laffi
fabio
marra
univers
florenc
florenc
itali
backgroundaim
alter
immun
common
find
patient
cirrhosi
presenc
subclin
system
inflamm
may
contribut
portal
hypertens
develop
acuteonchron
liver
failur
cirrhot
patient
suscept
bacteri
infect
aim
studi
compar
respons
peripher
blood
monocyt
bm
lp
stimul
patient
undergo
placement
tip
method
patient
male
age
year
cirrhosi
portal
hypertens
indic
tip
placement
bleed
andor
refractori
ascit
enrol
etiolog
hcv
hbv
alcohol
multifactori
meld
score
time
tip
procedur
blood
drawn
peripher
vein
portal
vein
deploy
prosthesi
week
tip
placement
sampl
peripher
vein
repeat
healthi
subject
hs
serv
control
peripher
blood
blood
mc
isol
ficol
allow
adher
plastic
dish
transfer
new
dish
cell
incub
without
lp
cytokin
express
measur
quantit
real
time
pcr
result
unstimul
condit
express
level
compar
cirrhot
patient
hs
portal
bm
express
significantli
higher
peripher
bm
cirrhot
patient
hs
upon
lp
stimul
mark
increas
three
cytokin
observ
bm
isol
differ
site
howev
lpsstimul
mrna
level
beta
higher
sampl
collect
tip
peripher
portal
collect
peripher
vein
tip
placement
latter
also
significantli
lower
observ
hs
tip
level
lp
stimul
significantli
higher
cirrhot
patient
hs
tip
mrna
reduc
reach
valu
similar
peripher
bm
hs
contrast
express
significantli
lower
sampl
cirrhot
patient
regardless
tip
placement
size
collect
hs
express
slightli
significantli
higher
sampl
cirrhot
patient
conclus
cirrhosi
portal
hypertens
differenti
affect
cytokin
express
lpsstimul
bm
reduct
portal
pressur
tip
result
induc
bm
phenotyp
similar
one
observ
peripher
bm
hs
data
suggest
effect
manag
portal
hypertens
may
impact
immun
respons
patient
cirrhosi
accumul
monocyt
myeloidderiv
suppressor
cell
liver
murin
model
nonalcohol
fatti
liver
diseas
masanori
abe
liy
yao
yoshiko
nakamura
teruki
miyak
yusuk
imai
takao
watanab
yohei
koizumi
osamu
yoshida
yoshio
tokumoto
masashi
hirooka
teru
kumagi
yoichi
hiasa
depart
gastroenterolog
metabolog
ehim
universiy
graduat
school
medicin
ehim
japan
backgroundaim
myeloidderiv
suppressor
cell
mdsc
compris
heterogen
popul
myeloid
cell
recogn
suppressor
cell
function
mice
cell
identifi
coexpress
surfac
marker
howev
mdscspecif
marker
describ
mdsc
myeloid
cell
display
marker
recent
report
ssc
dim
cell
ssc
low
hi
cell
repres
authent
monocyt
mdsc
liver
addit
increas
number
monocyt
mdsc
observ
liver
murin
model
nonalcohol
liver
diseas
nafld
studi
aim
understand
biolog
mdsc
accumul
nafld
liver
method
mice
fed
normal
diet
highfat
diet
nafld
model
month
differ
subtyp
cell
sort
liver
nonparenchym
cell
fac
cell
surfac
marker
analyz
flowcytometri
observ
effect
steatosi
hepatocyt
cell
expos
oleic
acid
palmit
acid
rna
extract
liver
cell
gene
express
mcsf
examin
realtim
rtpcr
analysi
protein
level
mcsf
analyz
immunohistochemistri
elisa
migratori
capac
monocyt
mdsc
examin
vitro
migrat
assay
final
bone
marrow
cell
mice
cultur
mcsf
day
induct
monocyt
mdsc
analyz
flowcytometri
result
among
cell
liver
monocyt
mdsc
subset
cell
express
surfac
mrna
protein
level
mcsf
higher
liver
nafld
mice
control
mice
result
confirm
use
cell
supplement
fatti
acid
vitro
migrat
assay
show
monocyt
mdsc
migrat
respons
dosedepend
manner
addit
increas
number
monocyt
mdsc
observ
cultur
grown
presenc
mcsf
dosedepend
manner
conclus
pathway
might
contribut
migrat
monocyt
mdsc
steatot
liver
addit
increas
mcsf
level
steatot
liver
might
contribut
induct
monocyt
mdsc
result
suggest
target
key
molecul
ration
strategi
regul
immun
environ
nafld
teru
kumagi
grantresearch
support
ea
pharma
co
ltd
follow
peopl
noth
disclos
masanori
abe
liy
yao
yoshiko
nakamura
teruki
miyak
yusuk
imai
takao
watanab
yohei
koizumi
osamu
yoshida
yoshio
tokumoto
masashi
hirooka
yoichi
hiasa
enhanc
poli
c
induc
typei
ifn
induct
dc
matur
yuika
innami
masao
honda
kazuhisa
murai
tetsuro
shimakami
takayoshi
shirasaki
seishi
murakami
shuichi
kaneko
kanazawa
univers
ishikawa
japan
object
singl
nucleotid
polymorph
interleukin
interferon
ifn
gene
strongli
associ
sustain
virolog
respons
rate
treat
patient
chronic
hepat
c
pegyl
interferon
ribavirin
combin
therapi
moreov
genotyp
potenti
associ
outcom
direct
antivir
agent
treatment
patient
decompens
cirrhosi
liver
transplant
although
express
dendrit
cell
dc
function
relev
innat
immun
respons
clarifi
fulli
method
knockout
ko
mice
gener
wildtyp
wt
ko
mice
inject
polyinosinicpolycytidyl
acid
poli
c
via
tail
vein
h
inject
immun
cell
dc
natur
killer
nk
cell
cell
liver
evalu
fluorescenceactiv
cell
sort
fac
analysi
bone
marrowderiv
dendrit
cell
bmdc
gener
bone
marrow
cell
cultur
media
contain
gmcsf
day
bmdc
pretreat
recombin
protein
neutral
antibodi
cell
stimul
poli
c
result
determin
whether
associ
immun
cell
activ
vivo
wt
ko
mice
stimul
poli
c
number
immun
cell
liver
analyz
ko
mice
number
dc
nk
cell
significantli
decreas
stimul
poli
c
compar
wt
mice
investig
effect
typei
ifn
induct
bmdc
deriv
wt
mice
stimul
poli
c
presenc
absenc
pretreat
pretreat
significantli
enhanc
poli
c
induc
induct
invers
pretreat
significantli
suppress
induct
addit
induct
poli
c
significantli
reduc
primari
mous
hepatocyt
deriv
ko
mice
compar
wt
mice
next
evalu
effect
dc
matur
upon
stimul
poli
c
bmdc
deriv
ko
mice
exhibit
lower
express
level
activ
marker
dc
mhc
class
ii
compar
wt
mice
conclus
result
suggest
play
import
role
dcmediat
immun
respons
expect
therapeut
potenti
hepat
bc
viru
infect
also
cancer
immunotherapi
hepatocellular
carcinoma
disclosur
shuichi
kaneko
grantresearch
support
md
co
inc
chugai
pharma
co
inc
toray
co
inc
daiichi
sankyo
co
inc
dainippon
sumitomo
co
inc
ajinomoto
co
inc
bristol
myer
squibb
inc
pfizer
co
inc
astella
inc
takeda
co
inc
otsuka
co
inc
eizai
co
object
acuteonchron
liver
failur
aclf
character
rapid
deterior
liver
function
cirrhosi
often
precipit
organ
failur
aclf
associ
sever
immunodysfunct
immun
activ
paresi
often
coexist
dysregul
immun
state
lead
sever
monocyt
dysfunct
may
precipit
bacteri
infect
although
aclf
diseas
entiti
attract
much
attent
littl
known
molecular
mechan
respons
alter
monocyt
function
condit
design
studi
patient
biopsi
proven
alcohol
liver
diseas
decompens
cirrhosi
alcohol
hepat
aclf
control
blood
obtain
admiss
biochem
test
gene
express
pbmc
flow
cytometri
function
monocyt
assay
plasma
use
determin
cytokinechemokin
level
addit
isol
po
monocyt
donor
wellcharacter
aclf
patient
determin
gene
express
nextgen
sequenc
character
key
molecular
factor
associ
monocyt
dysfunct
use
pathway
analysi
addit
function
assay
perform
healthi
aclf
monocyt
presenc
absenc
normal
aclf
serum
result
observ
decreas
express
hladr
within
classic
monocyt
subset
elev
number
produc
intermedi
monocyt
aclf
function
analysi
total
pbmc
isol
po
monocyt
show
sever
impair
phagocytosi
oxid
burst
aclf
increas
gene
express
pbmc
elev
plasma
level
aclf
associ
decreas
surviv
month
pathway
analysi
reveal
signific
downregul
gene
associ
immunolog
process
monocyt
phagocytosi
cytokinecytokin
interact
respons
bacteri
infect
importantli
cultur
healthi
monocyt
aclf
serum
induc
aclf
dysfunct
phenotyp
convers
cultur
aclfmonocyt
healthi
plasma
revers
aclf
phenotyp
restor
phagocytosi
final
data
indic
central
role
molecular
pathway
associ
aclf
conclus
aclf
associ
sever
immun
dysfunct
induc
aclf
signatur
healthi
monocyt
use
aclf
serumcontain
media
revers
monocyt
dysfunct
aclf
monocyt
use
normal
serum
contain
medium
suggest
circul
factor
promot
syndrom
associ
sever
immun
dysfunct
poor
surviv
aclf
express
analysi
suggest
crucial
role
driver
condit
frederik
neven
consult
msd
caf
intercept
gore
bm
abbvi
novarti
durect
janssenscilag
ono
pharma
promethera
bioscienc
grant
research
support
fer
roch
astella
novarti
janssencilag
abbvi
follow
peopl
noth
disclos
hanneli
korf
johanni
du
plessi
johann
van
pelt
schalk
van
der
merw
elien
de
smidt
introduct
neutrophil
dysfunct
close
correl
suscept
bacteri
infect
observ
alcoholrel
cirrhosi
arc
primarili
thought
consequ
defect
phagocytosi
reactiv
oxygen
speci
ro
product
emerg
evid
suggest
type
iii
interferon
possess
antipathogen
anticanc
immunomodulatori
properti
interplay
neutrophil
health
arc
examin
aim
explor
whether
neutrophil
produc
respond
health
arc
method
whole
blood
healthi
control
hc
patient
arc
median
child
pugh
score
cultur
without
e
coli
patient
superimpos
alcohol
hepat
df
rna
extract
isol
neutrophil
total
leukocyt
fraction
quantit
pcr
receptor
endogen
control
perform
patient
whole
blood
incub
examin
express
neutrophil
phagocytosi
ro
product
also
assess
fac
result
notabl
find
seen
neutrophil
mrna
express
amongst
patient
group
emerg
e
colistimul
induct
group
group
although
lower
level
hc
e
colistimul
neutrophil
express
group
significantli
less
hc
group
p
observ
e
colichalleng
product
leukocyt
fraction
also
compromis
group
group
significantli
higher
childpugh
score
ast
compar
group
respect
profound
differ
observ
group
seen
neutrophil
leucocyt
express
receptor
express
addit
significantli
alter
neutrophil
phagocytosi
burst
cell
surfac
receptor
express
conclus
first
time
identifi
neutrophil
produc
innat
type
iii
interferon
reveal
previous
unknown
defici
product
arc
confirm
respons
bacteri
infect
elucid
mechan
may
import
implic
therapeut
develop
era
multidrug
resist
background
cell
intrins
innat
immun
provid
rapid
first
line
defens
thwart
invad
viral
pathogen
product
antivir
cytokin
inflammatori
chemokin
howev
presenc
mani
signal
pathway
liver
role
hbv
pathogenesi
unknown
recent
identif
intracellular
dna
sens
pathway
involv
numer
divers
diseas
process
includ
viral
pathogenesi
carcinogenesi
suggest
role
process
hbv
infect
dna
genom
method
order
character
hbv
intrins
innat
immun
respons
role
dna
rna
sens
pathway
liver
recognit
hbv
util
vivo
vitro
model
includ
analysi
gene
express
liver
biopsi
hbv
infect
patient
addit
mrna
protein
express
measur
hbv
stimul
dna
treat
hepatoma
cell
line
primari
human
hepatocyt
phh
specif
rna
dna
depend
innat
inflammatori
pathway
signal
studi
well
addit
pathway
involv
product
interferon
chemokin
may
drive
subsequ
liver
diseas
sirna
experi
util
determin
signal
pathway
involv
hbv
recognit
microarray
analys
use
character
global
transcriptom
chang
hbv
infect
primari
human
hepatocyt
uv
inactiv
hbv
util
determin
effect
observ
viral
replic
result
hbv
foreign
dna
result
rapid
innat
immun
respons
hepatocyt
character
product
inflammatori
chemokin
mrna
protein
level
analysi
liver
biopsi
hbvinfect
patient
support
correl
among
hepat
express
specif
antivir
gene
includ
addit
hbv
elicit
much
broader
rang
gene
express
alter
demonstr
microarray
analysi
induct
chemokin
includ
mediat
predominantli
nfkbdepend
pathway
follow
hbv
stimul
conclus
hbv
stimul
pathway
predominantli
activ
inflammatori
respons
would
promot
develop
hepat
hcv
stimul
much
stronger
interferon
antivir
respons
understand
mechan
underli
inflammatori
antivir
respons
may
provid
new
strategi
trigger
noncytopath
clearanc
cccdna
ultim
cure
patient
hbv
infect
addit
data
offer
addit
insight
hbv
driven
hepatocarcinogenesi
activ
induc
autophagi
macrophag
protect
proinflammatori
cytokin
activ
induc
free
fatti
acid
xiaoj
wang
ambika
pandita
abhishek
satishchandran
karen
kodi
aditya
ambad
gyongyi
szabo
medicin
univers
massachusett
medic
school
worcest
background
aim
hypoxiainduc
factor
hif
recent
identifi
import
regul
immun
inflamm
play
role
pathogenesi
nonalcohol
steatohepat
nash
macrophag
activ
determin
event
diseas
progress
upregul
nash
hepatocyt
induc
steatosi
also
found
induc
autophagi
fibroblast
howev
role
macrophag
metabol
stress
explor
studi
hypothes
modul
macrophag
autophagi
respons
free
fatti
acid
method
macrophag
treat
free
fatti
acid
ffa
oleic
acid
plu
palmit
acid
differ
time
period
rna
level
target
gene
examin
qpcr
protein
level
autophagi
relat
molecul
mtor
examin
westernblot
dnabind
test
emsa
silenc
overexpress
achiev
use
sirna
respect
cell
supernat
collect
test
elisa
proinflammatori
antiinflammatori
cytokin
chemokin
result
ffa
treatment
cell
mrna
level
show
rapid
increas
follow
upregul
target
gene
protein
level
dnabind
activ
also
increas
upon
ffa
treatment
ffasinduc
macrophag
autophagi
indic
increas
protein
level
decreas
mtor
level
event
parallel
induct
proand
antiinflammatori
cytokin
ffatreat
cell
silenc
sirna
result
downregul
express
increas
product
proinflammatori
cytokin
decreas
antiinflammatori
suggest
regul
ffasinduc
autophagi
well
inflamm
macrophag
convers
overexpress
augment
express
reduc
increas
level
macrophag
provid
addit
evid
regul
autophagi
inflamm
macrophag
conclus
result
indic
upregul
play
protect
role
macrophageinduc
inflamm
nash
regul
autophagi
pathway
respons
free
fatti
acid
stimul
find
highlight
complex
role
macrophag
regul
metabol
stress
nash
l
coppl
ryan
albe
carli
gerhardt
cheryl
rockwel
pharmacolog
toxicolog
michigan
state
univers
east
lans
mi
liver
contain
two
distinct
popul
macrophag
monocytederiv
macrophag
mdm
low
hi
kupffer
cell
hi
low
mdm
primarili
resid
within
around
preand
postsinusoid
vessel
wherea
kupffer
cell
resid
within
sinusoid
mdm
replenish
myeloid
progenitor
bone
marrow
wherea
kupffer
cell
replenish
local
prolifer
matur
kupffer
cell
beyond
observ
littl
inform
whether
function
differ
macrophag
cell
type
present
studi
determin
whether
two
macrophag
popul
produc
differ
level
cytokin
activ
bacteri
lipopolysaccharid
lp
mdm
kupffer
cell
purifi
liver
mice
use
antibodylabel
magnet
bead
digest
liver
collagenas
dendrit
cell
remov
neg
select
magnet
bead
next
mdm
purifi
liver
digest
use
magnet
bead
label
antibodi
final
kupffer
cell
purifi
remain
digest
use
magnet
bead
analysi
content
flow
cytometri
indic
mdm
kupffer
cell
greater
pure
basal
level
tumor
necrosi
mrna
higher
mdm
compar
kupffer
cell
treatment
kupffer
cell
lp
increas
respect
treatment
mdm
lp
increas
fold
respect
indic
lp
upregul
cytokin
greater
extent
mdm
lastli
basal
level
induc
nitric
oxid
synthas
higher
mdm
compar
kupffer
cell
suggest
mdm
skew
toward
macrophag
phenotyp
collect
result
indic
mdm
proinflammatori
kupffer
cell
mdm
may
main
sourc
cytokin
vivo
liver
exposur
bacteri
product
lp
disclosur
follow
peopl
noth
disclos
bryan
l
coppl
ryan
albe
carli
gerhardt
cheryl
rockwel
long
term
mortal
patient
nonalcohol
fatti
liver
diseas
nafld
background
nafld
one
common
caus
chronic
liver
diseas
long
term
outcom
nafld
gener
popul
set
well
studi
object
compar
risk
death
caus
well
cardiovascular
liverspecif
caus
nafld
subject
accord
presenc
absenc
metabol
syndrom
ms
condit
method
use
populationbas
survey
nation
health
nutrit
examin
surveyiii
nhane
iii
linkag
nation
death
index
ndi
death
certif
record
follow
decemb
examin
associ
compon
ms
mortal
adult
age
nafld
ms
defin
ncepatpiii
guidelin
nafld
identifi
hepat
ultrasound
presenc
mild
moder
sever
grade
steatosi
absenc
caus
liver
diseas
excess
alcohol
use
cox
proport
hazard
model
use
estim
hazard
ratio
hr
confid
interv
ci
result
studi
includ
particip
median
follow
year
year
followup
period
subject
die
cardiovascular
diseas
liver
diseas
preval
nafld
without
ms
preval
nafld
one
ms
two
ms
three
ms
four
ms
comparison
absenc
ms
condit
hr
allcaus
mortal
one
ms
condit
two
ms
condit
three
ms
condit
four
ms
condit
age
histori
cardiovascular
diseas
mutual
adjust
model
dm
independ
associ
increas
risk
death
caus
cardiovascular
caus
allcaus
mortal
cardiovascular
diseas
caus
mortal
addit
nafld
four
ms
fold
increas
risk
death
liverspecif
caus
compar
nafld
without
ms
conclus
increas
number
metabol
condit
associ
increas
risk
mortal
nafld
dm
import
predictor
nafld
denot
aasld
presidenti
poster
distinct
gastroenterolog
brook
armi
medic
center
fort
sam
houston
tx
radiolog
brook
armi
medic
center
fort
sam
houston
tx
patholog
brook
armi
medic
center
fort
sam
houston
tx
biomed
statist
institut
surgic
research
fort
sam
houston
tx
cardiolog
brook
armi
medic
center
fort
sam
houston
tx
background
nafld
preval
estim
high
usa
larg
prospect
studi
lack
correl
demograph
clinic
novel
radiograph
data
histopatholog
method
adult
patient
prospect
enrol
predominantli
time
referr
routin
colon
cancer
screen
screen
evid
nafld
fibroscan
livermultiscan
lm
mr
elastographi
mre
prior
histori
liver
diseas
alcohol
ingest
greater
accept
rang
nafld
consid
exclusionari
patient
exceed
prespecifi
cutoff
valu
imag
test
offer
liver
biopsi
liver
biopsi
read
expert
pathologist
use
brunt
criteria
result
date
particip
enrol
result
avail
interim
analysi
mean
age
year
mean
bmi
male
diabet
preval
nafld
defin
proton
densiti
fat
fraction
pdff
among
complet
radiograph
studi
fig
pdff
valu
nafld
patient
distribut
follow
onehundredseven
biopsi
perform
date
normal
nonnashnafld
nash
among
nash
patient
diabet
diabet
diabet
diabet
patient
diabet
nafld
compar
nonnafld
higher
lsm
cap
steatosi
grade
p
fibrosi
stage
among
nash
vs
nonnash
nafld
mean
lsm
vs
kpa
gastroenterolog
hepatolog
mayo
clinic
rochest
mn
biomed
statist
informat
mayo
clinic
rochest
mn
background
aim
pauciti
data
regard
incid
nonalcohol
fatti
liver
diseas
nafld
popul
aim
determin
timetrend
nafld
incid
mortal
cardiovascular
cv
event
us
commun
method
use
rochest
epidemiolog
project
databas
construct
commun
cohort
subject
diagnos
nafld
olmst
counti
mn
nafld
defin
use
diagnost
code
algorithm
subject
follow
april
mortal
cv
outcom
myocardi
infarct
angina
atrial
fibril
cerebrovascular
diseas
compar
ageand
sexmatch
control
group
identifi
gener
popul
multivari
cox
regress
analysi
perform
determin
impact
nafld
mortal
cv
event
result
total
subject
nafld
median
age
femal
identifi
incid
rate
increas
per
personyear
without
consider
sexdiffer
figur
compar
ageand
sexmatch
control
nafld
subject
like
diabet
vs
p
hypertens
vs
p
hyperlipidemia
vs
p
nafld
subject
higher
mortal
vs
cv
event
vs
adjust
presenc
diabet
hypertens
hyperlipidemia
addit
age
sex
nafld
independ
associ
mortal
hr
cv
event
hr
conclus
mostli
white
popul
nafld
incid
increas
consider
nafld
independ
predictor
overal
mortal
cv
event
fibrosi
progress
mortal
nonalcohol
fatti
liver
diseas
olof
per
rolf
w
hultcrantz
hann
center
digest
diseas
unit
hepatolog
karolinska
univers
hospit
depart
medicin
hudding
karolinska
institutet
stockholm
sweden
stockholm
sweden
karolinska
institutet
stockholm
sweden
introduct
nonalcohol
fatti
liver
diseas
nafld
common
liver
diseas
global
patient
nafld
inflamm
liver
nonalcohol
steatohepat
nash
wherea
fatti
liver
without
inflamm
nonalcohol
fatti
liver
nafl
nash
nafl
previous
consid
potenti
progress
fibrosi
develop
cirrhosi
aim
investig
risk
factor
progress
fibrosi
patient
nafld
impact
subsequ
mortal
materi
method
identifi
patient
undergon
liver
biopsi
find
nafld
karolinska
univers
hospit
stockholm
sweden
patient
perform
two
liver
biopsi
year
part
complet
data
possibl
risk
factor
includ
age
sex
presenc
comorbid
diseas
bmi
biochem
paramet
identifi
cohort
divid
two
group
one
fibrosi
progress
one
without
fibrosi
progress
follow
death
end
studi
period
biopsi
central
read
one
expert
liver
pathologist
defin
nash
base
flip
algorithm
score
fibrosi
use
nash
crn
system
differ
paramet
two
cohort
analyz
use
mannwhitney
utest
continu
variabl
fischer
exact
test
categor
variabl
result
patient
serial
biopsi
median
interv
year
rang
year
patient
fibrosi
progress
median
age
baselin
year
male
median
bmi
kgm
diabet
mellitu
type
found
signific
risk
factor
progress
fibrosi
among
patient
fibrosi
progress
nafl
nash
baselin
differ
fibrosi
progress
rate
patient
nafl
nash
baselin
vs
stage
per
year
second
biopsi
patient
follow
median
year
rang
hospit
depart
medicin
hudding
karolinska
institutet
stockholm
sweden
stockholm
sweden
karolinska
institutet
stockholm
sweden
introduct
nonalcohol
fatti
liver
diseas
nafld
affect
around
global
popul
highli
associ
metabol
syndrom
mani
patient
develop
type
diabet
mellitu
nafld
patient
develop
like
progress
nonalcohol
steatohepat
nash
liver
fibrosi
need
diagnost
tool
identifi
nafld
patient
highest
risk
develop
aim
studi
find
predict
factor
risk
develop
nafld
patient
materi
method
cohort
patient
biopsyproven
nafld
diagnos
analyz
data
develop
collect
electron
paper
patient
chart
biomark
clinic
paramet
baselin
compar
patient
develop
patient
hazard
ratio
hr
develop
number
baselin
variabl
calcul
use
multivari
cox
regress
final
model
adjust
sex
age
hypertens
bmi
triglycerid
glucos
well
histolog
score
fat
lobular
inflamm
balloon
fibrosi
portal
inflamm
result
exclud
patient
baselin
patient
outcom
data
leav
patient
final
analysi
baselin
patient
mean
age
year
women
patient
gener
overweight
mean
bmi
mean
followup
year
rang
individu
develop
age
time
biopsi
ahr
p
serum
triglycerid
ahr
p
higher
stage
fibrosi
ahr
liver
diseas
branch
nation
institut
health
niddk
bethesda
md
medicin
indiana
univers
school
medicin
indianapoli
statist
john
hopkin
univers
bloomberg
school
public
health
indianapoli
patholog
nation
institut
healthnat
cancer
institut
indianapoli
medicin
univers
california
san
diego
indianapoli
background
nonalcohol
fatti
liver
diseas
nafld
common
caus
liver
diseas
us
affect
third
adult
preval
nafld
appear
vari
race
ethnic
variat
may
mere
reflect
differ
risk
factor
obes
dyslipidemia
diabet
hypertens
e
metabol
syndrom
use
data
nash
crn
cohort
studi
assess
variat
common
risk
factor
clinic
featur
sever
nafld
race
ethnic
method
niddk
nash
crn
multicent
cohort
studi
aim
help
elucid
pathogenesi
natur
histori
therapi
nafld
analysi
adult
subject
select
enrol
nash
crn
liver
biopsi
clinic
assess
laboratori
result
within
month
base
upon
selfreport
patient
categor
nonhispan
white
nhw
hispan
white
hw
asian
black
compar
regard
clinic
laboratori
histolog
featur
result
subject
nhw
hw
asian
black
patient
frequent
women
rang
group
except
asian
men
slightli
outnumb
women
preval
diabet
hypertens
coronari
arteri
diseas
cad
highest
black
lowest
hw
mean
weight
kilogram
group
lowest
asian
intermedi
hw
highest
nhw
black
p
normal
bodi
mass
index
bmi
frequent
asian
least
frequent
black
nafld
activ
score
na
increas
increas
bmi
categori
nhw
asian
black
chang
bmi
hw
frequenc
gg
genotyp
highest
black
follow
asian
nhw
other
lowest
hispan
proport
patient
definit
nash
vs
borderlin
nafld
without
nash
significantli
differ
among
group
conclus
signific
differ
clinic
featur
associ
nafld
base
race
ethnic
femal
predomin
group
except
asian
mean
weight
patient
nafld
lowest
asian
hispan
white
intermedi
nonhispan
white
highest
black
although
black
repres
small
percentag
cohort
high
percentag
diabet
hypertens
cad
gg
genotyp
suggest
presenc
cumul
risk
factor
burden
develop
nafld
group
gastroenterolog
hepatolog
nutrit
depart
intern
medicin
virginia
commonwealth
univers
school
medicin
richmond
va
background
urgent
need
develop
comprehens
rigor
model
current
futur
burden
diseas
due
nafld
impact
health
care
resourc
util
guid
polici
decis
health
care
drug
develop
aim
develop
comprehens
model
burden
diseas
financi
impact
method
preval
nafld
histolog
subtyp
nafl
nash
comput
robust
nation
data
trend
obes
separ
appli
preval
rate
nafl
nash
publish
literatur
data
two
data
set
integr
develop
comprehens
model
nafld
us
popul
transit
rate
toward
cirrhosi
end
stage
liver
diseas
cancer
correct
comput
comprehens
literatur
search
compet
mortal
background
caus
estim
assess
impact
nafld
excess
caus
liverrel
cardiovascular
death
model
result
valid
base
upon
nation
surveil
data
annual
hcc
incid
attribut
nash
analyt
approach
similar
previous
publish
studi
popul
health
burden
jama
result
current
trend
continu
total
nafld
case
increas
million
million
increas
total
nash
case
increas
million
million
increas
preval
nafld
popul
age
year
increas
next
year
among
total
nash
case
approxim
classifi
increas
number
incid
nashrel
hcc
case
project
increas
nearli
compar
case
preval
number
compens
decompens
cirrhosi
case
project
increas
case
respect
project
direct
healthcar
cost
nafldrel
end
stage
liver
diseas
increas
usd
liver
relat
mortal
estim
death
increas
death
conclus
project
increas
flatten
obes
preval
disproportion
increas
nash
next
year
translat
substanti
increas
burden
cirrhosi
end
stage
liver
diseas
hcc
result
commensur
increas
health
care
cost
disclosur
arun
j
sanyal
advisori
committe
review
panel
bristol
myer
gilead
genfit
abbott
ikaria
exhalenz
pfizer
novarti
consult
salix
immuron
exhalenz
nimbu
genentech
echosen
takeda
merck
enanta
zafgen
jd
pharma
islet
scienc
hemoshear
grantresearch
support
salix
genentech
intercept
ikaria
takeda
galm
novarti
gilead
tobira
independ
contractor
express
hepat
progenitor
cell
signific
biomark
human
earli
nonalcohol
steatohepat
hiroaki
yokomori
yutaka
inagaki
wataru
ando
masaya
oda
isao
okazaki
intern
medicin
kitasato
univers
medic
center
saitama
japan
center
matrix
biolog
medicin
tokai
univers
graduat
school
medicin
isehara
japan
depart
pharmaceut
scienc
kitasato
univers
tokyo
japan
organ
center
clinic
medicin
sanno
medic
center
intern
univers
health
welfar
tokyo
japan
depart
regen
medicin
tokai
univers
graduat
school
medicin
kanagawa
japan
intern
medicin
sanno
hostit
intern
univers
health
welfar
hospit
tokyo
japan
background
aim
nonalcohol
fatti
liver
diseas
nafld
includ
nonalcohol
fatti
liver
nafl
nonalcohol
steatohepat
nash
latter
character
presenc
hepat
steatosi
inflamm
accompani
hepatocyt
injuri
without
fibrosi
human
matrix
shown
contribut
regress
experiment
liver
fibrosi
ectop
express
rodent
actual
acceler
tissu
fibrosi
human
nash
studi
recent
shown
signific
upregul
express
advanc
stage
nash
j
mod
hum
pathol
studi
conduct
evalu
signific
express
diagnost
marker
earli
nash
method
eleven
sampl
histolog
proven
earli
nash
nafl
specimen
examin
along
five
normal
liver
specimen
discrimin
cell
type
express
dual
immunohistochem
stain
perform
use
antibodi
recogn
specif
marker
either
kupffer
cell
kc
capillari
endotheli
cell
hepat
stellat
cell
hepat
progenitor
cell
hpc
precis
local
examin
immunoelectron
microscopi
iem
serum
level
measur
fluoresc
beadsbas
immunoassay
express
also
examin
use
western
blot
analys
result
express
normal
nafl
liver
specimen
observ
number
kc
sinusoid
endotheli
cell
blood
vessel
extrem
weak
immunoreact
earli
stage
nash
local
predominantli
kc
monocyt
partial
local
hpc
immunoreact
product
visual
iem
ablumin
portion
cell
membran
kupffer
cell
monocyt
hpc
serum
concentr
patient
earli
stage
nash
ngml
show
higher
tendenc
compar
healthi
person
ngml
conclus
increas
express
associ
diseas
progress
earli
stage
nash
result
show
hpc
express
might
contribut
repair
regener
earli
nash
liver
serum
level
use
marker
detect
hpc
respons
earli
stage
nash
promis
biomark
therapeut
target
nash
patholog
borama
medic
center
seoul
korea
republ
background
aim
compar
diagnost
perform
transient
elastographi
te
superson
shearwav
imag
ssi
acoust
radiat
forc
impuls
imag
arfi
stage
fibrosi
identifi
clinic
factor
affect
liver
stiff
measur
lsm
prospect
nafld
cohort
method
ninetyfour
subject
biopsyproven
nafld
includ
subject
liver
stiff
measur
use
te
ssi
arfi
within
month
liver
biopsi
diagnost
perform
stage
liver
fibrosi
evalu
use
receiv
oper
characterist
roc
analysi
anthropometr
data
use
fatamount
ct
bioelectr
imped
analysi
evalu
covari
influenc
lsm
regress
analys
result
lsm
modal
correl
fibrosi
stage
p
exhibit
similar
perform
stage
fibrosi
p
area
roc
curv
te
kpa
ssi
ms
kpa
arfi
ms
signific
fibrosi
advanc
fibrosi
cirrhosi
arfi
tend
specif
ssi
tend
sensit
differenti
fibrosi
stage
best
diagnost
perform
anthropometr
data
correl
failur
unreli
lsm
especi
ssi
regress
analysi
anthropometr
data
might
confound
lsm
use
ssi
serum
liver
injuryrel
marker
might
confound
lsm
use
te
arfi
conclus
diagnost
perform
individu
lsm
modal
stage
fibrosi
nafld
significantli
differ
te
arfi
might
fit
better
suspicion
advanc
fibrosi
te
ssi
might
advantag
suspicion
mild
fibrosi
prelsm
anthropometr
evalu
may
help
predict
lsm
reliabl
especi
ssi
keyword
steatosi
fibrosi
shearwav
veloc
elastometri
nonalcohol
fatti
liver
disclosur
follow
peopl
noth
disclos
kim
myoung
seok
lee
young
ho
jung
ho
kim
sae
kyung
joo
yong
jin
jung
us
fatti
liver
index
fatti
liver
index
potenti
steatosi
marker
predict
liver
diseas
mortal
u
aynur
unalparida
constanc
e
ruhl
nation
institut
diabet
digest
kidney
diseas
bethesda
md
social
scientif
system
inc
silver
spring
md
fatti
liver
diseas
common
contribut
prematur
death
examin
whether
u
fatti
liver
index
usfli
ruhl
aliment
pharmacol
ther
fatti
liver
index
fli
serum
marker
steatosi
associ
increas
overal
causespecif
mortal
u
populationbas
prospect
survey
year
linkedmort
data
method
studi
fast
viral
hepat
neg
adult
particip
third
u
nation
health
nutrit
examin
survey
nhane
intermedi
high
steatosi
probabl
defin
base
publish
cutoff
particip
passiv
follow
mortal
identifi
death
certif
underli
contribut
caus
diagnos
linkag
nation
death
index
record
hazard
rate
ratio
hr
mortal
calcul
use
cox
proport
hazard
regress
adjust
common
mortal
risk
factor
result
preval
intermedi
high
steatosi
probabl
use
usfli
marker
respect
followup
death
caus
liver
diseas
includ
primari
liver
cancer
high
usfli
associ
increas
liver
diseas
mortal
ageadjust
analysi
hr
ci
multivari
adjust
risk
increas
figur
high
fli
also
associ
increas
liver
diseas
mortal
figur
associ
higher
usfli
fli
allcaus
cardiovascular
diseas
cancer
diabet
mortal
multivariateadjust
analys
figur
conclus
u
popul
higher
steatosi
probabl
use
usfli
fli
independ
associ
increas
liver
diseas
mortal
mortal
outcom
liver
health
manag
steatosi
risk
stratif
merit
studi
disclosur
follow
peopl
noth
disclos
aynur
unalparida
constanc
e
ruhl
upregul
palmit
acid
absorpt
alter
intestin
transport
nonalcohol
steatohepat
nash
hiroki
utsunomiya
yasunori
yamamoto
eiji
takeshita
yoshio
tokumoto
fujimasa
tada
teruki
miyak
masashi
hirooka
masanori
abe
teru
kumagi
bunzo
matsuura
yoshio
ikeda
yoichi
hiasa
depart
gastroenterolog
metabolog
ehim
univers
hospit
toon
japan
background
aim
satur
fatti
acid
sfa
import
risk
factor
develop
nash
via
endoplasm
reticulum
stress
oxid
stress
major
sourc
hepat
sfa
adipos
tissu
hepat
lipogenesi
de
novo
diet
report
indic
amount
sfa
deriv
adipos
tissu
de
novo
lipogenesi
increas
nash
chang
dietari
sfa
absorpt
unclear
thu
aim
clarifi
chang
absorpt
dietari
palmit
acid
common
dietari
sfa
induc
hepat
inflamm
also
assess
associ
pathogenesi
nash
patient
method
studi
includ
control
well
patient
brunt
stage
defin
earli
enash
advanc
anash
nash
respect
palmit
label
c
administ
directli
duodenum
use
gastrointestin
endoscopi
avoid
delay
result
deliveri
via
stomach
breath
level
co
measur
quantifi
metabol
sfa
everi
min
administr
next
min
express
locat
sfa
transport
assess
jejun
biopsi
sampl
western
blot
immunohistochem
stain
associ
breath
co
level
hepat
steatosi
fibrosi
insulin
resist
evalu
laboratori
test
elastographi
liver
histolog
result
significantli
co
excret
minut
patient
enash
control
p
earli
phase
min
patient
anash
compar
control
p
western
blot
reveal
higher
level
glycosyl
microsom
triglycerid
transfer
protein
mttp
patient
enash
anash
control
immunohistochem
stain
reveal
strong
glycosyl
express
blood
vessel
excret
co
patient
enash
earli
phase
auc
posit
correl
laboratori
valu
type
iv
collagen
correl
control
attenu
paramet
cap
liver
stiff
measur
lsm
determin
elastographi
addit
auc
significantli
increas
brunt
stage
stage
amount
excret
co
late
phase
auc
posit
correl
insulin
background
aim
nonalcohol
fatti
liver
diseas
nafld
associ
increas
risk
coronari
arteri
diseas
cad
underli
mechan
link
nafld
cad
entir
clear
nitrotyrosin
identifi
marker
inflamm
nitric
oxid
product
aim
assess
role
nitrotyrosin
potenti
link
hepat
steatosi
atherosclerosi
method
prospect
enrol
patient
undergo
elect
coronari
angiographi
suspicion
cad
inform
consent
patient
underw
hepat
ultrasound
us
addit
clinic
data
fast
serum
obtain
coronari
angiographi
ca
result
obtain
us
imag
read
central
radiologist
nafld
defin
presenc
hepat
steatosi
us
absenc
caus
liver
diseas
excess
alcohol
use
accord
ca
find
patient
divid
nafld
cad
nafld
minim
lumin
irregular
mli
stenosi
coronari
arteri
nafld
without
cad
concentr
nitrotyrosin
nm
endotheli
nitric
oxid
synthas
eno
pgml
determin
serum
use
elisa
assay
result
nitrotyrosin
level
highli
express
nafld
patient
cad
nafld
mli
compar
patient
nafld
without
cad
p
multivari
analysi
show
nitrotyrosin
age
histori
hyperlipidemia
independ
associ
increas
risk
cad
nafld
patient
furthermor
nitrotyrosin
neg
associ
high
densiti
lipoprotein
p
posit
associ
triglycerid
level
level
eno
significantli
associ
cad
nafld
conclus
increas
level
serum
nitrotyrosin
nafld
may
associ
risk
cad
sinc
eno
level
increas
sourc
nitrotyrosin
potenti
patholog
product
induc
nitric
oxid
synthas
ino
gastroenterolog
hepatolog
stanford
univers
medic
center
palo
alto
ca
stanford
univers
school
medicin
stanford
ca
digest
diseas
institut
cleveland
clinic
cleveland
oh
school
medicin
univers
california
davi
sacramento
ca
depart
gastroenterolog
hanyang
univers
medic
center
seoul
korea
republ
section
gastroenterolog
hepatolog
nutrit
depart
medicin
univers
chicago
medicin
chicago
il
divis
gastroenterolog
hepatolog
veteran
affair
palo
alto
health
care
system
palo
alto
ca
background
overal
mortal
patient
nafld
increas
except
nafld
patient
signific
fibrosi
howev
predictor
signific
fibrosi
nafld
wide
examin
conduct
studi
determin
predictor
nafld
high
risk
fibrosi
stage
nafld
patient
gener
unit
state
popul
use
nation
health
nutrit
examin
survey
nhane
conduct
method
nafld
defin
unit
state
fatti
liver
index
u
fli
inclus
age
ethnic
ggt
waist
circumfer
fast
insulin
glucos
includ
age
year
attend
medic
examin
fast
particip
exclud
test
posit
viral
hepat
signific
alcohol
use
miss
data
either
u
fli
data
use
nafld
fibrosi
score
nf
determin
risk
fibrosi
stage
result
fast
person
age
year
attend
medic
examin
person
met
inclus
exclus
criteria
nafld
subject
nafld
older
vs
p
like
male
vs
p
mexican
american
vs
p
lower
incom
vs
p
signific
independ
predictor
nafld
age
year
male
sex
mexican
american
ethnic
high
bmi
diabet
mellitu
dm
control
uncontrol
metabol
syndrom
tabl
among
nafld
popul
high
probabl
fibrosi
stage
nf
signific
independ
predictor
high
risk
stage
fibrosi
subject
nafld
age
year
high
bmi
dm
control
uncontrol
tabl
conclus
older
obes
diabet
patient
nafld
higher
risk
stage
fibrosi
target
addit
intervent
circul
microrna
marker
liver
histolog
lesion
patient
nonalcohol
steatohepat
nandita
sarkar
annapoorna
gururajan
biao
li
zhaoshi
jiang
ren
xu
constantin
djedjo
scott
patterson
robert
p
myer
zachari
goodman
michael
r
charlton
nezam
h
afdhal
rohit
loomba
gilead
scienc
inc
foster
citi
ca
inova
fairfax
hospit
fall
church
va
intermountain
medic
center
salt
lake
citi
ut
harvard
medic
school
boston
univers
california
san
diego
san
diego
ca
background
microrna
mir
small
noncod
rna
molecul
involv
posttranscript
regul
gene
express
implic
pathogenesi
nonalcohol
steatohepat
nash
object
determin
util
noninvas
marker
nashrel
liver
histolog
lesion
method
differenti
mir
analysi
perform
plasma
sampl
subject
suspect
nash
snash
fail
screen
phase
trial
evalu
inhibitor
apoptosi
signalregul
kinas
mean
age
year
male
mean
bmi
kgm
agesexmatch
control
mean
bmi
kgm
mir
isol
spikein
control
use
total
rna
isol
kit
norgen
corp
canada
complementari
dna
gener
use
quantimir
kit
mir
measur
qpcr
use
mirnom
profil
system
bioscienc
mountain
view
calcul
differenti
mir
express
perform
use
nnct
method
either
spliceosom
rna
spikein
c
elegan
control
statist
analys
perform
use
signific
analysi
microarray
sam
method
mir
minimum
differ
express
subject
control
select
correl
mir
express
fibrosi
stage
nafld
activ
score
na
determin
use
random
decis
forest
method
perform
mir
panel
distinguish
snash
subject
control
determin
result
sampl
snash
control
pass
qualitycontrol
standard
among
biopsi
snash
subject
na
stage
fibrosi
use
sam
mir
differenti
express
snash
subject
control
mir
significantli
upregul
downregul
use
minimum
chang
select
criteria
highest
foldchang
mir
associ
nash
pathogenesi
sever
novel
mir
identifi
one
upregul
mir
distinguish
snash
subject
control
area
roc
curv
auroc
strongli
correl
fibrosi
spearman
na
panel
upregul
downregul
mir
auroc
differenti
snash
subject
control
sensit
specif
conclus
exploratori
studi
panel
mir
differenti
snash
subject
healthi
control
correl
fibrosi
stage
na
although
valid
find
necessari
mir
potenti
util
noninvas
diagnosi
nash
background
oral
avail
nonsteroid
agonist
farnesoid
x
receptor
fxr
key
regul
bile
acid
glucos
lipid
homeostasi
first
clinic
studi
administ
nafld
patient
aim
method
perform
singl
center
proof
concept
phase
iia
studi
evalu
efficaci
safeti
toler
nondiabet
nafld
patient
patient
enrol
diagnosi
nafld
base
liver
biopsi
hepat
steatosi
ultrasound
magnet
reson
spectroscopi
mr
continu
attenu
paramet
cap
patient
treat
mg
oral
daili
week
serum
liver
enzym
insulin
sensit
clamplik
index
clix
hepat
fat
proton
h
mr
mriestim
proton
densiti
fat
fraction
mripdff
cap
assess
evalu
chang
hepat
energi
metabol
kupffer
cell
function
perform
phosphoru
p
mr
superparamagnet
iron
oxid
spio
magnet
reson
imag
spiomri
respect
readout
includ
serum
lipid
marker
bile
acid
ba
metabolismsign
result
patient
alloc
treatment
signific
decreas
alt
ggt
observ
week
treatment
tabl
chang
serum
alkalin
phosphatas
hdlldl
cholesterol
triglycerid
seen
insulin
sensit
assess
clix
improv
patient
vs
howev
hepat
steatosi
measur
pdffmri
hmr
cap
well
extend
serum
lipid
ba
profil
includ
chang
ratio
pmr
significantli
decreas
patient
indic
reduc
hepat
inflammatori
stress
spiomri
show
differ
seriou
advers
event
occur
short
interv
cardiac
arrhythmia
record
patient
led
termin
studi
conclus
nonsteroid
fxr
agonist
improv
insulin
sensit
decreas
serum
ggt
alt
level
week
treatment
nondiabet
nafld
patient
followup
compound
show
improv
fxr
efficaci
safeti
profil
appear
justifi
clinic
paramet
liver
enzym
metabol
marker
background
aim
increasingli
recogn
nonalcohol
fatti
liver
diseas
nafld
may
present
nonobes
individu
use
individu
patient
level
data
two
random
trial
compar
nonobes
obes
patient
nonalcohol
steatohepat
nash
regard
clinic
histolog
characterist
baselin
determin
advanc
fibrosi
respons
therapi
method
two
trial
combin
biopsyproven
nash
patient
receiv
placebo
activ
treatment
includ
vitamin
e
pioglitazon
obetichol
acid
subject
divid
bodi
mass
index
bmi
obes
nonobes
bmi
result
compar
obes
patient
nonobes
patient
like
older
mean
age
versu
nonwhit
versu
less
diabet
versu
higher
level
lower
level
homair
versu
p
differ
baselin
histolog
nonobes
obes
nash
patient
except
balloon
less
common
nonobes
patient
versu
logist
regress
analys
determin
advanc
fibrosi
nonobes
patient
includ
aspart
aminotransferas
ast
odd
ratio
confid
interv
ci
diabet
platelet
count
similar
obes
nash
among
treat
patient
pair
biopsi
chang
sever
lobular
inflamm
steatosi
balloon
fibrosi
significantli
differ
nonobes
obes
nash
patient
tabl
nafld
activ
score
platelet
count
ci
baselin
associ
respons
nonobes
nash
patient
conclus
phenotyp
differ
obes
patient
nash
nonobes
patient
display
similar
degre
histolog
sever
respons
therapi
high
index
suspicion
nash
need
recogn
nonobes
patient
background
aim
nafld
increasingli
report
caus
hcc
worldwid
studi
determin
tempor
trend
preval
nafld
patient
pt
hcc
undergo
liver
resect
lr
past
year
clinic
characterist
outcom
patient
method
retrospect
analysi
pt
undergo
lr
hcc
surgic
team
hcc
confirm
histolog
nafld
diagnos
base
past
present
exposur
obes
diabet
without
caus
chronic
liver
diseas
peritumor
liver
assess
histolog
fibrosi
stage
metavir
result
patient
includ
mean
age
yr
male
cirrhosi
liver
diseas
etiolog
hcv
hbv
nafld
alcohol
liver
diseas
ald
mix
nafldald
caus
pt
nafld
older
yr
vs
ald
hcv
hbv
p
mainli
male
preval
nafld
steadili
increas
hbv
increas
hcv
decreas
ald
remain
stabl
vs
hcc
develop
absenc
bridg
fibrosiscirrhosi
pt
nafld
vs
hbv
ald
hcv
p
nafld
tumor
less
well
differenti
larger
ald
hcv
mm
vs
mm
mm
respect
p
similar
hbv
mm
within
nafld
group
tumor
characterist
differ
pt
except
much
higher
proport
singl
nodul
vs
respect
p
pt
nafld
underw
major
hepatectomi
vs
ald
hcv
hbv
whole
cohort
patient
tumor
recurr
nafld
alcohol
hcv
hbv
die
nafld
hbv
hcv
ald
mean
time
recurr
yr
without
signific
differ
accord
etiolog
factor
associ
hcc
recurr
tumor
size
number
nodul
satellit
nodul
p
micro
macrovascular
invas
p
respect
satellit
nodul
microvascular
invas
male
sex
etiolog
liver
diseas
independ
associ
recurr
conclus
past
year
strong
increas
nafld
among
resect
hcc
nafld
pt
older
overwhelmingli
male
larger
tumor
develop
mostli
earli
fibrosi
surviv
recurr
rate
similar
etiolog
justifi
cur
therapeut
approach
lr
olivi
rosmorduc
advisori
committe
review
panel
syrtex
ipsen
speak
teach
bayer
background
treatment
diabet
patient
full
agonist
peroxisom
proliferatoractiv
receptor
gamma
improv
insulin
sensit
associ
weight
gain
heart
failur
peripher
oedema
bone
loss
endotrophin
ctermin
fragment
chain
procollagen
type
vi
involv
adipos
tissu
extracellular
matrix
ecm
remodel
metabol
control
establish
serum
assay
endotrophin
assess
novel
ecm
marker
adipokin
could
identifi
type
diabet
nash
patient
respond
optim
agonist
improv
risk
benefit
ratio
method
ballet
trial
aim
compar
glucoselow
effect
safeti
partial
agonist
balaglitazon
pioglitazon
patient
stabl
insulin
therapi
month
per
protocol
patient
stratifi
tertil
baselin
level
followup
therapi
correl
achiev
glucos
control
tertil
end
sixmonth
treatment
period
result
endotrophin
significantli
associ
therapeut
respons
balaglitazon
pioglitazon
studi
end
subject
two
highest
tertil
show
signific
reduct
fast
serum
glucos
compar
baselin
odd
ratio
reduct
two
upper
tertil
p
p
respect
endotrophin
level
correl
adipos
tissu
mass
insulin
resist
fatti
liver
index
compos
triglycerid
bmi
ggt
waist
circumfer
notabl
advers
event
moder
sever
lower
extrem
oedema
occur
lower
tertil
conclus
elev
serum
level
endotrophin
predict
respons
two
insulin
sensit
lower
sideeffect
identifi
patient
profit
agonist
treatment
impact
control
attenu
paramet
liver
stiff
measur
use
transient
elastographi
patient
nonalcohol
fatti
liver
diseas
dong
hyeon
lee
kim
yong
jin
jung
intern
medicin
smgsnu
borama
medic
center
seoul
korea
republ
background
accord
recent
report
sever
steatosi
like
affect
liver
elast
e
measur
transient
elastographi
te
subject
nonalcohol
fatti
liver
diseas
nafld
howev
littl
known
impact
control
attenu
paramet
cap
assess
te
measur
liver
e
subject
nafld
method
two
hundr
eleven
subject
biopsyproven
nafld
includ
prospect
analysi
patient
underw
acoust
radiat
forc
impuls
elastographi
arfi
te
cap
measur
logist
regress
analysi
discrimin
function
analysi
use
calcul
two
kind
capadjust
e
area
roc
curv
auroc
use
determin
optim
cutoff
sensit
specif
capadjust
e
valu
detect
advanc
fibrosi
cirrhosi
result
diagnos
advanc
fibrosi
auroc
te
capadjust
e
optim
cutoff
sensit
se
specif
sp
log
odd
optim
cutoff
se
sp
formula
calcul
use
discrimin
function
analysi
diagnos
cirrhosi
te
capadjust
e
optim
cutoff
se
sp
log
odd
optim
cutoff
se
sp
formula
calcul
use
discrimin
function
analysi
auroc
te
e
significantli
differ
te
capadjust
e
howev
specif
te
markedli
improv
adjust
cap
without
diminish
sensit
te
optim
cutoff
valu
conclus
signific
posit
correl
capadjust
e
fibrosi
stage
subject
nafld
although
capadjust
e
superior
e
diagnos
advanc
fibrosi
cirrhosi
measur
capadjust
e
might
obviat
need
liver
biopsi
nafld
acoust
radiat
forc
impuls
arfi
sonograph
transient
sonoelastograph
te
control
attenu
paramet
disclosur
follow
peopl
noth
disclos
dong
hyeon
lee
kim
yong
jin
jung
hepat
macrophag
activ
associ
adipos
tissu
insulin
resist
nondiabet
patient
nonalcohol
fatti
liver
diseas
gastroenterolog
aarhu
univers
hospit
aarhu
denmark
cardiometabol
risk
unit
institut
clinic
physiolog
cnr
pisa
itali
depart
clinic
biochemistri
aarhu
univers
hospit
aarhu
denmark
depart
oncolog
univers
turin
turin
itali
storr
liver
centr
univers
sydney
westmead
hospit
sidney
wa
australia
background
aim
onset
progress
liver
damag
nonalcohol
fatti
liver
diseas
nafld
tightli
associ
insulin
resist
ir
dysfunct
adipos
tissu
macrophag
activ
key
step
chronic
low
inflammatori
state
ir
hepat
damag
aim
studi
elucid
pathway
link
ir
circul
hepat
macrophag
activ
liver
damag
nondiabet
patient
biopsyproven
nafld
materi
method
glycerol
infus
studi
subject
evalu
glycerolra
lipolysi
adipos
tissueir
atir
calcul
ffa
insulin
in
glycerolra
in
solubl
marker
hepat
macrophag
activ
measur
enzymelink
immunosorb
assay
elisa
mrna
express
liver
evalu
qpcr
use
biorad
supermix
biorad
histolog
score
accord
kleiner
hepat
fat
assess
liver
biopsi
viscer
fat
vf
subcutan
fat
sf
measur
standard
nuclear
magnet
reson
nmr
result
atir
show
signific
associ
featur
liver
damag
liver
biopsi
includ
hepat
fat
na
score
respect
fibrosi
plasma
level
significantli
associ
fast
plasma
level
ffa
lipolysi
r
circul
increas
proport
liver
fat
viscer
subcutan
fat
pn
hepat
express
linear
correl
plasma
level
nafld
subject
twofold
hepat
express
significantli
higher
hepat
fat
content
hepat
express
higher
twofold
nafld
patient
moder
sever
fibrosi
conclus
specul
nafld
patient
hepat
macrophag
activ
directli
stimul
increas
flux
ffa
due
atir
thu
directli
link
ir
dysfunct
adipos
tissu
liver
damag
background
aim
reliabl
noninvas
biomark
need
diagnosi
monitor
patient
nonalcohol
steatohepat
nash
studi
set
determin
perform
new
score
develop
echosen
differenti
nash
simpl
steatosi
base
singl
fibroscan
examin
liver
stiff
control
attenu
paramet
cap
method
patient
suspect
nafld
prospect
underw
fibroscan
examin
within
week
standard
care
liver
biopsi
lb
march
januari
seven
uk
center
lb
read
blind
manner
two
expert
pathologist
nash
diagnos
use
flip
algorithm
nash
sever
grade
accord
na
score
develop
score
diagnos
nash
cohort
split
randomli
train
valid
set
sampl
split
repeat
time
lead
select
optimum
model
test
extern
valid
cohort
consist
nafld
patient
singl
liver
centr
franc
patient
underw
fibroscan
examin
within
day
lb
read
pathologist
result
patient
bmi
kg
studi
follow
patient
exclud
score
develop
lb
interpretablediagnost
nafld
fibroscan
possibl
fibroscan
unreli
accord
boursier
criteria
patient
median
bmi
kgm
age
year
male
na
score
nash
extern
valid
cohort
median
bmi
kgm
age
year
male
na
score
nash
reliabl
fibroscan
examin
perform
score
shown
tabl
conclus
novel
score
base
measur
liver
stiff
cap
singl
fibroscan
examin
abl
correctli
classifi
patient
withwithout
nash
well
correctli
stage
sever
promis
noninvas
marker
detectingstag
diseas
activ
patient
nash
nash
aaron
p
thrift
hashem
b
elserag
xiaoy
yu
fasiha
kanwal
medicin
baylor
colleg
medicin
houston
tx
background
nonalcohol
fatti
liver
diseas
nafld
lead
caus
chronic
liver
diseas
u
nafld
result
progress
liver
fibrosi
cirrhosi
howev
risk
fibrosi
progress
well
determin
risk
unselect
unref
patient
nafld
remain
larg
unknown
aim
examin
proport
patient
nafld
develop
advanc
fibrosi
defin
time
identifi
predictor
progress
among
patient
low
defin
fib
intermedi
defin
fibrosi
baselin
method
identifi
cohort
patient
nafld
nation
va
databas
use
previous
valid
algorithm
base
persist
alt
elev
valu
iuml
month
apart
absenc
hepat
b
hepat
c
excess
alcohol
use
calcul
annual
use
laboratori
result
ast
alt
platelet
test
perform
within
month
event
multipl
test
per
year
patient
use
median
defin
annual
valu
analysi
includ
nafld
patient
least
annual
valu
exclud
patient
advanc
fibrosi
cirrhosi
baselin
defin
basi
cirrhosi
code
use
kaplanmei
km
curv
surviv
function
estim
compar
risk
fibrosi
progress
among
patient
subgroup
cox
proport
hazard
model
examin
risk
factor
fibrosi
progress
result
analysi
includ
cohort
patient
nafld
mean
follow
sd
year
patient
male
nonhispan
white
among
patient
first
baselin
fib
progress
advanc
fibrosi
year
progress
year
among
patient
first
intermedi
rang
progress
advanc
fibrosi
year
year
respect
multivari
model
patient
baselin
higher
risk
fibrosi
progress
patient
fib
hazard
ratio
confid
interv
age
sex
race
bodi
mass
index
diabet
hypertens
dyslipidemia
significantli
associ
fibrosi
progress
overal
analys
stratifi
baselin
degre
fibrosi
conclus
larg
nation
cohort
unselect
patient
nafld
baselin
degre
fibrosi
strong
predictor
risk
progress
among
intermedi
fibrosi
larg
fraction
patient
progress
high
risk
fibrosi
guy
bilal
hame
arun
j
sanyal
virginia
commonwealth
univers
richmond
va
john
hopkin
univers
baltimor
md
indiana
univers
indianapoli
duke
univers
durham
nc
ucsf
san
francisco
ca
coronari
heart
diseas
chd
lead
caus
mortal
patient
nonalcohol
fatti
liver
diseas
nafld
interrelationship
risk
factor
chd
sever
underli
liver
diseas
unknown
aim
current
studi
evalu
relationship
sever
liver
histolog
framingham
risk
score
fr
patient
nafld
niddk
nash
crn
cohort
method
crosssect
analysi
adult
patient
enrol
liver
biopsi
framingham
risk
score
fr
within
month
enrol
perform
fraction
logist
regress
model
fr
outcom
e
probabl
chd
use
evalu
relationship
fr
diabet
statu
coronari
arteri
diseas
bodi
mass
index
homair
antilipidem
therapi
histolog
featur
result
total
patient
met
criteria
includ
analysi
unadjust
regress
analysi
strong
relationship
observ
fr
metabol
medic
comorbid
includ
diabet
p
use
antilipidem
therapi
p
waist
circumfer
per
cm
p
known
histori
coronari
arteri
diseas
p
patient
nafld
higher
fr
directli
relat
histolog
featur
includ
balloon
per
score
p
fibrosi
per
stage
p
portal
inflamm
per
score
p
lower
fr
associ
higher
steatosi
fr
per
score
p
definit
nash
associ
higher
fr
per
categori
p
multipl
fraction
regress
model
independ
relationship
higher
fr
includ
circumfer
use
antilipidem
therapi
known
histori
cad
increas
sever
fibrosi
definit
nash
decreas
sever
steatosi
remain
signific
conclus
patient
nafld
increasingli
higher
risk
chd
associ
metabol
comorbid
also
worsen
histolog
includ
presenc
nash
sever
fibrosi
howev
fr
went
increas
steatosi
disclosur
naga
p
chalasani
consult
abbvi
lilli
ds
biopharma
tobira
nusirt
domain
grantresearch
support
intercept
gilead
galectin
arun
j
sanyal
advisori
committe
review
panel
bristol
myer
gilead
genfit
abbott
ikaria
exhalenz
pfizer
novarti
consult
salix
immuron
exhalenz
nimbu
genentech
echosen
takeda
merck
enanta
zafgen
jd
pharma
islet
scienc
hemoshear
grantresearch
support
salix
genentech
intercept
ikaria
takeda
galm
novarti
gilead
tobira
independ
contractor
cleveland
clinic
cleveland
oh
duke
univers
durham
nc
swedish
medic
center
seattl
wa
saint
loui
univers
saint
loui
mo
virginia
commonwealth
univers
richmond
va
intercept
pharmaceut
inc
san
diego
ca
indiana
univers
indianapoli
background
aim
potent
select
fxr
agonist
obetichol
acid
oca
shown
significantli
improv
fibrosi
flint
studi
week
multicent
doubleblind
trial
nonalcohol
steatohepat
nash
patient
aim
posthoc
analysi
explor
whether
specif
subgroup
may
respond
differ
oca
treatment
respect
fibrosi
improv
method
flint
studi
patient
nash
random
mg
oca
placebo
pbo
week
treatment
patient
baselin
end
studi
biopsi
includ
analysi
oca
pbo
fibrosi
improv
defin
stage
improv
week
treatment
base
nash
crn
score
criteria
evalu
central
pathologist
subgroup
categori
age
sex
bodi
mass
index
bmi
baselin
diabet
statu
baselin
weight
loss
week
evalu
treatment
effect
within
subgroup
assess
univari
multivari
analys
order
determin
whether
effect
treatment
vari
significantli
among
subgroup
interact
treatment
subgroup
assess
result
subgroup
evalu
analysi
higher
percentag
ocatr
patient
show
improv
fibrosi
vs
pbotreat
patient
tabl
critic
interact
treatment
subgroup
significantli
differ
within
subgroup
categori
similar
result
observ
na
improv
point
without
worsen
fibrosi
data
shown
conclus
overal
ocatr
patient
subgroup
evalu
analysi
achiev
fibrosi
improv
specif
subgroup
respond
differ
oca
treatment
interact
treatment
subgroup
found
evalu
larger
number
patient
warrant
impact
vitamin
replac
liver
enzym
nonalcohol
fatti
liver
diseas
patient
suparuede
boonyagard
karjpong
techathuvanan
medicin
vajira
hospit
bangsu
thailand
background
nonalcohol
fatti
liver
diseas
nafld
relat
insulin
resist
metabol
syndrom
diseas
commonli
found
progress
steatohepat
also
evidenc
major
caus
cryptogen
cirrhosi
sever
recent
studi
show
vitamin
play
import
role
pathogenesi
treatment
chronic
liver
diseas
mani
caus
includ
nafld
howev
studi
specif
involv
role
vitamin
replac
nafld
extrem
limit
object
demonstr
effect
vitamin
replac
liver
enzym
inflammatori
marker
nafld
patient
method
random
control
trial
conduct
liver
clinic
vajira
hospit
januari
decemb
sixti
elig
nafld
particip
alt
elev
vitamin
insuffici
randomli
split
two
group
patient
per
group
assign
receiv
either
vitamin
replac
placebo
week
studi
particip
ask
maintain
lifestyl
medic
experi
well
serum
calcium
level
monitor
everi
four
week
side
effect
hypervitaminosi
serum
alt
inflammatori
marker
homeostasi
model
assess
homa
includ
compar
vitamin
replac
period
evalu
antiinflammatori
effect
vitamin
result
begin
studi
statist
differ
two
group
patient
baselin
characterist
includ
gender
age
bmi
underli
diseas
except
alt
inflammatori
marker
end
studi
alt
ul
p
pgml
p
ferritin
ngml
p
decreas
significantli
vitamin
group
cap
dbm
hscrp
mgl
liver
stiff
kpa
tend
decreas
placebo
group
ferritin
ng
ml
hscrp
mgl
cap
dbm
liver
stiff
kpa
increas
although
statist
insignific
addit
decreas
serum
alt
vitamin
group
significantli
greater
placebo
group
ul
vs
ul
respect
p
furthermor
patient
vitamin
group
experi
side
effect
hypervitaminosi
conclus
vitamin
replac
could
significantli
reduc
liver
inflamm
well
contribut
decreas
steatosi
quantif
nafld
patient
alt
elev
without
evid
shortterm
advers
effect
follow
peopl
noth
disclos
suparuede
boonyagard
karjpong
techathuvanan
associ
insulinlik
growth
sever
nonalcohol
fatti
liver
diseas
popul
base
studi
nation
health
nutrit
examin
survey
ye
eun
kwak
albert
joseph
k
lim
depart
intern
medicin
bridgeport
hospit
yale
univers
school
medicin
bridgeport
ct
depart
intern
medicin
yale
univers
school
medicin
new
ct
section
digest
diseas
depart
intern
medicin
yale
univers
school
medicin
new
ct
background
growth
hormon
gh
defici
may
relat
metabol
syndrom
associ
nonalcohol
fatti
liver
diseas
nafld
insulinlik
growth
produc
hepatocyt
secret
stimul
gh
aim
determin
associ
level
sever
nafld
method
use
third
nation
health
nutrit
examin
survey
nhane
iii
data
includ
adult
age
year
gradabl
ultrasonographi
us
imag
hepat
steatosi
identifi
nafld
presenc
moder
sever
hepat
steatosi
us
without
chronic
liver
diseas
chronic
hepat
b
chronic
hepat
c
iron
overload
excess
alcohol
consumpt
control
nafld
control
avail
serum
data
nafld
control
group
stratifi
base
bodi
mass
index
bmi
lean
bmi
obes
result
serum
level
nafld
group
significantli
lower
mean
ngml
compar
background
aim
investig
whether
nonalcohol
fatti
liver
diseas
nafld
associ
increas
risk
colorect
neoplasia
crn
method
crosssect
data
comprehens
health
screen
program
includ
particip
without
malign
chronic
liver
diseas
heavi
drink
underw
firsttim
screen
colonoscopi
abdomin
ultrasonographi
samsung
medic
center
april
decemb
analyz
advanc
crn
defin
cancer
adenoma
least
mm
diamet
highgrad
dysplasia
villou
tubulovil
histolog
characterist
combin
thereof
presenc
nafld
diagnos
abdomin
ultrasonographi
exclus
secondari
caus
sever
hepat
fibrosi
patient
nafld
determin
nafld
fibrosi
score
nf
backgroundaim
metabol
syndrom
ms
individu
compon
associ
nonalcohol
fatti
liver
diseas
nafld
sever
progress
sought
evalu
nafld
patient
discrimin
age
effect
compon
ms
combin
risk
sever
hepat
fibrosi
method
consid
consecut
biopsyproven
nafld
patient
fulli
evalu
compon
msviscer
obes
ifgdiabet
hdl
triglycerid
arteri
hypertens
result
multivari
logist
regress
analysi
associ
viscer
obes
ifg
diabet
ci
p
low
hdl
cholesterol
mgdl
triglycerid
arteri
hypertens
signific
interact
found
age
viscer
obes
stratifi
patient
age
confirm
interact
third
age
tertil
viscer
obes
consist
lower
middl
year
age
tertil
risk
fibrosi
mostli
driven
viscer
obes
ifgdiabet
higher
three
metabol
risk
factor
lower
middl
age
tertil
respect
final
among
patient
higher
age
tertil
obes
affect
fibrosi
sever
risk
sever
fibrosi
higher
low
hdl
ifgdiabet
withwithout
viscer
obes
conclus
nafld
metabol
profil
risk
sever
fibrosi
chang
accord
age
low
hdl
mostli
obes
ifgdiabet
domin
patient
lower
middl
age
tertil
hdl
ifgdiabet
viscer
obes
highest
age
tertil
experiment
medicin
pragu
czech
republ
pragu
czech
republ
center
experiment
medicin
institut
clinic
experiment
medicin
pragu
czech
republ
depart
clinic
transplant
immunolog
institut
clinic
experiment
medicin
pragu
czech
republ
depart
clinic
transplant
patholog
institut
clinic
experiment
medicin
pragu
czech
republ
depart
biostatist
institut
clinic
experiment
medicin
pragu
czech
republ
background
aim
polymorph
c
c
v
transmembran
superfamili
member
one
genet
factor
predispos
develop
nonalcohol
fatti
liver
diseas
nafld
aim
evalu
influenc
recipi
donor
genotyp
develop
steatosi
liver
transplant
lt
recipi
method
studi
group
includ
adult
lt
recipi
transplant
occurr
steatosi
evalu
liver
biopsi
first
posttranspl
year
analyz
patatinlik
phospholipas
genotyp
recipi
donor
clinic
laboratori
data
patient
steatosi
grade
compar
patient
without
steatosi
grade
result
steatosi
grade
found
patient
patient
develop
steatosi
grade
distribut
donor
genotyp
differ
significantli
patient
steatosi
cccttt
without
steatosi
cccttt
distribut
recipi
genotyp
similar
patient
steatosi
cccttt
without
steatosi
cccttt
multivari
analysi
donor
noncc
genotyp
donor
noncc
genotyp
bmi
year
lt
ci
independ
risk
factor
develop
posttranspl
steatosi
effect
donor
pnpla
g
allel
donor
allel
synerg
ci
presenc
donor
risk
allel
presenc
one
risk
allel
g
allel
allel
conclus
donor
noncc
genotyp
independ
risk
factor
steatosi
liver
transplant
recipi
effect
donor
genotyp
synerg
effect
donor
genotyp
background
aim
cirrhosi
one
lead
caus
death
worldwid
diagnosi
usual
made
late
stage
acut
decompens
liver
cancer
develop
ideal
diagnosi
made
earli
stage
cirrhosi
occur
current
analyt
imag
method
inaccur
earli
detect
hepat
fibrosi
aim
studi
investig
use
te
earli
detect
silent
chronic
liver
diseas
hepat
fibrosi
presum
healthi
subject
gener
popul
method
crosssect
descript
populationbas
studi
subject
age
yr
randomli
identifi
peopl
attend
primari
care
center
barcelona
metro
area
april
januari
patient
known
liver
diseas
exclud
subject
invit
particip
phone
call
accept
medic
examin
lab
test
liver
stiff
measur
lsm
te
perform
day
singl
experienc
oper
accord
publish
data
lsm
kpa
use
cutoff
clinicallyrelev
fibrosi
liver
biopsi
suggest
subject
abnorm
lsm
result
subject
femal
caucasian
mean
age
yr
includ
among
metabol
syndrom
ms
excess
alcohol
consumpt
less
found
hbv
hcv
high
aminotransferas
level
percentag
subject
increas
lsm
accord
cutoff
use
respect
multivari
analysi
age
sex
high
aminotransferas
presenc
ms
associ
increas
lsm
liver
biopsi
perform
elig
patient
histolog
diagnosi
nafldnash
alcoholrel
normal
liver
degre
fibrosi
respect
signific
relationship
lsm
degre
fibrosi
kpa
respect
p
percentag
patient
signific
fibrosi
relat
lsm
cutoff
cutoff
kpa
respect
cutoff
lsm
greatest
accuraci
diagnosi
signific
fibrosi
kpa
sensit
specif
auroc
conclus
high
percentag
presum
healthi
adult
spanish
popul
use
cutoff
lsm
extrapol
biopsi
data
liver
fibrosi
case
relat
nafld
te
good
noninvas
method
screen
liver
fibrosi
gener
popul
background
aim
posit
phenotyp
macrophag
display
antiinflammatori
properti
implic
tissu
repair
type
macrophag
may
contribut
progress
fibrosi
stage
nonalcohol
fatti
liver
diseas
activ
score
na
nonalcohol
fatti
liver
diseas
nafld
measur
level
macrophag
activ
marker
solubl
nash
investig
relationship
progress
liver
histolog
nafld
evalu
posit
macrophag
play
role
pathogenesi
nafld
immunohistochem
stain
perform
tissu
repeat
liver
biopsi
target
method
serum
liver
biopsi
obtain
patient
nonalcohol
fatti
liver
diseas
nafld
patient
undergon
repeat
liver
biopsi
patient
divid
five
group
base
fibrosi
stage
na
mean
age
year
men
stage
grade
measur
elisa
human
elisa
kit
quantikain
immunohistochem
stain
done
repeat
biopsi
randomli
select
patient
nash
primari
antibodi
mous
monoclon
anti
human
leica
dilut
result
level
correl
fibrosi
stage
p
level
significantli
elev
advanc
fibrosi
stage
group
vs
p
auc
level
correl
na
p
howev
spite
low
na
level
significantli
elev
burnedout
nash
among
patient
underw
repeat
biopsi
patient
improv
fibrot
degre
improv
na
level
significantli
reduc
patient
improv
fibrot
degre
na
convers
level
elev
patient
whose
fibrosi
na
worsen
posit
macrophag
exist
liver
sinusoid
relationship
amount
posit
macrophag
progress
liver
histolog
nafld
conclus
level
reflect
progress
fibrosi
inflamm
liver
tissu
could
use
noninvas
biomark
nash
nafld
nafld
usual
link
obes
howev
recent
data
shown
presenc
nafld
also
patient
normal
bmi
defin
new
concept
leannafld
leannafld
share
mani
metabol
characterist
overweight
nafld
although
lower
preval
metabol
syndrom
met
liver
damag
report
evalu
liver
cardiovascular
damag
leannafld
studi
consecut
patient
biopsi
proven
nafld
italian
liver
unit
method
biochem
paramet
carotid
atherosclerot
lesion
ultrasonographi
genotyp
liver
histolog
record
subject
divid
accord
bmi
defin
leannafld
waist
circumfer
wc
surrog
marker
viscer
obes
cm
femal
cm
male
result
leannafld
patient
femal
mean
age
significantli
lower
preval
hypertens
vs
diabet
vs
met
vs
lower
total
cholesterol
vs
triglycerid
vs
overweightobes
nafld
patient
femal
mean
age
carotid
intimamedia
thick
vs
preval
nash
vs
signific
fibrosi
higher
vs
significantli
lower
leannafld
preval
carotid
plaqu
similar
preval
g
allel
carriag
differ
two
group
allel
preval
lean
nafld
vs
twentyseven
lean
nafld
steatosi
grade
lobular
inflamm
balloon
score
fibrosi
multivari
analysi
overal
seri
wc
higher
cm
femal
cm
male
significantli
associ
femal
gender
met
nash
fibrosi
diabet
logist
regress
analys
mutual
adjust
bmi
wc
overal
seri
nafld
indic
wc
predict
better
bmi
presenc
nash
p
vs
fibrosi
p
vs
diabet
p
vs
hypertens
vs
plaqu
p
vs
wc
stronger
risk
factor
nash
lean
subject
overweight
subject
conclus
find
indic
nafld
normal
bmi
one
third
carotid
atherosclerosi
sever
liver
damag
evalu
bmi
wc
allow
better
definit
sever
liver
cardiovascular
damag
lean
patient
nafld
background
impact
alcohol
liver
injuri
nonalcohol
fatti
liver
diseas
nafld
unclear
alcohol
may
increas
fibrosi
progress
chronic
liver
diseas
hepat
c
yet
moder
consumpt
may
protect
cardiovascular
diseas
lead
caus
death
nafld
patient
aim
determin
associ
quantiti
pattern
alcohol
consumpt
liver
fibrosi
patient
nafld
method
patient
nafld
consum
gram
alcoholweek
seen
tertiari
hepatolog
clinic
undergo
bariatr
surgeri
underw
detail
evalu
includ
assess
pattern
type
durat
alcohol
consumpt
liver
biopsi
score
accord
nash
crn
score
system
fibrosi
stage
result
patient
includ
mean
age
year
femal
obes
diabet
mean
fibrosi
stage
advanc
fibrosi
patient
lifelong
abstain
previous
drunk
alcohol
current
consum
alcohol
median
consumpt
gweek
median
interquartil
rang
total
lifetim
alcohol
consumpt
amongst
drinker
kilogram
median
durat
year
thirtyon
patient
consum
alcohol
bing
pattern
lifetim
abstin
associ
higher
mean
fibrosi
stage
compar
drank
gweek
gweek
abstin
also
associ
higher
mean
fibrosi
stage
comparison
nonbing
drinker
howev
protect
effect
lost
bing
drinker
alcohol
consumpt
g
week
compar
lifelong
abstin
associ
lower
odd
advanc
fibrosi
ci
adjust
age
diabet
bmi
sex
total
lifetim
consumpt
nonbing
drinker
lower
odd
advanc
fibrosi
compar
abstain
adjust
ci
wherea
protect
associ
note
bing
drinker
neither
averag
lifetim
intak
per
week
cumul
lifetim
intak
smoke
statu
associ
advanc
fibrosi
p
conclus
weekli
alcohol
intak
gram
less
nonbing
pattern
associ
lower
fibrosi
stage
patient
nafld
given
possibl
protect
effect
moder
alcohol
consumpt
cardiovascular
outcom
patient
nafld
without
cirrhosi
may
benefit
modest
alcohol
consumpt
etiolog
nonalcohol
steatohepat
nash
due
part
insulin
resist
oxid
stress
remogliflozin
etabon
remo
inhibitor
shown
previou
clinic
studi
reduc
improv
glycem
control
post
hoc
analysi
examin
whether
improv
glycem
control
associ
chang
insulin
sensit
extent
remo
may
affect
noninvas
marker
fibrosi
nafld
fibrosi
score
method
doubleblind
random
placebocontrol
trial
conduct
subject
type
diabet
subject
equal
random
remo
treatment
mg
bid
placebo
pioglitazon
qd
serum
alanin
aminotransferas
alt
homeostat
model
assess
homa
insulin
sensit
homai
beta
cell
function
homa
bcf
assess
baselin
week
week
week
postprandi
assess
glucos
insulin
cpeptid
perform
baselin
week
use
oral
glucos
toler
test
ogtt
subgroup
subject
nafld
fibrosi
score
determin
baselin
week
result
week
remo
improv
insulin
sensit
beta
cell
function
dosedepend
manner
statist
signific
decreas
baselin
auc
hour
weight
mean
plasma
glucos
follow
ogtt
observ
remo
treatment
group
subject
elev
baselin
alt
remo
treatment
result
signific
reduct
alt
week
baselin
score
indic
broad
rang
fibrosi
stage
remo
dose
effect
reduc
score
reduct
compar
placebo
treatment
remo
score
consist
predict
improv
fibrosi
stage
similar
result
note
nafldfibrosi
score
conclus
previou
studi
use
mous
model
fatti
liver
diseas
remo
significantli
improv
steatohepat
compar
inhibitor
remo
also
display
signific
antioxid
activ
vitro
vivo
clinic
studi
show
abil
remo
revers
insulin
resist
associ
signific
lower
alt
improv
nafldfibrosi
score
remo
safe
potent
late
stage
clinic
compound
taken
togeth
preclin
clinic
data
highli
suggest
remo
may
use
treatment
nash
background
aim
diabet
mellitu
dm
frequent
seen
patient
nonalcohol
fatti
liver
diseas
nafld
risk
factor
develop
hepatocellular
carcinoma
ectop
fat
deposit
liver
pancrea
muscl
caus
factor
dm
howev
remain
unclear
ectop
fat
deposit
associ
dm
patient
nafld
recent
mri
use
proton
densiti
fatfract
mripdff
develop
allow
us
quantifi
accur
fat
content
variou
organ
aim
studi
investig
associ
ectop
fat
deposit
dm
patient
nafld
use
mripdff
materi
method
studi
enrol
nafld
patient
year
femalemal
nonnafld
patient
year
femalemal
control
group
nafld
patient
classifi
nafld
patient
dm
naflddm
group
nafld
patient
without
dm
nafldnon
dm
group
mripdff
valu
measur
liver
liverff
pancrea
pancreasff
muscl
muscleff
differ
mripdff
valu
evalu
anova
follow
scheff
post
hoc
test
use
mripdff
valu
differenti
naflddm
group
nafldnon
dm
group
evalu
use
receiv
oper
characterist
roc
analysi
addit
decisiontre
analysi
employ
identifi
import
factor
naflddm
group
result
liverff
pancreasff
muscleff
valu
significantli
higher
nafddm
nafldnon
dm
group
compar
control
group
signific
differ
liverff
pancreasff
valu
naflddm
nafldnon
dm
group
liverff
vs
n
pancreasff
vs
n
howev
muscleff
valu
significantli
higher
naflddm
group
compar
nafldnon
dm
group
vs
p
roc
analysi
reveal
muscleff
use
marker
differenti
naflddm
group
nafldnon
dm
group
p
cutoffvalu
muscleff
sensit
specif
posit
neg
predict
valu
respect
addit
decisiontre
analysi
reveal
muscleff
valu
initi
diverg
variabl
presenc
diabet
mellitu
nafld
patient
conclus
first
show
ectop
fat
deposit
muscl
associ
dm
patient
nafld
use
mripdff
thu
muscl
steatosi
may
import
therapeut
target
patient
nafld
follow
peopl
noth
disclos
takumi
background
although
obes
import
risk
factor
nonalcohol
fatti
liver
diseas
nafld
signific
number
patient
normal
bodi
mass
index
bmi
also
develop
nafld
leannafld
high
waisttohip
ratio
whr
indic
central
fat
distribut
associ
metabol
syndrom
cardiovascular
diseas
turn
may
relat
nafld
object
determin
associ
central
bodi
fat
distribut
lean
nafld
unit
state
popul
use
larg
nationallyrepres
databas
method
use
data
third
nation
health
nutrit
examin
survey
nhane
iii
gradabl
hepat
ultrasonographi
us
hepat
steatosi
adult
age
year
nafld
defin
presenc
moderatetosever
hepat
steatosi
us
absenc
chronic
liver
diseas
posit
hepat
b
surfac
antigen
posit
hepat
c
antibodi
iron
overload
excess
alcohol
consumpt
control
group
defin
normal
serum
aminotransferas
level
without
moderatetosever
hepat
steatosi
chronic
liver
diseas
lean
group
nafld
control
defin
bmi
less
whr
bioelectr
imped
analysi
bia
resist
predict
total
bodi
fat
mass
homeostat
model
assess
insulin
resist
homair
triglycerid
tg
lowdens
lipoprotein
cholesterol
ldlc
highdens
lipoprotein
cholesterol
hdlc
record
result
adult
age
year
gradabl
us
imag
identifi
nafld
control
identifi
leannafld
leancontrol
differ
bmi
leannafld
leancontrol
group
mean
vs
whr
significantli
higher
leannafld
group
leancontrol
group
mean
vs
p
although
differ
bia
resist
mean
vs
predictor
total
bodi
fat
mass
multivari
logist
regress
show
lean
nafld
independ
associ
higher
whr
adjust
odd
confid
p
adjust
age
sex
bmi
homair
biaresist
tg
ldlc
hdlc
conclus
increas
central
fat
distribut
associ
risk
nafld
irrespect
total
bodi
fat
mass
individu
normal
bmi
follow
peopl
noth
disclos
ye
eun
kwak
albert
impact
liver
histolog
postop
morbid
mortal
bariatr
surgeri
guillaum
lassailli
robert
caiazzo
charlott
vanveuren
vivian
gnemmi
emmanuel
leteurtr
helen
verkindt
gregori
baud
florent
artru
valeri
canvadelcambr
alexandr
louvet
sebastien
dharanc
pattou
philipp
mathurin
chru
lill
lill
franc
epidem
problem
obes
bariatr
surgeri
becom
increas
treatment
option
benefici
impact
diabet
steatohepat
nash
increas
rate
candid
sever
comorbid
postop
morbid
mortal
patient
sever
liver
diseas
poorli
known
preliminari
studi
suggest
liver
injuri
could
increas
postop
complic
howev
morbid
obes
patient
liver
injuri
frequent
vari
true
impact
nash
unknown
aim
evalu
impact
liver
histolog
postop
morbid
mortal
bariatr
surgeri
method
patient
oper
bariatr
surgeri
includ
prospect
follow
lill
bariatr
cohort
chru
de
lill
clinic
biolog
histolog
data
well
postop
morbid
within
day
collect
studi
histolog
data
could
impact
postop
morbid
signific
fibrosi
metavir
cirrhosi
nash
sever
nafld
distribut
type
surgeri
differ
group
complic
studi
surgic
procedur
gastric
band
sleev
gastrectomi
bypass
result
patient
includ
characterist
age
women
bmi
kgm
nash
cirrhosi
ast
iul
alt
ggt
main
procedur
bypass
gastric
band
rate
complic
frequent
infect
hemorrhag
rhabdomyolysi
univari
analysi
histolog
lesion
associ
morbid
cirrhosi
vs
whatev
procedur
fibrosi
bypass
vs
nash
vs
vs
associ
morbid
infect
frequent
complic
incid
increas
accord
sever
fibrosi
multivari
analysi
data
associ
morbid
age
bmi
p
fibrosi
steatosi
term
mortal
followup
patient
die
among
die
within
postop
day
overal
year
surviv
conclus
morbid
associ
higher
age
bmi
fibrosi
steatosi
even
morbid
higher
patient
fibrosi
sever
liver
diseas
benefit
strategi
prove
excel
surviv
year
follow
peopl
noth
disclos
guillaum
lassailli
robert
caiazzo
charlott
vanveuren
vivian
gnemmi
helen
verkindt
gregori
baud
florent
artru
valeri
canvadelcambr
alexandr
louvet
sebastien
dharanc
pattou
nextgen
sequenc
uncov
increas
express
fibrogen
extracellular
matrixrel
gene
nonalcohol
steatohepat
patient
iron
deposit
reticuloendotheli
system
cell
background
previous
show
presenc
reticuloendotheli
system
re
cell
iron
stain
associ
sever
histolog
featur
diseas
includ
advanc
fibrosi
increas
apoptosi
increas
balloon
definit
diagnosi
nonalcohol
steatohepat
nash
patient
nonalcohol
fatti
liver
diseas
nafld
aim
studi
aim
map
transcriptom
liver
nash
patient
hepat
iron
phenotyp
iron
hepatocellular
hc
iron
re
iron
mix
hcre
iron
nash
crn
util
nextgen
rna
sequenc
goal
identifi
specif
pathway
gene
differenti
express
nash
patient
re
iron
method
rnasequenc
librari
construct
liver
tissu
librari
cluster
flowcel
use
truseq
pairedend
cluster
kit
v
use
cbot
cluster
instrument
follow
pairedend
sequenc
hiscansq
cycl
either
direct
run
complet
read
demultiplex
fastq
file
gener
use
casava
softwar
sampl
output
read
qualiti
analyz
gener
qc
plot
r
bioconductor
packag
edger
use
determin
differenti
express
re
iron
non
re
iron
sampl
result
transcriptom
analysi
reveal
gene
belong
pathway
extracellular
matrix
deposit
cellular
anchor
fibrogenesi
liver
develop
regener
show
significantli
increas
express
re
liver
gene
express
level
protein
aforement
pathway
collagen
type
iv
x
versican
lumican
laminin
fibulin
lectin
lysyl
oxidas
like
adam
metallopeptidas
thrombospondin
previous
demonstr
import
fibrogenesi
significantli
elev
re
liver
rel
group
addit
valid
find
nextgen
rna
sequenc
use
quantit
rtpcr
analysi
found
express
level
abovement
gene
significantli
augment
re
sampl
rel
group
conclus
util
nextgen
sequenc
establish
direct
relationship
hepat
re
iron
fibrogen
extracellular
matrix
deposit
pathway
detail
analysi
pathway
specif
molecular
factor
therein
util
avail
gener
tissuespecif
knockout
mous
model
andor
specif
inhibitor
mous
model
cell
line
vitro
clarifi
presenc
re
iron
lead
fibrosi
therebi
worsen
nash
background
young
hyperandrogen
women
high
risk
metabol
syndrom
includ
increas
risk
nafld
whether
testosteron
predomin
androgen
associ
nafld
risk
independ
metabol
cofactor
clear
also
unknown
whether
normal
rang
testosteron
level
women
confer
increas
risk
nafld
method
among
women
follow
prospect
multicent
coronari
arteri
risk
develop
young
adult
cardia
studi
assess
associ
testosteron
level
year
year
preval
nafld
year
nafld
defin
noncontrast
ct
scan
liver
attenu
hounsfield
unit
exclus
caus
hepat
steatosi
primari
predictor
free
testosteron
secondari
predictor
total
testosteron
adjust
sex
hormon
bind
globulin
shbg
logist
regress
perform
includ
subgroup
analysi
among
nonhyperandrogen
women
result
women
black
white
mean
age
entri
year
nafld
present
women
year
increas
quintil
free
testosteron
associ
increas
odd
preval
nafld
adjust
analys
tabl
importantli
free
testosteron
remain
strongli
associ
preval
nafld
even
women
normal
rang
testosteron
level
ci
estim
similar
use
total
testosteron
adjust
shbg
aor
entir
cohort
ci
includ
subgroup
nonhyperandrogen
women
aor
ci
conclus
increas
level
free
testosteron
even
within
normal
rang
independ
associ
preval
nafld
middl
age
androgen
may
import
role
develop
nafld
women
provid
potenti
novel
target
nafld
therapeut
acut
alcohol
hepat
aah
seriou
clinic
present
associ
high
mortal
thu
acut
natur
aah
necessit
reliabl
predict
prognost
measur
pathophysiolog
event
aah
lead
increas
hepatocyt
death
may
reflect
prognosi
liver
injuri
studi
aim
identifi
alter
level
marker
hepatocyt
death
defin
clinic
relev
marker
aah
hypothes
replac
total
bilirubin
necrot
marker
meld
score
could
increas
predict
relev
clinic
laboratori
marker
aah
fortyon
male
femal
patient
age
year
aah
classifi
sever
moder
sever
base
meld
score
data
demograph
drink
histori
audit
meld
maddrey
df
liver
injuri
marker
collect
addit
healthi
volunt
also
enrol
comparison
group
serum
protein
analyz
use
elisa
apoptosens
kit
fragment
level
healthi
control
aah
patient
sever
compar
use
anova
fragment
assess
within
sever
group
expect
sever
aah
patient
significantli
higher
meld
maddrey
df
ast
alt
score
compar
moder
aah
patient
fragment
show
clinic
relev
level
aah
patient
ratio
indic
highli
increas
hepatocyt
necrosi
moder
sever
aah
patient
sever
arm
patient
significantli
higher
compar
moder
arm
patient
wherea
statist
differ
two
arm
show
signific
associ
ast
alt
ratio
moder
sever
arm
meld
show
associ
ast
alt
ratio
either
moder
sever
arm
howev
modifi
meld
score
substitut
total
bilirubin
found
strong
signific
associ
ast
alt
ratio
sever
arm
patient
also
show
trend
toward
signific
associ
audit
score
sever
aah
patient
meld
highli
signific
effect
adjust
r
also
observ
df
maddrey
moder
sever
arm
patient
studi
support
import
assess
liver
injuri
sever
aah
provid
altern
benchmark
incorpor
mode
hepatocyt
death
assess
sever
provid
effect
prognost
marker
sever
aah
disclosur
follow
peopl
noth
disclos
vatsalya
vatsalya
matthew
cave
heather
b
clair
tom
burk
keith
c
falkner
craig
mcclain
background
aim
fibrosi
import
predictor
outcom
patient
nonalcohol
fatti
liver
diseas
nafld
quantit
risk
fibrosi
stage
systemat
assess
metaanalysi
publish
unpublish
data
aim
quantifi
fibrosi
stagespecif
risk
allcaus
mortal
among
wellcharacter
nafld
cohort
method
systemat
search
multipl
databas
author
contact
februari
identifi
adult
nafld
cohort
studi
report
allcaus
mortal
accord
fibrosi
stage
studi
use
nonalcohol
steatohepat
clinic
research
network
nash
crn
histolog
score
system
grade
blind
liver
pathologist
use
fibrosi
stage
refer
popul
fibrosi
stagespecif
risk
ratio
rr
mortal
estim
account
variabl
followup
among
cohort
fibrosi
stagespecif
mortal
rate
ratio
mrr
also
calcul
result
nafld
patient
mean
age
year
men
includ
distribut
fibrosi
stage
baselin
respect
compar
nafld
patient
fibrosi
stage
fibrosi
increas
risk
mortal
risk
increment
accord
fibrosi
stage
fig
similar
trend
seen
increment
increas
incid
mortal
stage
mrr
ci
stage
mrr
ci
stage
mrr
stage
mrr
ci
conclus
nafld
patient
fibrosi
increas
risk
allcaus
mortal
risk
increment
accord
fibrosi
stage
furthermor
nafld
patient
increas
risk
mortal
earli
stage
fibrosi
earli
treatment
intervent
may
consid
popul
background
nonalcohol
fatti
liver
diseas
associ
excess
fat
accumul
liver
progress
nonalcohol
steatohepat
nash
defin
histolog
hallmark
inflamm
cell
death
fibrosi
histolog
nash
rather
similar
alcoholinduc
steatohepat
liver
biopsi
consid
necessari
diagnos
nash
presenc
fibrosi
typic
predict
patient
outcom
us
popul
nash
approxim
advanc
liver
fibrosi
due
diseas
thu
earli
diagnosi
crucial
liver
microenviron
chemic
morpholog
modifi
diseas
progress
depend
diseas
etiolog
biochem
chang
within
liver
milieu
cell
due
liver
injuri
nash
progress
rel
poorli
defin
fourier
transform
infrar
ftir
spectroscop
imag
emerg
approach
obtain
detail
imag
associ
biochem
inform
ftir
imag
tissu
base
principl
differ
region
midir
absorb
differ
chemic
bond
e
g
co
ch
nh
within
cell
tissu
relat
presenc
composit
biomolecul
e
g
lipid
dna
glycogen
protein
collagen
ftir
imag
everi
pixel
within
imag
compris
entir
ir
spectrum
give
inform
biochem
statu
cell
exploit
celltyp
diseasetyp
classif
studi
use
ftir
spectroscop
imag
examin
earli
transform
well
biochem
chang
patient
nash
progress
stage
iv
find
indic
biochemistri
stage
ii
distinctli
differ
could
classifi
perfectli
base
ir
signatur
use
multivari
analysi
sampl
patient
stage
iii
iv
also
found
biochem
differ
patient
stage
ii
current
focus
refin
classif
extract
biochemistri
region
fibrosi
steatosi
inflamm
improv
classif
among
four
stage
determin
precis
biomolecular
chang
occur
could
occur
conclus
ftir
imag
hold
excit
applic
novel
way
obtain
biochem
inform
cell
tissu
entir
labelfre
nonperturb
rout
toward
give
new
insight
biomolecular
chang
take
place
part
nash
progress
biochem
inform
potenti
allow
object
autom
analysi
certain
aspect
nash
diagnosi
prognosi
disclosur
follow
peopl
noth
disclos
christin
massi
vishal
varma
hari
sreedhar
grace
guzman
michael
j
walsh
natalia
nieto
effect
dapagliflozin
sodiumglucos
cotransport
inhibitor
free
carboxyl
acid
liver
steatosi
hepatocyt
damag
biomark
type
diabet
patient
nonalcohol
fatti
liver
diseas
studi
purpos
primari
aim
studi
investig
effect
dapagliflozin
dapa
free
fatti
acid
carboxyl
acid
ca
alon
combin
liver
fat
content
overweight
type
diabet
patient
nonalcohol
fatti
liver
diseas
nafld
method
patient
bmi
kgm
liver
fat
stabl
metformin
andor
sulfonylurea
treatment
random
placebo
mg
dapa
od
g
ca
od
combin
dapa
ca
week
parallel
group
doubl
blind
studi
patient
complet
studi
investig
baselin
week
includ
abdomin
mri
liver
adipos
tissu
fat
content
assess
g
oral
glucos
toler
test
ogtt
full
analysi
set
use
statist
rel
chang
calcul
geometr
mean
ratio
result
full
analysi
set
mean
sd
age
year
bmi
kgm
male
mean
liver
fat
activ
treatment
significantli
reduc
liver
fat
baselin
rel
reduct
liver
fat
combin
ca
signific
adjust
signific
dapa
ca
alon
compar
placebo
total
liver
fat
volum
l
chang
similarli
liver
fat
suggest
chang
liver
fat
secondari
chang
hepat
water
volum
dapa
ca
significantli
reduc
bodi
weight
abdomin
subcutan
viscer
fat
volum
well
improv
glucos
control
includ
fast
glucos
glucos
ogtt
hepatocyt
damag
biomark
ast
alt
ggt
reduc
dapa
ca
ca
advers
event
mild
moder
intens
expect
previou
studi
treatment
two
patient
one
dapa
group
one
placebo
group
experienc
sever
advers
event
assess
investig
unlik
caus
investig
drug
conclus
combin
dapa
ca
result
signific
reduct
percentag
total
liver
fat
monotherapi
result
numer
smaller
nonsignific
reduct
dapa
uniqu
effect
measur
hepatocyt
injuri
evid
combin
group
indic
effect
liver
fat
reduct
hepatocyt
damag
biomark
necessarili
associ
studi
suggest
benefici
effect
inhibit
alon
combin
ca
nafld
type
diabet
kidney
diseas
ckd
relationship
reduc
kidney
function
histolog
featur
patient
biopsyproven
nafld
fulli
elucid
method
total
adult
patient
biopsyproven
nafld
center
countri
spain
patient
australia
patient
cuba
patient
consecut
enrol
biopsi
review
local
pathologist
score
use
nashcrn
score
system
fibrosi
f
stage
subsequ
classifi
nafl
nash
combin
presenc
steatosi
balloon
lobular
inflamm
studi
includ
patient
decompens
cirrhosi
kidney
function
assess
ckdepi
estim
glomerular
filtrat
rate
egfr
formula
ckd
defin
egfr
less
mlmin
p
conclus
biopsyproven
nafld
patient
advanc
fibrosi
strongli
associ
either
decreas
egfr
presenc
ckd
determin
egfr
ml
irrespect
wellknown
risk
factor
obes
diabet
compon
metabol
syndrom
transient
elastographi
combin
clinic
marker
bard
score
nf
use
predict
presenc
absenc
advanc
fibrosi
patient
non
alcohol
fatti
liver
diseas
amreen
dinani
rachel
jeffer
arifa
toor
rolland
c
dickson
gastroenterolog
hepatolog
dartmouth
hitchcock
medic
center
lebanon
nh
background
nonalcohol
fatti
liver
diseas
nafld
increas
preval
may
soon
major
caus
end
stage
liver
diseas
nonivas
strategi
defin
fibrosi
stage
import
diseas
manag
aim
studi
determin
util
transient
elastographi
te
either
alon
combin
clinic
marker
assess
fibrosi
stage
method
electron
medic
record
patient
diagnosi
nafldnash
undergo
te
may
decemb
singl
institut
review
patient
includ
reliabl
liver
stiff
measur
lsm
adequ
liver
biopsi
sampl
within
year
te
lsm
use
divid
patient
two
group
advanc
fibrosi
absenc
advanc
fibrosi
clinic
marker
bard
score
nf
calcul
subpopul
combin
lsm
compar
liver
biopsi
determin
fibrosi
stage
result
patient
diagnosi
nashnafld
reliabl
lsm
liver
biopsi
includ
studi
lsm
consist
fibrosi
fibroscan
use
alon
accur
predict
fibrosi
stage
patient
differ
predict
valu
individu
noninvas
marker
fibrosi
marker
increas
posit
predict
valu
neg
predict
valu
lsm
three
clinic
marker
correl
fibrosi
stage
liver
fibrosi
accur
predict
case
presenc
marker
correl
te
led
accur
predicit
patient
lost
liver
biopsi
fibrosi
addit
clinic
marker
improv
accur
te
conclus
te
valuabl
tool
detect
exclud
presenc
advanc
fibrosi
nafldnash
patient
addit
calcul
clinic
marker
increas
accuraci
te
discrep
te
clinic
marker
fibrosi
liver
biopsi
consid
prospect
larger
studi
util
te
clinic
marker
liver
biopsi
requir
confirm
result
gastroenterolog
hepatolog
univers
medic
center
groningen
groningen
netherland
endocrinolog
univers
medic
center
groningen
groningen
netherland
epidemiolog
univers
medic
center
groningen
groningen
netherland
background
nonalcohol
fatti
live
diseas
nafld
becom
lead
caus
chronic
liver
diseas
de
western
world
liver
play
crucial
role
metabol
cholesterol
triglycerid
thyroid
hormon
interact
hepat
lipid
homeostasi
given
import
variat
thyroid
function
within
euthyroid
rang
consider
number
health
issu
includ
subclin
atherosclerosi
biochem
marker
increas
cardiovascular
risk
relev
examin
relationship
nafld
thyroid
function
paramet
euthyroid
popul
method
studi
conduct
lifelin
cohort
studi
populationbas
cohort
studi
examin
health
healthrel
behavior
particip
live
north
netherland
euthyroid
subject
pmoll
older
year
includ
exclus
criteria
particip
miss
data
excess
alcohol
use
known
hepat
cirrhosi
liver
function
three
time
upper
limit
current
cancer
nonwhit
ancestri
previou
current
use
thyroid
medic
current
use
lipid
glucos
lower
medic
priori
defin
liver
biochemistri
thyroid
function
paramet
metabol
syndrom
met
studi
nafld
defin
use
valid
fatti
liver
index
fli
fli
categor
nafld
p
consid
signific
result
particip
fli
found
individu
men
median
age
year
particip
fli
higher
alt
ast
alp
ggt
valu
higher
preval
met
vs
p
ageand
sexadjust
analysi
fli
independ
predict
higher
per
sd
increment
lower
ci
p
tsh
strongest
associ
found
ratio
ci
p
associ
remain
similar
addit
adjust
presenc
met
subject
enlarg
waist
circumfer
tsh
lower
higher
result
higher
ratio
p
conclus
larg
crosssect
studi
particip
discov
euthyroid
peopl
suspect
nafld
character
higher
ratio
probabl
secondari
central
obes
follow
peopl
noth
disclos
elin
van
den
berg
lynnda
van
tienhovenwind
marzyeh
amini
behrooz
z
alizadeh
tim
c
schreuder
klaa
nico
faber
h
blokzijl
robin
p
f
dullaart
nonalcohol
fatti
liver
diseas
relat
cirrhosi
frequent
incident
diagnosi
background
aim
determin
presenc
cirrhosi
nonalcohol
fatti
liver
diseas
nafld
import
alter
prognosi
mandat
screen
hepatocellular
carcinoma
hcc
sought
determin
cohort
patient
nafld
relat
cirrhosi
whether
cirrhosi
discov
incident
diagnos
intent
whether
patient
screen
hcc
method
patient
nafld
cirrhosi
seen
tertiari
academ
centr
medic
record
review
determin
mode
cirrhosi
diagnosi
incident
intent
specialti
diagnostician
evid
previou
clinic
imag
laboratori
featur
unrecogn
cirrhosi
result
nafld
relat
cirrhosi
patient
mean
age
year
male
major
discov
incident
major
nafld
diagnos
time
cirrhosi
diagnosi
incident
diagnosi
commonli
made
imag
perform
reason
unrel
liver
diseas
follow
liver
test
perform
reason
unrel
nafld
liver
diseas
follow
incident
find
varic
endoscopi
unexpect
find
surgeri
intent
diagnosi
predominantli
made
gastroenterologistshepatologist
patient
wherea
gener
practition
surgeon
physician
like
diagnos
cirrhosi
incident
p
high
proport
patient
diagnos
incident
previou
evid
cirrhosi
unexplain
thrombocytopenia
splenomegali
previou
outpati
clinic
review
hospit
although
patient
undergon
noninvas
fibrosi
test
calcul
retrospect
major
high
noninvas
score
prior
diagnosi
hepascor
nafld
fibrosi
score
thirtynin
total
cohort
diagnos
hcc
half
receiv
previou
screen
patient
hcc
screen
program
like
higher
bclc
stage
screen
program
stage
c
vs
conclus
major
nafld
cirrhosi
patient
diagnos
incident
despit
prior
clinic
biochem
evid
screen
noninvas
fibrosi
marker
done
outsid
specialti
clinic
would
detect
patient
screen
hcc
nafld
cirrhot
associ
lower
bclc
stage
time
diagnosi
increas
awar
screen
cirrhosi
hcc
need
patient
nafld
clinic
gastroenterolog
eguchi
hospit
ogi
japan
background
aim
nonalcohol
fatti
liver
diseas
nafld
nonalcohol
steatohepat
nash
manifest
metabol
syndrom
associ
arteriosclerosi
increas
risk
vascular
diseas
stroke
cardiovascular
diseas
chronic
kidney
diseas
ckd
howev
impact
liver
fibrosi
ckd
nafldnash
wholli
understood
aim
clarifi
relationship
progress
liver
fibrosi
ckd
nafld
method
total
nafld
patient
male
n
year
femal
n
year
diagnos
ultrasonographi
enrol
crosssect
studi
ckd
evalu
bapwv
brachialankl
puls
wave
veloc
egfr
estim
glomerular
filtrat
rate
liver
fibrosi
estim
index
low
cutoff
index
categol
group
l
nafl
nonnash
group
h
nash
possibl
progress
fibrosi
accordingli
effect
liver
fibrosi
bapwv
egfr
examin
multipl
logist
regress
analysi
result
index
posit
correl
bapwv
r
p
neg
correl
egfr
r
p
bapwv
group
h
n
significantli
higher
egfr
significantli
lower
group
l
n
bapwv
cmsec
cmsec
p
egfr
p
multivari
analysi
indic
group
h
signific
risk
increas
bapwv
decreas
egfr
independ
age
diabet
dm
obes
bapwv
odd
ratio
p
egfr
odd
ratio
p
furthermor
dm
liver
fibrosi
addit
increas
risk
group
ldm
odd
ratio
p
group
hdm
odd
ratio
p
group
hdm
odd
ratio
p
conclus
progress
liver
fibrosi
nafld
signific
risk
ckd
affect
sever
ckd
ckd
care
monitor
nafld
regardless
comorbid
diabet
follow
peopl
noth
disclos
yoshihito
kubotsu
hirokazu
takahashi
yoichiro
kitajima
satoshi
oeda
keizo
anzai
yuichiro
eguchi
high
risk
popul
attitud
nafld
among
diabetologist
introduct
nonalcohol
fatti
liver
diseas
nafld
type
diabet
common
condit
regularli
coexist
act
synergist
drive
advers
outcom
preval
nafld
evid
advanc
hepat
fibrosi
accumul
evid
role
screen
nafld
fibrosi
diabet
popul
aim
studi
therefor
aim
firstli
defin
attitud
current
clinic
practic
diabet
specialist
toward
nafld
across
uk
secondli
implement
evidencedbas
pathway
assess
nafld
patient
attend
diabet
outpati
clinic
final
assess
impact
multidisciplinari
approach
combin
hepatolog
diabet
input
clinic
manag
materi
method
onlin
survey
dissemin
diabetologist
across
uk
base
find
survey
diabet
patient
attend
outpati
clinic
oxford
univers
hospit
screen
advanc
fibrosi
use
score
elev
score
may
benefit
referr
multidisciplinari
metabol
hepatolog
clinic
result
diabet
specialist
respond
survey
respond
correctli
judg
preval
nafld
diabet
patient
even
fewer
correctli
judg
preval
advanc
fibrot
diseas
whilst
diabetologist
perform
liver
function
test
vast
major
use
noninvas
score
system
assess
risk
advanc
diseas
within
last
month
respond
diagnosi
nafld
affect
approach
manag
light
find
local
think
nafld
campaign
launch
educ
diabetologist
assess
risk
impact
nafld
patient
diabet
subsequ
month
patient
attend
diabet
clinic
screen
advanc
fibrosi
use
screen
elev
data
analyz
patient
attend
multidisciplinari
clinic
month
follow
weight
reduc
alt
conclus
amongst
diabetologist
remain
limit
awar
preval
sever
nafld
patient
treat
score
easili
use
clinic
practic
identifi
patient
risk
advanc
fibrosi
like
benefit
dedic
multidisciplinari
approach
manag
nonalcohol
fatti
liver
diseas
nafld
common
caus
chronic
liver
diseas
western
countri
may
progress
cirrhosi
liver
failur
complic
hepatocellular
carcinoma
recent
nonsurg
bariatr
techniqu
endobarri
gi
dynam
endoscopicallydeliv
devic
mimic
gastric
bypass
surgeri
shield
duodenum
upper
jejunum
contact
chyme
report
lead
signific
weight
loss
rapid
improv
type
diabet
condit
import
risk
factor
nafld
therefor
investig
effect
endobarri
treatment
noninvas
hepat
paramet
obes
uncontrol
patient
nafld
endobarri
devic
implant
month
duodenum
via
endoscop
procedur
uncontrol
diabet
obes
nafld
subject
age
male
bmi
kg
bmi
waist
circumfer
serum
liver
enzym
level
glucos
lipid
profil
perform
well
shear
wave
elastographi
swe
aixplor
superson
imagin
franc
fibromax
fibrotest
actitest
steatotest
nashtest
biopredict
franc
noninvas
evalu
hepat
injuri
month
follow
endobarri
implant
bmi
waist
circumfer
serum
liver
enzym
level
glucos
lipid
profil
fibrosi
stage
swe
fibromax
decreas
significantli
baselin
addit
activitytest
steatotest
fat
liver
content
nashtest
steatohepat
score
fibromax
improv
significantli
baselin
month
endobarri
remov
subject
endobarri
endoscop
explant
earlier
due
side
effect
conclus
endobarri
minim
invas
bariatr
techniqu
achiev
signific
improv
hepat
fat
liver
content
steatohepat
score
fibrosi
stage
uncontrol
obes
diabet
nafld
patient
devic
may
suitabl
treatment
morbid
obes
relat
comorbid
includ
nafld
follow
peopl
noth
disclos
oranit
cohenezra
gabriella
segallieberman
alon
lang
yeroham
kleinbaum
yael
inbar
sima
katsherginski
keren
tsaraf
ziv
ben
ari
fibrosi
adipos
tissu
associ
liver
damag
fibrosi
nafld
background
aim
fibrosi
occur
differ
organ
associ
damag
nonalcohol
fatti
liver
diseas
nafld
liver
fibrosi
also
sign
progress
adipos
tissu
seem
play
import
role
progress
nafld
contribut
adipos
tissu
fibrosi
unclear
aim
studi
check
adipos
tissu
obes
exhibit
fibrosi
ii
fibrosi
adipos
tissu
correl
liver
damag
fibrosi
iii
autophagi
adipos
tissu
associ
fibrosi
adipos
tissu
method
blood
viscer
adipos
liver
tissu
sampl
obtain
mean
age
morbidli
obes
patient
undergo
bariatr
surgeri
fibrosi
assess
siriu
red
stain
adipos
liver
tissu
mrna
express
gene
relat
fibrosi
collagen
autophagi
beclin
measur
adipos
liver
tissu
qrtpcr
atg
stain
adipos
tissu
perform
immunohistochemistri
quantit
analyz
blood
sampl
analyz
routin
paramet
surrog
marker
apoptosi
cell
death
elisa
result
increas
fibrosi
observ
siriu
red
collagen
express
significantli
upregul
p
adipos
tissu
morbidli
obes
patient
compar
control
mrna
level
beclin
significantli
increas
adipos
tissu
obes
patient
compar
control
p
beclin
p
addit
amount
cell
adipos
tissu
significantli
correl
fibrosi
adipos
tissu
signific
correl
also
found
adipos
tissu
fibrosi
serum
well
express
autophagi
relat
gene
adipos
tissu
autophagi
relat
gene
express
liver
adipos
tissu
also
correl
conclus
morbid
obes
lead
fibrosi
adipos
tissu
associ
elev
express
autophagi
relat
gene
moreov
autophagi
adipos
tissu
liver
tissu
correl
implic
possibl
common
signal
axi
lead
increas
autophag
process
differ
tissu
underli
mechan
need
character
follow
peopl
noth
disclos
annasophia
leven
martin
schlattjan
janpet
sowa
till
hasenberg
lar
bechmann
guido
gerken
ali
canbay
nonbil
acid
intestineselect
fxr
agonist
reduc
liver
steatosi
mice
helen
baribault
jianhua
chao
kenji
kozuka
ihsin
hsu
limin
padmapriya
kumaraswami
matthew
siegel
ying
baom
nie
samantha
koomccoy
christoph
carrera
qumber
jafri
christin
dowd
patricia
finn
jason
lewi
rakesh
jain
andrew
king
jeremi
caldwel
ardelyx
inc
fremont
ca
farnesoid
x
receptor
fxr
nuclear
receptor
activ
directli
bile
acid
fxr
express
high
level
liver
intestin
play
central
role
regul
bile
lipid
homeostasi
obetichol
acid
oca
system
semisynthet
bile
acid
fxr
agonist
recent
approv
fda
treatment
primari
biliari
cirrhosi
demonstr
benefici
effect
patient
nonalcohol
steatohepat
nash
howev
treatment
associ
advers
effect
particularli
pruritu
elev
ldlcholesterol
intestineselect
fxr
agonist
potenti
offer
therapeut
efficaci
improv
safeti
profil
test
recent
discov
novel
oral
activ
nonbil
acid
intestineselect
fxr
agonist
pharmacokinet
studi
peripher
circul
portal
vein
bile
gut
tissu
fece
support
intestineselect
profil
activ
fxr
target
gene
express
intestin
includ
minim
effect
fxr
target
gene
express
liver
includ
ostbeta
contrast
system
fxr
agonist
oca
global
activ
fxr
target
gene
includ
intestin
liver
evalu
effect
hepat
steatosi
mice
per
group
fed
western
diet
wd
week
treat
vehicl
mgkg
qd
mgkg
qd
bid
week
wd
feed
significantli
increas
serum
liver
cholesterol
p
liver
triglycerid
p
compar
mice
fed
standard
chow
qd
bid
qd
normal
serum
cholesterol
liver
triglycerid
liver
cholesterol
content
level
compar
observ
mice
fed
standard
chow
consist
biochem
chang
histopatholog
analysi
show
improv
macrovesicular
steatosi
score
vehicl
treatment
p
bid
p
qd
efficaci
appear
mediat
primarili
intestin
indic
minim
increas
serum
alp
fxr
target
gene
product
wherea
markedli
increas
serum
alp
level
treatment
qd
bid
qd
lower
serum
bile
acid
level
result
suggest
intestineselect
fxr
agonist
could
use
treatment
hepatosteatosi
nash
patient
background
nonalcohol
fatti
liver
diseas
nafld
includ
spectrum
histolog
phenotyp
includ
steatosi
steatohepat
nash
fibrosi
liver
biopsi
refer
diagnosi
invas
associ
procedur
risk
sampl
variabl
thu
urgent
need
noninvas
robust
diagnost
procedur
recent
describ
serumbas
lipidom
signatur
associ
nafld
abl
fulfil
unmet
clinic
diagnost
need
differenti
nafld
healthi
cohort
discrimin
steatosi
nash
aim
valid
noninvas
assay
nafld
diagnosi
use
blindhistolog
refer
standard
appli
test
followup
patient
method
thirti
patient
enrol
blind
biopsyproven
nafld
cohort
collect
serum
sampl
time
liver
biopsi
metabol
syndrom
assess
base
presenc
least
three
condit
list
ncep
atpiii
patient
prescrib
hypocalor
diet
aerob
exercis
monitor
year
point
new
serum
sampl
collect
lipidom
test
establish
basi
biopsyproven
patient
two
bmidepend
logist
regress
algorithm
discrimin
nafld
healthi
liver
assay
name
owliv
care
nash
steatosi
owliv
diagnost
perform
assay
assess
area
roc
curv
posit
neg
predict
valu
respect
result
appli
independ
biopsyproven
cohort
femal
test
diagnos
correctli
patient
misclassifi
one
patient
nash
na
present
metabol
syndrom
one
patient
steatosi
na
although
without
balloon
valid
test
appli
followup
patient
patient
lose
least
baselin
bodi
weight
among
respond
improv
diagnosi
present
posit
postintervent
shift
nash
steatosi
steatosi
healthi
liver
interestingli
origin
diagnosi
remain
unchang
nonrespond
patient
conclus
result
obtain
independ
cohort
support
feasibl
lipidom
test
noninvas
tool
nafld
diagnosi
monitor
diseas
progress
regress
circumv
need
repeat
liver
biopsi
background
chang
liver
histolog
current
standard
nafld
treatment
respons
liver
histolog
limit
includ
risk
high
cost
imprecis
alt
commonli
use
surrog
marker
relationship
alt
histolog
chang
adequ
defin
particularli
children
hypothes
combin
alt
measur
time
durat
alt
chang
would
predict
histolog
chang
better
reduct
ratio
current
use
method
retrospect
analysi
random
control
tonic
trial
publish
nash
clinic
research
network
compar
placebo
metformin
vitamin
e
along
lifestyl
advic
particip
liver
biopsi
screen
week
includ
analysi
alt
standard
time
averag
alt
sta
combin
level
alt
time
durat
level
calcul
use
area
curv
percent
chang
alt
plot
time
patient
three
method
assess
alt
compar
alt
reduct
ratio
baselin
compar
final
mean
alt
alt
sta
result
averag
fibrosi
score
baselin
na
possibl
alt
significantli
differ
improv
progress
fibrosi
separ
greatest
week
figur
improv
na
also
associ
significantli
improv
alt
howev
separ
seen
week
alt
sta
superior
alt
reduct
ratio
mean
alt
predict
fibrosi
na
improv
auc
fibrosi
na
respect
p
except
alt
reduct
ratio
fibrosi
conclus
alt
sta
best
predictor
histolog
improv
short
term
alt
less
week
fibrosi
week
na
differenti
well
improv
versu
progress
alt
sta
may
use
surrog
marker
fibrosi
chang
na
improv
clinic
trial
pediatr
nafld
alt
trend
fibrosi
progress
versu
improv
background
nonalcohol
fatti
liver
diseas
nafld
global
health
concern
increas
preval
nafld
associ
increas
cardiovascular
diseas
relationship
evalu
limit
observ
studi
prospect
data
associ
nafld
coronari
arteri
diseas
cad
lack
purpos
ongo
studi
defin
preval
sever
cad
among
patient
biopsyproven
nonalcohol
steatohepat
nash
nonnash
nafld
method
adult
patient
prospect
enrol
predominantli
time
referr
routin
colon
cancer
screen
screen
evid
nafld
fibroscan
livermultiscan
lm
mr
elastographi
mre
prior
histori
liver
diseas
alcohol
ingest
greater
accept
rang
nafld
consid
exclusionari
patient
exceed
prespecifi
cutoff
valu
imag
test
offer
liver
biopsi
coronari
ct
angiographycoronari
arteri
calcium
cctacac
screen
presenc
sever
cad
cad
determin
perpati
pervessel
basi
use
segment
model
sever
defin
obstruct
stenosi
nonobstruct
stenosi
cad
vessel
free
plaqu
segment
involv
score
si
defin
atherosclerot
plaqu
coronari
segment
diffus
cad
defin
si
cac
quantifi
accord
agatston
method
result
date
particip
enrol
complet
biopsi
patient
complet
ccta
liver
biopsi
among
patient
evid
nafld
biopsi
cad
found
patient
diffus
cad
present
patient
obstruct
cad
patient
median
coronari
arteri
calcium
cac
score
iqr
patient
nonnash
nafld
cad
detect
patient
diffus
cad
present
patient
found
obstruct
cad
median
cac
score
patient
biopsyproven
nash
cad
present
diffus
cad
present
median
cac
score
iqr
differ
found
rate
cad
diffus
cad
median
cac
score
patient
nonnash
nafld
compar
nash
patient
conclus
preval
cad
particularli
diffus
cad
high
among
patient
nonnash
nafld
nash
median
cac
score
observ
biopsyproven
nash
patient
may
portend
increas
risk
cardiovascular
event
frequent
reliabl
biomark
liver
injuri
although
ast
alt
play
central
role
glutam
product
transaminas
peripher
blood
level
ast
alt
regard
liver
injuri
biomark
ast
alt
catalyz
transamin
aspart
alanin
glutam
import
posit
regul
tissu
glutam
level
glutam
princip
excitatori
neurotransmitt
affect
memori
function
brain
blood
glutam
level
report
alter
mani
cognit
function
disord
studi
investig
impact
blood
transaminas
level
blood
glutam
concentr
memori
method
psychiatr
medic
neurolog
healthi
subject
femal
male
enrol
studi
local
advertis
plasma
ast
alt
level
measur
convent
autom
analyz
plasma
amino
acid
glutam
glutamin
glycin
dserin
lserin
measur
use
high
perform
liquid
chromatographi
hplc
system
five
indic
verbal
memori
visual
memori
gener
memori
attentionconcentr
delay
recal
wechsler
memori
scalerevis
wmsr
use
measur
memori
function
result
plasma
ast
alt
signific
posit
correl
plasma
glutam
level
ast
plasma
glutam
significantli
neg
correl
three
five
memori
function
multivari
analys
demonstr
plasma
ast
alt
glutam
level
significantli
correl
memori
function
even
adjust
gender
educ
conclus
far
know
first
report
could
demonstr
impact
blood
transaminas
level
blood
glutam
concentr
memori
function
human
find
import
interpret
obesityinduc
metabol
syndrom
elev
transaminas
cognit
dysfunct
background
aim
current
knowledg
genet
basi
nonalcohol
fatti
liver
diseas
nafld
demonstr
variant
contribut
diseas
suscept
sever
locat
gene
regul
lipid
metabol
specif
consist
associ
nafld
sever
fibrosi
stage
across
differ
popul
adult
children
howev
associ
discov
variant
locat
lipidrel
loci
includ
recent
identifi
p
membran
bound
oacyltransferas
domain
contain
consist
replic
across
ethnic
group
encod
member
membranebound
oacyltransferas
famili
specif
arachidonoylcoa
acyl
donor
notabl
report
result
show
genotyp
frequenc
deviat
hardyweinberg
equilibrium
hwe
explor
whether
associ
genet
risk
nafld
diseas
sever
casecontrol
studi
patient
nafld
proven
liver
biopsi
method
studi
includ
individu
patient
nafld
healthi
control
genotyp
perform
taqman
assay
sampl
power
addit
genet
model
account
possibl
popul
stratif
use
collect
snp
differ
loci
analyz
structur
program
show
similar
cluster
case
control
result
popul
genotyp
frequenc
control
n
cc
ct
tt
patient
cc
ct
tt
hwe
minor
allel
frequenc
variant
neither
associ
increas
suscept
nafld
cochranarmitag
test
trend
chisq
p
diseas
sever
p
howev
univari
analysi
observ
signific
associ
circul
triglycerid
tg
associ
either
glucos
metabol
homaindex
total
hdl
ldlcholesterol
met
compon
conclus
role
nafld
seem
conclus
variant
may
associ
tg
level
might
indirectli
regul
intermedi
step
fatti
acid
polyunsatur
fatti
acidspufa
pufacontain
tg
biosynthesi
still
unexplor
genediet
interact
may
explain
disproportion
impact
variant
nafld
among
differ
ethnic
group
replic
observ
among
differ
popul
inde
may
result
dispar
dietari
composit
inc
silver
spring
md
chronic
liver
diseas
cirrhosi
th
lead
caus
death
u
use
nation
databas
updat
estim
liver
diseas
burden
u
method
nation
ambulatori
hospit
ambulatori
medic
care
survey
nationwid
inpati
sampl
vital
statist
u
databas
use
estim
medic
care
mortal
primari
diagnosi
liver
diseas
exclud
viral
hepat
hepatocellular
carcinoma
rate
ageadjust
shown
per
popul
recent
year
avail
result
liver
diseas
contribut
million
ambulatori
visit
million
hospit
discharg
death
ambulatori
visit
rate
liver
diseas
diagnosi
higher
among
women
compar
men
vs
white
compar
african
american
vs
hispan
compar
nonhispan
vs
hospit
discharg
rate
also
increas
among
hispan
compar
nonhispan
vs
higher
among
men
compar
women
vs
similar
among
white
african
american
vs
ambulatori
visit
rate
rose
hospit
discharg
rate
doubl
mortal
rate
higher
among
men
compar
women
vs
hispan
compar
nonhispan
vs
slightli
higher
among
white
compar
african
american
vs
mortal
rate
declin
slowli
increas
slowli
declin
steepest
among
african
american
recent
revers
among
subgroup
figur
conclus
burden
liver
diseas
u
substanti
increas
revers
declin
mortal
trend
concern
deserv
popul
monitor
liverrel
outcom
disclosur
follow
peopl
noth
disclos
aynur
unalparida
constanc
e
ruhl
background
aim
remain
unknown
inflamm
promot
liver
fibrosi
earli
stage
nonalcohol
steatohepat
nash
previous
found
use
immunoelectron
microscopi
iem
express
apj
angiotensin
receptorlik
receptor
upregul
relat
angiogenesi
human
liver
cirrhosi
apelin
select
endogen
ligand
apj
receptor
recent
report
liver
fibrosi
marker
present
studi
examin
serum
apelin
level
hepat
express
apj
earli
advanc
stage
nash
patient
materi
method
studi
enrol
histolog
proven
nash
patient
healthi
control
serum
level
measur
elisa
compar
histopatholog
find
estim
brunt
fibrosi
stage
local
apj
receptor
examin
ihc
iem
use
liver
sampl
nash
patient
normal
liver
specimen
express
apj
receptor
also
examin
western
blot
analysi
result
serum
level
earli
stage
pgml
advanc
stage
nash
pgml
significantli
higher
control
pg
ml
p
p
respect
serum
level
increas
parallel
fibrosi
stage
western
blot
analysi
confirm
increas
express
apj
receptor
earli
nash
liver
compar
control
liver
p
interestingli
advanc
stage
nash
liver
exhibit
lower
express
apj
receptor
compar
earli
nash
liver
p
ihc
reveal
apj
receptor
local
mainli
arteri
capillari
lesser
extent
sinusoid
control
liver
earli
stage
nash
apj
receptor
show
strong
posit
stain
hepat
sinusoid
line
cell
inflammatori
cell
pericentr
area
weakli
hepat
sinusoid
line
cell
periport
area
advanc
nash
apj
observ
mainli
sinusoid
line
cell
region
portal
fibrosi
arteri
capillari
fibrot
septum
howev
apj
express
weaker
earli
nash
liver
iem
examin
reveal
aberr
express
apj
receptor
prolifer
arteri
capillari
open
sinusoid
apj
receptor
also
found
caveola
prolifer
capillari
endotheli
cell
pericyt
conclus
local
apj
receptor
shown
iem
suggest
associ
angiogenesi
even
earli
stage
nash
apelin
apj
receptor
close
relat
fibrosi
angiogenesi
nash
background
select
potent
small
molecul
inhibitor
clinic
develop
treatment
nonalcohol
steatohepat
nash
sever
alcohol
hepat
studi
evalu
shortterm
safeti
pk
subject
mild
moder
sever
hepat
impair
hi
subject
normal
hepat
function
support
develop
dose
recommend
patient
cirrhosi
method
subject
stabl
mild
moder
sever
hi
childpughturcott
b
c
respect
per
group
healthi
control
normal
hepat
function
match
age
year
gender
bmi
per
hi
group
receiv
singl
mg
oral
dose
follow
intens
pk
sampl
hour
safeti
monitor
parametr
analysi
varianc
use
mix
effect
model
use
fit
logarithmicallytransform
pk
paramet
auc
c
max
confid
interv
ci
construct
geometr
mean
ratio
gmr
paramet
hi
group
match
control
subject
sinc
hi
may
alter
protein
bind
free
fraction
plasma
also
determin
summar
hepat
function
result
subject
complet
studi
treatmentemerg
advers
event
ae
mild
grade
moder
grade
one
ae
grade
headach
occur
one
subject
total
plasma
exposur
c
max
auc
similar
subject
mild
moder
hi
compar
healthi
control
tabl
modest
increas
auc
subject
sever
hi
versu
control
subject
compar
control
subject
free
fraction
increas
subject
sever
hi
mild
moder
hi
compar
control
unbound
vs
unbound
conclus
safeti
result
studi
consist
overal
safeti
profil
exposur
similar
subject
mild
moder
hi
compar
normal
hepat
function
subject
sever
hi
modestli
higher
exposur
result
studi
support
continu
clinic
develop
patient
liver
dysfunct
due
nash
alcohol
hepat
without
dose
adjust
regardless
presenc
hi
background
fibroblast
growth
factor
nonmitogen
hormon
import
regul
glucos
lipid
metabol
analog
improv
insulin
sensit
lipid
profil
contribut
nash
pathogenesi
preclin
model
well
obes
human
type
diabet
first
gener
pegyl
human
variant
extend
elimin
halflif
compar
endogen
human
enabl
daili
weekli
regimen
studi
pegyl
variant
modifi
decreas
proteolysi
extend
halflif
support
least
onceweekli
dose
method
random
placebocontrol
singl
ascend
dose
studi
obes
bmi
kgm
healthi
subject
conduct
cohort
subject
random
subcutan
sc
mg
mg
mg
mg
mg
vs
placebo
serum
concentr
vs
time
data
use
deriv
cmax
tmax
auc
inf
total
clearanc
cltf
compartment
pk
model
develop
simul
concentr
vs
time
profil
weekli
dose
regimen
result
baselin
mean
age
male
hispan
death
sae
discontinu
due
ae
treatmentrel
ae
mild
intens
pk
result
tabl
averag
termin
h
cmax
observ
h
dose
dosenorm
cmax
auc
inf
consist
across
dose
indic
pk
linear
doseproport
steadyst
pk
project
achiev
within
wk
accumul
index
fold
weekli
dose
conclus
welltoler
singl
dose
mg
compar
show
improv
pk
exposur
due
prolong
termin
pk
safeti
data
support
continu
clinic
develop
weekli
dose
nash
background
aim
exercis
firstlin
therapi
patient
nonalcohol
fatti
liver
diseas
nafld
aerob
resist
exercis
improv
nafld
howev
effect
exercis
protocol
remain
unclear
moreov
given
high
preval
cardiovascular
diseas
nafld
choic
exercis
type
relat
exercis
energi
consumpt
compar
sought
assess
requir
frequenc
intens
durat
aerob
resist
exercis
requir
improv
hepat
steatosi
compar
exercis
regimen
regard
energi
consumpt
patient
nafld
method
literatur
search
perform
use
pubm
web
scienc
scopa
januari
articl
assess
effect
aerob
resist
hepat
steatosi
total
articl
studi
includ
aerob
resist
exercis
protocol
select
systemat
review
result
aerob
exercis
decreas
hepat
steatosi
seen
protocol
n
median
effect
protocol
metabol
equival
met
minsess
timesweek
week
resist
exercis
reduct
hepat
steatosi
seen
protocol
n
median
effect
protocol
met
min
session
timesweek
week
aerob
resist
exercis
reduc
intrahepat
lipid
respect
signific
differ
seen
durat
frequenc
period
exercis
two
exercis
regimen
energi
consumpt
significantli
lower
resist
aerob
exercis
group
vs
kcaltot
period
p
conclus
resist
exercis
improv
nafld
less
energi
consumpt
resist
exercis
may
feasibl
benefici
aerob
regimen
nafld
patient
poor
cardiorespiratori
fit
toler
particip
aerob
exercis
data
also
suggest
possibl
link
mode
exercis
hepat
lipid
metabol
jacob
georg
advisori
committe
review
panel
pharmaxi
bm
msd
gilead
janssen
abbvi
grantresearch
support
msd
follow
peopl
noth
disclos
takumi
kawaguchi
ryuki
hashida
takato
ueno
hironori
koga
naoto
shiba
takuji
torimura
effect
lactobacillu
reuteri
associ
guar
gum
inulin
gut
permeabl
nonalcohol
steatohepat
silvia
ferolla
claudia
couto
geyza
n
armiliato
paula
v
vidig
gabriela
ataliba
maria
de
lourd
ferrari
eduardo
g
vilela
henriqu
g
torr
aloisio
cunha
teresa
c
ferrari
hospit
da
clinica
instituto
alfa
de
gastroenterologia
feder
univers
mina
gerai
belo
horizont
brazil
probabl
role
gut
nonalcohol
steatohepat
nash
progress
still
elucid
although
evid
anim
human
studi
suggest
increas
gut
permeabl
could
allow
passag
gutderiv
endotoxin
liver
enhanc
inflamm
aim
investig
preval
increas
intestin
permeabl
subject
nash
synbiot
supplement
contain
coloni
form
unit
cfu
lreuteri
plu
partial
hydrolyz
guar
gum
inulin
twice
daili
could
improv
paramet
includ
biopsyproven
nash
patient
random
control
clinic
trial
twentyseven
subject
receiv
synbiot
supplement
healthi
nutrit
counsel
three
month
individu
receiv
healthi
nutrit
counsel
period
time
clinic
appoint
schedul
everi
month
provid
synbiot
gut
permeabl
evalu
baselin
intervent
lactulosemannitol
urinari
excret
test
urin
sampl
taken
patient
drunk
isosolar
solut
contain
lactulos
mannitol
measur
perform
high
perform
liquid
chromatographi
hplc
result
report
percentag
urinari
excret
probe
relat
amount
ingest
final
result
test
ratio
excret
percentag
lactulos
mannitol
result
test
compar
refer
valu
establish
healthi
popul
baselin
median
age
ys
patient
femal
patient
obes
hypertens
dyslipidem
sedentari
present
alter
glucos
metabol
classifi
metabol
syndrom
difer
clinic
histolog
paramet
group
patient
nash
present
high
preval
increas
gut
permeabl
baselin
differ
frequenc
increas
gut
permeabl
group
studi
group
control
group
three
month
synbiot
supplement
differ
percentag
lactulos
mannitol
excret
neither
lactulosemannitol
excret
ratio
intervent
group
respect
well
control
group
respect
patient
nash
present
high
frequenc
increas
gut
permeabl
improv
l
reuteri
plu
partial
hydrolyz
guar
gum
inulin
supplement
background
extracellular
vesicl
ev
membranebound
particl
releas
die
activ
cell
experiment
model
ev
releas
hepatocyt
lipotox
intern
neighbor
cell
contribut
liver
fibrosi
angiogenesi
object
studi
quantifi
character
ev
serum
patient
nonalcohol
steatohepat
nash
method
ev
isol
use
sequenti
centrifug
process
serum
healthi
control
nash
patient
advanc
fibrosi
ishak
dynam
light
scatter
analysi
zetas
malvern
worcestershir
uk
electron
microscopi
determin
size
morpholog
ev
flow
cytometri
quantifi
total
number
ev
calceinfitc
hepatocytederiv
ev
asialoglycoprotein
receptor
ev
number
compar
nash
patient
control
associ
ev
number
nash
characterist
includ
liver
biochemistri
nafld
activ
score
compon
fibrosi
stage
hepat
collagen
content
muscl
actin
express
morphometri
serum
fibrosi
marker
hepat
venou
pressur
gradient
hvpg
cirrhot
subject
determin
result
nash
patient
median
age
yr
femal
cirrhot
control
yr
femal
includ
ev
detect
subject
exosom
microparticl
identifi
background
aim
patient
cirrhosi
due
nonalcohol
fatti
liver
diseas
nafld
risk
liver
cardiac
relat
morbid
mortal
lifestyl
chang
incorpor
exercis
recommend
may
improv
cardiorespiratori
fit
peak
predict
mortal
cirrhosi
patient
efficaci
safeti
patient
popul
well
establish
aim
determin
impact
exercis
train
aerob
fit
secondari
outcom
includ
hepat
steatosi
liver
injuri
insulin
resist
bodi
composit
muscl
strength
safeti
qualiti
life
measur
method
patient
histolog
confirm
nafld
cirrhosi
low
baselin
physic
activ
level
underw
week
progress
aerob
resist
exercis
min
thrice
weekli
supervis
exercis
physiologist
aerob
capac
assess
use
grade
cardiopulmonari
exercis
test
strength
via
repetit
maximum
test
liver
steatosi
magnet
reson
spectroscopi
bodi
composit
dexa
qualiti
life
use
valid
questionnair
cldq
result
eight
patient
approach
consent
studi
lack
interest
avail
main
reason
refus
subject
femal
mean
age
year
bmi
child
portal
hypertens
baselin
week
exercis
intervent
produc
signific
improv
peak
mlkgmin
mlkgmin
respect
maxim
strength
leg
press
kg
kg
seat
row
kg
kg
function
capac
improv
occur
improv
six
minut
walk
test
distanc
time
go
lean
muscl
mass
increas
overal
fat
mass
fell
trend
toward
signific
seen
reduct
waist
circumfer
total
fat
mass
p
signific
effect
note
hepat
steatosi
liver
enzym
insulin
resist
lipid
profil
qualiti
life
improv
chang
chronic
liver
diseas
questionnair
score
physic
domain
advers
event
note
conclus
uptak
exercis
poor
among
nafld
cirrhot
patient
howev
appropri
exercis
lead
clinic
signific
improv
aerob
fit
strength
function
capac
associ
reduct
fat
mass
improv
qualiti
life
strategi
increas
patient
particip
requir
background
aim
exercis
therapi
effect
recommend
nonalcohol
fatti
liver
diseas
nafld
report
examin
whether
signific
reduct
serum
level
alanin
aminotransferas
alt
achiev
exercis
therapi
patient
nafld
aim
studi
assess
effect
simpl
resist
exercis
week
nafld
method
fifti
nine
patient
nafld
assign
resist
exercis
group
n
control
group
n
resist
exercis
group
perform
exercis
pushup
squat
time
week
nonconsecut
day
trial
period
week
patient
control
group
proceed
regular
physic
activ
restrict
diet
throughout
studi
effect
exercis
compar
group
week
biochem
blood
paramet
hepat
steatosi
bodi
composit
assess
hepat
steatosi
bodi
composit
evalu
ultrasound
bioelectr
imped
analysi
respect
result
signific
timebytreat
interact
seen
alt
level
homair
alt
level
vs
iul
p
homair
vs
p
significantli
decreas
exercis
control
group
also
found
signific
timebytreat
interact
hepat
steatosi
grade
p
moreov
hepat
steatosi
grade
vs
p
significantli
decreas
exercis
control
group
chang
alt
level
correl
neg
chang
muscl
bodi
weight
ratio
exercis
group
conclus
data
demonstr
week
simpl
resist
exercis
compris
squat
pushup
repres
effect
treatment
nafld
follow
peopl
noth
disclos
manabu
hayashi
atsushi
takahashi
hiromichi
imaizumi
masashi
fujita
ken
okai
kazumichi
abe
hiromasa
ohira
intragastr
balloon
igb
endoscop
treatment
option
obes
nafld
vi
nguyen
jiawei
li
paul
cordero
gilberto
alejandro
cueva
mai
khatib
jude
oben
institut
liver
digest
health
ucl
london
unit
kingdom
background
aim
incid
nafld
continu
parallel
rise
obes
rate
bariatr
surgeri
provid
effect
tool
weight
loss
feasibl
option
endobariatr
devic
includ
intragastr
balloon
igb
may
provid
altern
option
weight
control
report
outcom
igb
treatment
obes
nafld
singl
centr
method
outcom
follow
igb
placement
obes
patient
insulin
resisbackground
purpos
proteas
activ
cell
surfac
gprotein
coupl
receptor
gpcr
highli
express
multipl
cell
type
liver
includ
hepatocyt
stellat
cell
inflammatori
macrophag
activ
proteolyt
cleavag
ntermin
exodomain
serin
proteas
recent
propos
import
regul
obes
metabol
syndrom
howev
connect
signal
metabol
liver
understood
aim
studi
evalu
role
signal
liver
metabol
lead
pathogenesi
fatti
liver
diseas
nash
method
use
methionin
cholin
defici
mcd
dietinduc
mous
model
nash
week
time
period
analyz
system
hepat
metabolit
nuclear
magnet
reson
nmr
liver
metabolit
extract
snapfrozen
liver
chloroformmethanol
extract
method
quantifi
enhanc
nmr
metabolom
compar
individu
metabolit
wild
type
versu
mice
mice
treat
pepducin
system
metabolit
extract
plasma
methanol
denatur
method
express
regulatori
enzym
critic
metabol
pathway
also
measur
result
found
defici
inhibit
provid
strike
protect
dietinduc
hepat
steatosi
inflamm
defici
well
treatment
significantli
decreas
hepat
triglycerid
p
plasma
level
liver
enzym
alt
p
ast
reduc
nafld
activ
score
na
nash
model
metabolom
gene
express
experi
show
inhibit
enhanc
betaoxid
fatti
acid
suppress
metabol
pathway
lead
reactiveoxygen
speci
ro
product
conclus
signal
play
critic
role
regul
hepat
steatosi
inflamm
ro
gener
nash
condit
lead
cirrhosi
hepatocellular
carcinoma
current
approv
mean
pharmacolog
intervent
develop
novel
inhibitor
exemplifi
pepducin
may
provid
blueprint
develop
efficaci
agent
suppress
nash
background
abnorm
liver
function
test
lft
frequent
observ
human
immunodefici
viru
hiv
monoinfect
individu
absenc
alcohol
excess
evid
emerg
nonalcohol
fatti
liver
diseas
nafld
may
import
caus
howev
aetiolog
nafld
hiv
infect
remain
unclear
aim
identifi
preval
risk
factor
nafld
patient
hiv
abnorm
lft
method
retrospect
casecontrol
studi
conduct
hiv
outpati
persist
abnorm
liver
function
alanin
aminotransferas
alt
upper
limit
normal
occas
month
apart
identifi
clinic
record
examin
assess
demograph
clinic
biochem
hiv
characterist
nafld
case
defin
patient
radiolog
evid
hepat
steatosi
absenc
viral
hepat
b
c
excess
alcohol
intak
caus
secondari
steatosi
control
defin
patient
evid
hepat
steatosi
ultrasound
identifi
caus
liver
diseas
result
among
hiv
cohort
patient
patient
persist
elev
alt
identifi
caus
elev
alt
hepat
c
viru
coinfect
hepat
b
viru
coinfect
alcohol
excess
nafld
drug
induc
hepat
liver
diseas
identifi
caus
patient
case
earli
stage
diseas
median
interquartil
rang
score
exclus
criteria
appli
nafld
case
compar
control
use
binari
logist
regress
bodi
mass
index
bmi
odd
ratio
confid
interv
ci
histori
hyperlipidaemia
ci
highdens
lipoprotein
hdl
cholesterol
ci
hdl
cholesterol
ratio
ci
significantli
associ
nafld
univari
analysi
multivari
analysi
bmi
adjust
ci
hyperlipidaemia
adjust
ci
independ
associ
nafld
hivrel
factor
significantli
associ
nafld
univari
multivari
analysi
conclus
nafld
import
caus
persist
rais
alt
larg
cohort
hivinfect
patient
associ
metabol
rather
hivrel
factor
manag
metabol
risk
factor
prioriti
patient
group
mark
nelson
advisori
committe
review
panel
janssen
msd
bm
abbvi
viiv
gilead
consult
janssen
msd
bm
abbvi
viiv
gilead
grantresearch
support
boehring
ingelheim
janssen
msd
bm
abbvi
viiv
gilead
roch
speak
teach
gsk
janssen
msd
bm
abbott
viiv
gilead
mark
r
thursz
advisori
committe
review
panel
gilead
bm
abbott
laboratori
cnbio
altimmun
follow
peopl
noth
disclos
rebekah
g
judg
jame
b
mauric
valid
guidelin
bloodelastographi
combin
noninvas
fibrosi
stage
nafld
recent
easl
intern
guidelin
suggest
combin
blood
test
liver
stiff
measur
lsm
stage
liver
fibrosi
nafld
howev
whether
combin
provid
gain
accuraci
compar
two
constitut
test
demonstr
statist
therefor
sought
firstli
compar
accuraci
three
test
categori
nafld
secondli
compar
accuraci
test
nafld
refer
etiolog
chronic
hepat
c
chc
test
develop
valid
method
popul
includ
patient
nafld
chc
total
sixteen
test
blood
test
lsm
fibroscan
combin
lsm
blood
marker
uniqu
score
fibromet
vcte
evalu
nafld
chc
refer
metavir
fibrosi
stage
liver
biopsi
chc
etiolog
accuraci
evalu
mainli
obuchowski
index
oi
target
fibrosi
stage
secondarili
auroc
binari
diagnost
target
result
popul
combin
fibromet
vcte
significantli
higher
oi
auroc
signific
sever
fibrosi
two
constitut
test
thu
oi
fibromet
vs
fibromet
vs
lsm
nafldspecif
test
less
accur
chcspecif
test
e
g
oi
conclus
nafld
singl
accur
test
develop
chc
perform
better
test
develop
specif
nafld
test
combin
blood
marker
lsm
outperform
constitut
test
valid
recent
easl
guidelin
nafld
noninvas
fibrosi
evalu
thu
simplifi
nafld
use
singl
test
lsm
one
bestperform
blood
test
develop
chc
either
alon
prefer
combin
blood
marker
e
bloodelastographi
test
develop
chc
background
aim
hepat
fibrosi
major
determin
clinic
outcom
nonalcohol
fatti
liver
diseas
nafld
remain
clear
need
establish
accuraci
noninvas
marker
fibrosi
studi
aim
prospect
compar
diagnost
perform
abil
exclud
advanc
fibrosi
follow
noninvas
test
nafld
fibroscan
fibromet
v
fibromet
nafld
fibromet
vcte
nafld
fibrosi
score
nf
apri
bard
astalt
ratio
method
patient
suspect
nafld
prospect
underw
fibroscan
examin
blood
sampl
within
week
standard
care
liver
biopsi
lb
march
januari
seven
uk
centr
lb
stage
blind
manner
two
expert
pathologist
accord
nash
crn
system
diagnost
perform
assess
term
area
roc
curv
auc
abil
exclud
advanc
fibrosi
assess
use
publish
cutoff
except
fibromet
fm
cutoff
yet
publish
cutoff
fm
determin
maxim
youden
index
result
patient
male
median
age
iqr
year
median
bmi
kgm
complet
dataset
analysi
fibrosi
distribut
patient
na
score
perform
summari
test
present
tabl
conclus
fibromet
vcte
combin
biochem
paramet
liver
stiff
measur
fibroscan
highest
perform
characterist
posit
neg
predict
valu
respect
confirm
exclud
fibrosi
relat
dna
damagerepair
pathway
along
pathway
cancer
oxid
stress
inflamm
cell
cycl
checkpoint
control
etc
conclus
ddr
relat
atm
pathway
separ
nash
fatti
liver
normal
liver
substanti
increas
atmrel
ddr
like
pathophysiolog
prognost
signific
liver
injuri
remodel
oncogenesi
nash
appropri
develop
marker
identifi
character
nash
earli
stage
disclosur
follow
peopl
noth
disclos
preeti
viswanathan
priya
gupta
yogeshwar
sharma
sanjeev
gupta
background
aim
role
internet
ever
increas
present
era
first
sourc
medic
inform
imprecis
partial
comprehens
textual
inform
limit
efficaci
commun
diseas
process
patient
initi
appli
militari
readabl
test
sinc
util
varieti
field
adjudg
comprehens
level
document
report
compar
readabl
analysi
onlin
patientcent
text
pertain
alcohol
hepat
ah
nonalcohol
steatohepat
nash
method
patientcent
inform
websit
acg
american
liver
foundat
alf
healthlin
com
institut
human
virolog
ihv
mayo
clinic
medlin
medicinenet
com
nation
institut
health
nih
patient
info
uptod
webmd
download
process
microsoft
word
data
format
categor
subsect
proprieti
inform
medic
term
expung
limit
bia
text
analyz
specif
level
readabl
use
six
valid
readabl
metric
result
modifi
document
nash
mean
grade
lower
origin
counterpart
lower
ah
highest
mean
readabl
grade
level
ah
record
ihv
grade
level
nash
acg
level
least
read
grade
level
ah
record
nih
webmd
nash
treatment
subsect
highest
mean
grade
level
ah
nash
anova
analysi
show
signific
differ
read
grade
level
depend
sourc
websit
p
subsect
compar
readabl
test
treatment
section
usual
difficult
section
written
compar
subsect
p
conclus
patient
educ
materi
except
webmd
recommend
grade
level
treatment
section
often
difficult
section
comprehend
greater
emphasi
clear
simpl
languag
warrant
increas
qualiti
comprehens
onlin
patient
educ
resourc
introduct
aim
vitamin
e
vite
effect
treatment
nonalcohol
steatohepat
nash
vite
associ
hemorrhag
stroke
platelet
dysfunct
similar
event
report
studi
vite
nash
encount
patient
gastrointestin
gi
bleed
vite
therapi
aim
determin
risk
iron
fe
defici
nonalcohol
fatti
liver
diseas
nafld
patient
treat
vite
method
hemoglobin
hb
mcv
rdw
ferritin
monitor
prospect
frequent
patient
biopsyproven
nafld
ongo
random
trial
differ
dose
natur
vite
iud
mean
treatment
durat
week
subject
decompens
cirrhosi
coagulopathi
thrombocytopenia
exclud
determin
specif
vite
treatment
compar
rate
fe
defici
histor
data
similar
trial
center
week
metformin
loomba
ap
well
avail
data
piven
trial
sanyal
nejm
result
subject
exhibit
newonset
worsen
preexist
fe
defici
median
vite
treatment
week
anemia
hb
gdl
seen
patient
median
week
subject
fe
defici
without
anemia
patient
complet
workup
gi
sourc
found
includ
colon
diverticulosi
gastric
ulcer
gastric
hyperplast
polyp
hemorrhoid
one
subject
aspirin
past
histori
fe
defici
notabl
fe
defici
spontan
resolv
without
vite
cessat
subject
bleed
anemia
occur
week
ontreat
liver
biopsi
fe
defici
occur
diabet
compar
nondiabet
p
mantelcox
age
sex
nash
activ
score
cirrhosi
vite
dose
associ
fe
loss
comparison
metformintr
patient
develop
mild
fe
defici
without
anemia
significantli
lower
rate
vite
mantelcox
piven
trial
exclud
diabet
anemia
hb
declin
differ
vite
placebo
arm
week
red
cell
indic
avail
conclus
occult
gi
bleed
fe
defici
common
vite
treatment
nafld
like
reflect
effect
platelet
function
turn
may
increas
risk
bleed
preexist
gi
lesion
close
monitor
iron
statu
warrant
first
month
treatment
especi
diabet
subject
past
histori
fe
defici
follow
peopl
noth
disclos
yaron
rotman
shilpa
lingala
nevitt
morri
reninangiotensin
system
inhibitor
type
diabet
fibrosi
progress
patient
nafld
background
aim
clinic
determin
fibrosi
progress
nonalcohol
fatti
liver
diseas
nafld
still
definit
aim
studi
assess
clinic
determin
fibrosi
progress
rate
fpr
nafld
patient
baselin
followup
histolog
evalu
special
focu
impact
pharmacolog
therapi
method
observ
cohort
italian
patient
tertiari
referr
center
liver
histolog
evalu
accord
kleiner
independ
predictor
fpr
select
stepwis
regress
approach
result
median
followup
month
iqr
twentyf
patient
show
amelior
stabil
progress
fibrosi
patient
nonalcohol
steatohepat
nash
similar
demograph
anthropometr
featur
higher
preval
type
diabet
use
reninangiotensin
axi
system
ra
inhibitor
fibrosi
progress
depend
length
followup
associ
requir
presenc
nash
p
fibrosi
progress
faster
fpr
independ
associ
higher
apri
score
followup
absenc
treatment
ra
inhibitor
diagnosi
baselin
signific
interact
use
ra
inhibitor
fpr
ra
inhibitor
associ
slower
fpr
patient
without
pn
conclus
nash
requir
fibrosi
progress
nafld
wherea
seem
drive
fibrogenesi
independ
hepat
inflamm
use
ra
inhibitor
may
contrast
fibrosi
progress
especi
highrisk
patient
affect
background
nonalcohol
steatohepat
nash
current
second
lead
indic
liver
transplant
lt
unit
state
sever
studi
predict
nash
becom
lead
indic
liver
transplant
howev
none
focus
whether
increas
trend
nash
continu
come
decad
aim
studi
predict
futur
trend
nash
among
adult
await
liver
transplant
unit
state
use
data
organ
procur
transplant
network
optn
well
nation
health
nutrit
examin
survey
nhane
method
extract
data
avail
nhane
round
preval
secular
trend
metabol
risk
factor
name
bmi
fast
plasma
glucos
dm
systol
blood
pressur
total
cholesterol
triglycerid
also
extract
data
optn
dataset
frequenc
secular
trend
primari
diagnos
time
liver
transplant
use
lag
time
use
preval
metabol
risk
factor
predict
futur
preval
nash
main
diagnosi
time
liver
transplant
result
nash
show
signific
increas
trend
main
diagnosi
time
liver
transplant
go
less
p
univari
analysi
popul
preval
metabol
risk
factor
name
bmi
p
fast
plasma
glucos
systol
blood
pressur
p
total
cholesterol
show
statist
signific
associ
frequenc
nash
main
diagnosi
time
liver
transplant
assum
observ
trend
continu
univari
model
base
calendar
year
predict
nash
main
diagnosi
liver
transplant
ci
best
multivari
model
includ
bmi
systol
blood
pressur
addit
calendar
year
decreas
predict
ci
conclus
previou
decad
preval
nash
main
caus
liver
diseas
increas
among
transplant
patient
observ
slow
increas
trend
obes
hypertens
predict
subsequ
slow
increas
trend
nash
next
decad
ibrahim
hanouneh
advisori
committe
review
panel
gilead
speak
teach
merck
aim
measur
hepat
multiparametr
magnet
reson
imag
mri
shown
correl
fibrosi
steatosi
inflamm
studi
aim
prospect
evalu
multiparametr
mri
patient
undergo
steatosi
found
case
nash
diagnos
patient
averag
time
steatosi
liver
transplant
year
patient
liver
steatosi
group
younger
without
liver
steatosi
steatosi
preval
steatosi
significantli
higher
donor
steatosi
without
steatosi
steatosi
p
likewis
donor
steatosi
found
significantli
associ
nash
nash
nafl
multivari
analysi
also
show
recipi
age
p
donor
steatosi
p
risk
factor
liver
steatosi
forti
three
recipi
donor
examin
singlenucleotid
polymorph
snp
patatinlik
phospholipas
gene
identifi
predictor
sever
nonalcohol
fatti
liver
diseas
signific
differ
preval
liver
steatosi
among
recipi
snp
hand
liver
steatosi
seen
significantli
higher
number
donor
gg
allel
cc
cg
cc
cg
p
patient
nash
show
gg
allel
conclus
donor
factor
donor
steatosi
genotyp
affect
risk
liver
steatosi
nash
live
liver
transplant
follow
peopl
noth
disclos
hisamistu
miyaaki
satoshi
miuma
naota
taura
hidetaka
shibata
kazuhiko
nakao
volixibat
minim
absorb
oral
apic
sodiumdepend
bile
acid
transport
asbt
inhibitor
increas
bile
acid
excret
reduc
serum
lipid
safe
toler
overweight
obes
subject
popul
characterist
nash
background
abnorm
cholesterol
metabol
accumul
toxic
free
cholesterol
hepatocyt
may
result
hepat
inflamm
fibrosi
potenti
factor
contribut
pathogenesi
nash
accordingli
remov
cholesterol
liver
treatment
approach
could
decreas
possibl
revers
damag
volixibat
formerli
block
bile
acid
ba
reabsorpt
inhibit
asbt
termin
ileum
consequ
ba
excret
fece
forc
liver
synthes
new
ba
cholesterol
liver
serum
hypothes
inhibit
ba
reuptak
could
lead
therapeut
benefici
metabol
antiinflammatori
antisteatot
antifibrot
effect
nash
aim
assess
safeti
toler
pharmacodynam
pd
pharmacokinet
pk
volixibat
administ
day
method
doubleblind
random
placebo
pbo
control
dosefind
phase
studi
overweight
obes
men
nonchildbear
women
year
old
random
cohort
vari
volixibat
dose
regimen
daili
qd
twice
daili
bid
titrat
evalu
includ
pd
assess
fecal
ba
serum
concentr
marker
synthesi
ba
cholesterol
pk
stool
hard
bristol
stool
chart
bsc
safeti
toler
result
subject
random
volixibat
pbo
consist
minim
absorpt
volixibat
pk
could
calcul
mean
daili
fecal
ba
excret
higher
subject
receiv
volixibat
receiv
pbo
maxim
inhibit
ba
reabsorpt
occur
volixibat
dose
qd
mg
qd
two
third
maxim
effect
mg
bid
one
third
greater
mg
qd
compar
mg
qd
final
day
dose
day
mean
serum
concentr
higher
volixibat
pbo
median
rang
reduct
mmoll
total
cholesterol
mmoll
ldl
cholesterol
observ
volixibat
overal
volixibat
consid
safe
welltoler
frequenc
bowel
movement
increas
overal
median
daili
evacu
rang
predos
evacu
rang
treatment
dosedepend
proportion
stool
sampl
rate
type
bsc
volixibat
pbo
seriou
advers
event
subject
complet
trial
conclus
dosefind
studi
support
investig
volixibat
patient
nash
hour
gener
auc
c
max
increas
less
doseproport
upon
singl
multipl
dose
expect
due
short
daili
dose
minim
accumul
observ
auc
c
max
c
singl
multipl
dose
administr
similar
mg
dose
auc
c
max
respect
valu
observ
conclus
singl
multipl
daili
dose
nonsteroid
fxr
agonist
well
toler
healthi
subject
safeti
pk
profil
biolog
activ
support
evalu
subject
nash
cholestat
liver
disord
background
multiecho
modifi
dixon
mdixon
sequenc
mrpdff
safe
noninvas
altern
quantif
hepat
fat
content
accept
reason
method
assess
chang
hepat
fat
amount
phase
ii
studi
recent
control
attenu
paramet
cap
show
good
correl
intrahepat
fat
amount
compar
liver
biopsi
well
mr
data
larg
cross
section
cohort
howev
littl
known
whether
chang
cap
score
use
clinic
trial
investig
correl
cap
mr
serial
examin
clinic
trial
set
method
sixtyf
nafld
patient
evalu
mr
transient
elastographi
includ
cap
clinic
studi
mr
cap
evalu
three
month
probiot
clinic
trial
patient
nafld
result
baselin
cap
mrpdff
show
good
correl
assess
hepat
steatosi
p
also
chang
cap
valu
also
correl
chang
intrahepat
fat
use
mrpdff
clinic
trial
set
concord
rate
improv
aggrav
compar
two
method
howev
less
chang
amount
small
cap
valu
less
concord
rate
show
weak
mrpdff
chang
cap
valu
treatment
less
concord
rate
mrpdff
decreas
conclus
cap
mr
compar
diagnost
valu
hepat
steatosi
quantif
well
assess
chang
hepat
fat
amount
clinic
trial
howev
care
interpret
steatosi
chang
use
cap
score
given
absolut
chang
valu
less
clinic
trial
set
follow
peopl
noth
disclos
sang
bong
ahn
dae
jun
jae
yoon
jeong
joo
hyun
sohn
emerg
increas
preval
sever
nonalcohol
fatti
liver
diseas
epidemiolog
studi
gener
mediterranean
popul
salvator
petta
carola
buscemi
silvio
buscemi
david
corleo
vito
di
marco
cattedra
ed
u
oc
di
gastroenterologia
ed
epatologia
palermo
itali
metabol
clinic
nutrit
laboratori
dibimi
univers
palermo
palermo
itali
palermo
itali
backgroundaim
worldwid
spread
obes
diabet
lead
drastic
increas
nonalcohol
fatti
liver
diseas
nafld
complic
aim
assess
preval
nafld
sever
among
gener
mediterranean
popul
method
consid
consecut
individu
includ
abcd
studi
longitudin
observ
singlecentr
studi
cohort
repres
gener
popul
sicili
patient
neg
hcv
hbv
hiv
infect
alcohol
intak
gday
femal
gday
male
hepat
ultrasound
us
use
diagnos
steatosi
fibroscan
xl
probe
measur
liver
stiff
control
attenu
paramet
cap
liver
stiff
kpa
consid
suggest
signific
liver
fibrosi
petta
et
al
hepatolog
db
consid
suggest
moderatesever
steatosi
de
ledinghen
v
et
al
jhep
result
steatosi
us
diagnos
individu
significantli
associ
male
gender
type
diabet
low
hdl
viscer
obes
split
analysi
accord
gender
steatosi
independ
link
viscer
obes
p
low
hdl
male
viscer
obes
p
type
diabet
femal
rate
us
steatosi
stiff
kpa
progress
increas
male
without
obes
low
hdl
steatosi
among
theme
stiff
one
risk
factor
steatosi
among
stiff
risk
factor
steatosi
among
stiff
similarli
femal
rate
us
steatosi
stiff
kpa
progress
increas
patient
without
obes
diabet
steatosi
among
stiff
one
risk
factor
steatosi
among
stiff
risk
factor
steatosi
among
stiff
conclus
nafld
present
gener
popul
preval
well
preval
liver
damag
increas
accord
presenc
obes
low
hdl
male
obes
diabet
femal
impact
variant
gene
steatosi
liver
damag
popul
investig
follow
peopl
noth
disclos
salvator
petta
carola
buscemi
silvio
buscemi
david
corleo
vito
di
marco
purpos
preval
nonalcohol
fatti
liver
diseas
nafld
may
correl
defici
acid
excess
fatti
acid
refin
carbohydr
western
diet
associ
coronari
arteri
diseas
metabol
syndrom
metaanalysi
collat
effect
supplement
hepat
steatosi
method
search
medlin
embas
ovid
databas
review
titlesabstract
full
text
data
extract
perform
studi
includ
hepat
steatosi
present
defin
mri
ultrasound
histolog
data
pool
metaanalysi
conduct
use
random
effect
model
data
present
standard
mean
differ
smd
mean
differ
md
result
total
studi
identifi
studi
includ
final
analysi
total
patient
pool
cohort
administ
dose
rang
gramsday
durat
treatment
week
month
decreas
hepat
fat
observ
arm
smd
ci
chi
pool
analysi
also
reveal
decreas
alt
arm
md
ci
chi
improv
homair
md
ci
triglycerid
md
ci
sensit
analysi
exclud
observ
studi
also
demonstr
reduct
liver
fat
smd
ci
chi
discuss
treatment
associ
reduct
liver
fat
patient
hepat
steatosi
conflict
data
regard
reduct
hepat
fibrosi
inflamm
balloon
degener
possibl
varianc
dosag
level
durat
treatment
subgroup
analys
demonstr
reduct
alt
decreas
triglycerid
insulin
resist
known
safeti
profil
supplement
may
benefici
reduc
hepat
steatosi
alt
improv
dyslipidemia
insulin
resist
decreas
cardiovascular
risk
background
endogen
sex
hormon
associ
risk
diabet
metabol
syndrom
recent
studi
suggest
role
hormon
nonalcohol
fatti
liver
diseas
nafld
conduct
systemat
review
metaanalysi
observ
studi
investig
associ
sex
hormon
nafld
method
comprehens
search
databas
medlin
embas
perform
incept
april
inclus
criterion
observ
studi
assess
associ
serum
total
testosteron
tt
sexhormon
bind
globulin
shbg
nafld
calcul
pool
mena
differ
md
odd
ratio
tt
shbg
confid
interv
ci
compar
subject
without
nafld
use
randomeffect
model
result
sixteen
trial
compris
men
women
met
inclus
criteria
tt
level
lower
men
nafld
md
nmoll
ci
without
men
higher
tt
level
lower
odd
nafld
ci
wherea
higher
tt
level
increas
odd
nafld
women
ci
sex
shbg
level
lower
patient
nafld
control
men
md
nmoll
higher
shbg
level
associ
reduc
odd
nafld
men
ci
women
ci
conclus
metaanalysi
demonstr
sexdepend
associ
tt
nafld
lower
tt
level
associ
men
nafld
invers
associ
women
nafld
wherea
higher
shbg
level
associ
lower
nafld
odd
men
women
random
effect
pool
mean
differ
tt
subject
without
nafld
men
women
disclosur
follow
peopl
noth
disclos
veeravich
jaruvongvanich
anawin
sanguankeo
sikarin
upala
center
durham
nc
electr
comput
engin
duke
univers
durham
nc
divis
gastroenterolog
duke
univers
medic
center
durham
nc
background
recent
gene
express
gex
profil
differenti
mild
sever
nonalcohol
fatti
liver
diseas
nafld
fibrosi
independ
clinic
factor
evalu
whether
gex
profil
associ
clinic
decompens
death
aim
identifi
molecular
pathway
link
morbid
mortal
nafld
method
perform
retrospect
analysi
patient
biopsyproven
nafld
whose
liver
tissu
previous
evalu
gex
via
microarray
patient
assess
liver
biopsi
death
liver
transplant
studi
end
outcom
includ
decompens
ascit
hepat
encephalopathi
hepatocellular
carcinoma
varic
bleed
composit
incorpor
stroke
myocardi
infarct
death
associ
composit
outcom
gex
quantifi
use
gener
linear
model
control
age
bodi
mass
index
diabet
mellitu
fibrosi
stage
result
patient
includ
femal
white
median
age
studi
entri
year
rang
median
follow
day
rang
four
patient
white
women
experienc
clinic
outcom
two
hepat
decompens
two
stroke
fibrosi
studi
entri
rang
stage
fortytwo
gene
show
signific
differenti
express
p
twofold
chang
express
patient
without
composit
outcom
two
probe
branch
chain
aminoacid
transaminas
upregul
fold
chang
princip
compon
analysi
hierarch
cluster
confirm
gex
aid
differenti
patient
outcom
without
conclus
initi
catabol
essenti
branch
chain
amino
acid
found
upregul
nafld
patient
clinic
decompens
upregul
previous
associ
high
liver
fat
content
poor
prognosi
hepatocellular
carcinoma
result
suggest
perturb
hepat
metabol
associ
poor
outcom
nafld
patient
point
toward
need
investig
target
gastroenterolog
hepatolog
duke
univers
medic
center
durham
nc
depart
electr
comput
engin
duke
univers
durham
nc
depart
patholog
duke
univers
medic
center
durham
nc
introduct
vitamin
vd
defici
associ
obes
insulin
resist
howev
role
vd
defici
nafld
well
understood
aim
determin
relationship
serum
level
hepat
express
vd
metabol
gene
clinic
histolog
featur
nafld
method
adult
duke
nafld
clinic
databas
vd
level
within
month
liver
biopsi
includ
nafld
histolog
featur
control
patholog
diagnosi
clinic
characterist
vd
level
nafld
histolog
featur
summar
compar
group
gener
linear
model
use
analyz
associ
vd
level
metabol
gene
includ
vd
receptor
vdr
vd
bind
protein
encod
group
specif
compon
gc
cytochrom
complex
parathyroid
hormon
receptor
retino
x
receptor
rxr
nuclear
receptor
coactiv
ncoa
smad
peroxisom
proliferatoractiv
receptor
ppar
nafld
histolog
sever
adjust
confound
correct
multipl
comparison
result
differ
age
gender
bmi
hypertens
htn
hyperlipidemia
hld
hypercholesterolemia
hcl
hypertriglyceridemia
htg
vd
level
ngml
vs
ngml
note
group
nafld
patient
like
higher
vs
light
skin
vs
vd
level
associ
sever
steatosi
lobular
inflamm
balloon
hepatocyt
fibrosi
univari
analysi
candid
gene
gene
probe
mild
stage
vs
advanc
stage
fibrosi
gene
gene
probe
signific
multipl
comparison
control
confound
associ
decreas
tabl
conclus
pilot
studi
vd
level
hepat
express
candid
gene
involv
vd
metabol
associ
nafld
histolog
sever
gene
interest
warrant
investig
larger
studi
background
aim
screen
nonalcohol
steatohepat
nash
subject
nonalcohol
fatti
liver
diseas
nafld
hamper
uncertainti
around
noninvas
tool
liver
damag
studi
aim
valid
recent
develop
ion
index
nash
assess
diagnost
perform
singl
combin
noninvas
tool
liver
damag
larg
cohort
patient
biopsyproven
nafld
materi
method
analys
data
italian
patient
southern
itali
northern
itali
consecut
enrol
biopsi
follow
noninvas
score
liver
fibrosi
calcul
accord
publish
algorithm
ion
nf
apoptot
fragment
measur
elisa
immunoassorb
assay
liver
stiff
ls
evalu
fibroscan
liver
histolog
score
accord
kleiner
nash
diagnos
local
pathologist
accord
join
presenc
steatosi
inflamm
balloon
without
fibrosi
sever
fibrosi
defin
fibrosi
cutoff
point
rulein
ruleout
fibrosi
calcul
youden
index
result
whole
cohort
auc
ion
diagnosi
nash
npv
ppv
npv
ppv
respect
confirm
poor
perform
test
noninvas
diagnosi
nash
test
perform
better
diagnosi
sever
fibrosi
auc
ion
npv
ppv
npv
ppv
popul
auc
nf
ls
diagnosi
sever
fibrosi
npv
ppv
npv
ppv
npv
ppv
respect
next
test
sever
combin
noninvas
tool
order
improv
diagnost
perform
risk
sever
fibrosi
combin
ion
plu
ls
nf
plu
ls
plu
ls
similarli
improv
perform
singl
test
provid
correct
classif
case
respect
conclus
combin
ls
either
ion
nf
better
singl
noninvas
test
accur
exclud
sever
liver
fibrosi
follow
peopl
noth
disclos
rami
ibrahim
kamal
jouness
chiara
rosso
salvator
petta
monica
cucco
milena
marietti
gian
paolo
caviglia
maria
lorena
abat
calogero
antonina
smedil
antonio
giorgio
maria
saracco
elisabetta
bugianesi
introduct
studi
suggest
circadian
rhythm
disrupt
result
liver
milieu
promot
steatosi
steatohepat
sinc
sleepwak
cycl
arguabl
bodi
import
circadian
rhythm
sleep
pattern
may
affect
natur
histori
nonalcohol
fatti
liver
diseas
nafld
studi
aim
determin
sleep
durat
particular
associ
nafld
methodolog
data
obtain
combin
nation
health
nutrit
examin
survey
nhane
subject
incomplet
data
hepat
b
c
infect
signific
alcohol
intak
hepatotox
medic
use
exclud
subject
divid
priori
group
base
sleep
durat
hour
hour
hour
multivari
regress
use
estim
effect
sleep
durat
nafld
fibrosi
score
nf
fatti
liver
index
fli
alt
adjust
age
sex
ethnic
smoke
alcohol
use
calor
intak
high
alt
defin
ul
men
ul
women
base
previou
nhane
analys
result
total
adult
fast
lab
includ
mean
sleep
durat
hour
total
hour
sleep
hour
hour
peopl
slept
hour
younger
nonhispan
black
obes
higher
triglycerid
slept
hour
older
femal
mexican
nonhispan
white
peopl
slept
hour
smoke
less
less
like
diabet
hypertens
nonalcohol
drinker
multivari
regress
sleep
hour
increas
odd
high
probabl
fli
high
alt
respect
sleep
hour
decreas
odd
high
probabl
fli
high
alt
respect
although
differ
statist
signific
mean
alt
hour
group
ul
higher
hour
group
odd
high
probabl
nf
increas
sleep
hour
univari
multivari
analysi
conclus
sleep
least
hour
per
night
may
protect
steatosi
steatohepat
sleep
durat
howev
appear
affect
fibrosi
risk
studi
suggest
sleep
may
modifi
risk
factor
nafld
research
warrant
use
biopsi
defin
nafld
phenotyp
liverrel
morbid
mortal
endpoint
multivari
odd
ratio
fatti
liver
fibrosi
high
alt
disclosur
follow
peopl
noth
disclos
jame
philip
g
esteban
lisa
e
rein
aniko
szabo
samer
gawrieh
kia
saeian
introduct
noninvas
approach
assess
nonalcohol
steatohepat
nash
variou
degre
fibrosi
context
clinic
trial
import
goal
drug
develop
three
lead
candid
noninvas
monitor
includ
multiparametr
magnet
reson
imag
livermultiscan
lm
liver
stiff
measur
use
vibrat
control
transient
elastographi
fibroscan
fs
liver
stiff
measur
use
magnet
reson
elastographi
mre
aim
examin
baselin
patient
characterist
relationship
lm
fs
mre
ongo
singl
site
trial
antifibrot
nash
patient
stage
three
fibrosi
http
clinicaltri
gov
method
patient
biopsi
confirm
nash
stage
fibrosi
enrol
doubleblind
placebocontrol
clinic
trial
compar
placebo
patient
mgkg
patient
enrol
patient
baselin
noninvas
assess
within
one
month
random
lm
perspectum
diagnost
mre
siemen
fs
echosen
result
mean
age
bmi
enrol
patient
year
respect
cohort
includ
men
women
white
hispan
one
asian
diabet
median
iqr
percentil
valu
lm
fs
mre
valu
millisecond
kpa
kpa
respect
signific
correl
fs
mre
measur
liver
stiff
r
p
two
fs
outlier
remov
correl
improv
r
p
contrast
signific
correl
lm
either
liver
stiff
measur
fs
mre
conclus
liver
stiff
measur
fs
mre
shown
relat
degre
liver
fibrosi
well
correl
cohort
nash
patient
biopsi
proven
stage
fibrosi
lm
lif
composit
steatosi
inflamm
fibrosi
well
correl
either
measur
liver
stiff
possibl
evalu
combin
fibrosi
necroinflamm
cannabinoid
cb
receptor
g
proteincoupl
receptor
gpcr
abundantli
express
gpcr
central
nervou
system
cn
low
express
level
peripher
tissu
howev
upregul
adipos
tissu
liver
kidney
diseas
implic
human
diseas
includ
obes
nash
diabet
diabet
nephropathi
fibrosi
previous
target
small
molecul
antagonist
treatment
obes
well
nonalcohol
steatohepat
nash
efficaci
clinic
trial
drug
ultim
discontinu
due
undesir
central
nervou
system
cn
side
effect
hypothes
monoclon
antibodi
similar
efficaci
nash
metabol
diseas
devoid
cn
liabil
due
restrict
access
antibodi
cn
import
peripher
tissu
drive
diseas
demonstr
includ
adipocyt
macrophag
hepatocyt
hepat
stellat
cell
play
import
role
lipid
synthesi
fatti
acid
oxid
adiponectin
product
insulin
sensit
product
profibrot
factor
condit
knockout
data
macrophag
hepatocyt
mous
model
metabol
diseas
demonstr
role
peripher
strengthen
data
new
gener
small
molecul
antagonist
remain
potent
anim
model
despit
limit
cn
penetr
howev
cn
drug
level
peripher
restrict
molecul
might
still
concern
monoclon
antibodi
might
suitabl
therapeut
modal
avoid
cn
effect
util
icap
technolog
stabil
gpcr
nativ
conform
select
monoclon
antibodi
receptor
identifi
panel
highli
select
binder
lead
demonstr
vitro
use
cell
line
human
hepat
stellat
cell
similar
rimonab
invers
agonist
antagon
receptor
compar
potenc
studi
rhesu
cynomolgu
monkey
show
less
found
cerebrospin
fluid
csf
label
pet
imag
demonstr
lack
cn
penetr
confirm
increas
express
increas
diseas
sever
nash
demonstr
activ
nash
model
stam
model
use
surrog
molecul
henc
believ
excit
potenti
therapeut
treatment
nash
metabol
diseas
benefit
previous
observ
small
molecul
lack
cn
liabil
commenc
clinic
trial
alt
noninvas
biomark
histolog
respons
pharmacotherapi
nash
patient
insight
elafibranor
trial
background
still
unknown
whether
genet
epigenet
factor
might
affect
pathogenesi
nonalcohol
fatti
liver
diseas
nafld
especi
clinic
util
genotyp
circul
histolog
featur
nafld
still
unclear
method
rate
surviv
hepatocellular
carcinoma
hcc
develop
year
followup
investig
japanes
patient
biopsyproven
nafld
patient
hcc
time
diagnosi
nafld
patient
develop
hcc
followup
impact
serum
level
histolog
featur
hcc
evalu
rel
express
serum
calcul
use
compar
cycl
threshold
ct
method
spike
normal
intern
control
result
cumul
surviv
rate
end
year
respect
cumul
hcc
rate
end
year
respect
cumul
surviv
hcc
rate
vari
significantli
accord
sever
fibrosi
stage
genotyp
fibrosi
stage
gg
type
significantli
progress
cg
type
multipl
comparison
multivari
analysi
identifi
genotyp
predictor
fibrosi
stage
impact
tend
decreas
fibrosi
stage
serum
level
partli
affect
sever
steatosi
balloon
lobular
inflamm
fibrosi
stage
tend
decreas
fibrosi
stage
compar
fibrosi
stage
multivari
analysi
identifi
hcc
andor
histolog
compon
nash
morpholog
factor
independ
influenc
serum
level
diagnosi
nafld
crosssect
evalu
serum
level
patient
without
hcc
significantli
higher
hcc
patient
fibrosi
stage
fibrosi
stage
longitudin
evalu
one
patient
followup
time
year
diagnosi
nafld
hcc
serum
level
alreadi
tend
decreas
progress
fibrosi
stage
conclus
genotyp
partli
affect
histolog
featur
includ
fibrosi
stage
hcc
andor
histolog
compon
nash
affect
serum
level
independ
impact
genotyp
level
serum
tend
decreas
fibrosi
stage
prospect
studi
need
investig
impact
genotyp
serum
histolog
featur
hepatocarcinogenesi
nafld
gastroenterolog
mitsui
memori
hospit
tokyo
japan
diabet
metabolizm
mitsui
memori
hospit
tokyo
japan
background
sodiumglucos
cotransport
inhibitor
newest
class
oral
diabet
agent
avail
market
import
advantag
inhibitor
favor
effect
reduct
bodi
weight
aim
aim
studi
elucid
effect
inhibitor
treatment
nafld
patient
method
retrospect
enrol
consecut
japanes
nafld
patient
treat
inhibitor
compar
chang
liver
inflamm
fibrosi
bodi
weight
end
followup
also
assess
factor
contribut
normal
alt
level
result
mean
age
year
old
patient
male
gender
mean
bmi
kgm
patient
administ
mg
ipragliflozin
daili
mean
dose
period
day
end
followup
bodi
weight
significantli
decreas
kg
kg
p
amelior
level
p
serum
alt
level
also
significantli
decreas
iul
iul
p
improv
index
p
final
patient
achiev
normal
alt
level
mean
reduct
weight
patient
achiev
normal
alt
level
kg
kg
patient
achiev
normal
alt
level
p
univari
logist
regress
analysi
indic
reduct
bodi
weight
per
kg
p
improv
level
per
p
factor
contribut
normal
alt
level
conclus
administr
inhibitor
led
good
glycaem
control
also
normal
alt
level
alter
index
favor
effect
bodi
weigh
reduct
isogawa
akihiro
speak
teach
astella
pharma
inc
follow
peopl
noth
disclos
takamasa
ohki
mayuko
kondo
shigeyuki
kurosaki
kazuyoshi
funato
satoshi
kawamura
shuya
maeshima
yuki
karasawa
kentaro
kojima
michiharu
seki
nobuo
toda
kazumi
tagawa
backgroundaim
nonalcohol
fatti
liver
diseas
nafld
associ
increas
risk
coronari
arteri
diseas
addit
advanc
fibrosi
nafld
patient
associ
cardiovascular
diseas
overal
mortal
therefor
investig
associ
coronari
atherosclerosi
noninvas
fibrosi
marker
detect
high
risk
popul
coronari
arteri
diseas
method
januari
decemb
total
subject
nafld
analyz
nafld
diagnos
ultrasonographi
st
vincent
hospit
heath
promot
center
coronari
atherosclerosi
repres
coronari
arteri
calcif
score
cac
assess
cardiac
comput
tomographi
nafld
fibrosi
score
nf
score
aspart
aminotransferas
ast
platelet
ratio
index
apri
score
forn
index
use
noninvas
fibrosi
marker
mean
age
studi
popul
year
subject
male
univari
analysi
high
cac
significantli
associ
old
age
year
diabet
mellitu
serum
glucos
estim
glomerular
filtrat
rate
gfr
ps
seem
associ
hypertens
bodi
mass
index
ps
multivari
analysi
old
age
male
gender
signific
risk
factor
p
p
nf
forn
index
significantli
associ
high
cac
ps
nf
score
significantli
factor
even
adjust
tradit
risk
factor
p
p
auroc
nf
predict
high
cac
cutoff
valu
respect
conclus
hepat
fibrosi
assess
noninvas
fibrosi
marker
nf
independ
associ
high
cac
therefor
noninvas
denot
aasld
presidenti
poster
distinct
fibrosi
marker
help
detect
high
risk
popul
coronari
arteri
diseas
gastroenterolog
takatsuki
gener
hospit
takatsuki
japan
background
aim
augment
patient
nonalcohol
fatti
liver
diseas
nafld
becom
big
publichealth
problem
industri
countri
present
hepatocarcinogenesi
relat
nafld
addit
critic
issu
solv
urgent
despit
mani
energet
investig
detail
patholog
mechan
hepatocarcinogenesi
patient
nafld
obscur
cours
hepatocellular
carcinoma
hcc
develop
liver
even
though
steatot
patient
posit
serum
hepat
virus
recogn
nafldrel
one
hand
occult
hepat
b
viru
hbv
infect
consid
one
potenti
factor
hepatocarcinogenesi
especi
hbvendem
area
hypothes
occult
hbv
may
contribut
nafldrel
hepatocarcinogenesi
carri
follow
molecular
patholog
studi
method
nine
nafld
patient
men
women
diagnos
patholog
hcc
subject
studi
besid
clinic
laboratori
data
analyz
liver
tissu
specimen
nontumor
portion
histolog
polymeras
chain
reaction
pcr
base
hbv
genom
studi
dna
extract
five
section
formalinfix
paraffinembed
tissu
pcr
perform
use
hbv
x
genespecif
primer
sampl
shown
posit
result
examin
direct
sequenc
result
patient
case
metabol
factor
diabet
dyslipidemia
obes
hypertens
factor
one
posit
hepat
b
surfac
antigen
patient
posit
hepat
b
core
antibodi
antihbc
collect
everi
patient
either
diabet
antihbc
posit
histolog
nontumor
portion
show
cirrhosi
case
mild
perivenular
fibrosi
case
dna
sampl
antihbcposit
case
pcr
amplicon
expect
size
gener
one
prove
target
hbv
x
gene
segment
direct
sequenc
case
simpl
steatosi
without
fibrosi
metabol
factor
conclus
present
studi
reveal
japan
nafldrel
hepatocarcinogenesi
least
part
associ
occult
hbv
infect
addit
result
suggest
diabet
antihbc
liver
histolog
might
use
predictor
nafldrel
hepatocarcinogenesi
disclosur
follow
peopl
noth
disclos
yoshihiro
ikura
kenichi
harada
tatsuya
osuga
valid
noninvas
score
system
predict
overal
mortal
liver
relat
event
nonalcohol
fatti
liver
diseas
lui
c
bertot
gari
p
jeffrey
gerri
c
macquillan
backgroundaim
predictor
mortal
liver
decompens
help
determin
prognosi
thu
influenc
manag
patient
nonalcohol
fatti
liver
diseas
nafld
examin
accuraci
four
clinic
model
predict
mortal
liver
relat
event
nafld
method
hepascor
nafld
fibrosi
score
nf
apri
fib
score
calcul
time
biopsi
patient
nafld
tertiari
centr
patient
follow
outcom
overal
mortalityliv
transplant
occurr
first
event
hepat
decompens
analysi
includ
multivari
cox
proport
hazard
model
c
statist
homerlemershow
test
hl
model
calibr
result
total
patient
mean
age
year
women
bmi
kgm
type
diabet
follow
mean
year
rang
patient
die
underw
liver
transplant
develop
liver
relat
event
hepascor
hazard
ratio
hr
confid
interv
ci
nf
hr
ci
apri
hr
ci
hr
ci
associ
overal
mortal
hr
liver
relat
event
ci
ci
ci
hepascor
nf
apri
fib
respect
nf
hepascor
similar
predict
accuraci
overal
mortalityliv
transplant
liver
relat
event
outcom
tabl
model
calibr
well
differ
observ
predict
risk
overal
mortalityliv
transplant
conclus
noninvas
score
system
use
tool
predict
overal
mortal
liver
relat
event
nafld
patient
accord
predefin
risk
group
gastroenterolog
hepatolog
univers
hospit
essen
essen
germani
depart
radiolog
school
medicin
public
health
madison
wi
depart
diagnost
intervent
radiolog
neuroradiolog
univers
hospit
essen
essen
germani
recent
studi
indic
increas
preval
hepat
steatosi
nonalcohol
steatohepat
nash
sever
alimentari
tract
diseas
includ
inflammatori
bowel
diseas
ibd
other
shown
nash
ibd
patient
associ
increas
suscept
acuteonchron
liver
failur
date
littl
known
mechan
lead
hepat
steatosi
ibd
studi
aim
analyz
compar
noninvas
predictor
liver
injuri
patient
nash
individu
crohn
diseas
cd
therefor
includ
patient
establish
nash
patient
establish
cd
without
histori
liver
diseas
analyz
serum
marker
liver
injuri
breath
test
small
intestin
bacteri
overgrowth
sibo
transient
elastographi
well
control
attenu
paramet
cap
assess
hepat
steatosi
expect
patient
nash
significantli
higher
bmi
compar
cd
accordingli
alt
ast
level
significantli
higher
nash
vs
cd
sibo
occur
two
individu
associ
steatosi
interestingli
transient
elastographi
reveal
increas
liver
stiff
nash
vs
cd
signific
differ
cap
measur
hepat
steatosi
group
fact
cd
patient
cap
previous
establish
cutoff
valu
signific
hepat
steatosi
maximum
cap
one
patient
although
patient
remain
within
normal
limit
ast
alt
significantli
higher
cd
patient
cap
compar
cd
patient
lower
cap
result
order
identifi
condit
associ
higher
cap
result
review
patient
drug
regimen
surpris
steroid
therapi
associ
cap
cohort
howev
individu
cap
like
treat
biolog
fact
cap
significantli
lower
patient
biolog
compar
treatment
strategi
vs
dbm
p
thu
cohort
nash
associ
higher
bmi
transaminas
level
liver
stiff
hepat
steatosi
assess
cap
pronounc
compar
cd
cd
patient
signific
steatosi
higher
transaminas
level
indic
sublimin
hepat
inflamm
despit
within
normal
level
treatment
biolog
seem
protect
cd
patient
hepat
steatosi
conlus
identifi
high
rate
hepat
steatosi
cd
alter
transaminas
level
potenti
associ
biolog
follow
peopl
noth
disclos
katharina
willuweit
malt
brandenburg
svenja
sydor
sophia
assmuth
annemari
wegehaupt
sonja
kinner
alisan
kahraman
guido
gerken
ali
canbay
lar
bechmann
prospect
studi
evalu
efficaci
standard
low
calori
diet
accord
genotyp
patient
non
alcohol
fatti
liver
diseas
nafld
week
data
interim
analysi
background
approxim
western
popul
suffer
nafld
rise
obes
peopl
complic
nafld
includ
non
alcohol
steatohepat
nash
liver
cirrhosi
hepatocellular
carcinoma
well
aggrav
diabet
cardiovascular
diseas
import
genet
factor
associ
nafld
aim
studi
analyz
efficaci
standard
low
calori
liver
diet
hepafast
bodym
kirkel
germani
especi
compound
nafld
patient
pt
influenc
genotyp
treatment
outcom
method
studi
non
cirrhot
patient
stratifi
accord
genotyp
patient
per
group
cc
cg
gg
patient
receiv
protein
shake
therapi
hepafast
week
instruct
follow
low
glycem
insulinem
logi
diet
anoth
week
eot
patient
seen
longitudin
four
time
point
baselin
week
month
monthsfollow
time
point
liver
fat
content
assess
independentblind
investig
fibroscan
cap
addit
fatti
liver
index
fli
waist
circumfer
wc
bmi
triglycerid
tg
ggt
analyz
result
date
patient
includ
studi
pt
age
genotyp
finish
hepafast
shake
therapi
baselin
week
outcom
variabl
decreas
till
week
second
time
point
fibroscan
cap
p
fli
p
wc
p
bmi
p
tg
p
ggt
p
backgroundobject
nonalcohol
fatti
liver
diseas
nafld
worldwid
public
health
concern
coffe
might
protect
effect
nafld
howev
result
previou
report
conflict
therefor
conduct
metaanalysi
summar
avail
data
method
studi
consist
two
metaanalys
first
metaanalysi
includ
observ
studi
compar
risk
nafld
drink
coffe
second
analysi
includ
studi
compar
risk
liver
fibrosi
nafld
patient
drink
coffe
pool
odd
ratio
confid
interv
ci
calcul
result
articl
five
studi
met
elig
criteria
includ
analysi
risk
nafld
subject
drank
coffe
significantli
lower
subject
pool
ci
also
found
significantli
decreas
risk
liver
fibrosi
among
nafld
patient
drank
coffe
compar
pool
ci
conclus
studi
demonstr
significantli
decreas
risk
nafld
among
coffe
drinker
significantli
decreas
risk
liver
fibrosi
among
patient
nafld
drank
coffe
regular
basi
whether
consumpt
coffe
could
consid
prevent
measur
nafld
need
investig
forest
plot
includ
studi
impact
coffe
presenc
nafld
liver
fibrosi
nafld
disclosur
follow
peopl
noth
disclos
karn
wijarnpreecha
charat
thongprayoon
patompong
ungprasert
endem
obes
metabol
syndrom
use
databas
tertiari
referr
center
method
conduct
retrospect
analysi
patient
seen
follow
liver
institut
one
satellit
clinic
diagnosi
nash
base
code
januari
jan
exclud
patient
incomplet
data
lost
follow
data
liver
biopsi
imag
lab
demograph
comorbid
link
metabol
syndrom
collect
irb
exempt
obtain
retrospect
analysi
deidentifi
data
result
analyz
chart
patient
complet
inform
patient
present
abnorm
lft
alt
uln
patient
present
fatti
liver
imag
entir
cohort
femal
self
report
race
distribut
caucasian
africanamerican
other
median
age
present
cohort
year
vari
differ
ethnic
group
hispan
asian
present
younger
age
other
differ
bmi
present
minor
racial
group
except
asian
patient
cirrhosi
present
either
biopsi
imag
characterist
sign
portal
hypertens
imag
endoscopi
term
metabol
syndrom
patient
diabet
patient
hypertens
patient
hyperlipidemia
present
patient
ethnic
distribut
bridg
fibrosi
cirrhosi
present
caucasian
hispan
differ
characterist
diseas
sever
present
conclus
present
analysi
larg
singl
center
tertiari
referr
center
databas
patient
nash
repres
cohort
southwest
region
us
term
ethnic
mix
asian
hispan
american
tend
present
younger
age
patient
present
cirrhosi
highlight
need
earli
referr
fibrosi
assess
patient
stronger
women
men
p
sex
conclus
nafld
also
associ
coronari
calcif
independ
tradit
risk
factor
obes
metabol
syndrom
asymptomat
individu
associ
appear
stronger
women
disclosur
follow
peopl
noth
disclos
veeravich
jaruvongvanich
anawin
sanguankeo
kamonkiat
wirunsawanya
sikarin
upala
exercis
train
mediat
lipid
infiltr
skelet
muscl
contribut
improv
pathogenesi
nafld
background
aim
physic
exercis
benefici
effect
metabol
homeostasi
exercis
train
increas
skelet
muscl
mass
decreas
lipid
infiltr
skelet
muscl
contribut
improv
insulin
resist
nafld
aim
analyz
actual
impact
chang
skelet
muscl
exercis
train
nafld
method
longitudin
studi
perform
patient
male
diagnos
fatti
liver
diseas
abdomin
ultrasound
saga
univers
hospit
affili
facil
patient
drink
histori
gday
alcohol
viral
hepat
autoimmun
liver
diseas
malign
diseas
exclud
patient
perform
exercis
metabol
equival
task
met
week
month
food
intak
adjust
kcalkg
bodyweight
evalu
abdomin
lumbar
muscl
area
ct
imag
obtain
skelet
muscl
area
index
sai
lumbar
muscl
area
cm
height
cm
lipid
infiltr
skelet
muscl
intramuscular
adipos
tissu
content
imac
liver
liverspleen
ratio
ls
ratio
also
measur
ct
imagingbas
techniqu
factor
contribut
improv
ls
ratio
alt
identifi
multipl
regress
model
result
exercis
train
decreas
imac
patient
decreas
bmi
decreas
fast
plasma
glucos
decreas
alt
improv
ls
ratio
p
respect
patient
without
decreas
imac
fail
improv
paramet
exercis
train
increas
sai
patient
decreas
bmi
decreas
alt
improv
ls
ratio
howev
interestingli
nonrespond
sai
also
show
signific
improv
paramet
decreas
imac
valu
p
increas
sai
valu
p
significantli
correl
improv
alt
level
decreas
imac
independ
factor
improv
ls
ratio
valu
p
signific
correl
increas
sai
improv
ls
ratio
conclus
although
increas
skelet
muscl
mass
factor
improv
liver
steatosi
nafld
decreas
lipid
infiltr
skelet
muscl
contribut
improv
liver
steatosi
well
alt
level
exercis
train
program
nafld
lipid
infiltr
skelet
muscl
could
indic
exercis
train
effect
nafld
possibl
therapeut
target
nafld
disclosur
follow
peopl
noth
disclos
hirokazu
takahashi
yoichiro
kitajima
yoshihito
kubotsu
satoshi
oeda
keizo
anzai
yuichiro
eguchi
elev
hepat
sparc
level
associ
increas
risk
hepatocellular
injuri
sever
obes
patient
nonalcohol
fatti
liver
diseas
background
aim
mechan
control
progress
simpl
steatosi
steatohepat
fibrosi
patient
nonalcohol
fatti
liver
diseas
nafld
still
matter
investig
sparc
secret
matricellular
protein
overexpress
liver
chronic
injuri
contribut
sparc
accumul
diseas
sever
mechan
involv
larg
unknown
nafld
assess
hypothesi
sparc
increas
liver
necrosi
inflamm
therefor
high
risk
fibrosi
method
qrtpcr
immunohistochemistri
elisa
employ
local
quantifi
chang
sparc
morbidli
obes
patient
nafld
mous
model
dietinducednash
result
correl
sever
liver
diseas
progress
simpl
steatosi
nash
result
obes
patient
subgroup
identifi
either
high
sparc
express
low
sparc
express
liver
tissu
high
express
sparc
parallel
extens
hepatocellular
necrosi
necroptosi
increas
profibrogen
factor
line
find
nash
anim
model
sparc
knockout
mice
protect
inflammatori
injuri
show
less
inflamm
fibrosi
conclus
sparc
accumul
associ
sever
liver
injuri
fibrogen
process
nafld
sparc
may
promis
diagnost
therapeut
target
monitor
progress
nafld
patient
follow
peopl
noth
disclos
guillermo
mazzolini
catalina
atorrasagasti
agostina
onorato
estanislao
peixoto
martin
schlattjan
svenja
sydor
janpet
sowa
guido
gerken
ali
canbay
introduct
pharmacolog
treatment
nonalcohol
fatti
liver
diseas
nafld
still
evolv
randomis
human
studi
histolog
end
point
adult
use
probiot
vsl
de
simon
formul
mix
lactic
acid
bacteria
bifidobacteria
patient
nafld
aim
present
studi
evalu
efficaci
probiot
vsl
adult
patient
nafld
methodolog
twocentr
prospect
doubl
blind
placebo
control
randomis
proof
concept
studi
patient
liver
biopsi
proven
nafld
random
two
group
clinic
trial
registri
india
patient
gave
written
inform
consent
studi
approv
respect
institut
ethic
committe
group
mean
yr
receiv
standard
medic
treatment
smt
life
style
modif
oral
probiot
vsl
cap
billion
cfuday
one
year
group
mean
yr
receiv
smt
ident
placebo
cap
one
year
primari
object
studi
histolog
improv
nafld
activ
score
na
compon
hepat
fibrosi
secondari
object
improv
serum
alt
cytokin
profil
result
ten
patient
vsl
group
placebo
group
underw
repeat
liver
biopsi
one
year
comparison
baselin
even
though
signific
improv
hepat
steatosi
hepatocyt
balloon
lobular
inflamm
na
score
improv
significantli
year
vsl
group
compar
placebo
improv
na
score
significantli
higher
vsl
group
vs
signific
differ
improv
individu
compon
hepatocy
balloon
hepat
fibrosi
addit
histolog
improv
signific
improv
serum
alt
vs
iul
leptin
vs
vs
vsl
group
comparison
placebo
year
conclus
proof
concept
studi
patient
nafld
manag
lifestyl
modif
probiot
vsl
show
signific
improv
liver
histolog
vsl
also
improv
serum
alt
cytokin
profil
patient
nafld
follow
peopl
noth
disclos
ajay
k
duseja
subrat
k
acharya
manu
mehta
shruti
chhabra
shalimar
satyavati
rana
ashim
da
siddhartha
datta
gupta
radha
k
dhiman
yogesh
k
chawla
background
treatment
extrahepat
bile
duct
disord
biliari
atresia
primari
scleros
cholang
biliari
strictur
limit
liver
transplant
hepatojejunostomi
due
lack
healthi
tissu
suitabl
biliari
reconstruct
object
develop
platform
largescal
vitro
expans
nativ
cholangiocyt
use
cell
gener
bioengin
biliari
tissu
perform
biliari
reconstruct
vivo
method
primari
human
cholangiocyt
isol
deceas
organ
donor
cultur
cell
base
establish
protocol
matur
mainten
stem
cell
deriv
cholangiocyt
extrahepat
cholangiocyt
organoid
eco
seed
bioengin
polyglycol
acid
pga
scaffold
gener
bioartifici
biliari
tissu
model
extrahepat
biliari
injuri
ehbi
gener
compromis
integr
biliari
tree
immunodefici
nsg
mice
longitudin
incis
gallbladd
wall
ecopopul
pga
scaffold
sutur
place
repair
wall
defect
acellular
scaffold
fibroblast
popul
scaffold
use
neg
control
result
eco
express
key
biliari
marker
ggt
cftr
maintain
function
properti
vitro
includ
alp
ggt
cftr
activ
transcriptom
analys
reveal
close
correl
eco
primari
cholangiocyt
eco
seed
pga
scaffold
form
structur
resembl
biliari
tissu
maintain
function
properti
marker
express
anim
undergo
biliari
reconstruct
ecopopul
scaffold
surviv
month
integr
cell
biliari
epithelium
anim
transplant
acellular
pga
scaffold
die
within
h
logrank
test
anim
receiv
fibroblastpopul
scaffold
surviv
none
transplant
gallbladd
success
reconstruct
biliari
epithelium
replac
fibrot
tissu
patenc
reconstruct
biliari
tree
confirm
use
magnet
reson
cholangiopancreatographi
mrcp
conclus
biliari
epitheli
cell
deriv
extrahepat
biliari
tree
effect
propag
vitro
maintain
transcript
function
ident
regen
potenti
eco
illustr
capac
organ
bioengin
function
biliari
epithelium
rescu
ehbi
murin
model
knowledg
first
report
organ
reconstruct
use
human
primari
cell
expand
vitro
background
aim
liver
well
known
possess
high
regen
capac
howev
regener
often
impair
patient
liver
cirrhosi
although
progenitor
cell
recruit
implic
regener
fibrot
liver
origin
natur
hepat
progenitor
cell
hpc
fulli
understood
hand
recent
studi
use
genet
lineag
trace
analysi
indic
dedifferenti
matur
hepatocyt
play
import
role
injuredfibrot
liver
regener
present
studi
show
signal
acceler
dedifferenti
process
contribut
regener
fibrot
liver
materi
method
liver
fibrosi
induc
wild
type
condit
knockout
cko
mice
repeat
carbon
tetrachlorid
ccl
inject
excis
liver
specimen
subject
immunohistochem
stain
quantit
gene
express
analys
fibrosisrel
molecul
hpc
marker
surviv
rate
extent
cell
prolifer
compar
wild
type
cko
mice
regen
process
alter
partial
hepatectomi
fibrot
liver
primari
matur
hepatocyt
cocultur
quiescent
activ
hepat
stellat
cell
hsc
dedifferenti
alphafetoprotein
afp
express
hpc
evalu
use
notch
inhibitor
hsc
obtain
cko
mice
result
signific
number
afpposit
cell
featur
hpc
high
prolif
abil
detect
along
fibrou
septa
repeat
ccl
inject
wild
type
mice
septal
myofibroblast
highli
express
notch
ligand
notch
signal
activ
adjac
afpexpress
hpc
studi
cko
mice
demonstr
delet
suppress
mobil
prolifer
afpposit
hpc
fibrot
liver
tissu
decreas
surviv
rate
ccl
fibrot
mice
untreat
normal
anim
partial
hepatectomi
consist
vivo
result
cell
cultur
experi
indic
increas
express
activ
hsc
upregul
afp
express
cocultur
hepatocyt
dedifferenti
hepatocyt
suppress
ad
notch
inhibitor
cultur
media
use
hsc
obtain
cko
mice
conclus
result
indic
signal
contribut
regener
fibrot
liver
possibl
dedifferenti
matur
hepatocyt
provid
insight
novel
import
role
signal
liver
pathophysiolog
disclosur
follow
peopl
noth
disclos
yasuhiro
nakano
sachi
nakao
hideaki
sumiyoshi
kenichiro
mikami
yuri
tanno
aim
deal
liver
failur
end
stage
liver
transplant
ultim
treatment
termin
stage
diseas
howev
demand
liver
transplant
number
provis
cadaver
liver
liver
tissu
live
donor
henc
develop
way
acquir
hepatocyt
consid
import
research
issu
decad
recent
direct
convers
technolog
develop
gener
induc
hepatocytelik
cell
ihep
ectop
express
liverspecif
transcript
factor
hand
tissueengin
includ
bioprint
technolog
advanc
organlik
structur
therebi
captur
complex
vivo
environ
therefor
herein
report
reconstruct
bioprint
hepat
architectur
recapitul
microenviron
liver
use
ihep
sourc
hepatocyt
method
gener
ihep
mous
embryon
fibroblast
x
cell
transduc
pmx
retrovirus
express
individu
hepat
transcript
factor
h
cell
cultur
hepatocyt
cultur
medium
hcm
type
collagenco
dish
induc
lineag
transit
toward
ihep
bioprint
ihep
encapsul
algin
hydrogel
extrud
nozzl
pressur
crosslink
calcium
chlorid
hepat
structur
form
mm
mm
result
day
transduct
observ
epitheli
ihep
coloni
high
prolifer
rate
upon
sever
passag
number
fibroblast
reduc
ihep
grew
domin
dish
qpcr
immunofluoresc
analys
reveal
ihep
share
typic
hepat
gene
protein
express
profil
liver
tissu
moreov
ihep
also
function
characterist
hepatocyt
glycogen
storag
xenobiot
activ
bioprint
method
effici
construct
multipl
hepat
structur
interestingli
found
mimick
hepat
structur
assist
ihep
stabli
repopul
also
enhanc
identif
preadult
hepat
stem
cell
nich
label
retain
cell
assay
fetal
develop
background
aim
label
retain
cell
assay
acetaminophen
injuri
model
previous
identifi
proxim
portion
biliari
tree
canal
here
coh
addit
peribiliari
hepatocyt
pbh
neighbor
coh
locat
potenti
function
stem
cell
nich
kuwahara
et
al
hepatolog
aim
studi
investig
possibl
role
coh
pbh
normal
liver
develop
absenc
injuri
method
label
divid
cell
fetal
liver
brdu
inject
intraperiton
pregnant
mice
time
point
postnat
mice
receiv
intraperiton
inject
brdu
age
day
confirm
brdu
label
fetal
postnat
liver
mice
sacrif
hour
label
pregnant
mice
allow
give
birth
newborn
mice
rais
week
old
growth
matur
liver
provid
chase
brdu
label
washout
follow
brdu
label
sacrif
likewis
postnat
label
mice
sacrif
age
week
pbh
biliari
cell
coh
analyz
doubl
immunohistochemistri
ihc
biliari
keratin
pank
brdu
cell
divis
prolifer
ratio
liver
weight
bodi
weight
lwbwr
analyz
everi
week
old
mice
result
stabil
brdu
label
liver
confirm
ihc
brdu
index
postnat
mice
liver
show
frequenc
cell
prolifer
hepatocyt
biliari
cell
coh
highest
age
day
diminish
steadili
peak
lwbwr
age
week
male
femal
mice
respect
week
post
chase
distribut
brduretain
pbh
biliari
cell
coh
total
brdu
posit
cell
lobular
peribiliari
hepatocyt
biliari
cell
coh
significantli
higher
prenat
label
liver
postnat
label
liver
postnat
label
liver
distribut
significantli
higher
liver
label
age
day
liver
label
age
day
respect
conclus
data
support
pbh
coh
cell
serv
resid
stem
cell
function
includ
contribut
parenchym
mass
organogenesi
earli
postnat
develop
also
suggest
stem
cell
nich
adult
may
quiescent
activ
kind
injuri
continu
activ
contribut
cell
lineag
develop
fetal
postnat
period
human
embryon
stem
cellsderiv
hepatocyt
heh
could
provid
power
tool
enabl
cellbas
therapi
clinic
studi
mechan
underli
human
liver
develop
diseas
test
efficaci
safeti
pharmaceut
howev
current
vitro
protocol
yield
heh
low
level
liver
function
rel
adult
primari
human
hepatocyt
investig
potenti
salvianol
acid
b
sal
b
activ
pharmaceut
compound
present
salvia
miltiorrhiza
exert
antifibrot
effect
previou
research
enhanc
hepatocyt
differenti
human
embryon
stem
cell
hesc
hesc
line
use
standard
differenti
protocol
treatment
sal
b
albumin
express
consist
increas
determin
qpcr
elisa
westenblot
indic
sal
b
might
promot
hepatocyt
differenti
process
express
larg
number
import
phase
ii
metabol
enzym
phase
iii
transport
also
increas
treat
cell
indic
biotransform
function
would
like
increas
addit
found
express
cholangiocyt
marker
significantli
reduc
treatment
sal
b
suggest
one
possibl
mechan
sal
b
may
promot
hepatocyt
differenti
inhibit
format
cholangiocyt
investig
reveal
activ
wnt
pathway
sal
btreat
cell
determin
upregul
wnt
result
increas
amount
nuclear
lead
increas
downstream
target
cyclin
cmyc
notch
receptor
notch
ligand
notch
receptor
target
downregul
treat
cell
suggest
notch
pathway
inhibit
numb
direct
transcript
target
wnt
signal
pathway
neg
regul
notch
pathway
upregul
indic
upregul
consist
activ
wnt
signal
suppress
notch
signal
thu
studi
demonstr
enhanc
hepatocyt
differenti
mediat
activ
wnt
signal
pathway
inhibit
notch
pathway
sal
b
conclus
sal
b
promot
hepatocyt
differenti
hesc
demonstr
sal
b
treatment
appear
enhanc
effort
gener
matur
hepatocyt
cellbas
therapeut
pharmacolog
toxicolog
studi
follow
peopl
noth
disclos
jiamei
chen
mark
zern
ping
liu
yuyou
duan
